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ABSTRACT 
Robert Jacks Sharpe: On the Merits of Stereoselective Desymmetrization Reactions in the 
Assembly of Complex Natural Molecules: The Total Synthesis of Pactamycin and Paspaline 
(Under the direction of Jeffrey S. Johnson) 
I.  Asymmetric Synthesis of the Aminocyclitol Pactamycin, a Universal 
Translocation Inhibitor 
 
A concise, enantioselective synthesis of the aminocyclopentitol natural product 
pactamycin is presented.  The critical feature of this approach was the execution of an 
asymmetric Mannich reaction and symmetry-breaking diketone monoreduction to assemble 
the C1, C2, and C7 relative stereochemistries early in the route, enabling facile construction of 
the remaining core functionalities.  A remarkable series of serendipitous stereochemical 
outcomes ensued in the sequence that followed, ultimately providing the title compound in 
fifteen steps from the commercially available 2,4-pentanedione, constituting the shortest 
reported synthesis to date. The development and evolution of this synthetic strategy is 
thoroughly detailed, and an analysis of observed outcomes is presented.  This synthesis was 
designed to immediately enable the facile preparation of structural analogs for the purposes of 
structure-activity relationship investigations. 
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II. Preparation and Biological Evaluation of Synthetic and Polymer-Encapsulated 
Congeners of the Antitumor Agent Pactamycin: Insight into Functional Group 
Effects and Biological Activity 
 
Using the previously described total synthesis of pactamycin as a platform for synthetic 
diversity, twenty-five unique synthetic congeners of the natural product have been prepared to 
provide greater understanding into the source of pactamycin’s biological profile.  Specific 
attention was given to the production of synthetic derivatives at the branch points of 
pactamycin’s unique functional groups (i.e. aniline, salicylate, and dimethylurea).  In addition, 
the encapsulation of pactamycin and its derivatives into the PRINT© technology was 
demonstrated.  This work has provided unprecedented access to a large number of pactamycin 
synthetic congeners, and subsequent in vitro analysis of the prepared compounds revealed a 
number of insights into the source of pactamycin’s activity. 
 
III. Inception and Development of a Global and Local Desymmetrization Approach 
to the Synthesis of Steroidal Alkaloids: Stereocontrolled Total Synthesis of 
Paspaline. 
 
An enantioselective synthesis of the indole diterpene alkaloid paspaline is described.  
Key features of this synthesis included the execution of both “global” and “local” 
desymmetrization reactions to enable expedient assembly of challenging quaternary centers in 
the core structure.  A complete account of the conception and development of this approach is 
described, and an analysis of desired (and undesired) outcomes is provided.  The described 
route affords a new conceptual blueprint for installing challenging stereocenters in this family 
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of molecules, and the steps contained therein provide the synthetic community with 
complimentary disconnections in the arena of steroid natural product synthesis. 
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CHAPTER ONE: 
ASYMMETRIC SYNTHESIS OF THE AMINOCYCLITOL PACTAMYCIN, A 
UNIVERSAL TRANSLOCATION INHIBITOR* 
 
1.1 Introduction 
 The value of the continued advancement of natural products synthesis cannot be 
understated.  The arena of preparing complex molecules serves as the ideal breeding (and 
proving) ground for innovation in organic synthesis, and successful total synthetic endeavors 
of biologically active “privileged” natural scaffolds have played a vital role in the betterment 
of global health.  In this chapter, we report the expedient total synthesis of the natural product 
pactamycin, a complex aminocyclitol alkaloid with a promising biological profile.  Key to this 
approach was the implementation of a complex symmetry-breaking reduction reaction for 
rapid incorporation of core stereochemistry.  The synthetic route provides the functionally and 
stereochemically dense natural product in fifteen steps from commodity chemicals, notably, in 
the absence of non-strategic downstream functional group or oxidation state manipulations.   
These studies were completed as part of a cooperative effort with Justin Malinowski of these 
laboratories and constitute the shortest synthesis of pactamycin reported to date. 
 
                                                          
*Reprinted in part with permission from Sharpe, R. J.; Malinowski, J. T.; Johnson, J. S. J. 
Am. Chem. Soc. 2013, 135, 17990, and Sharpe, R. J.; Malinowski, J. T.; Sorana, F.; Luft, J. 
C.; Bowerman, C. J.; DeSimone, J. M.; Johnson, J. S. Bioorg. Med. Chem. 2015, 23, 1849. 
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1.2 Background 
1.2.1 Introduction, History, and Biological Activity of Pactamycin 
Nature continues to test the state of the art in organic synthesis by providing chemists 
with both structurally complex, biologically relevant molecules.  Construction of these natural 
products often requires the expansion of known synthetic methods to previously unreported 
substrate classes or the development of new approaches for the assembly of natural 
frameworks.1  Isolated in 1961 from Streptomyces pactum by scientists at the former UpJohn 
Chemical Co., pactamycin (1.1, Figure 1-1) remains one of the most complex 
aminocyclopentitol antibiotics known, bearing a remarkable array of unique functionality and 
exceptional bioactivity.2 
Figure 1-1. Structure and Atom Numbering of Pactamycin 
 
 
 
 
 
 
Pactamycin exhibits activity against both Gram-positive and Gram-negative bacteria and is a 
powerful antitumor agent.3  More recent biological studies have demonstrated 1.1 to have 
potent antiviral (complete inhibition of polio-infected HeLa cells at 10-7 M) and antiprotozoal 
qualities (P.f. K1: IC50 = 14.2 nM).
4  However, despite the obvious application of these qualities 
to medicinal development, pactamycin’s known cytotoxicity against certain human eukaryotic 
cell lines (MRC-5: IC50 = 95 nM) have to date precluded its use in human disease treatments.
4  
The source of these activities was elucidated by Ramakrishnan and co-workers via X-ray 
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crystallographic studies.5 These investigations showed that pactamycin inhibits protein 
synthesis via its action as an RNA dinucleotide mimic, employing its unique aromatic 
appendages (C3 aniline, C6 salicylate) in H-bonding interactions with the 30S ribosomal 
subunit.  This activity prevents translocation and leads ultimately to cell death.  
 Given the above facts, it is evident that if the promising biological traits of this molecule 
are ever to probed further for the betterment of global health, they will be explored not in the 
environment of the parent structure but in the structural congeners derived thereof.  In support 
of this claim, a number of biosynthetically engineered congeners of the parent pactamycin 
structure have been recently reported which display diminished cytotoxicity relative to 1.1.6  
These data will be described in detail in Chapter Two and have reignited promise for structure-
activity relationship (SAR) investigations of 1.1 toward the goal of obtaining a useful drug 
molecule.  In order to further investigate the medicinal development of 1.1 through chemical 
approaches, the necessity of a practical and flexible synthesis of the target molecule is 
paramount for the success of such endeavors. 
1.2.2  Pactamycin Structural Features, Biosynthesis, and Previous Synthetic Endeavors 
 Pactamycin bears a densely-functionalized cyclopentane core featuring six contiguous 
stereogenic centers, three of which are fully substituted.7  Additionally, unusual dimethylurea, 
aniline, and salicylate moieties adorn the core structure, presenting numerous synthetic 
challenges. The biosynthesis of pactamycin has been proposed by Mahmud and co-workers to 
originate from m-acetylaniline 1.2 and UDP-N-acetyl-α-D-glucosamine 1.3;8 a subsequent 
series of enzymatic functional group and oxidation state transformations ensue to efficiently 
produce the title compound. This sequence is summarized in Scheme 1-1. 
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Scheme 1-1. Summary of Proposed Pactamycin Biosynthesis 
 
 
The unique challenges presented by pactamycin’s architecture have been addressed in 
a number of approaches as synthetic interest in 1.1 has flourished over the past decade.  
Synthetic efforts by Isobe,9 Knapp,10 Looper,11 Nishikawa,12 and our group13 have been 
recently disclosed.  While our studies were underway, the Hanessian group disclosed the 
landmark first total synthesis of pactamycin.14 Their approach was comprised of a thirty-two-
step manipulation of L-threonine (1.4) and is summarized in Scheme 1-2.  From L-threonine, 
a three-step sequence provided the known oxazoline 1.5, setting the stage for the assembly of 
cyclopentenone 1.6 in eight manipulations.  The C3 and C4 stereocenters were initially 
established via nucleophilic epoxidation of the alkene in 1.6 to provide epoxyketone 1.7, and 
the C2 amine functionality was incorporated via SN2 addition of NaN3 to the triflate 
electrophile derived from ketone 1.7.  It is important to note that the epoxide stereochemistry 
in 1.8 corresponds to the incorrect C4 stereochemistry needed for pactamycin at this juncture.  
Following deprotection and oxidation of the C5 alcohol in 1.8, the “incorrect” epoxide was 
then leveraged to enable stereoselective introduction of the C5 methyl group 
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Scheme 1-2. Summary of Hanessian Total Synthesis of Pactamycin 
 
via convex surface addition to the bicyclic ketone 1.9 to afford alcohol 1.10.  A four-step 
protocol was employed from 1.10 to “correct” the epoxide stereochemistry and afford 1.11, 
giving thence the m-propenyl aniline 1.12 after a Lewis acid mediated epoxide addition. 
 A significant challenge Hanessian faced in synthesis completion was introduction of 
the C1 dimethylurea functionality via acylation of a primary amine bound to the fully-
substituted C1 atom.  After extensive experimentation, acylation of 1.13 (prepared in three 
steps from aniline addition product 1.12) was accomplished upon generation of a transient 
isocyanate intermediate, which subsequently underwent trapping with dimethylamine to 
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furnish urea 1.14.  Oxidation of the m-propenyl aniline to the acetophenone, salicylate 
introduction, and deprotection afforded pactamycin in thirty-two steps and 1.1% overall yield. 
 A close inspection of this route and the published partial synthetic studies reveals two 
challenges one faces in assembling the core structure of pactamycin: (i) execution of chemo- 
and stereoselective reactions in a highly congested chemical environment and (ii) the method 
by which the unusual functionality of 1.1 is introduced.  In their total synthesis, the Hanessian 
group observed numerous side reactions due to functional group propinquity.14 Looper and 
Hanessian also noted the importance of the order in which functional group manipulations 
were executed.11,14  Regarding the dimethylurea, Hanessian relied on an oxazoline protecting 
group at C1 from the outset, necessitating the challenging deprotection and acylation 
previously described.  In the development of a synthesis plan, we took note of these issues and 
sought to develop a synthesis of 1.1 that rapidly assembled the core structure and incorporated 
all unique functionality in its final form, precluding the use of nonstrategic redox and 
protecting group manipulations.16  This flexible route, we surmised, would provide access to 
the title compound in a manner amenable to the synthesis of analogs for biological 
examination. 
1.2.3  Initial Retrosynthetic Analysis and Summary of Preliminary Route 
 Our original retrosynthetic disconnection began with simplification of 1.1 to 
functionalized cyclopentane 1.15 (Scheme 1-3).  C2 (allylic) functionalization, C4 
hydroxylation, and C3 aniline installation might be possible from a C3-C4 alkene in 1.16, 
accessed by a ring-closing metathesis (RCM) reaction.  The requisite precursor would be 
derived from nucleophilic addition to methyl ketone 1.17.  We surmised that this addition could 
occur either by intermolecular or intramolecular nucleophile delivery, the latter facilitated by  
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Scheme 1-3. Initial Retrosynthetic Analysis of Pactamycin 
 
the C7 secondary carbinol.  Two approaches to β-hydroxyketone 1.17 were envisioned, 
dependent upon the identity of the R-substituent.  If R = OMe (1.18), we proposed an 
enantioselective Tsuji−Trost allylation of ketoester 1.20 followed by diastereoselective ketone 
reduction and esterketone conversion.16  Alternatively, if R = Me (1.19), we would invoke 
an enantioselective, symmetry-breaking reduction strategy via diketone monoreduction, 
exploiting the hidden symmetry (see outlined region) in the northeast quadrant of 1.1.17 Critical 
to our strategy in either case was the early-stage installation of the dimethylurea functionality 
in its final, native form, an approach divergent from those previously reported.  α-
Ureidodicarbonyls 1.20 or 1.21 would serve as our points of origin, synthesized from 
commodity chemicals (methyl acetoacetate 1.22 or 2,4-pentanedione 1.23, respectively).   
In pursuit of this approach, our group published a preliminary synthetic study that 
provided a highly advanced intermediate for pactamycin core assembly and synthesis 
completion;13 the results and challenges that this synthesis faced are summarized in Scheme 1-
4.  Using methyl acetoacetate 1.22 as the point of origin, diazo transfer followed by a Rh-
catalyzed N−H insertion reaction provided urea 1.20 in 79% yield.18  The C1 carbon atom was 
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further functionalized via Tsuji−Trost allylation to install an allyl group; stereoselective 
reduction of the ketone followed by silyl protection furnished β-silyloxyester 1.24 in 52% 
yield. From 1.24, C5 carbinol installation became the next challenge.  Thus, the C1 ester was 
converted to its methyl ketone upon treatment with Me3SiCH2Li to afford β-silyloxyketone 
1.25 poised for nucleophilic addition.  From 1.25, a screen of nucleophiles and conditions were 
investigated for access to the requisite C5 carbinol; however, while addition of a model 2-
propenylmetal nucleophile mediated by CeCl3 proceeded in good yield, this reaction gave 
consistent preference for epimeric C5 stereochemistry (1.26).  This stereoerror  
Scheme 1-4. Previously Reported Approach to Pactamycin by our Laboratory 
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necessitated synthesis of ketone 1.27, which upon methide addition mediated by CeCl3, 
provided the desired C5 stereochemistry with >20:1 dr.  This intermediate was then elaborated 
to 1.28 in three steps, setting the stage for leveraging the C3 ketone to install the critical C2 
amine functionality; however, attempts to introduce the amine (or a suitable surrogate) at C2 
from 1.28 failed under a variety of conditions examined.   
1.3 Results and Discussion 
1.3.1 C2 Unfunctionalized Desymmetrization Approach: Strategy Development 
While the route described in Scheme 1-4 was scalable and effective for accessing 
advanced intermediate 1.28, the synthesis of ketone 1.27 required a number of nonstrategic 
redox and protecting group manipulations and lacked efficiency. As a result, we sought a 
streamlined approach to its synthesis in parallel to the C2 functionalization studies described 
above.  Cognizant of the undesired stereoselectivity encountered in intermolecular addition to 
methyl ketone 1.25, we envisaged that an intramolecular addition might provide the opposite 
facial preference. Delivery of a tethered nucleophile from the C7 hydroxyl followed by 
reduction and RCM would intercept our previous intermediate 1.28.  This intermediate could 
be synthesized from our proposed enantioselective desymmetrization strategy from urea 1.19, 
the diketone analog of 1.18.  
1.3.2 Substrate Preparation for Symmetry-Breaking Reduction 
The diketone reduction precursor 1.19 was prepared in three steps (Scheme 1-5).  We 
were pleased to find that the sequence used to synthesize ketoester 1.20 could be directly 
applied to 2,4-pentanedione 1.23 with minimal reoptimization.13  In practice, the reaction of 
2,4-pentanedione 1.23 with p-ABSA and NEt3 afforded the corresponding diazoketone in 
nearly quantitative yield.  An N−H insertion reaction analogous to that used in our previous  
10 
 
Scheme 1-5. Synthesis of C2 Unfunctionalized Desymmetrization Precursor  
 
studies delivered the desired ureidodiketone 1.21 in 67% yield, and a Tsuji−Trost allylation 
provided the necessary diketone precursor 1.19 in 81% yield. 
1.3.3  Symmetry-Breaking Reduction and Stereochemical Analysis 
 Having diketone 1.19 in our possession set the stage for development of the proposed 
symmetry-breaking reduction (Scheme 1-6). Working first to optimize the racemic reaction, 
we began screening reducing agents and conditions for selectivity.  Gratifyingly, 
LiAl(OtBu3)H (LTBA) emerged early in our evaluation, providing β-hydroxyketone (±)-1.17 
in 75% yield with >20:1 diastereoselection.  The desired stereochemistry was confirmed via 
TBS protection of the ketoalcohol and direct 1H NMR comparison with 1.25 (see Scheme          
1-4), which had been independently synthesized our in laboratory via our previous route.13 
 
Scheme 1-6. Racemic Diketone Desymmetrization and Stereochemical Confirmation 
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We speculate that this reduction proceeds via chelated structure 1.29, in which steric 
demand of the dimethyl urea functionality directs hydride addition to the least hindered 
diastereoface of the enantiotopic ketones, delivering (±)-1.17 in high selectivity.  Also of note 
in this reaction is the temperature required for successful reduction to occur; when the 
reduction is carried out at -78 °C, no reaction is observed, and if the reaction is warmed past 
the ideal temperature of -40 °C, retroaldol fragmentation ensues, presumably via instability of 
the alkoxide anion derived from hydroxyketone 1.17.   
1.3.4  Intramolecular C5 Addition 
 From β-hydroxyketone 1.17, we began investigating intramolecular additions to the C5 
ketone (Scheme 1-7).  Specifically, we were motivated by extant methods reported for 
reductive (or alkylative) cyclizations of ynoates to carbonyls and hoped that the same protocol 
might be applied to our system.  Thus, acylation of monoalcohol 1.17 with 2-butynoic acid 1.30 
cleanly delivered ynoate 1.31 in 79% yield.  1.30 was selected over the corresponding 
propiolate ester due to a significant decrease in yield observed in the analogous esterification 
with propiolic acid. 
Scheme 1-7. Attempts at Intramolecular Carbon Delivery to C5 Ketone. 
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From ester 1.31, we began screening known conditions for allenoate generation.  
Reducing agents such as SmI2 failed to promote any desired reactivity, returning only 
recovered starting material.19  Soft hydride reducing agents also gave little promise as starting 
material decomposition was observed.20  We were encouraged, however, by the work of 
Crimmins and co-workers in the use of organocuprate nucleophiles for initiating 
intramolecular, alkylative cyclizations and hoped this reaction manifold might be more 
compatible.21  Indeed, treatment of 1.31 with Me2CuLi delivered lactone 1.33 in 53% yield 
and 3:1 dr.  The desired relative configuration of the C1/C5/C7 stereotriad in 1.33 was 
confirmed by nuclear Overhauser effect spectroscopy (nOesy) analysis. 
1.3.5  Attempts at Lactone Reduction 
 At this juncture, only reduction of lactone 1.33 remained to provide triol 1.34; this 
intermediate would effectively intercept the synthesis of cyclopentanone 1.28. (Table 1-1).  
Table 1-1. Failed Attempts at Lactone Reduction 
 
Reductant Conditions Result 
DIBAL-H CH2Cl2, 0 °C to rt no reaction 
DIBAL-H C7H8, 0 °C to rt urea reduced 
LiBH4 Et2O, 0 °C to rt no reaction 
LTBA THF, rt no reaction 
LiAlH4 Et2O, 0 °C to rt urea reduced 
LiBEt3H THF, -78 °C to 0 °C lactol isolated 
LiBEt3H THF, 0 °C to rt urea reduced 
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However, an exhaustive screen of reducing agents and conditions failed to provide triol 1.34.  
Hindered reducing agents such as LTBA displayed no reactivity even at elevated temperatures, 
while stronger reducing agents (LiAlH4, LiBEt3H, DIBAL-H) resulted only in complex 
mixtures or reduction of the dimethylurea functionality.  Additionally, attempts at ring opening 
of 1.33 via transesterification to its corresponding ester or thioester failed to show any desired 
reactivity.  These failed attempts led to the conclusion that intramolecular 
addition/ring−opening strategies to establish the C5 stereochemistry might not be viable in 
providing access to 1.1, and as a result, this approach was abandoned. 
1.3.6  Revision of Strategy and Early Stage Incorporation of C2 Functionality 
At this impasse, we began to form conclusions regarding our original and revised 
strategies.  First, early-stage incorporation of the dimethylurea functionality, while a strategic 
risk at the onset of this work, had proven useful in directing desirable stereochemical outcomes 
in each of our initial routes.  The impressive diastereoselectivity accessed from symmetry-
breaking reduction of diketone 1.19 gave us cause to incorporate this strategy again in future 
routes to 1.1. However, neither our previously reported approach nor the above strategy 
addressed a major problem facing the endgame of our synthesis, namely, late-stage installation 
of the primary amine at C2. In devising a new approach, we determined that this issue would 
need to be addressed in any future iteration of our synthetic strategy.  Consequently, we 
envisioned enantioselective installation of C2 functionality on ureidodiketone 1.21 prior to the 
symmetry-breaking reduction (Scheme 1-8).    Monoreduction of this substrate would provide 
access to the C1/C2/C7 stereotriad within the first four steps of the synthesis, from which 
strategic manipulation of the available functional handles might give expedient access to 1.1.  
Beginning from the previously synthesized α-ureidodiketone 1.21, an enantioselective 
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Tsuji−Trost allylation with difurylidene acetate 1.35 would install a 2-furyl group at the C2 
center (1.36); we felt that this group could function as an amine surrogate via downstream 
oxidative cleavage and Curtius rearrangement.22  Since the ideal functionality at C2 would be 
the amine itself, a catalytic, asymmetric Mannich reaction of 1.21 with a strategically 
configured imine such as  1.37 was projected to deliver diketone 1.38 with carbamate-protected 
amine installed directly at C2.23  
Scheme 1-8. Proposed Routes to C2-Functionalized Desymmetrization Precursors 
 
In both the allylation and Mannich scenarios, enantioselective formation of the C2 
asymmetric center would be the lone initial challenge. The ensuing diastereoselective 
symmetry-breaking monoreduction of a chiral diketone would be the key for controlling the 
C1/C7 configurations and would require effective guidance from the initially-installed C2 
stereocenter.  The identities of the alkene termini in the generic structures 1.36 and 1.38 can 
be disregarded since downstream operations would purge these functionalities.  Both of these 
proposed pathways would deliver the entire core skeleton of 1.1 within the first three steps, 
providing all carbons necessary for cyclopentane assembly.  Equipped with these new 
hypotheses, we began pursuing each in parallel. 
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1.3.7 C2 Furan Approach – Substrate Preparation and Desymmetrization Studies 
 Our first challenge in realizing the Tsuji−Trost allylation strategy was the synthesis of 
the allylic acetate 1.35, which surprisingly had not been previously reported (Scheme 1-9).  To 
this end, reduction of difurylpropenone 1.39 afforded the corresponding alcohol 1.40; however, 
upon concentration of the crude mixture, this product rapidly decomposed.  The observed 
decomposition was unexpected since this compound had been previously reported, although 
no notes had been made regarding its instability.24 A screen of conditions designed to 
circumvent this problem revealed that NaBH4 reduction of 1.39 followed by immediate 
acylation using ethereal solvents provided 1.35 in crude form.   Acetate 1.35 was also found to 
be unstable, but could be stored in solution for up to thirty days at 0 °C. 
Scheme 1-9. Synthesis of Difurylketone for Tsuji−Trost Allylation 
 
With the desired electrophile in our possession, the reaction of diketone 1.21 with 
difurylidene acetate 1.35 under the previously optimized allylation conditions afforded C2-
functionalized diketone (±)-1.36 in 80% yield.  From this compound, we began to examine 
conditions by which we might effect symmetry-breaking reduction (Figure 1-2). 
Monoreduction of the chiral diketone 1.36 presented a complicated scenario, however, since 
four diastereomeric products could result.   In the first case, exposure of diketone 1.36 to our 
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previously optimized desymmetrization conditions (LTBA, -40 °C) resulted only in retro-aldol 
decomposition.   A brief screen of reducing agents revealed that the reaction of 1.36 with the 
recently reported LiAl(OtBu)(iBu)2H (LDBBA) afforded mono-alcohol (±)-1.41 with 
moderate diastereoselectivity (4:1 1.41:Σ other diastereomers).25  While the reduction of 
diketone 1.19 (lacking any C2 substituent) required warmer temperatures and extended 
reaction times, reduction of 1.36 was complete within ten minutes at -78 °C. An X-ray 
diffraction study of the major diastereomer confirmed the exact relative configuration needed 
for elaboration to 1.1.   While we envision a chelation mode similar to transition structure 1.29 
might be taking place in this reduction, the involvement of the C2 furan in directing the C1/C7 
relative configuration and dramatically affecting the reactivity is not well understood. 
Figure 1-2. Symmetry-Breaking Reduction of Difurylketone and X-ray Analysis 
 
 
1.3.8 Advancement of Desymmetrization Product to Pactamycin 
 Having accessed this key intermediate, we proceeded to test conditions for 
functionalization of the C5 methyl ketone (Scheme 1-10).  Based on our previous studies,13 we 
anticipated potential stereoselectivity and reactivity problems associated with nucleophilic 
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addition to the C5 carbonyl and accordingly decided initially to invoke the ability of 1.41 to 
participate in enolate chemistry. To this end, silyl protection of β-hydroxyketone 1.41 
proceeded smoothly to deliver ketone 1.42 in 96% yield. The reaction of the lithium enolate 
derived from 1.42 with ethyl cyanoformate provided β-ketoester 1.43 in 80% yield.26    
Scheme 1-10. Advancement of Furan Reduction Product Toward Pactamycin 
 
To access the cyclic core of 1.1 from this functionality, we proposed two parallel 
strategies: i) alkene oxidative cleavage followed by aldol condensation or ii) α-methylenation 
with subsequent RCM. As these routes were pursued, however, it was quickly found that the 
furan functionality in 1.43 was not compatible with standard oxidative cleavage conditions 
(O3, Johnson-Lemieux, RuCl3, etc.), giving only complex mixtures or starting material 
decomposition. Turning to the metathesis strategy, we began investigating α-methylenation 
protocols.  Using the conditions recently reported by Connell and co-workers, treatment of 
1.43 with (HCHO)n and diisopropylammonium trifluoroacetate afforded the undesired 
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Diels−Alder adduct 1.44, effectively rendering our RCM approach unfeasible.27 These results 
caused doubt as to whether our proposed C2-furan approach would provide access to 
pactamycin. In addition, the problems encountered in attempted oxidative cleavage of ketoester 
1.43 gave us concern as to whether a late-stage unmasking of C2-furan (via oxidation and 
Curtius rearrangement) could be realized.  With these data points in hand, we abandoned this 
route and turned our attention toward developing a route to 1.1 from an early-stage Mannich 
reaction. 
1.3.9 C2 Mannich Reaction Development 
Our strategy for direct installation of a protected amine at C2 required an expansion of 
the work of Schaus and co-workers to N-substituted dicarbonyls (Table 1-2).23 Also crucial to 
the success of this approach would be selection of the appropriately-protected imine 
electrophile.  In the event, we proceeded with Cbz-protected cinnamyl imine 1.45 and began 
testing conditions for the Mannich reaction. Working first to develop the racemic reaction, the 
union of α-ureidodiketone 1.21 with imine 1.45 in the presence of catalytic quantities of 
Hunig’s base delivered Mannich product (±)-1.38 in 90% yield.  With the feasibility of this 
bond construction established, focus turned to finding a suitable chiral catalyst for the reaction.   
In order to develop the corresponding asymmetric reaction, we initially applied 
Schaus’s unmodified conditions to the union of 1.21 and 1.45 (cinchonidine [20 mol %], 
CH2Cl2, -35 °C, 24 h).  We were pleased to obtain the crude Mannich adduct 1.38 in 24:76 er.  
An extensive screen of known Mannich reaction promotors then ensued.  These findings are 
summarized in Table 1-2 and detailed in Section 1.5 of this Chapter.  Toward these aims, 
quinine thiourea 1.47 gave increased levels of induction (83:17 er), although these selectivities 
were still below desirable levels.28   
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Table 1-2. Development of an Asymmetric C2 Mannich Reaction 
 
Thioureas of class 1.48 gave no enantioinduction.  BINOL-derived phosphoric acid 
catalysts 1.49 showed no improvement in selectivity, and the same was true for copper(box) 
1.50,29 Pd-BINAP 1.5130 and the free base of Johnston’s organocatalyst (1.52).31 The results 
led to the conclusion that cinchonidine 1.46, the catalyst originally examined, might be the best 
promoter for this transformation.   
After optimizing the reaction further for cinchonidine by lowering the reaction 
temperature (-65 °C), an initial 84:16 er was obtained.  We then began examining conditions 
for recrystallizing this crude enantioselectivity up to suitable levels for advancement to 1.1 
(Scheme 1-11).  However, upon trituration of crude 1.38 (84:16 er) for purposes of purification, 
we found that crystalline racemic product could be removed by filtration, leaving highly 
enantioenriched (+)-1.38 (98:2 er) in 70% yield.  The simplicity and scalability of this protocol 
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allowed for large scale material throughput.  Unsure of the absolute configuration of (+)-1.38, 
we proceeded in our studies with racemic material assuming that the Mannich catalyst 
enantiomer could be inverted if necessary to access the correct antipode of pactamycin.  
Scheme 1-11. Optimized Protocol for Asymmetric Mannich Reaction 
 
1.3.10 C2 Mannich Product Symmetry-Breaking Reduction Studies 
From functionalized dicarbonyl 1.38, we turned towards assembly of the C1/C2/C7 
stereotriad via symmetry-breaking reduction (Scheme 1-12).  Referring to our previously 
optimized conditions in the C2-unsubstituted case, monoreduction of 1.38 with LiAl(OtBu3)H 
at -35 °C provided β-hydroxy ketone 1.53 in 72% yield with high diastereoselectivity (>10:1 
1.53:Σ other diastereomers).  Efforts to determine the relative configuration of this 
monoalcohol became challenging, however, when initial studies toward accessing a crystalline 
derivative proved fruitless.  Turning to spectroscopic methods, ozonolysis of the styrene 
moiety provided lactol derivative 1.54 in 59% yield from which nOesy analysis suggested the 
relative configuration of the C1/C2/C7 stereotriad illustrated in Scheme 1-12.  Alternatively, 
when viewed as its enantiomer, the reduction product may be depicted as ent-(1.53). 
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Scheme 1-12. Symmetry-Breaking Reduction and Initial Stereochemical Analysis 
 
With this result in hand, we began to analyze the stereochemical outcome, considering 
the two illustrated product enantiomers.  β-Hydroxyketone 1.53 is epimeric at C2 relative to 
pactamycin (1.1), a stereochemical error for which a solution was not immediately obvious 
given our projected synthetic plan.  Alternatively, the enantiomeric form (ent-1.53) presents 
C1 and C2 in the correct pactamycin configuration, but is a product resulting from incorrect 
diastereotopic ketone site selectivity in the desymmetrization.  Although this was a 
discouraging initial result, we remained confident in our symmetry-breaking approach to 1.1 
and began pursuing myriad strategies in parallel for the elaboration of diketone 1.38 to our 
desired reduction diastereomer.    
We first pursued an exhaustive screen of reducing agents and conditions in hopes that 
reagent control would provide stereoselectivity opposite to that observed using LiAl(OtBu3)H.   
Monoreduction with a number of bulky hydride sources (L-Selectride®, LDBBA, Red-Al®, 
DIBAL-H) resulted only in the formation of stereoisomer 1.53 in lower yields.  Unhindered 
hydride sources (LiAlH4, Super Hydride, NaBH4), gave only minimal amounts of 1.53 
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accompanied with retro-aldol decomposition pathways.  Finally, alternative reduction 
pathways (enzymatic reduction, transfer hydrogenation) gave no promise for delivering 
diastereoselectivity opposite to that observed in LTBA reduction of diketone 1.38. These 
unsuccessful efforts led us to the conclusion that this reduction was proceeding with virtually 
complete substrate control, and as a result, direct reduction strategies of 1.38 towards the 
desired diastereomer were abandoned. 
In an effort to alter the apparent conformational bias associated with the acyclic 
structure 1.38, the diketone was engaged as its derived cyclic iodoimidate 1.55 through the 
action of I2 and NaHCO3  (Scheme 1-13). Subsequent monoreduction of diketone 1.55 followed 
by retrocyclization (mediated by Zn/HOAc) gave the acyclic hydroxy ketone 1.56 in 61% yield 
over two steps as a single diastereomer. Ketone 1.56 is a diastereomer different from that 
accessed via LiAl(OtBu3)H reduction of 1.38.  We immediately began work in establishing its 
stereochemical identity; however, nOesy analysis in a strategy analogous to that used for 1.53 
was inconclusive. 
Scheme 1-13. Iodoimidate Synthesis and Symmetry-Breaking Reduction 
 
Concurrent with these studies, we pursued an alternate strategy from the perspective of 
ent-1.53.  Namely, if the original monoreduction product could be further reduced to its 
corresponding diol (syn or anti), a site selective oxidation might deliver the desired C1/C2/C7 
23 
 
configuration (Scheme 1-14).  To this end, a screen of conditions revealed that direduction of 
1.38 with excess LDBBA afforded diol 1.57 as a 3:1 mixture of separable diastereomers.  The 
major isomer was determined to be the 1,3-trans diol via nOesy and 13C NMR analysis of the 
derived acetonide 1.58.32 Control experiments revealed that this reduction proceeds via the 
intermediacy of β-hydroxyketone 1.53.  Consequently, the relative stereochemistry at C2 was 
assigned according to that shown in alcohol 1.57.    
Scheme 1-14. Bis-Ketone Reduction and Symmetry-Breaking Oxidation Studies 
 
With this diol in hand, we began evaluating oxidants for symmetry-breaking oxidation. 
Treating diol 1.57 with Dess-Martin periodinane (DMP) showed complete selectivity for 
oxidation of a single site, returning the original hydroxyketone 1.53.  Alternatively, 
tetrapropylammonium perruthenate (TPAP) gave preference for the opposite alcohol, 
delivering monoalcohol 1.56 whose spectral characteristics matched those of the compound 
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prepared via the iodoimidate reduction.  The ability to access 1.56 from this route enabled us 
to assign its relative stereochemistry, which had previously remained ambiguous via nOesy 
analysis of its derivatives. 
1.3.11 Stereochemical Analysis: Conclusions 
The stereochemical analysis that follows provides the context for the experimental plan 
that we elected to pursue (Scheme 1-15).  It is germane to emphasize at the outset that all of 
our conclusions thus far hinged on the nOesy analysis of lactol derivative 1.54, which was 
suggestive of its illustrated structure, but not unambiguous. Thus, while two of the four 
possible monoreduction diastereomers (1.53, 1.56) had been accessed, we sought 
crystallographic evidence for conclusive stereochemical assignment.  Diastereoselective 
oxidation of trans-diol 1.57 gives access to two (of the four possible) monoreduction 
diastereomers of diketone 1.38 (the identities depending on assignment of 1.54).  Should our 
nOesy analysis of lactol 1.54 prove correct, then the identity of the trans-diol would be 1.57, 
giving access to the C7-epimeric diastereomer 1.56 (via symmetry-breaking oxidation), which 
could potentially be inverted downstream in the synthesis.  Alternatively, should our 
assignment of 1.54 be incorrect, the configuration of the trans-diol would be 1.61, enabling 
access to the desired C1/C2/C7 stereotriad 1.62. With this information in hand, we concluded 
that this selective oxidation pathway could provide entry to a useful monoreduction 
diastereomer for elaboration to 1.1 regardless of the stereochemical identity of 1.53.  Because 
it was so easily accessible, we moved forward with keto alcohol 1.53 to explore the viability 
of our remaining synthetic plan.  It was our hope that unambiguous stereochemical assignment 
would be realized via a suitable crystalline derivative later in the route and that the chemistry 
developed during those studies could be translated to whatever diastereomer was needed.   
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Scheme 1-15. Stereochemical Possibilities Arising From Diketone Monoreduction 
 
1.3.12  Attempted Acylation/Cyclocondensation Route 
Silyl protection of 1.53 under typical conditions proceeded smoothly, delivering β-
silyloxy ketone 1.64 in 86% yield (Scheme 1-16).  Some trepidation accompanied the 
subsequent enolate acylation in light of the possibility for undesired side reactions associated 
with deprotonation of the NHCbz group (i.e. retro-Mannich cleavage), but carboalkoxylation 
of the lithium enolate derived from 1.64 with ethyl cyanoformate cleanly delivered β-ketoester 
1.65 in 79% yield.  Hoping to access cyclopentenone 1.67 via our two previous strategies in 
the C2 furan approach, we began testing α-methylenation protocols to set the stage for RCM.   
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Scheme 1-16. Ring Closure Strategies Examined from Mander’s Acylation Adduct 
 
Unfortunately, treatment of 1.65 with known conditions for α-methylenation 
(diisopropylammonium trifluoroacetate/(HCHO)n, Eschenmoser salt, etc.) failed to give any 
promise as only starting material decomposition was observed.  However, ozonolysis of 1.65 
followed by reductive workup delivered reactive α-aminoaldehyde 1.66 which could not be 
isolated by chromatography.   We then began an extensive screen of conditions with which to 
effect an intramolecular condensation.  Treatment of the crude aldehyde 1.66 with amine bases 
(NEt3, DIPEA, pyridine) gave rise only to complex mixtures, while carbonate bases and typical 
Knoevenagel conditions resulted in starting material decomposition.  Furthermore, exposure 
of 1.66 to mild bicarbonate bases resulted in the formation of a single product; however, this 
product could never be identified nor manipulated into a useful intermediate.   
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1.3.13  Formaldehyde Aldol/Cyclocondensation Approach 
From these results, we concluded that our desired cyclization from 1.66 could not 
proceed via the β-ketoester moiety, and we began to investigate routes by which we might 
directly install the requisite C4 hydroxymethylene in its correct oxidation state for elaboration 
to 1.1 (Scheme 1-17).  This route would deliver the less activated β-hydroxyketone for 
subsequent intramolecular condensation.  Although few examples exist in the literature for the 
use of formaldehyde as an aldol electrophile in complex synthesis, Trost and co-workers have 
demonstrated its use in their synthesis of corianin.33  The Cao group, likewise, has shown the 
use of CH2O in aldol reactions en route to a total synthesis of malyngamide U.
34  After 
significant experimentation in our system, we found that by bubbling gaseous CH2O (generated 
by the pyrolysis of paraformaldehyde) through a solution of the lithium enolate of 1.64 at              
-45 °C, the desired primary alcohol 1.68 was isolated in 70% yield.   
Scheme 1-17. Development of a Formaldehyde Aldol Hydroxymethylation 
 
Ozonolysis of the styrene in 1.68 delivered the corresponding crude α-aminoaldehyde 
1.69 poised for intramolecular condensation (Scheme 1-18).  NaOMe emerged early as a 
superior promoter from our screen of conditions, delivering cyclopentenone 1.70 in 50% yield 
from 1.68.  Enone 1.70 contains all of the core carbon atoms necessary for synthesis completion 
and is ideally functionalized at C2 for late stage revelation of the requisite primary amine.   
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Scheme 1-18. Intramolecular Aldol Condensation for Access to Cyclopentane Core 
 
Interestingly, the condensation of 1.69 to 1.70 was rendered ineffective if the C6 hydroxyl 
group was protected.35  Fortunately, elimination of H2O strongly favors the formation of the 
endocyclic alkene (1.70) over its constitutional isomer, the α-methylidene cyclopentanone 
(1.71). 
1.3.14  Installation of C3, C4, C5 Stereocenters 
With cyclopentenone 1.70 in hand, only C5 nucleophilic addition, C4 hydroxylation, 
and installation of the C3 aniline remained to complete the core structure of 1.1.  We were still 
without stereochemical confirmation at C1, C2, and C7 at this juncture; however, given the 
promising access to cyclopentenone 1.70 and its obvious potential for elaboration to 1.1, we 
continued to move forward in exploring these remaining core functionalizations (Scheme          
1-19).  An epoxidation/nucleophilic aniline ring-opening sequence was pursued to access the 
C3,C4 trans-anilinoalcohol, inspired by a related approach by Hanessian and co-workers.14  
We surmised that addition of a suitable methide nucleophile to the C5 ketone would install the 
final stereogenic center.   Our experiments revealed that the order of these steps and the identity 
of the C6 hydroxymethylene protecting group were critical.   
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Scheme 1-19. Installation of Remaining Core Stereocenters 
 
In the permutation of these reactions that ultimately proved successful, we found 
epoxidation of 1.70 to be the most viable initial transformation.  Thus, treatment of enone 1.70 
with NaOH/H2O2 delivered epoxy-alcohol 1.72 in 81% yield and >20:1 dr.  Notably, as in the 
case of the intramolecular aldol condensation (1.69 → 1.70), this reaction was ineffective if 
the C6 hydroxyl was protected.  Further experimentation led to the conclusion that 
functionalization of the C5 ketone would be the most feasible next step in the sequence.  
However, treatment of epoxide 1.72 with MeMgBr returned only recovered starting material 
(even when the reaction was warmed to rt).  Surmising that the unprotected C6 hydroxyl might 
be reducing the electrophilicity of the ketone, the C6 hydroxyl in 1.72 was protected as its 
sterically-demanding TBDPS derivative 1.73 in 76% yield.36 With silyl ether 1.73 in our 
possession, treatment with MeMgBr at 0 °C proceeded smoothly to provide carbinol 1.74 in 
75% yield and excellent diastereoselection (>10:1).   
1.3.15  Unambiguous Assignment of Stereochemical Identity 
  Having arrived at an intermediate bearing all six stereocenters of 1.1, we were aware 
that unambiguous confirmation of the relative stereochemistry of 1.74 was essential before any 
further chemical manipulations could be probed (Figure 1-3).  Consequently, we began 
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aggressively pursuing recrystallization of 1.74 (or derived compounds thereof) to confirm or 
disprove our earlier stereochemical analyses.  Fortunately, carboxybenzyl deprotection of 1.74 
occurred readily under hydrogenolysis conditions to deliver the corresponding C2 primary 
amine 1.75, which crystallized readily.  X-ray analysis of this derivative confirmed the desired 
relative stereochemistry at all six centers. This surprising confirmation prompted us to 
examine this result further.  Two points were of interest and will be discussed in the following 
sections: i) the apparent concave-selective C5 ketone methylation (1.73 → 1.74) and ii) the 
apparent disproval of our originally determined stereochemistry of 1.53. 
Figure 1-3. Cbz Deprotection and Critical X-ray Diffraction Study 
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1.3.16  Implications of C5 Ketone Methylation 
With regard to the C5 ketone methylation, nucleophile addition to the convex surface 
of similar oxabicyclo[3.1.0]hexanone systems is well documented; in our system, this 
trajectory would have delivered the incorrect C5 configuration in the conversion of 1.73 to 
1.74 (Figure 1-4). 
Figure 1-4. Analysis of Addition to Oxabicyclo[3.1.0]hexanes 
 
As was discussed in Section 1.2.2, Hanessian and co-workers witnessed exclusively 
convex surface addition of a methide nucleophile to ketone 1.9 in their total synthesis of 1.1.14 
Greaney and co-workers, likewise, observed this facial preference in the addition of an 
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alkyllithium nucleophile to ketone 1.77 in their syntheses of merrilactone A and anislactone 
A.37  In our system, however, this inherent preference was seemingly overridden, delivering 
the desired stereochemistry at C5 (1.73 → 1.74). In the present case, we surmise this selectivity 
is observed at least in part due to direction by the C1-dimethylurea, providing additional 
support to the decision to incorporate this functionality in its native form early in the synthesis.  
Furthermore, the presence of two large silyl groups on the convex face of epoxide 1.73 might 
serve to block the undesired facial approach.
1.3.17  Implications of X-ray Study to the Symmetry Breaking Reduction 
The presence of the desired C1/C2/C7 stereotriad in 1.74 seemed to refute our original 
stereochemical determination of hydroxyketone 1.53 based on nOesy analysis of lactol 
derivative 1.54; however, in employing an intramolecular condensation to access the 
cyclopentane core or 1.1, the C2 stereocenter had become configurationally labile upon 
ozonolysis of styrene 1.68 to aldehyde 1.69.  This would leave an acidic aminomethine proton 
at C2 during the aldol condensation reaction (1.69 → 1.70). This led us to consider the 
possibility of epimerization in the conversion of 1.69 to 1.70 during base-promoted 
condensation to deliver the desired C2 configuration.  We devised a deuterium labeling 
experiment to examine the possibility of this pathway (Scheme 1-20). Treating α-carbamoyl 
aldehyde 1.69 with NaOMe in CD3OD using the optimized conditions afforded enone 
1.70−(D) with complete incorporation of deuterium at C2.  When this experiment was 
conducted at -10 °C for the same time duration, a complex mixture of products was observed 
by 1H NMR spectroscopy.  Resubmission of this unpurified mixture to the reaction conditions 
at 0 °C afforded enone 1.70−(D) with complete D-incorporation.  Finally, submission of the 
product enone 1.70−d0 to NaOMe in CD3OD returned the starting material with no deuterium 
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Scheme 1-20. Deuterium Labeling Studies on the Intramolecular Aldol Condensation 
 
incorporation.  These results indicate that the C2 methine undergoes proton exchange prior to 
the condensation. 
1.3.18 Absolute Confirmation of Symmetry-Breaking Reduction Stereochemistry,     
Desymmetrization Analysis, and a Fortuitous Stereochemical Correction 
 
In order to unambiguously confirm an epimerization event in the intramolecular aldol 
condensation, X-ray diffraction analysis of an intermediate upstream of aldehyde 1.69 would 
be required (Figure 1-5).  Returning to our previous attempts at derivatization of 
hydroxyketone 1.53, we found that acylation of the previously-synthesized lactol 1.54 with p-
nitrobenzoyl chloride provided benzoate derivative 1.79, which crystallized readily.  X-ray 
analysis of 1.79 (derived from enantioenriched 1.38) established the sense of enantioinduction 
in the asymmetric Mannich addition and confirmed the existence of the incorrect C2 
configuration in the desymmetrization product 1.53. 
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Figure 1-5. Absolute Confirmation of Symmetry-Breaking Reduction Stereochemistry 
 
 
 In light of this result, we became interested in the origin of the selectivity afforded in 
the symmetry-breaking reduction of 1.38.  A survey of the literature led to the discovery of a 
stereochemical model devised by Davis and co-workers for the selective reduction of 1,3-
aminoketones.38 An application of this model to the reduction of 1.38 is given in Figure 1-6.  
As predicted by Davis, preferential re-face addition of hydride to pseudochair conformer 1.80 
gives rise to the observed monoreduction diastereomer. 
 
 
 
 
1.79 
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Figure 1-6. Proposed Model for Stereoinduction in the Symmetry-Breaking Reduction 
 
These results collectively led us to deduce the following (Figure 1-7): i) our original 
stereochemical assignment of hydroxyketone 1.53 via nOesy analysis of 1.54 was correct; ii) 
the enantioselective Mannich addition (1.21  1.38) had yielded the incorrect enantiomer 
nominally required for elaboration to 1.1; and iii) this stereochemical “mistake”, compulsory 
for directing the correct C1/C7 stereochemistry in the symmetry-breaking reduction (1.38  
1.53), was later corrected via epimerization in the aldol condensation (1.69  1.70).  
Incredibly, this series of events had taken place unbeknownst to us until crystallographic 
evidence of a much later intermediate led us to suspect the validity of our original 
stereochemical analysis.  Having arrived at these conclusions, we moved forward in our 
endgame strategy towards synthesis completion. 
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Figure 1-7. A Fortuitous Stereochemical Correction: Conclusions 
 
1.3.19 Endgame and Synthesis Completion 
 Our plan to complete the synthesis began with the development of a Lewis acid-
promoted aniline epoxide opening to install the required m-acetylaniline in 1.1 (Scheme 1-21). 
A similar approach had been employed by Hanessian and co-workers for introduction of the 
C3/C4 trans-anilinoalcohol whereupon the requisite aniline was incorporated via its m-
propenyl derivative (1.14).14 The necessary acetophenone was later revealed via oxidative 
cleavage of the olefin (1.14  1.81).  By contrast, we hoped that the required m-acetylaniline 
1.2 could be installed in its native form, obviating downstream introduction of the ketone.  An 
extensive screen of conditions ensued, and these results are briefly summarized in Scheme 1-
19.  We found that the conversion of 1.74 to 1.82 was promoted by a variety of Lewis acids, 
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Scheme 1-21. Development of a Lewis Acid Catalyzed Aniline Epoxide Opening 
 
Lewis Acid (equiv) Conditions Result 
Yb(OTf)3 (3.5) C7H8, 80 °C 45% conversion, 29% yield 
Dy(OTf)3 (5.0)  C7H8, 80 °C 100% conversion, 35% yield 
Pm(OTf)3 C7H8, 80 °C <50% conversion 
Sc(OTf)3 (3.5) C7H8, 80 °C 100% conversion, 27% yield 
Sc(OTf)3 (1.0) C7H8, 80 °C 75% conversion 
Sc(OTf)3 (1.5) C7H8, 65 °C 70% conversion, 48% yield 
Sc(OTf)3 (3.0) C7H8, 60 °C 80% conversion, 65% yield 
 
although stoichiometric amounts of promoter were necessary to achieve suitable levels of 
conversion (presumably due to the Lewis basic ketone on 1.2).  Highest conversions were 
achieved when Sc(OTf)3 was employed, albeit yields decreased at 80 °C.  Determining that 
three equivalents of the Lewis acid were optimal, we probed lowering of the reaction 
temperature.  This feature resulted in decreased product decomposition and elevated yields, 
leading to our optimized conditions (Sc(OTf)3 [3.0 equiv], C7H8, 60 °C) which consistently 
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provided aniline 1.82 in 66% yield with ~18% recovery of unreacted 1.74. It is important to 
note that while this transformation proceeds in moderate yield, the use of more electron-rich 
anilines in the reaction delivers the corresponding epoxide-opened products in high yield, a 
valuable result as this step is a crucial branch point for analog synthesis.   
 From 1.82, we set out to install the remaining salicylate functionality and eliminate all 
protecting groups (Scheme 1-22).  Fortunately, global silyl deprotection proceeded readily 
upon treatment with tetrabutylammonium fluoride (TBAF), providing tetraol 1.83 in 90% 
yield.  To incorporate the salicylate moiety, we employed the method developed by Porco and 
later employed by Hanessian wherein the requisite electrophile is generated via 
deprotonation/elimination of cyanomethyl ester 1.84, providing a ketene electrophile selective 
for the C6 primary hydroxyl.39  Execution of this protocol on 1.83 occurred with minimal 
optimization, providing ester 1.85 in 80% yield.  This left only removal of the C2 protecting 
group to complete our synthesis.  Cbz-deprotection was effected readily upon hydrogenolysis 
of 1.85 in the presence of Pearlman’s catalyst to deliver pactamycin (1.1) in 82% yield.40 
Scheme 1-22. Salicylate Installation and Total Synthesis Completion 
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A survey of our completed synthesis of 1.1 demonstrates the immediate applicability 
of this route to modular incorporation of functional diversity towards future SAR studies 
(Figure 1-8).  Late stage ketone intermediate 1.74 (which can be prepared in gram scale in a 
single pass) is considered to be a valuable branch point for synthetic diversification at the C5, 
C3, and C6 positions.  Additionally, based on Hanessian’s strategy for late stage C1 
functionalization, it is envisioned that even the C1 dimethylurea may be modulated via a 
transiently-generated isocyanate intermediate.  These studies will be further detailed in   
Chapter Two. 
Figure 1-8. Synthetic Plan for Preparation of Pactamycin Structural Congeners 
 
1.4 Conclusion 
In summary, we have detailed a fifteen-step total synthesis of pactamycin in 1.9% 
overall yield from commodity chemical 2,4-pentanedione.   Emphasis was placed on 
incorporation of all unique functionality (dimethylurea, aniline, salicylate) in its native form 
for minimization of protecting group manipulations.  Revision of our originally published 
strategy13 led to the development of a novel alkylative cyclization for intramolecular delivery 
of C5 stereochemistry.  A need to incorporate C2 functionality early-stage gave rise to the 
synthesis of a new difurylidene acetate reagent which was employed in a complex Tsuji−Trost 
allylation, and an enantioselective Mannich addition of α-ureidodicarbonyls was developed via 
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an adaptation of the Schaus conditions.23 A symmetry-breaking reduction was employed for 
rapid delivery of the C1/C2/C7 stereotriad in 1.1, and proposed stereochemical models for 
these reductions are presented.   In the case of the C2-carbamate approach, a thorough analysis 
of monoreduction stereochemical outcomes is presented.  These studies culminated with the 
conclusion that selective oxidation of trans-diol 1.57 could allow access to a suitable 
monoreduction diastereomer of 1.38 for elaboration to 1.1. This deduction directed the decision 
to move forward in our strategy without unambiguous stereochemical confirmation of alcohol 
1.53 with the assumption that the necessary relative configuration of 1.1 could be realized later 
in the synthesis.  The stereochemical identity of 1.53 was later unambiguously determined to 
be incorrect at C2, although this “stereochemical error” was corrected via epimerization during 
a downstream aldol condensation.  This fortuitous turn of events allowed facile access to 1.1 
in the absence of non-strategic stereochemical manipulations.  This route is flexible and 
immediately amenable to the synthesis of structural analogs as major functional groups 
(aniline, salicylate) are incorporated in a late-stage fashion.   
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1.5 Experimental Details 
Methods: General. Infrared (IR) spectra were obtained using a Jasco 460 Plus Fourier 
transform infrared spectrometer. Proton and carbon magnetic resonance spectra (1H NMR and 
13C NMR) were recorded on a Bruker model Avance 400 (1H NMR at 500 MHz and 13C NMR 
at 125 MHz) or a Bruker Avance III 600 (1H NMR at 600 MHz and 13C NMR at 150 MHz) 
spectrometer with solvent resonance as the internal standard (1H NMR: CDCl3 at 7.26 ppm; 
13C NMR: CDCl3 at 77.0 ppm). 
1H NMR data are reported as follows: chemical shift, 
multiplicity (s = singlet, br s = broad singlet, d = doublet, br d = broad doublet, t = triplet, q = 
quartet, m = multiplet), coupling constants (Hz), and integration. Mass spectra were obtained 
using a Micromass Quattro-II triple quadrupole mass spectrometer in combination with an 
Advion NanoMate chip-based electrospray sample introduction system and nozzle or a Thermo 
LTqFT mass spectrometer with electrospray introduction and external calibration. All samples 
were prepared in methanol. Analytical thin layer chromatography (TLC) was performed on 
Sorbent Technologies 0.20 mm Silica Gel TLC plates. Visualization was accomplished with 
UV light, KMnO4, and/or aqueous ceric ammonium nitrate solution followed by heating. 
Purification of the reaction products was carried out by flash chromatography using Siliaflash-
P60 silica gel (40-63μm) purchased from Silicycle. Supercritical fluid chromatography was 
performed on a Berger SFC system equipped with a Chiralcel OD column. Samples were 
eluted with SFC grade CO2 at the indicated percentage of MeOH. Unless otherwise noted, all 
reactions were carried out under an atmosphere of dry nitrogen in oven-dried glassware with 
magnetic stirring. Yield refers to isolated yield of analytically pure material unless otherwise 
noted. Yields are reported for a specific experiment and as a result may differ slightly from 
those found in figures, which are averages of at least two experiments.   
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Materials: General. Tetrahydrofuran (THF), diethyl ether (Et2O), dichloromethane (CH2Cl2), 
and toluene (C7H8) were dried by passage through a column of neutral alumina under nitrogen 
prior to use. Acetonitrile (CH3CN), Triethylamine (NEt3) and diisopropylamine were freshly 
distilled from calcium hydride prior to use. Cinnamaldehyde was distilled under reduced 
pressure and elevated temperature immediately prior to use. LiAl(iBu)2(O
tBu)H,25 Imine 1.4541 
and cyanomethyl ester 1.8442 were prepared by known procedures. All other reagents were 
purchased from commercial sources and were used as received unless otherwise noted. 
Experimental Procedures: 
 
3-diazopentane-2,4-dione (S1): A 1-L round-bottomed flask was charged with acetylacetone 
(1.23) (10.25 mL, 100 mmol, 1.0 equiv) and acetonitrile (600 mL). p-Acetamidobenzene 
sulfonyl azide (p-ABSA) (24.0 g, 100 mmol, 1.0 equiv) was added and the reaction was cooled 
to 0 °C. Triethylamine (NEt3) (41.8 mL, 300 mmol, 3 equiv) was added dropwise and the 
reaction was warmed to rt for 1 hour. The resulting suspension was filtered through a fritted 
funnel and concentrated. The obtained residue was triturated with 1:1 ether:petroleum ether 
and the precipitated white soilds were removed via filtration. Solvents were removed in vacuo 
providing analytically pure S1 as a yellow oil in quantitative yield. Spectral data matched those 
reported in the literature.42 
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3-(2,4-dioxopentan-3-yl)-1,1-dimethylurea (1.21): A 1-L round-bottomed flask was charged 
with finely ground 1,1-dimethylurea (21.0 g, 237.0 mmol, 1.5 equiv). C7H8 (400 mL) and 1,2-
dichlorethane (400 mL) were added, followed by diazodiketone S1 (20 g, 158.0 mmol, 1.0 
equiv). The suspension was heated to 80 °C in a sand bath with magnetic stirring and gradually 
became homogeneous. Rh2(Oct)4 (0.492 g, 0.632 mmol, 0.004 equiv) suspended in C7H8 (10 
mL) was added in four portions over 30 min. The reaction temperature was maintained at 80 
°C and stirred until complete consumption of S1 was indicated by TLC analysis, typically 1 h. 
The reaction was allowed to cool to rt whereupon the excess 1,1-dimethylurea precipitated 
from solution. Solids were removed by vacuum filtration and the filtrate was concentrated in 
vacuo. The crude product was purified via flash chromatography (70:30 to 60:40 petroleum 
ether/acetone) to provide the title compound as a yellow solid (19.8 g, 67%). Note: NMR 
analyses typically showed a ~2:1 mixture of enol:keto tautomers. Analytical data: mp 105-109 
°C; 1H NMR (600 MHz, CDCl3): keto-tautomer: δ 5.92 (br s, 1H), 5.03 (d, J = 4.8 Hz, 1H), 
2.92 (s, 6H), 2.20 (s, 6H); enol-tautomer: δ 15.77 (s, 1H), 5.99 (s, 1H), 2.94 (s, 6H), 2.03 (s, 
6H); 13C NMR (150 MHz, CDCl3): δ 201.7, 191.8, 157.5, 157.2, 112.3, 72.8, 36.5, 36.3, 36.2, 
27.2, 23.9, 21.9; HRMS (ESI+) Calcd. for C8H14N2O3+H, 187.1084; Found, 187.1091; IR 
(thin film, cm-1) 3419, 2360, 2126, 1636, 1317, 1315, 1022, 914, 889; TLC (60:40 petroleum 
ether/acetone): Rf = 0.30. 
 
44 
 
 
3-(3-acetyl-2-oxohex-5-en-3-yl)-1,1-dimethylurea (1.19). In a nitrogen-filled glove box a 
flame-dried 100-mL round-bottomed flask was charged with allylpalladium chloride dimer 
(0.02 g, 0.05 mmol, 0.005 equiv) and rac-BINAP (0.07 g, 0.11 mmol, 0.0106 equiv). C7H8 (10 
mL) was added and the suspension was stirred for 10 min, capped with a rubber septum, and 
removed from the glove box. Allyl acetate (1.75 mL, 16.1 mmol, 1.50 equiv) was added and 
the catalyst solution was stirred for an additional 10 min. A separate flame-dried 250-mL 
round-bottomed flask was charged with diketone 1.21 (2.0 g, 10.7 mmol, 1.00 equiv) and 
tBuOK (1.27 g, 11.31 mmol, 1.05 equiv). C7H8 (54 mL) was added and the suspension was 
stirred under a nitrogen atmosphere. The catalyst solution was introduced via cannula transfer, 
and the reaction was stirred for 12 h at room temperature. The reaction was quenched with 1 
M HCl (30 mL) and extracted with EtOAc (3 x 40 mL). The combined organic extracts were 
washed with brine (30 mL), dried with magnesium sulfate, and concentrated in vacuo. The 
product was purified via flash chromatography (70:30 petroleum ether/acetone) to give the 
desired product (1.93 g, 80%) as a pale yellow oil. Analytical data: 1H NMR  (600 MHz, 
CDCl3): δ 6.22 (s, 1H), 5.39 (m, 1H), 5.04 (m, 2H), 3.07 (dd, J = 1.2, 6.6 Hz, 2H), 2.92 (s, 6H), 
2.06 (s, 6H); 13C NMR (150 MHz, CDCl3): δ 202.0, 155.8, 131.3, 119.3, 78.9, 36.0, 24.7; 
HRMS (ESI+) Calcd. for C11H18N2O3+H, 227.1396; Found, 227.1407; IR (thin film, cm
-1) 
3146, 2979, 2925, 1707, 1638, 1519, 1369, 1227, 1119, 923; TLC (75:25 petroleum 
ether:acetone): Rf = 0.30.  
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3-(3-acetyl-2-hydroxyhex-5-en-3-yl)-1,1-dimethylurea (1.17). A flame-dried 250-mL 
round-bottomed flask was charged with diketone 1.19 (6.8 g, 30.1 mmol, 1.00 equiv) and THF 
(232 mL). The solution was cooled to -78 °C, and lithium tri-tert-butoxyaluminum hydride 
(1.1 M in THF, 43.8 mL, 48.2 mmol, 1.60 equiv) was added slowly. The resulting mixture was 
warmed to -40 °C and stirred until complete consumption of diketone 1.19 was indicated by 
TLC analysis, typically 12 h. The reaction was quenched by the addition of saturated NH4Cl(aq) 
(100 mL) and the mixture was extracted with EtOAc (3 x 60 mL). The combined organic 
extracts were washed with brine (70 mL), dried with magnesium sulfate, and concentrated in 
vacuo. The crude product was purified via flash chromatography (80:20 to 70:30 petroleum 
ether:acetone) to afford alcohol17 (5.16 g, 75%) as a yellow viscous oil with >20:1 ratio of  
diastereomers.  The stereochemical relationship of 1.17 was confirmed via TBS protection and 
direct 1H NMR comparison with the corresponding TBS ether 1.25 that has previously been 
reported.13 Analytical data: 1H NMR  (600 MHz, CDCl3): δ 6.03 (d, J = 9.0 Hz, 1H), 5.44 (m, 
1H), 4.88 (s, 1H), 4.13 (t, J = 8.4 Hz, 1H), 2.86 (s, 6H), 2.62 (ddd, J = 1.2, 4.2, 7.8 Hz, 1H), 
2.40 (dd, J = 4.8 , 9.6 Hz, 1H), 2.25 (s, 3H), 1.12 (dd, J = 1.8, 7.2 Hz, 3H); 13C NMR (150 
MHz, CDCl3): δ 206.7, 158.6, 120.6, 72.2, 70.3, 38.8, 36.5, 36.4, 25.8, 18.2; HRMS (ESI+) 
Calcd. for C11H20N2O3+Na, 251.1371; Found, 251.1367; IR (thin film, cm
-1) 3410, 2979, 2932, 
1711, 1639, 1526, 1378, 1229, 1118, 920; TLC (70:30 petroleum ether:acetone): Rf = 0.25. 
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Crude 1H NMR Spectrum of 1.17 
 
 
3-acetyl-3-(3,3-dimethylureido)hex-5-en-2-yl but-2-ynoate (1.31). A flame-dried 100 mL 
round-bottomed flask was charged with alcohol 1.17 (0.82 g, 3.6 mmol, 1.00 equiv), 2-
butynoic acid (0.60 g, 7.1 mmol, 2.00 equiv), and Et2O (30 mL).  The resulting mixture was 
cooled to -20 °C, and a solution of diisopropylcarbodiimide (1.1 mL, 7.1 mmol, 2.00 equiv) 
and DMAP (0.04 g, 0.36 mmol, 0.10 equiv) in Et2O (6 mL) was added dropwise.  The reaction 
mixture was allowed to slowly warm to rt overnight. The resulting solution was filtered, and 
the filtrate was washed with Et2O (15 mL).  The resulting solution was washed with 0.5 M 
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HCl(aq) (15 mL) and Brine (15 mL), dried with magnesium sulfate, and concentrated in vacuo.  
The product was purified via flash chromatography (65:35 hexanes:EtOAc) to afford ynoate 
1.31 (0.82 g, 79%) as a clear, viscous oil. Analytical data: 1H NMR  (600 MHz, CDCl3): δ 
5.80 (s, 1H), 5.76 (q, J = 6.6 Hz, 1H), 5.46 (m, 1H), 5.05 (dd, J = 1.8, 13.8 Hz, 1H), 5.01 (dd, 
J = 1.8, 15.0 Hz, 1H), 3.36 (dd, J = 6.6, 7.8 Hz, 1H), 2.85 (s, 6H), 2.62 (dd, J = 8.4, 6.6 Hz, 
1H), 2.28 (s, 3H), 1.95 (s, 3H), 1.11 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 206.6, 
156.2, 152.3, 131.8, 118.7, 86.3, 72.5, 72.4, 72.0, 69.8, 36.1, 36.0, 35.9, 34.3, 26.4, 15.2, 3.7; 
HRMS (ESI+) Calcd. for C15H22N2O4+Na, 317.1477; Found, 317.1508; IR (thin film, cm
-1) 
3411, 1978, 2937, 2240, 1711, 1657, 1513, 1371, 1258, 1063, 923; TLC (65:45 
EtOAc:hexanes): Rf = 0.65. 
 
3-(3-allyl-4-hydroxy-2,4-dimethyl-6-oxo-5-(propan-2-ylidene)tetrahydro-2H-pyran-3-
yl)-1,1-dimethylurea (1.33).  A flame-dried, 10 mL round-bottomed flask was charged with 
CuI (0.39 g, 2.00 mmol, 5.00 equiv) and Et2O (5 mL).  The resulting suspension was cooled to 
-20 °C, and MeLi (1.6 M, 2.55 mL, 10 equiv) was added dropwise.  The solution was allowed 
stir at -20 °C for 1 hour, cooled to -78 °C, and a solution of ynoate 1.31 (0.12 g, 0.81 mmol, 
1.00 equiv.) in Et2O (1 mL) was added dropwise.  The resulting mixture was allowed to slowly 
warm to rt overnight, quenched with 10 % AcOH (5 mL), and poured into a separatory funnel 
containing saturated NaHCO3(aq) (15 mL).  The aqueous layer was extracted with EtOAc (3 x 
10 mL), and the combined organics were washed with saturated NaHCO3(aq), dried with 
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magnesium sulfate, and concentrated in vacuo.  The product was purified via flash 
chromatography (60:40 to 70:30 EtOAc:hexanes) to afford lactone 1.33 (0.07 g, 53%) as a 
clear, viscous oil in a 3:1 ratio of separable diastereomers. Analytical data: 1H NMR  (600 
MHz, CDCl3): δ 6.18 (s, 1H), 5.90 (m, 1H), 5.18 (d, J = 16.8 Hz, 1H), 5.10 (d, J = 9.6 Hz, 1H), 
5.01 (q, J = 6.0 Hz, 1H), 2.89 (s, 3H), 2.88 (s, 3H), 2.59 (dd, J = 5.4, 9.0 Hz, 1H), 2.53 (dd, J 
= 5.4, 9.0 Hz, 1H), 2.20 (s, 3H), 2.00 (s, 3H), 1.42 (s, 3H), 1.33 (d, J = 6.0 Hz, 3H); 13C NMR 
(150 MHz, CDCl3): δ 169.4, 155.4, 147.4, 134.8, 131.6, 118.5, 80.2, 73.7, 65.4, 36.6, 29.7, 
23.6, 21.3, 16.6; HRMS (ESI+) Calcd. for C16H26N2O4+Na, 333.1790; Found, 333.1786; IR 
(thin film, cm-1) 3399, 2923, 2853, 1688, 1642, 1442, 1186, 1054, 909; TLC (65:45 
EtOAc:hexanes): Rf = 0.35. 
Crude 1H NMR Spectrum of 1.33 
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(E)-1,3-di(furan-2-yl)allyl acetate (1.35).  A 250 mL round-bottomed flask was charged with 
NaBH4 (1.21 g, 31.9 mmol, 6.00 equiv), THF (27 mL) and H2O (27 mL).  The mixture was 
cooled to 0 °C and ketone 1.39 (1.0 g, 5.32 mmol, 1.00 equiv) was added as a solution in THF 
(3 mL).  The reaction mixture was allowed to warm to rt and stirred until TLC analysis 
confirmed complete consumption of the starting material, typically 2 h.  The resulting mixture 
was diluted with brine (30 mL), and the aqueous layer was extracted with Et20 (3 x 30 mL).  
The combined organic extracts were dried with magnesium sulfate.  The crude solution was 
concentrated on a rotary evaporator to a volume of ca. 5 mL and immediately redissolved in 
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anhydrous Et2O (27 mL).  A stir bar was added followed by NEt3 (2.22 mL, 15.95 mmol, 3.00 
equiv), DMAP (0.03 g, 0.27 mmol, 0.05 equiv.) and lastly Ac2O (0.88 mL, 9.30 mmol, 1.75 
equiv) at rt.  The resulting mixture was allowed to stir for 4 h whereupon the reaction was 
quenched via addition of saturated NaHCO3(aq.) (20 mL).  The resulting mixture was transferred 
to a separatory funnel, and the aqueous layer was extracted with Et2O (3 x 20 mL).  The 
combined organic extracts were dried with magnesium sulfate and concentrated in vacuo to 
afford crude difurylidine acetate 1.35 (1.10 g) as a reddish brown viscous oil.  This material 
was dissolved in anhydrous C7H8 and was used in the next step without further purification.  
 
(E)-3-(3-acetyl-4,6-di(furan-2-yl)-2-oxohex-5-en-3-yl)-1,1-dimethylurea (1.36).  In a 
nitrogen-filled glove box a flame-dried 100-mL round-bottomed flask was charged with 
allylpalladium chloride dimer (0.04 g, 0.11 mmol, 0.025 equiv) and rac-BINAP (0.14 g, 0.23 
mmol, 0.053 equiv). C7H8 (5 mL) was added and the suspension was stirred for 10 min, capped 
with a rubber septum, and removed from the glove box. To this mixture was added crude 
difurylidine acetate 1.35 (1.49 g, 6.44 mmol, 1.50 equiv) as a solution in C7H8, and the catalyst 
solution was stirred for an additional 10 min upon which a reddish brown color was observed. 
A separate flame-dried 250-mL round-bottomed flask was charged with diketone 1.21 (0.80 g, 
4.29 mmol, 1.00 equiv) and tBuOK (0.51 g, 4.51 mmol, 1.05 equiv). C7H8 (25 mL) was added 
and the suspension was stirred under a nitrogen atmosphere. The catalyst solution was 
introduced via cannula transfer, and the reaction was stirred for 12 h at room temperature. The 
51 
 
reaction was quenched with 1 M HCl (25 mL) and extracted with EtOAc (3 x 20 mL). The 
combined organic extracts were washed with brine (200 mL), dried with magnesium sulfate, 
and concentrated in vacuo. The product was purified via flash chromatography (50:50 
hexanes:EtOAc) to give the desired product (1.22 g, 80%) as a dark brown, viscous oil. 
Analytical data: 1H NMR  (600 MHz, CDCl3): δ 7.31 (dd, J = 1.2, 7.2 Hz, 1H), 6.36 (dd, J = 
7.2, 8.4 Hz, 1H), 6.30 (m, 2H), 6.22 (d, J = 3.0 Hz, 1H), 6.17-6.15 (m, 2H), 6.03 (s, 1H), 4.85 
(d, J = 8.4 Hz, 1H), 2.86 (s, 6H), 2.13 (s, 3H), 2.03 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 
201.8, 201.5, 156.6, 152.3, 151.6, 141.9, 123.7, 121.3, 111.1, 110.5, 108.8, 107.8, 79.4, 46.3, 
36.1, 26.8, 26.1; HRMS (ESI+) Calcd. for C19H22N2O5+Na, 381.1426; Found, 381.1424; IR 
(thin film, cm-1) 3414, 3118, 2929, 1708, 1656, 1511, 1357, 1196, 1012, 735; TLC (65:45 
EtOAc:hexanes): Rf = 0.63. 
 
(E)-3-(3-acetyl-4,6-di(furan-2-yl)-2-hydroxyhex-5-en-3-yl)-1,1-dimethylurea (1.41). A 
flame dried 100 mL round-bottomed flask was charged with diketone 1.36 (0.84 g, 2.17 mmol, 
1.0 equiv) and THF (31 mL).  The resulting mixture was cooled to -78 °C and 
LiAl(iBu)2(O
tBu)H (0.9M in THF:hexanes, 6.02 mL, 5.42 mmol, 2.5 equiv) was added 
dropwise.  TLC analysis of the resulting mixture showed remaining starting material, at which 
point an additional 2.89 mL (1.2 equiv) of LiAl(iBu)2(O
tBu)H was added.  At this point, TLC 
analysis confirmed complete consumption of the starting material and the reaction was 
quenched via addition of saturated HCl(aq) (15 mL).  The mixture was warmed to rt and 
extracted with Et2O (3 x 20 mL).  The combined organic extracts were dried with magnesium 
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sulfate and concentrated in vacuo.  The product was purified via flash chromatography (60:40 
EtOAc:hexanes) afforded alcohol 1.41 (0.54 g, 63%) as a brown solid in a 4:1 ratio of separable 
diastereomers.  Slow evaporation (CH2Cl2) at room temperature provided crystals suitable for 
X-ray analysis. Analytical data: mp: 155-156 °C 1H NMR  (600 MHz, CDCl3): δ 7.4 (d, J = 
0.9 Hz, 1H), 7.33 (d, J = 1.8 Hz, 1H), 6.35-6.33 (m, 3H), 6.30-6.18 (m, 4H), 5.28 (s, 1H), 4.32 
(m, 1H), 3.93 (d, J = 8.4 Hz, 1H), 2.94 (s, 6H), 2.29 (s, 3H), 0.94 (d, J = 6.0 Hz, 3H); 13C NMR 
(150 MHz, CDCl3): δ 206.2, 159.2, 151.4, 150.9, 142.5, 142.4, 122.6, 122.0, 111.3, 110.7, 
109.2, 108.9, 76.1, 70.1, 47.7, 36.7, 28.0, 18.1; HRMS (ESI+) Calcd. for C19H24N2O5+H, 
361.1763; Found, 361.1762; IR (thin film, cm-1) 3403, 3125, 2930, 1709, 1641, 1529, 1376, 
1256, 1013, 766; TLC (65:45 EtOAc:hexanes): Rf = 0.40. 
Crude 1HNMR Spectrum of 1.41 
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3-(E)-3-acetyl-2-((tert-butyldimethylsilyl)oxy)-4,6-di(furan-2-yl)hex-5-en-3-yl)-1,1-
dimethylurea (1.42). A flame dried 25 mL round-bottomed flask was charged with alcohol 
1.41 (0.54 g, 1.49 mmol, 1.00 equiv) and CH2Cl2 (7 mL).  The resulting mixture was cooled 
to 0 °C and imidazole (0.41 g, 5.96 mmol, 4.00 equiv) was added followed by TBSCl (0.56 g, 
3.73 g, 2.50 equiv).  The reaction was warmed to rt and stirred until TLC analysis confirmed 
complete consumption of the starting material, typically 15 h.  The reaction was quenched via 
addition of saturated NaHCO3(aq) (5 mL), and the resulting mixture was extracted with EtOAc 
(3 x 15 mL).  The combined organic extracts were washed with 1 M HCl(aq) (10 mL) and brine, 
dried with magnesium sulfate, and concentrated in vacuo.  The product was purified via flash 
chromatography (70:30 hexanes:EtOAc) to afford silyl ether 1.42 (0.67 g, 96%) as a pale 
brown, viscous oil. Analytical data: 1H NMR  (600 MHz, CDCl3): δ 7.30 (dd, J = 1.2, 9.0 Hz, 
2H), 6.54 (dd, J = 7.8, 8.4 Hz, 1H), 6.31 (dd, J = 1.2, 1.8 Hz, 1H), 6.28 (dd, J = 1.2, 1.8 Hz, 
1H), 6.13 (t, J = 3.6 Hz, 2H), 6.06 (d, J = 16.2 Hz, 1H), 5.79 (s, 1H), 4.85 (d, J = 8.4 Hz, 1H), 
4.66 (q, J = 6.0 Hz, 1H), 2.85 (s, 6H), 2.30 (s, 3H), 1.16 (d, J = 6.6 Hz, 3H), 0.86 (s, 9H), 0.07 
(s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 206.2, 157.4, 153.3, 152.7, 141.7, 141.2, 
126.4, 120.5, 111.1, 110.2, 108.2, 107.4, 73.4, 70.7, 43.8, 36.3, 36.2, 27.7, 25.8, 19.1, 18.0, -
3.9, -4.9; HRMS (ESI+) Calcd. for C25H38N2O5Si+H, 475.2628; Found, 475.2627; IR (thin 
film, cm-1) 3434, 2953, 2856, 1711, 1658, 1503, 1361, 1253, 1149, 1011, 835, 732; TLC 
(65:45 EtOAc:hexanes): Rf = 0.90. 
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Ethyl (tert-butyldimethylsilyl)oxy)ethyl)-4-(3,3-dimethylureido)-5,7-di(furan-2-yl)-3-
oxohept-6-enoate (1.43).  A flame-dried 250-mL round-bottomed flask was charged with 
diisopropylamine (0.16 mL, 1.11 mmol, 3.50 equiv) and THF (2.5 mL). The resulting solution 
was cooled to 0 °C and n-butyllithium (1.72 M in hexanes, 0.65 mL, 1.11 mmol, 3.50 equiv) 
was added dropwise. The solution was stirred at 0 °C for 30 min and then cooled to -78 °C. A 
solution of ketone 1.42 (0.15 g, 0.32 mmol, 1.0 equiv) in THF (1 mL) was added dropwise, 
and the resulting solution was stirred at -78 °C for 45 min whereupon ethyl cyanoformate (0.05 
mL, 0.52 mmol, 1.7 equiv) was added dropwise.  The reaction was allowed to slowly warm to 
-20 °C over 2 h and quenched via addition of saturated NH4Cl(aq.) (4 mL).  The mixture was 
warmed to rt and extracted with Et2O (3 x 10 mL).  The combined organic extracts were dried 
with magnesium sulfate and concentrated in vacuo.  The product was purified via flash 
chromatography (80:20 to 70:30 hexanes:EtOAc) to afford ketoester 1.43 (0.14 g, 80%) as a 
pale brown, viscous oil. Analytical data: 1H NMR  (600 MHz, CDCl3): δ 7.30 (d, J = 1.2, Hz, 
1H), 7.27 (d, J = 1.2 Hz, 1H), 6.46 (dd, J = 7.8, 8.4 Hz, 1H), 6.29 (m, 2H), 6.16 (d, J = 3.0 Hz, 
1H), 6.11 (d, J = 3.6 Hz, 1H), 5.99 (d, J = 15.6 Hz, 1H), 5.79 (s, 1H), 4.73 (d, J = 7.8 Hz, 1H), 
4.57 (q, J = 6.0 Hz, 1H), 4.11 (m, 2H), 3.80 (d, J = 15.6 Hz, 1H), 3.72 (d, J = 15.6 Hz, 1H), 
2.86 (s, 6H), 1.21 (t, J = 7.2 Hz, 3H), 1.17 (d, J = 6.0 Hz, 3H), 0.85 (s, 9H), 0.05 (s, 3H), 0.02 
(s, 3H); 13C NMR (150 MHz, CDCl3): δ 200.3, 167.8, 157.4, 153.1, 152.8, 141.6, 141.2, 126.4, 
120.3, 111.0, 110.3, 108.3, 107.2, 73.0, 70.1, 61.0, 45.5, 43.6, 36.3, 36.2, 29.6, 25.8, 18.5, 17.9, 
14.0, -4.2, -4.9; HRMS (ESI+) Calcd. for C28H42N2O7Si+Na, 569.2659; Found, 569.2657; IR 
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(thin film, cm-1) 3432, 2929, 2856, 1744, 1711, 1657, 1502, 1367, 1256, 1150, 1012, 836, 734; 
TLC (65:45 EtOAc:hexanes): Rf = 0.95. 
 
Ethyl (tert-butyldimethylsilyl)oxy)ethyl)-2-(3,3-dimethylureido)-3-((E)-2-(furan-2-
yl)vinyl)-1-oxo-2,3,6,7-tetrahydro-3a,6-epoxyindene-7a(1H)-carboxylate (1.44). A 5 mL 
dram vial was charged with ketoester 1.43 (0.035 g, 0.064 mmol, 1.00 equiv) and THF (1.5 
mL).  To the resulting solution was added diisopropylammonium trifluoroacetate (0.014 g, 
0.064 mmol, 1.00 equiv), and lastly (HCHO)n (0.009 g, 0.26 mmol, 4.00 equiv), and the 
reaction was warmed to 65 °C for 15 hours.  The resulting solution was cooled to rt and diluted 
with H2O (10 mL) and Et2O (10 mL).  The resulting mixture was extracted with Et2O (3 x 10 
mL), and the combined organic extracts were washed with 1 M HCl(aq.) (5 mL), 1 M NaOH(aq.) 
(5 mL), and brine (5 mL), washed with magnesium sulfate and concentrated in vacuo.  The 
product was purified via flash chromatography (80:20 to 70:30 hexanes:EtOAc) to afford 
tricycle 1.44 (0.017 g, 48%) as a clear, viscous oil. Analytical data: 1H NMR  (600 MHz, 
CDCl3): δ 7.30 (d, J = 1.8 Hz, 1H), 6.78 (d, J = 6.0 Hz, 1H), 6.44 (d, J = 15,6 Hz, 1H), 6.38-
6.31 (m, 3H), 6.19 (d, J = 3.0 Hz, 1H), 5.57 (s, 1H), 4.96 (dd, J = 6.0, 3.0 Hz, 1H), 4.34 (m, 
2H), 4.24 (m, 1H), 4.14 (m, 1H), 2.85 (s, 6H), 2.59 (dd, J = 4.8, 7.2 Hz, 1H), 1.83 (d, J = 12.0 
Hz, 1H), 1.27-1.21 (m, 6H), 0.83 (s, 9H), 0.02 (s, 6H); 13C NMR (150 MHz, CDCl3): δ 206.8, 
169.4, 156.8, 152.8, 141.6, 137.1, 135.0, 123.9, 121.0, 111.0, 107.2, 94.0, 78.2, 72.8, 71.7, 
66.4, 61.3, 48.2, 39.8, 36.2, 29.7, 25.7, 21.8, 17.8, 14.1, 14.0, -4.0, -4.7; HRMS (ESI+) Calcd. 
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for C29H42N2O7Si+H, 559.2840; Found, 559.2881; IR (thin film, cm
-1) 3438, 2956, 2925, 
2853, 1759, 1655, 1508, 1463, 1254, 1088, 836, 733; TLC (65:45 EtOAc:hexanes): Rf = 0.95. 
 
1H COSY Spectrum of 1.44 
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Benzyl ((E)-3-phenylallylidene)carbamate (1.45): A 500-mL round-bottomed flask was 
charged with N, N-hexamethyldisilazane (20.6 mL, 98.4 mmol, 1.3 equiv) and was cooled to 
0 °C under a nitrogen atmostphere.  nBuLi (60 mL, 99 mmol, 1.654 M in Hexanes, 1.3 equiv) 
was added dropwise, and the resulting mixture was warmed to rt and stirred for 30 minutes.  
The freshly prepared LiHMDS solution was cooled to 0 °C, and freshly distilled trans-
cinnamaldehyde (9.5 mL, 75.7 mmol, 1.0 equiv) was added dropwise.  The resulting mixture 
was warmed to rt and stirred for 45 minutes.  The reaction mixture was concentrated in vacuo 
to remove hexanes, and the residue was redissolved in CH2Cl2 (96 mL) under a nitrogen 
atmosphere.  The reaction mixture was cooled to 0 °C, and CbzCl (14.2 mL, 99 mmol, 1.3 
equiv) was added dropwise.  The resulting mixture was warmed to rt and stirred overnight.  
The reaction was diluted with hexanes (75 mL), filtered through celite, and concentrated in 
vacuo.  The resulting orange residue was triturated (90:10 Hexanes:EtOAc) and the filtrate 
removed to give aldimine 1.45 as a pale orange solid.  Analytical data matched those reported 
in the literature.41 
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(R,E)-benzyl (4-acetyl-4-(3,3-dimethylureido)-5-oxo-1-phenylhex-1-en-3-yl)carbamate 
(1.38): A flame-dried 250-mL round-bottomed flask was charged with urea 1.21 (2.38 g, 12.28 
mmol, 1.0 equiv), cinchonidine (0.72 g, 2.46 mmol, 0.2 equiv), and CH2Cl2 (65 mL). The 
resulting suspension was cooled to -78 °C and a cold solution of imine 1.45 (5.1 g, 19.24 mmol, 
1.5 equiv) in CH2Cl2 (35 mL) was added via cannula transfer. The reaction was warmed to -65 
°C and stirred until complete consumption of urea 1.21 was indicated by TLC analysis, 
typically 14-36 h (scale-dependent). The crude reaction was filtered through a short silica plug 
and rinsed with EtOAc (300 mL). The filtrate was concentrated in vacuo to give a pale yellow 
foam with a 84:16 enantiomeric ratio. Crystalline racemic product was isolated via trituration 
with 60:40 (v/v) hexanes:EtOAc (300 mL). The analytically-pure white solid was removed by 
filtration (1.33 g, 24%) and the filtrate was concentrated in vacuo to give a yellow oil. The 
crude oil was purified by flash chromatography (60:40 to 50:50 hexanes:EtOAc) affording 
diketone 1.38 as a pale yellow foam (3.87 g, 70%, 97:3 er). The enantiomeric ratio was 
determined by SFC analysis (Chiralcel, OD, 9.0% MeOH, 1.5 mL/min, 150 bar, 210 nm; tR-
minor 12.8 min, tR-major 14.7 min). Analytical data: [α]D19 +16.5 (c = 1.00, CHCl3); mp 
(racemate) 130-134 °C; 1H NMR  (600 MHz, CDCl3): δ 7.37-7.21 (m, 10H), 7.07 (br d, J = 
6.0 Hz, 1H), 6.59 (d, J = 16.2 Hz, 1H), 6.50 (s, 1H), 5.96 (dd, J = 7.2, 16.2 Hz, 1H), 5.40 (t, J 
= 7.2 Hz, 1H), 5.14 (d, J = 12.0 Hz, 1H), 5.11 (d, J = 12.0 Hz, 1H), 2.97 (s, 6H), 2.28 (s, 3H), 
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2.14 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 200.9, 200.4, 157.6, 156.7, 136.9, 136.5, 133.2, 
128.7, 128.6, 128.2, 128.2, 128.1, 126.9, 124.6, 81.7, 67.0, 57.2, 36.8, 26.2, 25.4; HRMS 
(ESI+) Calcd. For C25H29N3O5+H, 452.2187; Found, 452.2212; IR (thin film, cm
-1) 3418, 
2243, 1702, 1635, 1507, 1371, 1249, 1066, 912, 693; TLC (60:40 hexanes:EtOAc): Rf = 0.20.  
Enantioselectivity Assays of Mannich Reaction (1.211.38): 
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Enantioselectivitiy Screenings for Asymmetric Mannich Reaction 
 
Entry Urea 
(equiv) 
Imine 
(equiv) 
Catalyst 
(mol %) 
Conditions Result 
(er) 
1 1.0 2.5 cinchonidine (20) CH2Cl2, 1d, -35 °C 24:76 
2 1.0 2.5 cinchonidine (20) CH2Cl2, 4d, -40 °C 20:80 
3 1.0 2.5 cinchonidine (20) CH2Cl2, 1d, rt 30:70 
4 1.0 2.5 cinchonine (20) CH2Cl2, 4d, -40 °C 75:25 
5 1.0 2.5 quinine (20) CH2Cl2, 4d, -40 °C 37:63 
6 1.0 2.5 quinidine (20) CH2Cl2, 4d, -40 °C 66:34 
7 1.0 2.5 (DHQ)2PHAL (20) CH2Cl2, 4d, -40 °C 60:40 
8 1.0 2.5 (DHQD)2PHAL  (20) CH2Cl2, 4d, -40 °C rac. 
9 1.0 2.5 1.49a (20) CH2Cl2, 1d, -40 °C 44:56 
10 1.0 2.5 1.49b (20) CH2Cl2, 1d, -40 °C 33:67 
11 1.0 2.5 1.47a (20) CH2Cl2, 1d, -40 °C 83:17 
12 1.0 2.5 1.47b (20) CH2Cl2, 1d, -40 °C 20:80 
13 1.0 2.5 1.47c (20) CH2Cl2, 1d, -40 °C 39:61 
14 1.0 2.5 1.47d (20) CH2Cl2, 1d, -40 °C 72:28 
15 1.0 1.0 1.48 (20) CH2Cl2, 1d, -40 °C rac. 
16 1.0 1.0 S2 (20) CH2Cl2, 1d, 0 °C 49:51 
17 1.0 1.0 S2 (20) THF, 1d, 0 °C 54:46 
18 1.0 1.0 S2 (20) toluene, 1d, 0 °C rac. 
19 1.0 1.0 S3 (20) CH2Cl2, 1d, 0 °C 49:51 
20 1.0 1.0 S3 (20) THF, 1d, 0 °C 46:54 
21 1.0 1.0 S3 (20) toluene, 1d, 0 °C 47:53 
22 1.0 1.5 1.52 (20) CH2Cl2, 1d rac. 
23 1.0 1.5 S4 (20) THF, 1d, -20 °C rac. 
24 1.0 1.0 1.51 (5) acetone, 3h 67:33 
25 1.0 1.0 S5(20) toluene, 2d, -78 °C 52:48 
26 1.0 1.0 S6 (20) THF, 8h rac. 
27 1.0 1.5 1.50 (10) CH2Cl2, 1d, -78 °C rac. 
28 1.0 1.0 cinchonidine (20) CH2Cl2, 1d, -65 °C 18:82 
29 1.0 1.0 cinchonidine (20) Et2O, 1d, -40 °C 35:65 
30 1.0 1.0 cinchonidine (20) toluene, 1d, -40 °C 36:64 
31 1.0 1.0 cinchonidine (20) THF, 1d, -40 °C 33:67 
32 1.0 1.0 cinchonidine (20) CH2Cl2, 17h, -45 °C 23:77 
33 2.0 1.0 cinchonidine (20) CH2Cl2, 17h, -45 °C 23:77 
34 1.0 1.5 cinchonidine (20) CH2Cl2, 14h, -78 to -65 °C 16:84 
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Benzyl ((3R,4R,5S,E)-4-acetyl-4-(3,3-dimethylureido)-5-hydroxy-1-phenylhex-1-en-3-yl) 
carbamate (1.53):  A flame-dried 250-mL round-bottomed flask was charged with diketone 
1.38  (8.5 g, 18.8 mmol, 1.0 equiv) and THF (188 mL). The solution was cooled to -78 °C, and 
lithium tri-tert-butoxyaluminum hydride (1.1 M in THF, 25.7 mL, 28.2 mmol, 2.0 equiv) was 
added dropwise. The resulting mixture was warmed to -35 °C and stirred until complete 
consumption of diketone 1.38 was indicated by TLC analysis, typically 12 h. The reaction was 
quenched by the addition of 1 M HCl(aq) (50 mL) and the biphasic mixture was extracted with 
EtOAc (3 x 50 mL). The combined organic extracts were washed with brine (50 mL), dried 
with magnesium sulfate, and concentrated in vacuo. The crude product was purified via flash 
chromatography (50:50 to 60:40 EtOAc/hexanes) to afford alcohol 1.53 as a yellow viscous 
oil with >10:1 ratio of 1.53:(other diastereomers) (6.2 g, 72%). Analytical data: [α]D19 +19.5 
(c = 1.00, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.36-7.25 (m, 10H), 6.67 (d, J = 16.2 Hz, 
1H), 6.59 (br s, 1H), 6.17 (dd, J = 9.0, 15.6 Hz, 1H), 5.47 (s, 1H), 5.11 (d, J = 12.0 Hz, 1H), 
5.07 (d, J = 12.0 Hz, 1H), 4.70 (t, J = 9.0 Hz, 1H), 4.60 (br s, 1H), 4.30 (br s, 1 H), 2.90 (s, 
6H), 2.28 (s, 3H), 1.23 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 207.9, 158.4, 
156.1, 136.2, 135.9, 133.8, 128.5, 128.3, 128.0, 127.9, 127.8, 126.5, 125.5, 73.7, 69.8, 66.8, 
57.2, 36.5, 27.6, 18.6; HRMS (ESI+) Calcd. for C25H31N3O5+H, 454.2344; Found, 454.2368; 
IR (thin film, cm-1) 3410, 2938, 2359, 2248, 1700, 1637, 1520, 1235, 909, 731; TLC (50:50 
hexanes:EtOAc): Rf = 0.20. 
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Benzyl ((3S,4R,5S)-4-acetyl-4-(3,3-dimethylureido)-2-hydroxy-5-methyl tetrahydro- 
furan-3-yl)carbamate (1.54): A 250-mL round-bottomed flask was charged with alcohol 1.53 
(1.4 g, 3.1 mmol, 1.0 equiv) and CH2Cl2 (62 mL). The resulting solution was cooled to -78 °C, 
and a stream of O3 was bubbled through the solution until a blue color was observed, typically 
5 min. The mixture was sparged with O2 for 5 min, and Me2S (0.9 mL, 12.4 mmol, 4.0 equiv) 
was added. The resulting mixture was warmed to rt and stirred for 12 h and concentrated in 
vacuo.  Flash chromatography (60:40 EtOAc:hexanes) afforded an inseparable ~5:1 
diastereomeric mixture  of lactols (1.54) (0.69 g, 58%) as a viscous oil. Analytical data: [α]D19 
+18.3 (c = 1.00, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 8.08 (d, J = 12.0 Hz, 1H), 7.37-7.28 
(m, 5H), 6.15 (br s, 1H), 5.53 (dd, J = 6.0, 6.6 Hz, 1H), 5.39 (d, J = 8.4 Hz, 1H), 5.10 (d, J = 
12.6 Hz, 1H), 4.98 (d, J = 12.6 Hz, 1H), 4.70 (q, J = 7.2 Hz, 1H), 4.63 (dd, J = 3.0, 6.0 Hz, 
1H), 2.83 (s, 1H), 2.80 (s, 6H), 2.38 (s, 3H), 1.17 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, 
CDCl3): δ 204.6, 157.0, 156.2, 136.1, 128.4, 128.1, 127.9, 95.9, 71.4, 66.7, 59.3, 36.0, 26.6, 
14.1; LRMS (ESI+) Calcd. for C18H25N3O6+H, 380.18; Found, 380.17; IR (thin film, cm
-1) 
3390, 2938, 2066, 1700, 1636, 1522, 1351, 1230, 1063, 752; TLC (60:40 EtOAc:hexanes): Rf 
= 0.35.      
 
 
64 
 
 
 
(3S,4R,5S)-4-Acetyl-3-(((benzyloxy)carbonyl)amino)-4-(3,3-dimethylureido)-5-methyl- 
tetrahydrofuran-2-yl 4-nitrobenzoate (1.79): A flame-dried, 50-mL round-bottomed flask 
was charged with diastereomeric lactols (1.54) (0.69 g, 1.8 mmol, 1.0 equiv) and CH2Cl2 (18 
mL). The resulting solution was cooled to 0 °C and NEt3 (0.76 mL, 5.4 mmol, 3.0 equiv), 
DMAP (0.02 g, 0.18 mmol, 0.1 equiv), and 4-nitrobenzoyl chloride (0.51 g, 2.7 mmol, 1.5 
equiv) were added sequentially. The reaction was stirred at 0 °C until TLC analysis indicated 
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complete consumption of the lactol, typically 30 min. H2O (10 mL) was added to the reaction 
and the resulting mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organic 
extracts were dried with magnesium sulfate and concentrated in vacuo. The crude residue was 
purified by flash chromatography (30:70 hexanes:EtOAc) afforded a ~5:1 diasteromeric 
mixture of 4-nitrobenzoate 1.79 (0.71 g, 74%) as a yellow powder. Slow evaporation (MeOH) 
at room temperature afforded crystals suitable for X-ray analysis. (Note: to obtain analytically 
pure 1.79, a small portion of the fractions were collected from column chromatography, 
resulting in a discrepancy in the diastereomeric ratio.) Analytical data: [α]D19 -11.8 (c = 1.00, 
CHCl3); 1H NMR  (600 MHz, CDCl3): δ 8.42 (d, J = 9.0 Hz, 2H), 8.27 (d, J = 9.0 Hz, 2H), 
7.31-7.24 (m, 5H), 6.82 (d, J = 6.0 Hz, 1H), 6.66 (d, J = 9.0 Hz, 1H), 5.94 (br s, 1H), 5.13 (q, 
J = 6.6 Hz, 1H), 5.06 (d, J = 12.0 Hz, 1H), 5.02 (d, J = 16.2 Hz, 1H), 4.99 (m, 1H), 2.90 (s, 
6H), 2.38 (s, 3H), 1.17 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 203.8, 163.5, 
157.4, 156.6, 150.6, 136.1, 135.0, 131.2, 128.4, 128.3, 128.1, 127.9, 123.5, 95.4, 72.5, 66.7, 
57.9, 36.2, 26.4, 14.4; LRMS (ESI+) Calcd. for C25H28N4O9+H, 529.19; Found, 529.20; IR 
(thin film, cm-1) 3393, 3113, 2944, 1715, 1637, 1526, 1349, 1271, 1081, 1011, 736; TLC 
(70:30 EtOAc:Hexanes): Rf = 0.30.    
 
Benzyl (4,4-diacetyl-2-(dimethylamino)-6-(iodo(phenyl)methyl)-5,6-dihydro-4H-1,3-
oxazin-5-yl)carbamate (1.55).  A flame dried 100 mL round-bottomed flask was charged with 
diketone 1.38 (0.20 g, 0.44 mmol, 1.00 equiv), 4Å molecular sieves (4.0 g), NaHCO3 (0.74 g, 
8.86 mmol, 20 equiv), and CH3CN (24.6 mL).  The resulting mixture was cooled to 0 °C and 
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I2 (0.35 g, 1.37 mmol, 3.1 equiv) was added.  The reaction mixture was warmed to rt and stirred 
until TLC analysis confirmed complete consumption of the starting material, typically 12 h.  
The reaction was quenched via addition of saturated NaHCO3(aq.) (20 mL), and the resulting 
mixture was extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed 
with saturated Na2S2O3(aq.) (30 mL) and brine (20 mL), dried with magnesium sulfate, and 
concentrated in vacuo.  The product was purified by flash chromatography (60:40 
hexanes:EtOAc) to afford imidate 1.55 (0.12 g, 48%) as a clear viscous oil in a 5:1 ratio of 
inseparable diastereomers.  Analytical data: 1H NMR  (600 MHz, CDCl3): δ 7.39-7.29 (m, 
10H), 5.71 (d, J = 10.2 Hz, 1H), 5.18 (d, J = 12.6 Hz, 1H), 5.08 (d, J = 12.6 Hz, 1H), 4.94 (t, 
J = 11.4 Hz, 1H), 4.80 (d, J = 10.8 Hz, 1H), 4.18 (t, J = 10.8 Hz, 1H), 2.98 (s, 1H), 2.17 (s, 
3H), 1.53 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 209.8, 162.2, 155.14, 139.0, 136.4, 128.8, 
128.6, 128.4, 128.3, 128.2, 128.1, 127.5, 109.0, 83.4, 80.0, 66.9, 56.6, 37.3, 34.3, 28.2, 20.5; 
HRMS (ESI+) Calcd. for C25H28IN3O5+Na, 600.0971; Found, 600.0971; IR (thin film, cm
-1) 
3407, 3033, 2942, 1724, 1661, 1497, 1239, 1085, 915, 877; TLC (65:45 EtOAc:hexanes): Rf 
= 0.75. 
 
Benzyl (4-acetyl-4-(3,3-dimethylureido)-5-hydroxy-1-phenylhex-1-en-3-yl)carbamate 
(1.56). A flame dried 10 mL round-bottomed flask was charged with imidate 1.55 (0.13 g, 0.22 
mmol, 1.00 equiv), and THF (2.3 mL).  The resulting mixture was cooled to -78 °C and lithium 
tri-tert-butoxyaluminum hydride (1.1 M in THF, 0.51 mL, 0.56 mmol, 2.50 equiv) was added 
dropwise.  The resulting mixture was slowly warmed to -10 °C and stirred overnight at that 
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temperature.  The reaction was then quenched via addition of saturated NH4Cl(aq.) (4 mL), and 
the resulting mixture was extracted with EtOAc (3 x 10 mL).  The combined organic extracts 
were washed with brine (10 mL), dried with magnesium sulfate, and concentrated in vacuo to 
afford the crude intermediate monoalcohol S7, which was used in the next step without further 
purification.   
The requisite alcohol was dissolved in Et2O (1.6 mL) and MeOH (1.6 mL) and transferred to 
a 25 mL round-bottomed flask.  Zinc powder (0.07 g, 1.09 mmol, 5.00 equiv) and AcOH ( 
0.075 mL, 1.32 mmol, 6.00 equiv) were added sequentially, and the reaction was allowed to 
stir for 1 h at rt.  The resulting mixture was filtered through a pad of celite and concentrated in 
vacuo.  The product was purified via flash chromatography (50:50 to 60:40 EtOAc:hexanes) 
to afford monoalcohol 1.56 (0.061 g, 61%) as clear viscous oil as a single diastereomer. 
Analytical data: 1H NMR  (600 MHz, CDCl3): δ 7.36-7.23 (m, 10H), 6.57 (d, J = 16.2 Hz, 
1H), 6.52 (d, J = 7.2 Hz, 1H), 6.43 (dd, J = 5.4, 10.2 Hz, 1H), 6.20 (s, 1H), 5.2 (t, J = 7.2 Hz, 
1H), 5.14 (d, J = 12.6 Hz, 1H), 5.07 (d, J = 12.0 Hz, 1H), 4.54 (t, J = 7.8 Hz, 1H), 2.83 (s, 6H), 
2.29 (s, 3H), 1.10 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 205.5, 158.1, 156.0, 
136.3, 136.1, 131.9, 128.6, 128.5, 128.2, 128.2, 127.9, 126.6, 125.8, 75.9, 68.2, 67.0, 56.2, 
36.5, 36.4, 29.7, 27.1, 19.2; HRMS (ESI+) Calcd. for C25H31N3O5+Na, 476.2161; Found, 
476.2176; IR (thin film, cm-1) 3390, 2925, 2097, 1709, 1631, 1563, 1528, 1501, 1244, 1051; 
TLC (65:45 EtOAc:hexanes): Rf = 0.55. 
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Benzyl (E)-(4-(3,3-dimethylureido)-5-hydroxy-4-(1-hydroxyethyl)-1-phenylhex-1-en-3-
yl)carbamate (1.57). A flame dried, 50 mL round-bottomed flask was charged with diketone 
1.53 (0.50 g, 1.11 mmol, 1.00 equiv) and C7H8 (8.6 mL).  The resulting solution was cooled to 
-78 °C, and LiAl(iBu)2(O
tBu)H (0.9 M in THF:Hexanes, 7.38 mL, 6.66 mmol, 6.0 equiv) was 
added dropwise.  The reaction was then warmed to -40 °C and stirred until TLC analysis 
confirmed complete consumption of the starting material, typically 12 h.  The reaction was 
quenched via addition of 1 M HCl(aq.) (10 mL), and the resulting mixture was extracted with 
Et2O (3 x 15 mL).  The combined organic extracts were dried with magnesium sulfate and 
concentrated in vacuo.  The product was purified via flash chromatography (60:40 
EtOAc:hexanes) to afford diol 1.57 (0.30 g, 59%) as a clear, viscous oil with a 3:1 ratio of 
diastereomers. Analytical data: 1H NMR  (600 MHz, CDCl3): δ 7.34-7.21 (m, 10H), 6.60 (s, 
1H), 6.53 (d, J = 16.2 Hz, 1H), 6.46 (dd, J = 7.8, 7.8 Hz, 1H), 5.58 (s, 1H), 5.47 (d, J = 16.2 
Hz, 1H), 5.26 (br s, 1H), 5.11 (d, J = 12.6 Hz, 1H), 5.06 (d, J = 12.6 Hz, 1H), 4.69 (t, J = 8.4 
Hz, 1H), 4.37 (t, J = 6.6 Hz, 1H), 4.00 (t, J = 6.6 Hz, 1H), 2.74 (s, 6H), 1.29 (dd, J = 2.4, 4.2 
Hz, 6H); 13C NMR (150 MHz, CDCl3): δ 158.6, 156.4, 136.3, 136.2, 132.2, 128.6, 128.5, 
128.4, 128.3, 128.0, 127.9, 127.8, 126.4, 70.0, 67.7, 66.9, 66.8, 57.2, 36.4, 18.5, 18.0; HRMS 
(ESI+) Calcd. for C25H33N3O5+Na, 478.2318; Found, 478.2322; IR (thin film, cm
-1) 3408, 
2090, 1691, 1630, 1545, 1378, 1234, 1066; TLC (65:45 EtOAc:hexanes): Rf = 0.50.   
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Crude 1H NMR Spectrum of 1.57 
 
Synthesis of monoalcohols 1.56 and 1.53 from selective oxidation of trans-diol 1.57. 
 
A flame dried 5 mL dram vial was charged with diol 1.57 (0.025 g, 0.06 mmol, 1.00 equiv), 
CH3CN (0.8 mL), and 4 Å molecular sieves (0.027 g).  The resulting mixture was cooled to -
40 °C and NMO (0.012 g, 0.1 mmol, 1.80 equiv) was added followed by a single flake of tetra-
N-propylammonium perruthenate.  The reaction was allowed to stir at -40 °C for 12 h then 
diluted with CH2Cl2 (2 mL) and filtered through a 1-inch Monstr-Pette plug of silica gel with 
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EtOAc (5 mL) and concentrated.  The product was purified via flash chromatography (50:50 
hexanes:EtOAc) to afford monoalcohol 1.56 (0.012 g, 48%) as a clear viscous oil.  Spectral 
data were identical with the monoalcohol isolated from reduction of 1.55. 
 
A 5 mL dram vial was charged with diol 1.57 (0.02 g, 0.044 mmol, 1.00 equiv) and CH2Cl2 (1 
mL).  The resulting solution was cooled to 0 °C and Dess-Martin Periodinane (0.016 g, 0.04 
mmol, 0.9 equiv) was added.  The reaction was allowed to stir for 2 h upon which TLC analysis 
confirmed no reaction had taken place.  The reaction was then slowly warmed to room 
temperature and stirred for 1 h.  A 1:1 mixture of saturated NaHCO3(aq.):saturated Na2S2O3(aq.) 
(2 mL) was added, and the mixture was extracted with Et2O (3 x 5 mL), dried with magnesium 
sulfate, and concentrated in vacuo.  1H NMR analysis showed ~80% conversion of the starting 
material exclusively to monoalochol 1.53, matching spectral data to that of the reduction of 
1.38.  Arriving at this result, no further optimization of this reaction was attempted. 
 
Benzyl (E)-(1-(5-(3,3-dimethylureido)-2,2,4,6-tetramethyl-1,3-dioxan-5-yl)-3-
phenylallyl)carbamate (1.58). A 20 mL scintillation vial was charged with diol 1.57 (0.07 g, 
0.16 mmol, 1.00 equiv), acetone (1 mL) and 2,2-dimethoxypropane (1 mL) with stirring.  
Camphorsulfonic acid (0.005 g, 0.016 g, 0.1 equiv) was added, and the reaction was allowed 
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to stir until TLC analysis confirmed complete consumption of the starting material, typically 
12 h.  The reaction mixture was quenched with saturated NaHCO3(aq.) (2 mL) and the resulting 
mixture was extracted with EtOAc (3 x 5 mL).  The combined organic extracts were dried with 
magnesium sulfate and concentrated in vacuo.  The product was purified via flash 
chromatography (50:50 hexanes:EtOAc) to afford acetonide 1.58 (0.04 g, 56%) as a clear, 
viscous oil. Analytical data: 1H NMR  (600 MHz, CDCl3): δ 7.38-7.22 (m, 10H), 6.19 (d, J = 
16.2 Hz, 1H), 6.53 (dd, J = 7.2, 8.4 Hz, 1H), 5.25 (s, 1H), 5.14 (d, J = 12.0 Hz, 1H), 5.06 (d, J 
= 12.0 Hz, 1H), 4.71 (d, J = 5.4 Hz, 1H), 4.38 (t, J = 8.4 Hz, 1H), 4.22 (q, J = 6.0 Hz, 1H), 
2.92 (s, 6H), 1.43 (s, 3H), 1.41 (s, 3H), 1.38 (d, J = 7.2 Hz, 3H), 1.21 (d, J = 6.0 Hz, 3H); 13C 
NMR (150 MHz, CDCl3): δ 158.2, 156.3, 136.7, 136.6, 132.3, 128.5, 128.4, 127.9, 127.7, 
127.6, 126.5, 101.0, 99.6, 67.7, 66.7, 36.6, 24.4, 17.2, 16.4; HRMS (ESI+) Calcd. for 
C28H37N3O5+Na, 518.2631; Found, 518.2636; IR (thin film, cm
-1) 3421, 3305, 3057, 2987, 
1709, 1650, 1524, 1380, 1225, 1067, 736; TLC (65:45 EtOAc:hexanes): Rf = 0.60. 
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13C NMR Spectrum of 1.58 
 
 
Benzyl ((3R,4R,5S,E)-4-acetyl-5-((tert-butyldimethylsilyl)oxy)-4-(3,3-dimethylureido)-1-
phenylhex-1-en-3-yl)carbamate (1.64): A flame-dried 100-mL round-bottomed flask was 
charged with alcohol 1.53 (6.2 g, 13.6 mmol, 1.0 equiv) and CH2Cl2 (68 mL). 2,6-Lutidine 
(4.7 mL, 40.7 mmol, 3.0 equiv) was added and the solution was cooled -78 °C. TBSOTf (3.7 
mL, 16.3 mmol, 1.2 equiv) was added dropwise and the reaction was stirred for 30 min at -78 
°C. Saturated NaHCO3(aq.) (30 mL) and EtOAc (30 mL) were added and the reaction was 
allowed to warm to rt. The layers were separated and the aqueous portion was extracted with 
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EtOAc (3 x 50 mL). The combined organic extracts were washed with 1M HCl (30 mL) and 
brine (30 mL), and dried with magnesium sulfate. The crude product was concentrated in vacuo 
and purified via flash chromatography (20:80 to 30:70 EtOAc:hexanes) to give the title 
compound as a pale yellow oil (6.8 g, 88%). Analytical data: [α]D19 -1.5 (c = 1.00, CHCl3); 1H 
NMR  (600 MHz, CDCl3): δ 7.37-7.27 (m, 10H), 7.22 (t, J = 7.2 Hz, 1H), 6.63 (d, J = 16.2 
Hz, 1H), 6.32 (dd, J = 7.8, 16.2 Hz, 1H), 5.31 (s, 1H), 5.11 (d, J = 12.6 Hz, 1H), 5.06 (d, J = 
12.6 Hz, 1H), 5.03 (t, J = 8.4 Hz, 1H), 4.48 (q, J = 6.0 Hz, 1H), 2.96 (s, 6H), 2.22 (s, 3H), 1.22 
(d, J = 6.0 Hz, 3H), 0.88 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 
205.2, 158.8, 155.7, 136.8, 136.6, 132.2, 128.2, 128.1, 127.7, 127.6, 127.3, 127.1, 126.4, 71.2, 
66.3, 54.8, 36.5, 26.5, 25.5, 19.1, 17.7, -3.9, -5.2; HRMS (ESI+) Calcd. for C31H45N3O5Si+H, 
568.3208; Found, 568.3237; IR (thin film, cm-1) 3417, 2954, 1857, 1714, 1651, 1517, 1253, 
1128, 1063, 837, 737; TLC (75:25 hexanes/EtOAc): Rf = 0.30. 
 
Ethyl ((((benzyloxy)carbonyl)amino)-4-(1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(3,3-
dimethylureido)-3-oxo-7-phenylhept-6-enoate (1.65). A flame-dried 250-mL round-
bottomed flask was charged with diisopropylamine (0.21 mL, 1.46 mmol, 3.50 equiv) and THF 
(4 mL). The resulting solution was cooled to 0 °C and n-butyllithium (1.72 M in hexanes, 0.85 
mL, 1.46 mmol, 3.50 equiv) was added dropwise. The solution was stirred at 0 °C for 30 min 
and then cooled to -78 °C. A solution of ketone 1.64 (0.24 g, 0.42 mmol, 1.0 equiv) in THF 
(0.5 mL) was added dropwise, and the resulting solution was stirred at -78 °C for 45 minutes 
upon which ethyl cyanoformate (0.1 mL, 1.04 mmol, 2.5 equiv) was added dropwise.  The 
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reaction was allowed to stir for 2 h and quenched via addition of saturated NH4Cl(aq.) (4 mL).  
The mixture was warmed to rt and extracted with Et2O (3 x 10 mL).  The combined organic 
extracts were dried with magnesium sulfate and concentrated in vacuo.  The product was 
purified via flash chromatography (80:20 to 70:30 hexanes:EtOAc) to afford ketoester 1.65 
(0.21 g, 79%) as clear, viscous oil. Analytical data: Analytical data: 1H NMR  (600 MHz, 
CDCl3): δ 7.35-7.25 (m, 10H), 7.21-7.17 (m, 1H), 6.60 (d, J = 15.6 Hz, 1H), 6.33 (dd, J = 6.6, 
9.0 Hz, 1H), 5.38 (s, 1H), 5.13 (m, 2H), 5.07 (d, J = 12.6 Hz, 1H), 4.48 (q, J = 6.0 Hz, 1H), 
4.14 (q, J = 7.2 Hz, 2H), 3.74 (d, J = 16.2 Hz, 1H), 3.71 (d, J = 16.2 Hz, 1H), 2.92 (s, 6H), 
1.26-1.22 (m, 6H), 0.9 (s, 9H), 0.12 (s, 6H); 13C NMR (150 MHz, CDCl3): δ 200.7, 167.3, 
158.3, 156.0, 136.8, 136.6, 132.0, 128.3, 128.2, 127.9, 127.8, 127.5, 126.9, 126.5, 74.3, 70.7, 
66.6, 61.1, 54.9, 45.7, 36.6, 25.7, 19.0, 17.8, 14.1, -3.8, -5.0; HRMS (ESI+) Calcd. for 
C34H49N3O7Si+Na, 662.3238; Found, 662.3242; IR (thin film, cm
-1) 3424, 2954, 2931, 2857, 
2249, 1745, 1650, 1513, 1259, 1128, 1060, 911; TLC (65:45 EtOAc:hexanes): Rf = 0.70. 
 
Benzyl ((3R,4R,E)-4-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(3,3-dimethylureido)-7-
hydroxy-5-oxo-1-phenylhept-1-en-3-yl)carbamate (1.68): A flame-dried 250-mL round-
bottomed flask was charged with diisopropylamine (5.8 mL, 41.3 mmol, 3.5 equiv) and THF 
(100 mL). The resulting solution was cooled to 0 °C and n-butyllithium (1.65 M in hexanes, 
25.0 mL, 41.3 mmol, 3.5 equiv) was added dropwise. The reaction was stirred at 0 °C for 30 
min and then cooled to -78 °C. A solution of ketone 1.64 (6.8 g, 11.8 mmol, 1.0 equiv) in THF 
(25 mL) was added dropwise, and the resulting mixture was stirred for 45 min and warmed to 
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-45 °C. Formaldehyde gas (CH2O(g), prepared by heating paraformaldehyde ((CH2O)n, 5.0 g, 
166.7 mmol, 14.1 equiv) to 145 °C under a positive pressure of nitrogen) was bubbled through 
the reaction. The reaction was stirred at -45 °C until full conversion to product was indicated 
by TLC analysis, typically 1 h. The reaction was quenched by the addition of a saturated 
NH4Cl(aq.) (30 mL), and the resulting mixture was extracted with Et2O (3 x 30 mL). The 
combined organic extracts were dried with magnesium sulfate and concentrated in vacuo. The 
crude product was purified via flash chromatography (50:50 to 60:40 EtOAc:hexanes) to give 
alcohol 1.68 as a clear, viscous oil (4.9 g, 70%). Analytical data: [α]D19 +11.2 (c = 1.00, CHCl3); 
1H NMR  (500 MHz, CDCl3): δ 7.35-7.26 (m, 10H), 7.21 (t, J = 7.0 Hz, 1H), 6.59 (d, J = 16.0 
Hz, 1H), 6.28 (dd, J = 9.0, 16.0 Hz 1H), 5.32 (s, 1H), 5.11 (d, J = 12.0 Hz, 1H), 5.02 (d, J = 
12.0 Hz, 1H), 4.98 (t, J = 8.5 Hz, 1H), 4.40 (q, J = 6.5 Hz, 1H), 3.85-3.82 (m, 1H), 3.73-3.71 
(m, 1H), 2.93 (s, 6H), 2.82-2.70 (m, 2H), 1.23 (d, J = 6.5 Hz, 3H), 0.87 (s, 9H), 0.10 (s, 3H), 
0.09 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 208.5, 158.7, 155.9, 136.8, 136.6, 132.3, 128.4, 
128.3, 128.1, 127.9, 127.5, 127.1, 126.6, 74.2, 71.7, 66.6, 58.1, 55.2, 40.7, 36.6, 25.7, 19.2, 
17.8, -3.7, -5.0; HRMS (ESI+) Calcd. for C32H47N3O6Si+H, 598.3314; Found, 598.3345; IR 
(thin film, cm-1) 3429, 2954, 1716, 1646, 1507, 1252, 966, 695, 530; TLC (50:50 
hexanes:EtOAc): Rf = 0.20. 
 
Benzyl ((1S,5R)-5-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-(3,3-dimethylureido)-3-
(hydroxymethyl)-4-oxocyclopent-2-en-1-yl)carbamate (1.70): A 250-mL round-bottomed 
flask was charged with alcohol 1.68 (2.5 g, 4.1 mmol, 1.0 equiv) and CH2Cl2 (82 mL). The 
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resulting solution was cooled to -78 °C, and a stream of ozone (O3) was bubbled through the 
solution until a blue color was observed, typically 5-15 min (scale dependent). The mixture 
was sparged with N2 for 5 min or until the full disappearance of blue color, and Me2S (6.0 mL, 
82.0 mmol, 20.0 equiv) was added. The reaction was warmed to rt, stirred for 12 h, and 
concentrated in vacuo affording the crude aldehyde (1.69) as a yellow oil. The unpurified 
product was taken on directly to the next step.  
Aldehyde 1.69 was dissolved in THF (103 mL) and cooled to 0 °C. Sodium methoxide 
(NaOMe) (0.5 M in MeOH, 24.6 mL, 12.3 mmol, 3.0 equiv) was added dropwise. The reaction 
was stirred at 0 °C until TLC analysis indicated complete consumption of the aldehyde, 
typically 30 min.  The reaction was quenched by the addition of saturated NaHCO3(aq.) (30 
mL), and the mixture was extracted with EtOAc (3 x 20 mL). The combined organic extracts 
were washed with brine (20 mL), dried with magnesium sulfate, and concentrated in vacuo.  
The product was purified by flash chromatography (70:30 to 60:40 petroleum ether:acetone) 
to afford enone 1.70 as a pale yellow, viscous oil with >20:1 diastereoselection (1.02 g, 50%).  
When this experiment was conducted replacing NaOMe in MeOH with a CD3OD solution of 
NaOCD3, complete D-incorporation was observed at the carbamate methine (C2 in pactamycin 
numbering; C1 in the IUPAC name given as the title for this experimental).  When this 
experiment is conducted for the same time duration at -10 °C, a complex product mixture is 
observed.  When this mixture is resubmitted to the reaction conditions at 0 °C, complete 
conversion to 1.70 is observed. Further evidence for inversion of the carbamate methine during 
this condensation was found in X-ray analysis analysis of nitrobenzoate 1.79 and by ultimate 
conversion of 1.70 to pactamycin. (Note: complete epimerization of C2 was confirmed based 
on crude 1HNMR analysis; however the reaction is generally low-yielding).   Analytical data: 
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[α]D19 -25.9 (c = 1.00, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.35-7.29 (m. 5H), 7.22 (d, J 
= 1.2, 1H), 5.47 (d, J = 10.2 Hz, 1H), 5.21 (d, J = 12.0 Hz, 1H), 5.08 (s, 1H), 5.06 (d, J = 10.2 
Hz, 1H), 4.97 (d, J = 12.0 Hz, 1H), 4.41 (s, 2H), 4.03 (q, J = 6.6 Hz, 1H), 2.75 (s, 6H), 1.04 
(d, J = 6.6 Hz, 3H), 0.89 (s, 9H), 0.12 (s, 3H), 0.10 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 
203.3, 158.3, 155.9, 151.8, 146.5, 136.8, 128.4, 128.0, 128.0, 71.9, 68.5, 66.3, 57.3, 54.1, 36.3, 
25.5, 18.1, 17.8, -3.7, -4.9; HRMS (ESI+) Calcd. for C25H39N3O6Si+H, 506.2688; Found, 
506.2715; IR (thin film, cm-1) 3431, 2953, 2857, 2125, 1715, 1634, 1514, 1220, 928, 830; 
TLC (35:65 Hexanes:EtOAc): Rf = 0.20. 
1H NMR Spectrum of 1.70 showing D-incorporation 
 
 
 
 
C2 methine 
carbamate absent 
No splitting for CbzNH 
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Crude 1H NMR Spectrum of NaOCD3 condensation in CD3OD when conducted for 0.5 h 
at -10 °C 
 
 
Benzyl ((1R,2R,3R,5R)-3-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-3-(3,3-
dimethylureido)-5-(hydroxymethyl)-4-oxo-6-oxabicyclo[3.1.0]hexan-2-yl)carbamate 
(1.72): A 200-mL round-bottomed flask was charged with enone 1.70 (1.1 g, 2.2 mmol, 1.0 
equiv) and MeOH:CH2Cl2 (7:1, 32 mL). The resulting solution was cooled to 0 °C, and a cooled 
solution of H2O2 (30% aq., 20 mL) and NaOH (20% aq., 5 mL) was added dropwise. The 
reaction was stirred at 0 °C for 2 h, and diluted with Et2O (30 mL). The layers were separated 
and the aqueous was extracted with Et2O (3 x 15 mL). The combined organics were washed 
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with H2O (3 x 30 mL), brine (20 mL), dried with magnesium sulfate, and concentrated in 
vacuo. The crude product was purified via flash chromatography (70:30 petroleum 
ether:acetone) affording the title compound as a clear, viscous oil with >20:1 diastereoselection 
(0.91 g, 81%). Analytical data: [α]D19 -22.4 (c = 1.00, CHCl3); 1H NMR  (600 MHz, CDCl3): 
δ 7.32-7.26 (m, 5H), 5.66 (d, J = 9.6 Hz, 1H), 5.20 (d, J = 12.0 Hz, 1H), 4.93 (d, J = 12.6 Hz, 
1H), 4.68 (s, 1H), 4.68-4.66 (m, 1H), 4.07-4.04 (m, 2H), 4.02-3.98 (m, 2H), 2.64 (s, 6H), 1.15 
(d, J = 6.6 Hz, 3H), 0.89 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 
204.4, 156.9, 156.0, 136.6, 128.3, 128.1, 128.0, 74.0, 69.3, 66.4, 65.9, 60.7, 56.0, 52.3, 36.1, 
25.5, 18.2, 17.7, -3.9, -4.8; HRMS (ESI+) Calcd. for C25H39N3O7Si+H, 522.2637; Found, 
522.2663; IR (thin film, cm-1) 3402, 2954, 2857, 2359, 2249, 2125, 1650, 1519, 1227, 830, 
732; TLC (70:30 petroleum ether/acetone): Rf = 0.30.  
 
Benzyl ((1R,2R,3R,5R)-3-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-(((tert-
butyldiphenylsilyl)oxy)methyl)-3-(3,3-dimethylureido)-4-oxo-6-oxabicyclo[3.1.0]hexan-
2-yl)carbamate (1.73): A flame-dried 25-mL round-bottomed flask was charged with alcohol 
1.72  (1.0 g, 1.9 mmol, 1.0 equiv) and CH2Cl2 (9.5 mL). NEt3 (0.8 mL, 5.7 mmol, 3.0 equiv) 
and DMAP (0.023 g, 0.19 mmol, 0.1 equiv) were added and the solution was cooled 0 °C. 
TBDPSCl (1.47 mL, 5.7 mmol, 3.0 equiv) was added dropwise and the reaction was warmed 
to rt and stirred for 8 h. Saturated NH4Cl(aq.) (10 mL) was added and the mixture was extracted 
with Et2O (3 x 15 mL). The combined organic extracts were washed with brine (10 mL), dried 
with magnesium sulfate, and concentrated in vacuo. The crude product was purified via flash 
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chromatography (70:30 hexanes:EtOAc) to give the title compound as a pale yellow oil (1.1 g, 
76%). Analytical data: [α]D19 -4.4 (c = 0.70, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.67 (d, 
J = 7.2 Hz, 2H), 7.62 (d, J = 7.2 Hz, 2H), 7.44-7.30 (m, 11H), 5.68 (d, J = 10.2 Hz, 1H), 5.23 
(d, J = 12.0 Hz, 1H), 4.97 (d, J = 12.6 Hz, 1H), 4.74 (dd, J = 3.0, 7.2 Hz, 1H), 4.70 (br s, 1H), 
4.26 (d, J = 12.6 Hz, 1H), 4.11 (d, J = 3.0 Hz, 1H), 4.03 (q, J = 6.0 Hz, 1H), 3.92 (d, J = 12.0 
Hz, 1H), 2.68 (s, 6H), 1.19 (d, J = 6.0 Hz, 3H), 1.01 (s, 9H), 0.92 (s, 9H), 0.13 (s, 6H); 13C 
NMR (150 MHz, CDCl3): δ 203.9, 156.8, 156.0, 136.7, 135.5, 135.4, 132.6, 132.3, 129.8, 
129.7, 128.3, 128.1, 127.9, 127.8, 127.7, 74.1, 69.4, 66.4, 66.2, 60.8, 57.5, 52.2, 36.1, 26.6, 
25.6, 19.1, 18.3, 17.8, -3.8, -4.8; HRMS (ESI+) Calcd. for C41H57N3O7Si2+H, 760.3815; 
Found, 760.3862; IR (thin film, cm-1) 3419, 2931, 2857, 2359, 1716, 1651, 1507, 1226, 1113, 
828, 733; TLC (70:30 hexanes/EtOAc): Rf = 0.30.  
 
Benzyl ((1R,2R,3R,4R,5R)-3-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-(((tert-
butyldiphenylsilyl)oxy)methyl)-3-(3,3-dimethylureido)-4-hydroxy-4-methyl-6-
oxabicyclo [3.1.0]hexan-2-yl)carbamate (1.74): A flame-dried 25-mL round-bottomed flask 
was charged with ketone 1.73 (1.7 g, 2.3 mmol, 1.0 equiv) and THF (23 mL). The solution was 
cooled to 0 °C and MeMgBr (3M in THF, 7.6 mL, 22.9 mmol, 10.0 equiv) was added dropwise. 
The reaction was stirred at 0 °C until TLC analysis indicated complete ketone consumption, 
typically 2 h.  Saturated NH4Cl(aq.) (20 mL) was carefully added dropwise and the resulting 
mixture was extracted with EtOAc (3 x 15 mL). The combined organic extracts were washed 
with brine (20 mL), dried with magnesium sulfate, and concentrated in vacuo. The crude 
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product was purified via flash chromatography (90:10 to 70:30 hexanes:EtOAc) to afford 
carbinol 1.74 as a clear, viscous oil with >10:1 diastereoselection (1.3 g, 75%). The 
enantiomeric ratio was assayed at this intermediate and was found to be 95:5. This composition 
was determined by SFC analysis (Chiralcel, OD, 4.0% MeOH, 1.5 mL/min, 150 bar, 210 nm; 
tR-minor 34.4 min, tR-major 37.6 min).  Analytical data: [α]D19 +7.2 (c = 0.70, CHCl3); 1H 
NMR  (600 MHz, CDCl3): δ 7.73 (d, J = 7.8 Hz, 2H), 7.70 (d, J = 7.2 Hz, 2H), 7.45-7.30 (m, 
12H), 5.55 (br s, 1H), 5.21 (d, J = 12.6 Hz, 1H), 5.17 (br s, 1H), 5.07 (d, J = 12.0 Hz, 1H), 4.77 
(br s, 1H), 4.64 (dd, J = 3.6, 8.4 Hz, 1H), 4.21 (d, J = 12.6 Hz, 1H), 4.12 (d, J = 12.6 Hz, 1H), 
3.90 (s, 1H), 2.75 (s, 6H), 1.30 (s, 3H), 1.25 (d J = 6.0 Hz, 3H), 1.07 (s, 9H), 0.97 (s, 9H), 0.11 
(s, 3H), -0.01 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 158.8, 156.5, 136.3, 135.6, 135.5, 134.7, 
133.3, 132.9, 129.6, 129.4, 128.4, 128.2, 128.1, 127.7, 127.6, 127.6, 67.1, 66.8, 62.1, 58.3, 
36.1, 26.7, 26.5, 25.7, 23.8, 19.6, 19.2, 17.8, -4.2, -5.5; HRMS (ESI+) Calcd. for 
C42H61N3O7Si2+H, 776.4128; Found, 776.4179; IR (thin film, cm
-1) 3430, 2429, 2359, 1716, 
1635, 1506, 1456, 1112, 831, 700; TLC (90:10 hexanes/EtOAc): Rf = 0.35. 
 
Benzyl ((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-2-((S)-1-((tert-
butyldimethylsilyl)oxy) ethyl)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(3,3 dimethyl 
ureido)-3,4-dihydroxy-3-methylcyclopentyl)carbamate (1.82): In a nitrogen-filled glove 
box, a flame-dried 100-mL round-bottomed flask was charged with Sc(OTf)3 (0.38 g, 0.77 
mmol, 3.0 equiv). The flask was capped with a rubber septum and removed from the glove 
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box. C7H8 (20 mL) was added and to the resulting suspension were added aniline 2 (0.35 g, 2.6 
mmol, 10.0 equiv) and a C7H8 solution (1.5 mL) of epoxide 1.74 (0.20 g, 0.26 mmol, 1.0 
equiv). The reaction was heated to 60 °C with vigorous stirring and maintained for 14 h. (Note: 
increased reaction times led to product decomposition). The reaction was cooled to rt, diluted 
with H2O (10 mL) and EtOAc (10 mL), and the resulting mixture was extracted with EtOAc 
(3 x 10 mL). The combined organic extracts were washed with 0.5 M HCl(aq.) (2 x 20 mL), 
saturated NaHCO3(aq.) (15 mL), dried with magnesium sulfate, and concentrated in vacuo. The 
crude product was purified via flash chromatography (90:10 to 80:20 hexanes:EtOAc) to afford 
anilino-alcohol 1.82 as a yellow, viscous oil (0.16 g, 66%) with recovery of the unreacted 
epoxide 1.74 (0.04 g, 18%). Analytical data: [α]D19 -39.3 (c = 0.70, CHCl3); 1H NMR  (600 
MHz, CDCl3): δ 8.21 (d, J = 6.6 Hz, 1H), 7.70 (d, J = 6.6 Hz, 2H), 7.51 (d, J = 7.2 Hz, 2H), 
7.39 (t, J = 7.2 Hz, 1H), 7.32 (t, J = 7.2 Hz, 2H), 7.28-7.22 (m, 8H), 7.16 (t, J = 7.2 Hz, 2H), 
7.12 (t, J = 7.8 Hz, 1H), 6.79 (d, J = 7.8 Hz, 1H), 6.13 (s, 1H), 5.88 (s, 1H), 5.39-5.36 (m, 1H), 
5.36 (s, 1H), 5.04 (d, J = 12.0 Hz, 1H), 5.01 (d, J = 12.0 Hz, 1H), 4.78 (dd, J = 4.6, 6.6 Hz, 
1H), 4.37 (d, J = 10.2 Hz, 1H), 4.13 (s, 1H), 3.68 (dd, J = 3.0, 4.6 Hz, 1H), 3.48 (d, J = 10.8 
Hz, 1H), 2.96 (s, 6H), 2.49 (s, 3H), 1.69 (s, 3H), 1.41 (d, J = 6.6 Hz, 3H), 0.98 (s, 9H), 0.92 (s, 
9H), 0.12 (s, 3H), 0.02 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 198.7, 158.6, 158.4, 149.5, 
137.7, 136.6, 135.6, 135.4, 132.4, 132.0, 129.6, 128.8, 128.2, 128.1, 127.8, 127.6, 118.2, 117.0, 
112.6, 83.6, 81.0, 70.3, 68.4, 66.9, 66.5, 63.0, 59.3, 36.6, 26.7, 26.7, 25.7, 21.2, 19.4, 19.0, 
17.7, -4.3, -6.1; HRMS (ESI+) Calcd. for C50H70N8Si2+H, 911.4812; Found, 911.4867; IR 
(thin film, cm-1) 3361, 2953, 2358, 1716, 1698, 1652, 1539, 1488, 1472, 1243, 1041, 829, 701; 
TLC (80:20 hexanes:EtOAc): Rf = 0.35.  
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Benzyl ((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-2-(3,3-dimethylureido)-3,4-
dihydroxy-2-((S)-1-hydroxyethyl)-4-(hydroxymethyl)-3-methylcyclopentyl)carbamate 
(1.83): A 20-mL scintillation vial was charged with silyl ether 1.82 (0.25 g, 0.28 mmol, 1.0 
equiv) and THF (5.5 mL). The resulting solution was cooled to 0 °C, and TBAF (1 M solution 
in THF, 1.1 mL, 1.1 mmol, 4.0 equiv) was added. The reaction was allowed to stir at 0 °C until 
TLC analysis indicated consumption of the starting material, typically 30 min. The reaction 
was diluted with brine (3 mL) and EtOAc (3 mL) and extracted with EtOAc (3 x 7 mL). The 
combined organic extracts were dried with magnesium sulfate and concentrated in vacuo. The 
crude product was purified via flash chromatography (60:40 petroleum ether:acetone) to afford 
tetraol 1.83 as a pale yellow, viscous oil (0.14 g, 90%). Analytical data: [α]D19 +26.0 (c = 0.70, 
CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.36 (s, 4H), 7.29 (br s, 1H), 7.23 (br s, 1H), 7.12 (br 
s, 1H), 6.99 (d, J = 7.8 Hz, 1H), 6.75 (d, J = 6.6 Hz, 1H), 6.02 (d, J = 7.2 Hz, 1H), 5.80 (br s, 
1H), 5.48 (d, J = 7.8 Hz, 1H), 5.27 (br s, 1H), 5.13 (br s, 2H), 4.14-4.10 (m, 1H), 4.06 (br s, 
2H), 3.80 (br s, 2H), 3.74-3.68 (m, 1H), 3.55 (m, 1H), 2.87 (s, 6H), 2.52 (s, 3H), 1.42 (s, 3H), 
1.25 (br s, 3H); 13C NMR (150 MHz, CDCl3): δ 198.7, 158.7, 155.8, 146.6, 138.3, 136.0, 
129.7, 128.6, 128.4, 118.4, 112.0, 88.2, 83.9, 73.2, 71.7, 67.4, 66.9, 64.2, 61.8, 61.2, 36.7, 29.7, 
26.7, 22.7, 21.2, 18.0, 14.1; HRMS (ESI+) Calcd. For C28H38N4O8+H, 559.2770; Found, 
559.2800; IR (thin film, cm-1) 3392, 2938, 1716, 1684, 1652, 1635, 1540, 1507, 1473, 1456, 
1361, 1243, 739; TLC (60:40 petroleum ether/acetone): Rf = 0.30. 
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((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-
hydroxy-6-methylbenzoate (1.85): A flame-dried 20-mL scintillation vial was charged with 
cyanomethyl ester 1.84 (0.0075 g, 0.044 mmol, 1.1 equiv) and dimethylacetamide (DMA) (0.3 
mL). K2CO3 (0.005 g, 0.04 mmol, 1.0 equiv) was added, and the resulting mixture was stirred 
for 1 h.  The in situ generated ketene solution was transferred to a stirred solution of tetraol 
1.83 (0.02 g, 0.04 mmol, 1.0 equiv) in DMA (0.7 mL). The reaction was stirred until TLC 
analysis indicated full consumption of the tetraol starting material, typically 3 h. The reaction 
was cooled to 0 °C and quenched by the dropwise addition of saturated NH4Cl(aq.) (1.5 mL). 
The resulting mixture was extracted with EtOAc (3 x 5 mL), washed with H2O (10 ml), brine 
(10 mL), dried with magnesium sulfate, and concentrated in vacuo. The crude product was 
purified via flash chromatography (50:50 hexanes:EtOAc) to afford an inseparable mixture of 
salicylate 1.85 (0.02 g, 80%) and an unknown impurity (15% by NMR analysis) as a pale 
yellow, viscous oil. Analytical data: [α]D19 +33.6 (c = 0.70, CHCl3); 1H NMR  (600 MHz, 
CDCl3): δ 10.87 (s, 1H), 7.52 (br s, 1H), 7.36 (br s, 5H), 7.30-7.22 (m, 4H), 7.10 (s, 1H), 6.81 
(d, J = 8.4 Hz, 1H), 6.63 (d, J = 7.2 Hz, 1H), 6.13 (s, 1H), 5.79 (d, J = 9.0 Hz, 1H), 5.72 (d, J 
= 9.6 Hz, 1H), 5.23-5.10 (m, 3H), 4.91-4.84 (m, 2H), 4.06 (br s, 2H), 3.80 (d, J = 9.6 Hz, 1H), 
3.69 (s, 1H), 2.85 (s, 7H), 2.30 (s, 3H), 1.42 (s, 3H), 1.26 (s, 3H); 13C NMR (150 MHz, CDCl3): 
δ 198.3, 173.4, 162.9, 158.5, 155.3, 146.0, 141.6, 138.3, 135.0, 129.7, 128.6, 128.5, 123.2, 
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119.4, 118.4, 115.8, 111.9, 111.6, 99.7, 88.6, 85.0, 73.9, 72.3, 67.5, 66.8, 66.6, 65.4, 62.7, 36.7, 
23.9, 21.0, 18.0, 17.4; HRMS (ESI+) Calcd. For C36H44N4O10+H, 693.3137; Found, 693.3172; 
IR (thin film, cm-1) 3392, 2965, 1867, 1698, 1670, 1541, 1456, 1374, 1249, 874, 737; TLC 
(50:50 EtOAc:Hexanes): Rf = 0.30. 
 
Pactamycin (1.1): A 4-mL vial was charged with salicylate 1.85 (0.0075 g, 0.01 mmol, 1.0 
equiv), and Pd(OH)2/C (20 wt.%, 0.005 g). MeOH (1 mL) was added and the vial was sealed 
with a Teflon cap. The atmosphere was replaced by H2 (balloon, ~1 atm.) and stirred until TLC 
analysis indicated complete consumption of the starting material, typically 20 min. The 
resulting suspension was filtered through a pad of celite and washed with MeOH. The 
homogeneous solution was concentrated in vacuo. The crude residue was purified by flash 
chromatography (98:2 CH2Cl2:MeOH) affording pactamycin (0.005 g, 82%) as a pale yellow 
solid. Analytical data: [α]D19 +27.4 (c = 0.40, CHCl3); 1H NMR  (600 MHz, CDCl3): δ  10.98 
(br s, 1H), 7.91 (d, J = 10.8 Hz, 1H), 7.26-7.23 (m, 4H), 7.18-7.16 (m, 2H), 6.81-6.78 (m, 2H), 
6.64 (d, J = 7.2 Hz, 1H), 5.78 (br s, 1H), 5.67 (d, J = 10.8 Hz, 1H), 4.84 and 4.79 (ABq, J = 
12.6 Hz, 2H), 3.93 (m, 1H), 3.80 (d, J = 10.2 Hz, 1H), 2.99 (s, 6H), 2.95 (s, 1H), 2.55 (s, 3H), 
2.38 (s, 3H), 1.55 (s, 3H), 1.04 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 198.5, 
172.6, 162.8. 159.2, 146.6, 141.2, 138.3, 134.6, 129.6, 123.0, 118.7, 118.4, 115.7, 112.0, 110.8, 
88.8, 84.9, 74.3, 71.5, 68.7, 65.4, 63.2, 36.9, 29.7, 26.7, 24.1, 21.1, 18.1; HRMS (ESI+) Calcd. 
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for C28H38N4O8+H, 559.2762; Found, 559.2763; IR (thin film, cm
-1) 3393, 2938, 2359, 2341, 
1698, 1652, 1520, 1473, 1418, 1338, 873, 668; TLC (95:5 CH2Cl2/MeOH): Rf = 0.30. 
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CHAPTER TWO: 
PREPARATION AND BIOLOGICAL EVALUATION OF SYNTHETIC AND POLYMER-
ENCAPSULATED CONGENERS OF THE ANTITUMOR AGENT PACTAMYCIN: 
INSIGHT INTO FUNCTIONAL GROUP EFFECTS AND BIOLOGICAL ACTIVITY† 
 
2.1 Introduction 
 An expeditious total synthesis of the aminocyclitol antibiotic pactamycin was described 
in Chapter One, enabling fifteen-step preparation of the natural product from commerically 
available materials.  Pactamycin, while bearing a remarkable arrray of valuable biological 
traits, is hindered in medicinal development by its high cytotoxicity.  For this molecule to 
achieve its full potential as a therapuetic, chemical modifications to the parent structure must 
be enabled for structure-activity relatioship (SAR) investigations to be possible.  Accordingly, 
our synthesis of pactamycin was designed with the goal of late-stage structural modification 
toward the preparation of heretofore inaccessible synthetic analogs of pactamycin.  This 
chapter will describe our successful efforts in the synthesis and  biological analysis of twenty-
five unique structural analogs of pactamycin.  Additionally, as part of a collaboration with the 
DeSimone group (UNC Chapel Hill), the encapsulation of pactamycin and select derivatives 
into the PRINT® nanoparticle technology is demonstrated as proof-of-concept. 
 
                                                          
†Reprinted in part with permission from Sharpe, R. J.; Malinowski, J. T.; Sorana, F.; Luft, J. 
C.; Bowerman, C. J.; DeSimone, J. M.; Johnson, J. S. Bioorg. Med. Chem. 2015, 23, 1849. 
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2.2 Background 
2.2.1 Importance of Natural Products in Pharmaceutical Development 
 Pharmaceutical development through organic synthesis remains a critical feature of the 
drug discovery process.1 Upon identification of an initial hit via high-throughput screening, a 
significant amount of structural modification is often required before a lead candidate can be 
advanced to clinical trials.  Natural molecules are frequently identified as initial hits in these 
screenings; a recent survey study showed that natural products and their derivatives comprise 
over one-third of all FDA-approved new molecular entities (NMEs).2 Furthermore, Reynisson 
and co-workers reported that of the 39% of known drug space (KDS) that is comprised of 
natural products and their derivatives, 74% of this subset is made up of natural product 
derivatives.3 Figure 2-1 illustrates a selection of natural product-derived structures (and their 
corresponding parent structures) approved for use by the FDA in the past decade.4 The 
morphine-derived methylnaltrexone is currently in use for the treatment of opiod-induced 
constipation.  Fingolimod, derived from myriocin, is being employed as a treatment for 
multiple sclerosis. Zucapsaicin and dapagliflozin (derived from the natural products capsaicin 
and phlorizin, respectively) are also in use as analgesic and diabetic medicines.  These 
examples speak to the power of natural product scaffolds in the continued development of the 
pharmaceutical industry. 
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Figure 2-1. Natural Product Derivatives Approved by FDA in the Past Ten Years 
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2.2.2  Medicinal Development of Pactamycin to Date 
Despite these demonstrated successes, efficient modification of complex natural 
product structures toward the preparation of useful drug molecules can often be hindered by 
the deficiency of a practical and flexible chemical synthesis.5   As a result, the continued 
advancement of synthetic organic methodology is critical for facile and flexible drug discovery 
and development.  Pactamycin (2.1, Figure 2-2) is an example of a valuable natural target that 
has yet to reach its full medicinal potential due to both its inherent cytotoxicity and challenges 
associated with preparation of structurally-distinct analogs.   
Figure 2-2. Pactamycin 
 
 
Its impressive biology has attracted the attention of a multidisciplinary field in hopes 
of transforming pactamycin into a suitable therapeutic. In addition to 2.1, a number of 
naturally-occurring structural congeners have been isolated from related Streptomyces 
bacteria, displaying varied bioactivities (Figure 2-3). Among these, 7-deoxypactamycin (2.2) 
and jogyamycin (2.3) have shown increased antiprotozoal activity relative to 2.1, albeit with 
increased cytotoxicity.6 Additionally, natural derivatives including pactamycate 2.4 (bearing 
an oxazolidinone ring in place of the dimethylurea) and the 8”-hydroxypactamycin series have 
also been recently reported.7 
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Figure 2-3. Naturally-Occurring Pactamycin Congeners 
 
Alternatively, biosynthetic engineering studies pioneered by Mahmud and co-workers 
have provided researchers with the first series of unnatural structural analogs (Figure 2-4).  An 
initial report disclosed the preparation of TM-025 (2.7) and TM-026 (2.8).  In contrast to 2.2, 
these compounds demonstrated an increase in activity against Plasmodium falciparum relative 
to pactamycin in combination with a decrease in cytotoxic effects.7b  In 2013, Mahmud 
described the preparation of biosynthetically-generated fluorinated analogs (2.9, 2.10) 
displaying comparable antimalarial activity to 2.1.8  These findings have renewed promise for 
pactamycin analogs in drug development.    
Figure 2-4. Biosynthetically-Engineered Derivatives Produced by Mahmud 
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Moreover, encapsulation of natural cytotoxic agents into nanoparticles (NPs) has also 
shown improved clinical benefits, the most germane of these being reduction of undesired toxic 
side effects and increased therapeutic delivery to the target of interest. This approach has been 
successfully implemented in the case of doxorubicin (Doxil©),9 paclitaxel (Abraxane©)10 and 
others.11 More recently, Bind Therapeutics12 and Cerulean13 have ongoing clinical trials in NP 
formulations of cancer therapeutics (docetaxel, irinotecan, and camptothecin).  DeSimone and 
co-workers have demonstrated the use of the Particle Replication in Non-Wetting Templates 
(PRINT®) technology to modulate the activity of cytotoxic agents such as docetaxel, reducing 
unwanted side-effects and increasing therapeutic activity in vivo.14   To the best of our 
knowledge, however, the incorporation of pactamycin or its congeners into NPs of any type 
with the goal of bioactivity attenuation has not yet been explored. 
While an efficient chemical synthesis of 2.1 might provide the most flexibility in 
structural derivatization, the inherent complexity of the molecule has rendered this a difficult 
undertaking.  Indeed, one researcher went so far as to argue that a chemical approach to 
derivatives of 2.1 was “inaccessible by synthetic organic chemistry.”7b  The heavily-compacted 
and heteroatom-rich functionality in pactamycin presents a number of challenges toward 
selective structural modification.  Additionally, while the unique functional groups present in 
the molecule (salicylate, dimethylurea, aniline) offer novel branch points for structural 
diversification, methods with which to install these moieties are underexplored in the 
literature.15 As discussed in Chapter One, a number of groups have undertaken this endeavor,16 
most notably the landmark Hanessian total synthesis in 2011.17  Since this initial publication, 
Hanessian has demonstrated the efficacy of his route in producing pactamycin derivatives 
(Figure 2-5).18  Entry into derivatives at the C1 position was accomplished via amine  
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Figure 2-5. Hanessian Approach to Pactamycin Derivatives 
 
addition to late stage isocyanate 2.11.  These analogs were carried through the remaining 
sequence to provide C1 derivatives 2.13-2.16.  In addition, C3-aniline derivatives were 
accessed via a Lewis acid catalyzed epoxide opening strategy (2.17→2.18), which ultimately 
provided aniline derivatives 2.19-2.22.  These compounds have provided the medicinal 
community with the first library of synthetically-generated pactamycin analogs to date. 
2.2.3 Application of the Johnson Synthesis to Structural Analog Preparation 
Our work on the synthesis of pactamycin culminated in 2013 with a fifteen-step, 
asymmetric synthesis from commercially available 2,4-pentanedione.19 Critical to our 
approach was to assemble the molecule in a fashion such that key functional groups were 
installed both in their native form and in a late-stage fashion; we surmised that this approach 
would provide our synthesis platform with the greatest possible flexibility, facilitating 
investigations of structure-activity relationships at all critical branch points (Figure 2-6).  To 
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Figure 2-6.  Synthon Analysis of Pactamycin with Branch Points for Structural Derivatization 
 
this end, we envisaged a synthon such as 2.23 in which exploitation of the appropriate 
functional handles at the correct stage would install the requisite functionalities. 
 Our synthesis endgame was described in detail in Chapter One and is summarized in 
Scheme 2-1.  Ketone intermediate 2.24 (synthesized in ten steps in gram quantities) would 
serve as our first point of derivatization.  Nucleophilic methylation of 2.24 provided carbinol 
2.25 in 75% yield of a single diastereomer at C5.  Sc(OTf)3-promoted addition of m-
acetylaniline installed the substituted C3-aniline necessary for elaboration to 2.1, upon which 
silyl deprotection afforded tetraol 2.26. Introduction of the remaining salicylate moiety to the 
C6-hydroxymethylene of 2.26 was accomplished via reaction with the reported acyl 
electrophile 2.27, which upon hydrogenative removal of the Cbz protecting group, delivered 
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Scheme 2-1. Pactamycin Synthesis Endgame: Summary 
 
pactamycin in fifteen steps and 1.9% overall yield.  These late stage introductions of core 
functionality (and in their final forms for elaboration to pactamycin) would enable direct access 
to synthetic diversity at the indicated positions. 
2.3  Results and Discussion 
2.3.1  C3 Aniline Derivative Preparation 
  We first pursued the preparation of pactamycin congeners at the C3-aniline position, 
inspired by the related epoxide-opening strategy by Hanessian and co-workers.17  At this 
juncture, it is valuable to recall from Chapter One that the union of epoxide 2.25 with m-
acetylaniline requisite for pactamycin synthesis suffered from incomplete starting material 
conversion, poor solubility of the aniline, and the requirement of superstoichiometric Lewis 
acid promoter (Scheme 2-2).  We initially surmised that this poor reactivity was a function of 
the electron-poor aniline employed and that the use of varied anilines in this reaction would  
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Scheme 2-2.  Reactivity difference of m-acetylaniline and p-anisidine in Epoxide Opening  
 
proceed more readily.  Indeed, we were pleased to find that when p-anisidine was substituted 
for m-acetylaniline in the epoxide opening, the reaction proceeded in 100% conversion and 
95% yield.  Additionally, the stoichiometry of Sc(OTf)3 could be lowered to catalytic amounts 
with no decrease in reaction efficiency. 
 With the aniline tolerance established, we turned our attention towards incorporation 
of a variety of anilines and nitrogen nucleophiles (Table 2-1).  In the event, epoxide 2.25 
reacted readily with a variety of electron-rich and electron-poor aniline nucleophiles.  Even 
sterically-demanding fluorenyl (entry 6) and 4-bromo-1-naphthyl anilines (entry 7) proceeded 
in 59% and 87% yields, respectively.  We surprised to find, however, that extension of the 
epoxide opening reaction to aliphatic amines (entries 10-11) resulted in no reaction.  
Additionally, NaN3 failed to react with 2.25, giving only cleavage of the TBS protecting group.  
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Table 2-1.  Scope of Addition of Nitrogen Nucleophiles in Epoxide Opening Reaction 
 
Entry Nucleophile Product % Yielda 
1 
 
2.28a 83 
2 
         
2.28b 43 
3 
 
2.28c 95 
4 
         
2.28d 71 
5 
  
2.28e 86 
6 2-aminofluorene 2.28f 59 
7 
       
2.28g 87 
8 
 
2.28h 47 
9 
 
2.28i 77 
10 
   
-- TBS deprotection 
11 BnNH2 -- No reaction 
12b NaN3 -- TBS deprotection 
 
 
 
aIsolated yields; bConditions: NaN3 (1.1 equiv), Oxone (0.5 equiv), 
CH3CN:H2O (9:1), rt. 
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 Although we were disappointed by the lack of reactivity observed in the use of non-
aromatic amines, we moved forward with aniline addition products 2.28a-i towards preparation 
of their corresponding pactamycin analogs (Figure 2-7). In general, this operation proceeded 
uneventfully to afford pactamycin derivatives 2.29a-h over the three-step sequence.  However, 
thioether substrate 2.28i failed to undergo Cbz deprotection in the final step (presumably due 
to poisoning of the catalyst by the substrate), rendering this derivative inaccessible via this 
route.  In the case of bromonaphthyl addition product 2.28g, reduction of the aryl bromide was 
observed during Cbz deprotection, providing naphthylaniline 2.29g in decreased yield as the 
final derivative. 
Figure 2-7. Synthesis Completion of C3 Aniline Pactamycin Derivatives 
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2.3.2 Derivatization at the C1 Dimethyl Urea: A Surprising Ring Closure 
Hanessian’s approach toward preparation of pactamycin analogs at the C1 
dimethylurea position substituent relied on the trapping of an in situ generated isocyanate 
electrophile late in the synthesis (2.11).17 This tactic proved effective in the preparation of a 
series of functionalized ureas in good yields.  By contrast, our synthesis of 2.1 utilized an early-
stage N–H insertion reaction to install the urea.19  Synthetic diversification from this early 
intermediate would be a significant challenge.  Consequently, we envisaged a similar 
isocyanate formation/trapping strategy from carbinol intermediate 2.25 via the acid-catalyzed 
elimination of dimethylamine (Scheme 2-3).  The literature showed that isocyanate generation 
from ureas could be readily accomplished via treatment with mildly acidic conditions;20 in a 
first pass, epoxide 2.25 was treated with NH4Cl in refluxing MeOH.  Upon observing clean 
conversion to a single product, we were surprised to isolate imidazolidinone 2.31 and not the 
desired isocyanate 2.30. Imidazolidinone 2.31 arises from intramolecular trapping of the in situ 
generated isocyanate with the C2 amine carbamate functionality.  
Scheme 2-3. Surprising Imidazolidinone Formation 
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 Considering that the facility of this intramolecular process might preclude all attempts 
at intermolecular isocyanate addition, focus shifted to other avenues of trapping isocyanate 
2.30 (Scheme 2-4).  We surmised that if the isocyanate were generated in the presence of an 
unprotected C7-hydroxyl (2.32), then intramolecular trapping would result preferentially in 
formation of the corresponding oxazolidinone 2.33 (and not the undesired imidazolidinone).  
This reactivity pattern would enable access to analogs of the naturally-occurring congener 
pactamycate (2.4), for which no synthetic derivatives had been previously reported.  In 
practice, we selected the aniline addition product 2.28 for investigation. A screen of 
deprotection conditions revealed that treatment of 2.28 with Oxone® in aqueous CH3CN  
Scheme 2-4. Investigating Access to Pactamycate Derivatives 
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furnished alcohol 2.32 in 84% yield.  Submission of this compound to the conditions developed 
for isocyanate generation resulted in the formation of a single product 2.33 in 73% yield, 
although we were unsure of whether 2.32 had undergone oxazolidinone or imidazolidinone 
formation.  To ascertain this structural confirmation, we subjected 2.33 to silyl deprotection 
and Cbz hydrogenation, whereupon we isolated de-6-MSA pactamycate 2.34, whose spectral 
data had been previously reported.17b  This result confirmed the identity of 2.33 as the product 
illustrated. 
2.3.3 Preparation of Pactamycate Derivatives 
 With the feasibility of this sequence established, we set out to prepare a series of C3-
aniline pactamycate derivatives (Scheme 2-5).  Initiating with anilines 2.28b, 2.28c, and 2.28e 
already in our possession, TBS deprotection followed by oxazolidinone formation proceeded  
Scheme 2-5. Preparation of Pactamycate Derivatives 
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smoothly to give the corresponding oxazolidinones, which upon desilylation, acylation, and 
hydrogenolysis, provided pactamycate derivatives 2.37a-c in 35%, 23%, and 25% yields, 
respectively, over the five-step sequence. 
2.3.4  C5 Derivatization 
 Access to pactamycin derivatives at C5 was envisioned via addition of alternative 
carbon nucleophiles to ketone 2.24.  We were concerned, however, that the steric encumbrance 
of ketone 2.24 might preclude the application of nucleophiles with elevated complexity relative 
to MeMgBr (Table 2-2).  Fortunately, we found that ketone 2.24 reacted efficiently with 
nucleophiles EtMgBr, n-hexylMgBr, and H2C=CHMgBr to give the corresponding carbinols  
Table 2-2.  Addition of Nucleophiles to Advanced Ketone Intermediate. 
 
Entry Nucleophile Product % Yielda 
1  2.38a 75 
2 
 
2.38b 73 
3  2.38c 43 
4 
 
-- no reaction 
5 
 
-- no reaction 
6b NaBH4 2.38d 88 
 aIsolated yields; bConditions: NaBH4, MeOH, -45 °C. 
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in 75%, 73%, and 43% yields, respectively.  Unfortunately, larger aliphatic nucleophiles (iPr, 
isopropenyl) failed to react with 2.24, returning only recovered starting material.  As an 
additional example, the ketone was also reduced with NaBH4 to give the seco-alcohol 2.38d 
in 88% yield. 
When a sterically-demanding aryl nucleophile (PhMgBr) was employed, complete 
conversion to a single product 2.39 matching the desired mass spectrum was observed (Scheme 
2-6), although the 1H NMR spectrum was significantly different from that expected.  
Additionally, this product was unreactive in the subsequent epoxide opening stage.  On the 
basis of these facts, we speculate that the most probable identity of 2.39 is the result of an in 
situ Payne rearrangement in order to relieve the additional strain associated with the 
encumbering nucleophile.21  Unfortunately, this unexpected side reaction was observed in the 
addition of all larger nucleophiles, precluding the further exploration of C5 ketone diversity. 
Scheme 2-6.  Rearrangement Observed in the Case of Aryl Nucleophiles 
 
2.3.5  Elaboration of C5 Addition Products to Pactamycin Derivatives 
 With addition products 2.38a-d in hand, we proceeded in our studies to complete C5 
analog preparation (Scheme 2-7). However, upon subjection of ethyl derivative 2.38a to the 
previously optimized conditions for m-acetylaniline addition, no reaction was observed.  
Increasing the loading of Sc(OTf)3 or the reaction time/temperature had seemingly no effect. 
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We reasoned at this impasse that the added steric encumbrance about C5 hinders addition of 
the electron-poor m-acetylaniline, either due to poor coordination of the Lewis acid or by an 
unfavorable substrate conformation for addition relative to the parent C5-methyl compound. 
Scheme 2-7.  Native Aniline Installation to Pactamycin C5 Derivatives 
 
 In order to circumvent this issue, we looked to the strategy of Hanessian and co-workers 
wherein the required m-acetylaniline was first incorporated as an m-isopropenyl derivative.17 
The ketone was then revealed via Johnson-Lemieux oxidation of the olefin.  Fortunately, 
epoxide opening of 2.38a with m-isopropenyl aniline afforded aniline 2.40a in 71% yield.   
Alkene 2.40a was then subjected to Johnson-Lemieux conditions, revealing acetophenone 
2.41a in 53% yield over two steps.  With this reactivity established, C5 addition products 2.38a, 
2.38b, and 2.38d were carried through the revised aniline addition sequence (Scheme 2-8).  
Elaboration of vinyl addition product 2.38c to the corresponding pactamycin derivative was 
not attempted as reduction of the alkene was expected to occur during the final hydrogenation 
stage. 
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Scheme 2-8.  Synthesis of C5 Pactamycin Derivatives 
 
Finally, in order to probe the activity profile of a C5 derivative bearing an alternate 
functional group at the aniline position, a second C5-hydrido analog was prepared via addition 
of p-methoxyaniline to 2.38d in the epoxide opening stage (Scheme 2-9). 
Scheme 2-9. Preparation of a C5,C3 Pactamycin Derivative 
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As anticipated based on the above studies, addition of this aniline proceeded uneventfully 
under the optimized conditions to give anisidine 2.43 in 83% yield.  Elaboration of this material 
through the remaining sequence provided derivative 2.44 in 30% yield over the three-step 
sequence. 
2.3.6  Derivative Preparation at the C6 Hydroxymethylene Position 
 The next point of synthetic diversification centered on manipulation of the salicylate-
bearing C6 ester in 2.1.  The esters we hoped to prepare included both simple esters as well as 
“salicylate-like” esters to examine the importance of this functional group in the key binding 
event of 2.1 (Scheme 2-10).  Accordingly, we employed a modified procedure for that reported 
in the synthesis of 2.2722 to prepare electrophiles 2.48 and 2.50.  Phenyl-substituted salicylate 
2.48 was synthesized via Suzuki reaction of triflate 2.46 followed by hydrolysis and 
esterification.  Differentiated methoxyphenol was prepared from the known phenol 2.45 via 
etherification and hydrolysis/esterification.   
Scheme 2-10. Synthesis of Varied Salicylate Electrophiles 
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With these electrophiles in hand, we began screening esters in the acylation of tetraol 
2.26 (Table 2-3).  Gratifyingly, efficient monoacylation was accomplished with a variety of the 
electrophiles examined in good yields.  Modified salicylates 2.50 (entry 1) and 2.48 (entry 2) 
both underwent esterification under the conditions optimized for esterification with 2.27.   An 
o-toluyl ester was also tolerated (entry 3).  Esterification of 2.26 with aliphatic electrophiles 
performed well (entries 4-5), and the corresponding mesylate ester could also be prepared  
Table 2-3. Synthesis of C6 Hydroxymethylene Pactamycin Derivatives 
 
Entry R Product % Yield 1a % Yield 2a 
1 
   
2.51ab 57 decomposition 
2 
   
2.51bb 43 62 
3 
   
2.51cc 60 73 
4 
 
2.51dc 83 76 
5 
 
2.51ec 87 61 
6 MsCl 2.51fc 54 decomposition 
 
 
aIsolated yields; bConditions: K2CO3, DMA, rt; 
cConditions: 2,4,6-collidine, 
CH2Cl2, -78 °C to rt; 
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(entry 6).  The resulting monoesters were then submitted to the optimized conditions for Cbz 
hydrogenolysis, affording C6 derivatives 2.51b-e.  Unfortuntately, in the case of the 
methoxyphenol 2.51a and mesylate 2.51f, only starting material decomposition was observed 
at this stage.   
2.3.7  Attempts to Prepare C7-Deoxypactamycin Derivatives 
 The next series of derivatives we sought to prepare were those in which the C7 hydroxyl 
was removed.  Cognizant of the known bioactivity differences between 2.1 and its 7-deoxy 
congener (2.2),7 we began probing selective reduction of the C7 hydroxyl to its corresponding 
methylene.  Scheme 2-11 summarizes the approaches we elected to pursue.  Because it was 
easily accessible and obviated potential issues associated with the reactive C3 acetophenone 
functionality, we selected aniline addition product 2.52 as a model substrate for examination 
(prepared via Oxone® deprotection of 2.28e).  We first pursued radical reduction of a suitable 
C7 ester such as 2.54.  To this end, we prepared the corresponding xanthate, oxalate, and 
diphenylsilyl ether.  Unfortunately, all conditions examined towards radical reduction of these 
compounds (SnBu3H, AIBN/Et3B/(TMS)3SiH) failed to provide 2.53.  In most cases, only 
deacylation was obtained to return 2.52.  A second approach envisioned dehydration of the C7 
hydroxyl followed by hydrogenation to arrive at 2.53.  This approach was also unsuccessful, 
as even the Burgess reagent and the Martin sulfurane showed no reactivity towards alcohol 
2.52.  In a final case, oxidation of the C7 hydroxyl (TPAP, NMO) furnished the resulting ketone 
2.56.  From this compound, we investigated deoxygenation of the ketone via its derived enol 
triflate or dithiolane.  However, this route also gave no promise for yielding access to 2.53. 
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Scheme 2-11. Attempts Directed at Reduction of the C7-Hydroxyl 
 
 As an alternative strategy, we envisaged masking of the C7 hydroxyl as its ester might 
serve the same purpose as deoxygenation (i.e. removal of the H-bonding interaction at C7).23  
From tetraol 2.26, this would take the form of bis-acylation of the C6 and C7 hydroxyl groups 
(Table 2-4).  In practice, we were pleased to find that tetraol 2.26 underwent clean bis-acylation 
with Ac2O, PivCl, and cyclohexoyl chloride to give the corresponding diesters in in 86%, 92%, 
and 76% yields, respectively.   
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Table 2-4. Synthesis of C6, C7 Bis-Acylated Pactamycin Derivatives 
 
Entry R Product % Yield 1a,b % Yield 2a,b 
1  2.57a
 86 38 
2 
 
2.57b 92 53 
3 
 
2.57c 76 72 
 
 
The ester identities were selected on the basis of varying levels of steric encumbrance about 
C7.  Cbz hydrogenolysis of these compounds provided the diesters 2.57a-c. 
2.3.8 Synthesis of Ent-Pactamycin 
 In order to better understand the effects of chirality on the parent pactamycin structure, 
we investigated the preparation of ent-2.1 (Scheme 2-12).  As described in Chapter One, the 
enantiomer identity in our total synthesis was established via an early-stage asymmetric 
Mannich addition    (2.58 → 2.60).19  To translate this chemistry to the synthesis of ent-2.1, 
cinchonine, the pseudoenantiomer of cinchonidine, would need to be employed.  To this end, 
we were pleased to find that the asymmetric Mannich addition proceeded smoothly when 
cinhonine was used (2.58 → ent-2.60) with a yield and selectivity comparable to that of the 
parent reaction (68%, 3:97 er).   
aIsolated yields; bConditions: electrophile (2.2 equiv), NEt3, DMAP                
(10 mol %), CH2Cl2, 0 °C to rt. 
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Scheme 2-12. Synthesis of ent-Pactamycin 
 
This material was advanced through the remaining steps of the synthesis to provide ent-2.1, 
the optical activity of which was confirmed via comparison of the specific rotation with natural 
pactamycin. 
2.3.9  Carcinoma In Vitro Biological Evaluation 
Having prepared a library of novel compounds, we set out to examine their varied 
biological profiles.  Specifically, compounds were tested against human breast (MDA-MB-
231), ovarian (SK-OV-3), and lung (A549) carcinoma cell lines.  Additionally, the human 
embryonic cell line for which pactamycin’s toxicity has been established (MRC-5) was 
assayed for comparison.24 The results for all derivatives are summarized in Table 2-5.   As 
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anticipated, pactamycin (2.1, entry 1) displayed exceptional potency, showing nanomolar 
inhibition against all three carcinoma cell lines.  For comparison, the penultimate intermediate 
in our synthesis of pactamycin (2.61, entry 2) bearing Cbz protection at the C2-aminomethine 
(entry 2) showed a dramatic decrease in activity relative to 2.1. ent-Pactamycin (ent-2.1, entry 
3) displayed a threefold order of magnitude decrease in bioactivity, illustrating the impact of 
the natural enantiomer of pactamycin to effective cell-growth inhibition. 
Generally, all C3-aniline derivatives (entries 4-11) showed a marginal to significant 
decrease in activity relative to 2.1 across all cell lines, although 2.29b (entry 5) showed 
comparable activity against A549 (EC50 = 141 nM) with a marginal decrease in MRC5 activity.  
With regard to the pactamycate series of analogs, De-6-MSA pactamycate 2.34 (entry 12) 
showed only minor cell-growth inhibition.  This was not an unexpected result, however, as 
biological assays of 2.34 conducted by Hanessian and co-workers also showed little promising 
activity.18Altering the C3 aniline position of the pactamycate parent structure (entries 13-15) 
resulted in complete loss of biological activity.  These results, in combination with those of the 
pactamycin C3 analogs, speak to the importance of the m-acetyl functionality in pactamycin 
to its bioactivity.25  
The results of compounds bearing diversity at C5 are shown in entries 16-19.  
Extending the length of the carbon chain at C5 (entries 16-17) had significantly deleterious 
effects to bioactivity as a complete loss of carcinoma activity was observed, leaving only low 
inhibition of MRC-5.  However, removing alkyl functionality altogether at C5 (entries 18-19) 
had the opposite effect, as these C5 hydrido analogs (2.42d, 2.44) displayed the greatest 
activity across all cell lines of any compound tested in our study (including pactamycin).  We 
speculate that these results are primarily a function of adjusting the lipophilicity of the structure  
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Table 2-5. Carcinoma Biological Evaluation of Pactamycin Derivativesa 
Entry Structure 
Code 
Number 
A549 
EC50 
MDA-
MB-231 
EC50 
SK-OV-3 
EC50 
MRC-5 
EC50 
1 
 
2.1 160 nM 124 nM 129 nM 53 nM 
2 
 
2.61 11.8 μM 10.4 μM 12 μM n.d.b 
3 
 
ent-2.1 2.1 μM 1.2 μM 1.6 μM 933 nM 
 
 
     
4           Ar =          2.29a 800 nM 659 nM 1.4 μM 380 nM 
5 
 
2.29b 141 nM 556 nM 434 nM 314 nM 
6  2.29c 1.0 μM n.d. 600 nM 582 nM 
7  2.29d 777 nM 4.0 μM 4.0 μM 682 nM 
8  2.29e 884 nM 3.3 μM 1.6 μM 2.3 μM 
9 
 
2.29f 324 nM 376 nM 145 nM 431 nM 
10 
 
 
 
2.29g 2.21 μM 1.84 μM 2.44 μM 860 nM 
11  2.29h 760 nM 800 nM 436 nM 366 nM 
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Entry Structure 
Code 
Number 
A549 
EC50 
MDA-
MB-231 
EC50 
SK-OV-3 
EC50 
MRC-5 
EC50 
12 
 
2.34 6.0 μM n.d. 3.8 μM 2.9 μM 
 
 
     
13        Ar =  2.37a n.d. n.d. n.d. n.d. 
14  2.37b n.d. n.d. n.d. n.d. 
15 
           
2.37c n.d. n.d. n.d. n.d. 
 
 
     
16 
             R = C2H5 
            Ar = m-acetyl 
2.42a n.d. n.d. n.d. 2.1 μM 
17 
             R = C6H14 
            Ar = m-acetyl 
2.42b n.d. n.d. n.d. 11 μM 
18 
             R = H 
            Ar = m-acetyl 
2.42d 32 nM 50 nM 7 nM 6.5 nM 
19 
           R = H 
          Ar = p-methoxy 
2.44 83 nM 356 nM 91 nM 49 nM 
 
 
     
20 
 
2.51b 88 nM 203 nM 103 nM 129 nM 
21  2.51c 114 nM 79 nM 80 nM 105 nM 
22  2.51d 118 nM 300 nM 75 nM 100 nM 
23  2.51e 194 nM 352 nM 436 nM 366 nM 
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Entry Structure 
Code 
Number 
A549 
EC50 
MDA-
MB-231 
EC50 
SK-OV-3 
EC50 
MRC-5 
EC50 
 
 
     
24 
 
2.57a 137 nM 458 nM 123 nM 132 nM 
25 
        
2.57b 175 nM 1.93 μM 86 nM 396 nM 
26 
 
2.57c 588 nM 2.44 μM 593 nM 778 Nm 
 
 
relative to 2.1.26 As further evidence to the importance of the m-acetyl functionality, 2.44 (entry 
19) showed less potency across all cell lines in comparison to 2.42d (entry 18).   
The results of our diversification of the C6 hydroxymethylene (entries 20-23) are in 
agreement with Hanessian’s earlier findings. Namely, no significant gain (or loss) of biological 
activity was observed when the salicylate ester was altered relative to the parent pactamycin 
structure.  These results further support the hypothesis that the C6 ester side chain has a limited 
role in the key binding event of 2.1 in the 30S ribosome.18  The three prepared C6,C7 bis-
acylated derivatives (entries 24-26) showed a linear decrease in activity with steric 
encumbrance of the ester group.  These results suggest that the C7 hydroxyl in 2.1 plays a 
larger role in the bioactivity of the structure than the C6 hydroxymethylene. 
 
 
 
 
R = Ac 
R = Piv 
R = CO(C6H11) 
a Assays were carried out as triplicates; b Not determined. 
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2.3.10 Analysis of Pactamycin Derivatives via NCI 60-Cell Line Screen 
Upon collection of these initial data, derivatives ent-(2.1), 2.42d, 2.51c, 2.29f, and 
2.57a were identified as the most promising lead compounds and assayed via the NCI-60 
human tumor cell line screen.  Upon initial one-dose screening, all five compounds were found 
to have sufficient activity to merit the subsequent five-dose assay.  These derivatives were 
evaluated to determine GI50 (50% growth inhibition) values.  The results of these assays are 
described in detail in the Section 2.5 and summarized in Table 2-6. Additionally, the previously 
documented cell data for 2.1 is shown for comparison.   
Table 2-6. Summary GI50 Values from NCI-60 Cell Line Screeninga 
GI50 (μM) 2.1b ent-2.1 2.42d 2.51c 2.29f 2.57a 
MOLT-4 <0.10 1.19 0.046 0.12 0.78 0.33 
NCI-H322M 0.12 3.72 0.016 0.33 1.07 0.48 
HCT-15 0.03 20.0 0.16 0.65 1.46 10.2 
SNB-19 <0.10 3.07 0.52 0.19 1.40 0.57 
M14 0.12 3.01 0.10 0.19 0.88 0.68 
OVCAR-3 <0.10 2.50 0.041 0.20 0.73 0.53 
RXF 393 <0.10 1.50 0.064 0.12 0.61 0.61 
DU-145 <0.01 7.26 0.15 0.26 1.37 0.34 
MCF7 <0.01 2.04 0.051 0.17 0.73 7.31 
 
 
 
As expected based on our initial screen, ent-(2.1) showed multiple orders of magnitude 
loss in activity across the entire assay.  By contrast, compound 2.42d bearing a secondary 
hydroxyl at C5 demonstrated exceptional activity, showing nM inhibition throughout the 
screen and outperforming pactamycin in multiple cell lines.  Derivatives 2.51c (modified 
salicylate ester) and 2.57a (C6, C7 diacetoxypactamycin) also demonstrated general nM 
aData obtained from NCI-60 screening.  See Section 2.5 for comprehensive results. MOLT-4, leukemia cell 
line; NCI-H322M, nonsmall-cell lung cancer cell line; HCT-15, colon cancer cell line; SNB-19, CNS tumor 
cell lines; M14, melanoma; OVCAR-3, ovarian cancer cell line; RXF 393, renal cancer cell line; DU-145, 
prostate cancer cell line; MCF7, breast cancer cell line. bData can be accessed from the CAS: 23668-11-3 at 
the following website: http://dtp.cancer.gov/dtpstandard/dwindex/index.jsp. 
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activity in the assay.  The final derivative 2.29f bearing a fluorenyl aniline at C3 showed a 
general decrease in biological activity relative to 2.1 by factors of 10-100.    
2.3.11 Pactamycin Nanoparticle Fabrication and Biological Evaluation 
With these studies completed, we set out to examine the efficacy of pactamycin and 
select analogs to activity modulation via nanoparticle encapsulation.  Polymeric PRINT® 
nanoparticles were fabricated by encapsulating compounds 2.1, 2.29e, and 2.42d, in poly(d,l-
lactide) using previously described methods.14b, 27 Compounds 2.29e and 2.42d were selected 
on the basis of observing the effect of nanoformulation on derivatives both more and less active 
than 2.1. PRINT® NPs containing 2.1 and derivatives 2.29e and 2.42d all showed similar 
hydrodynamic radii and PDI as determined by dynamic light scattering (DLS).28 Scanning 
electron microscopy (SEM) analysis confirmed uniform particle size and shape regardless of 
compound identity, and drug loading of each sample was found to be ~10% as determined by 
HPLC.29 NP-encapsulated compounds NP-2.1, NP-2.29e, and NP-2.42d, were then examined 
in our assay, and the results are given in Table 2-7 where the baseline toxicity values for each 
compound are restated for comparison. 
In vitro analysis of the derivative NP formulations showed bimodal effects on 
therapeutic activity. In the A549 assay, nanoparticle delivery increased the cytotoxicity of the 
therapeutic cargo. NP-2.1 demonstrated an EC50 threefold more potent than pactamycin itself 
(52 nm to 160 nm, respectively). NP-2.42d showed a near fivefold increase in potency when 
compared to the unadultered small molecule (6.5 nM to 32 nM, respectively).  Even compound 
2.29e, a less active drug in comparison to 2.1, showing a nominal reduction in EC50 value for 
the A549 cell line.  Of significant interest was the increase in selectivity observed for 2.42d, 
wherein the EC50 for A549 decreased while the EC50 for MDA-MB-231 and MRC5 increased. 
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Table 2-7. Cell-Based Assay Comparison for Pactamycin Derivatives and NP Counterpartsa 
Compound A549 EC50 MDA-MB-231 EC50 MRC-5 EC50 
2.1 160 nM 124 nM 53 nM 
NP-2.1 52 nM 117 nM 52 nM 
2.29e 884 nM 3.3 μM 2.3 μM 
NP-2.29e 693 nM 5.5 μM 1.8 μM 
2.42d 32 nM 50 nM 6.5 nM 
NP-2.42d 6.5 nM 724 nM 18 nM 
 
2.4  Conclusion 
In summary, we have demonstrated the efficacy of our synthesis of pactamycin to 
efficient and modular production of structural derivatives with a range of varied bioactivities.  
Enabled branch points for derivatization include the C3 aniline, C5 carbinol, and the C6 
hydroxymethylene position.  Additionally, this route has enabled unprecedented access to 
derivatives of the natural congener pactamycate and the enantiomeric series of pactamycin.  
These results have provided additional insight into the roles that each functional group plays 
in providing the observed activity of the parent structure.  Additionally, we have established a 
heretofore undocumented proof-of-concept for modulation of pactamycin bioactivities via the 
use of the PRINT® nanoparticle delivery vehicle.  
 
 
 
 
 
 
aAssays were carried out as triplicates. 
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2.5 Experimental Details 
Methods: General. Infrared (IR) spectra were obtained using a Jasco 460 Plus Fourier 
transform infrared spectrometer. Proton and carbon magnetic resonance spectra (1H NMR and 
13C NMR) were recorded on a Bruker Avance 400 (1H NMR at 400 MHz and 13C NMR at 100 
MHz), Bruker Avance III 500 (1H NMR at 500 MHz and 13C NMR at 125 MHz) or a Bruker 
Avance III 600 (1H NMR at 600 MHz and 13C NMR at 150 MHz) spectrometer with solvent 
resonance as the internal standard (1H NMR: CDCl3 at 7.26 ppm; 
13C NMR: CDCl3 at 77.0 
ppm, 1H NMR: CD3OD at 3.34 ppm; 
13C NMR: CD3OD at 49.8 ppm). 
1H NMR data are 
reported as follows: chemical shift, multiplicity (s = singlet, br s = broad singlet, d = doublet, 
br d = broad doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet), coupling 
constants (Hz), and integration. Mass spectra were obtained using a Micromass Quattro-II 
triple quadrupole mass spectrometer in combination with an Advion NanoMate chip-based 
electrospray sample introduction system and nozzle or a Thermo LTqFT mass spectrometer 
with electrospray introduction and external calibration. All samples were prepared in methanol. 
Analytical thin layer chromatography (TLC) was performed on Sorbent Technologies 0.20 mm 
Silica Gel TLC plates. Visualization was accomplished with UV light, KMnO4, and/or aqueous 
ceric ammonium nitrate solution followed by heating. Purification of the reaction products was 
carried out by flash chromatography using Siliaflash-P60 silica gel (40-63μm) purchased from 
Silicycle. Supercritical fluid chromatography was performed on a Berger SFC system equipped 
with a Chiralcel OD column. Samples were eluted with SFC grade CO2 at the indicated 
percentage of MeOH. Unless otherwise noted, all reactions were carried out under an 
atmosphere of dry nitrogen in oven-dried glassware with magnetic stirring.  
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Materials: General. Tetrahydrofuran (THF), diethyl ether (Et2O), dichloromethane (CH2Cl2), 
and toluene (C7H8) were dried by passage through a column of neutral alumina under nitrogen 
prior to use. Acetonitrile (CH3CN), Triethylamine (NEt3) and diisopropylamine were freshly 
distilled from calcium hydride prior to use. All other reagents were purchased from commercial 
sources and were used as received unless otherwise noted. Poly(D,L-lactide) (lactide: 75,000–
120,000; 0.55-0.75 dL/g Inherent Viscosity) (PLA) was purchased from Sigma-Aldrich. 
Chloroform and solvents (acetonitrile and water) for high performance liquid chromatography 
(HPLC) were purchased from Fisher Scientific. Poly(ethylene terephthalate) (PET) sheets (6” 
width) were purchased from KRS plastics.  Fluorocur®, diameter (d) = 80 nm; height (h) = 
320 nm; (80x320 nm) prefabricated molds were provided by Liquidia Technologies.   
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Experimental Procedures: 
General procedure A for the addition of m-acetylaniline to epoxide 2.25. 
 
Benzyl ((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-2-((S)-1-((tert-butyldimethylsilyl) 
oxy) ethyl)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(3,3 dimethyl ureido)-3,4-
dihydroxy-3-methylcyclopentyl)carbamate (2.28): In a nitrogen-filled glove box, a flame-
dried 100-mL round-bottomed flask was charged with Sc(OTf)3 (0.38 g, 0.77 mmol, 3.0 equiv). 
The flask was capped with a rubber septum and removed from the glove box. Toluene (20 mL) 
was added and to the resulting suspension were added m-acetylaniline (0.35 g, 2.6 mmol, 10.0 
equiv) and a toluene solution (1.5 mL) of epoxide 2.25 (0.20 g, 0.26 mmol, 1.0 equiv). The 
reaction was heated to 60 °C with vigorous stirring and maintained for 14 h. (Note: increased 
reaction times led to product decomposition). The reaction was cooled to rt, diluted with H2O 
(10 mL) and EtOAc (10 mL), and the resulting mixture was extracted with EtOAc (3 x 10 mL). 
The combined organic extracts were washed with 0.5 M HCl(aq.) (2 x 20 mL), saturated 
NaHCO3(aq.) (15 mL), dried with magnesium sulfate, and concentrated in vacuo. The crude 
product was purified via flash chromatography (90:10 to 80:20 hexanes:EtOAc) to afford 
anilino-alcohol 2.28 as a yellow, viscous oil (0.16 g, 66%) with recovery of the unreacted 
epoxide 2.25 (0.04 g, 18%). Analytical data: [α]D19 -39.3 (c = 0.70, CHCl3); 1H NMR  (600 
MHz, CDCl3): δ 8.21 (d, J = 6.6 Hz, 1H), 7.70 (d, J = 6.6 Hz, 2H), 7.51 (d, J = 7.2 Hz, 2H), 
7.39 (t, J = 7.2 Hz, 1H), 7.32 (t, J = 7.2 Hz, 2H), 7.28-7.22 (m, 8H), 7.16 (t, J = 7.2 Hz, 2H), 
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7.12 (t, J = 7.8 Hz, 1H), 6.79 (d, J = 7.8 Hz, 1H), 6.13 (s, 1H), 5.88 (s, 1H), 5.39-5.36 (m, 1H), 
5.36 (s, 1H), 5.04 (d, J = 12.0 Hz, 1H), 5.01 (d, J = 12.0 Hz, 1H), 4.78 (dd, J = 4.6, 6.6 Hz, 
1H), 4.37 (d, J = 10.2 Hz, 1H), 4.13 (s, 1H), 3.68 (dd, J = 4.6, 3.0 Hz, 1H), 3.48 (d, J = 10.8 
Hz, 1H), 2.96 (s, 6H), 2.49 (s, 3H), 1.69 (s, 3H), 1.41 (d, J = 6.6 Hz, 3H), 0.98 (s, 9H), 0.92 (s, 
9H), 0.12 (s, 3H), 0.02 (s, 3H); MS (ESI+) Calcd. for C50H70N8Si2+H, 911.4812; Found, 
911.4867. 
General procedure B for the addition of varied anilines to epoxide 2.25. 
 
(Benzyl ((1S,2R,3R,4S,5S)-2-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(((tert-
butyldiphenylsilyl)oxy)methyl)-2-(3,3-dimethylureido)-3,4-dihydroxy-5-((4-
methoxyphenyl )amino)-3-methylcyclopentyl)carbamate) (2.28c): In a nitrogen-filled 
glove box, a flame-dried 100-mL round-bottomed flask was charged with Sc(OTf)3 (0.035 g, 
0.065 mmol, 0.5 equiv). The flask was capped with a rubber septum and removed from the 
glove box. Toluene (9 mL) was added and to the resulting suspension were added p-anisidine 
(0.160 g,  1.29 mmol, 10 equiv) and a toluene solution (2 mL) of epoxide 2.25 (0.10 g, 0.129 
mmol, 1.0 equiv). The reaction was heated to 60 °C with vigorous stirring and maintained for 
14 h. (Note: increased reaction times led to product decomposition). The reaction was cooled 
to rt, diluted with H2O (15 mL) and EtOAc (15 mL), and the resulting mixture was extracted 
with EtOAc (3 x 10 mL). The combined organic extracts were washed with 0.5 M HCl(aq.) (2 
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x 20 mL), saturated NaHCO3(aq.) (15 mL), dried with magnesium sulfate, and concentrated in 
vacuo. The crude product was purified via flash chromatography (90:10 to 80:20 
hexanes:EtOAc) to afford anilino-alcohol 2.28c as a yellow, viscous oil (0.110 g, 95%).  
Analytical data: 1H NMR  (400 MHz, CDCl3): δ 8.10 (d, J = 6.4 Hz, 1H); 7.71 (d, J = 6.4 Hz 
, 2H); 7.56 (d, J = 6.8 Hz , 2H); 7.40-7.30 (m, 12H); 6.67 (d, J = 8.8 Hz, 2H); 6.56 (d, J = 8.8 
Hz, 2H); 6.17 (s, 1H); 5.83 (s, 1H); 5.37 (q, J = 6.8 Hz, 1H); 5.02 (br s, 2H); 4.96 (s, 1H); 4.75-
4.73 (m, 1H); 4.39 (d, J =10.8 Hz, 1H); 3.74 (s, 3H); 3.61-3.54 (m, 2H); 2.95 (s, 2H); 1.67 (s 
3H); 1.40 (d, J = 6.4 Hz, 3H); 1.01 (s, 9H); 0.92 (s, 9H); 0.11 (s, 3H); 0.02 (s, 3H). MS (ESI+) 
Calcd. For C49H70N4O8Si2+H, 899.48; Found, 899.47. 
 
 Benzyl ((1S,2R,3R,4S,5S)-2-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(((tert-
butyldiphenylsilyl)oxy)methyl)-2-(3,3-dimethylureido)-3,4-dihydroxy-3-methyl-5-((4-
(trifluoromethoxy)phenyl)amino)cyclopentyl)carbamate (2.28a): Isolated from 2.25 via 
general procedure B using 4-trifluoromethoxyaniline as the nucleophile in 83% yield. 
Analytical data: 1H NMR (400 MHz, CDCl3): δ 8.21 (d, J = 6.8 Hz, 1H); 7.71 (d, J = 6.4 Hz, 
2H); 7.56 (d, J = 6.8 Hz, 2H); 7.55-7.44 (m, 6H); 7.03 (d, J = 8.0 Hz, 2H); 6.92 (d, J = 8.4 Hz, 
2H); 6.66 (d, J = 8.8 Hz, 2H); 5.56 (d, J = 8.8 Hz, 2H); 6.14 (s, 1H); 5.90 (s, 1H); 5.38 (q, J = 
6.4 Hz, 1H); 5.30 (d, J = 3.2 Hz, 1H); 5.08 (d, J = 12.4 Hz, 1H); 5.02 (d, J = 12.0 Hz, 1H);4.78 
(dd, J = 6.4, 10.0 Hz, 1H); 4.39 (d, J = 10.8 Hz, 1H); 4.13 (s, 1H); 3.75 (br s, 1H); 3.59 (dd, J 
= 2.8, 9.8, 1H); 3.48 (d, J = 10.8 Hz, 1H); 2.97 (s, 6H); 1.71 (s, 3H); 1.44 (d, J=6.4 Hz, 3H); 
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1.04 (s, 9H); 0.95 (s, 9H); 0.14 (s, 3H); 0.04 (s, 3H); MS (ESI+) Calcd. For 
C49H67F3N4O8Si2+H, 953.45; Found, 953.22. 
 
Benzyl ((1S,2R,3R,4S,5S)-2-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(((tert-
butyldiphenylsilyl)oxy)methyl)-2-(3,3-dimethylureido)-5-((3-fluorophenyl)amino)-3,4-
dihydroxy-3-methylcyclopentyl)carbamate (2.28b): Isolated from 2.25 via general 
procedure B using 3-fluoroaniline as the nucleophile in 43% yield. Analytical data: 1H NMR 
(400 MHz, CDCl3): δ 8.18 (d, J = 6.6 Hz, 1H); 7.73 (d, J = 7.1 Hz, 2H); 7.36 (d, J = 6.6, 2H); 
7.42 (d, J = 7.6 Hz, 1H); 7.39-7.25 (m, 11H); 6.96 (d, J = 7.2 Hz, 1H); 6.42-6.31 (m, 3H); 6.12 
(s, 1H); 5.86 (s, 1H); 5.38 (q, J = 6.8 Hz, 1H); 5.32 (br s, 1H); 4.75 (dd, J = 9.8, 6.8 Hz, 1H); 
4.35 (d, J = 10.4 Hz, 1H); 4.13 (s, 1H); 3.6 (dd, J = 9.8, 3.6 Hz, 1H); 3.52 (d, J = 10.8 Hz, 1H) 
2.97 (s, 6H); 1.68 (s, 3H); 1.42 (d, J = 6.8 Hz, 1H), 3H); 1.01 (s, 9H); 0.93 (s, 9H); 0.12 (s, 
3H); 0.02 (s, 3H);  MS (ESI+) Calcd. For C48H67FN4O7Si2+H, 887.46; Found, 887.32. 
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Benzyl ((1S,2R,3R,4S,5S)-2-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(((tert-
butyldiphenylsilyl)oxy)methyl)-2-(3,3-dimethylureido)-3,4-dihydroxy-3-methyl-5-
(phenylamino)cyclopentyl)carbamate (2.28d): Isolated from 2.25 via general procedure B 
using aniline as the nucleophile in 71% yield. Analytical data: 1H NMR  (400 MHz, CDCl3): 
δ 8.09 (d, J = 6.8 Hz, 1H); 7.71 (d, J = 8.0 Hz, 2H); 7.55 (d, J = 7.6 Hz, 2H); 7.41-7.21 (m, 
12H); 7.09-7.05 (m, 2H); 6.65-6.62 (m, 3H); 6.17 (s, 1H); 5.85 (s, 1H); 5.37 (q, J = 6.8 Hz, 
1H); 5.14 (br s, 1H); 5.02 (s, 2H); 4.76 (dd, J = 9.8, 6.4 Hz, 1H); 4.37 (d, J = 10.8 Hz, 1H); 
3.63 (d, J = 10.4 Hz, 1H); 3.60 (d, J = 10.8 Hz, 1H); 2.96 (s, 6H); 1.67 (s, 3H); 1.40 (d, J = 6.8 
Hz, 3H); 1.00 (s, 9H); 0.92 (s, 9H); 0.11 (s, 3H); 0.02 (s, 3H); MS (ESI+) Calcd. For 
C48H68N4O7Si2+H, 869.47; Found, 869.61. 
 
Benzyl ((1S,2R,3R,4S,5S)-5-((4-(tert-butyl)phenyl)amino)-2-((S)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(3,3-
dimethylureido)-3,4-dihydroxy-3-methylcyclopentyl)carbamate (2.28e): Isolated from 
2.25 via general procedure B using 4-tert-butylaniline as the nucleophile in 86% yield. 
Analytical data: 1H NMR  (600 MHz, CDCl3): δ 8.11 (d, J = 6.6 Hz, 1H); 7.73 (d, J = 7.2 Hz, 
2H); 7.56 (d, J = 7.2 Hz, 2H); 7.40 (d, J = 6.6 Hz, 1H); 7.36-7.31 (m, 5H); 7.27-7.23 (m, 5H); 
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7.20 (d, J = 8.4 Hz, 2H); 6.60 (d, J = 8.4 Hz, 2H); 6.20 (s, 1H); 5.83 (s, 1H); 5.38 (q, J = 6.6 
Hz, 1H); 5.12 (s, 1H); 5.05 (d, J = 12.6 Hz, 1H); 5.00 (d, J = 12.0 Hz, 1H); 4.77 (m, 1H); 4.37 
(d, J = 10.8 Hz, 1H); 4.16 (s, 1H); 4.14 (d, J = 7.2 Hz, 1H); 3.64-3.60 (m, 2H); 2.96 (s, 6H); 
1.68 (s, 3H); 1.42 (d, J = 6.6 Hz, 3H); 1.29 (s, 9H); 1.01 (s, 9H); 0.93 (s, 9H); 0.12 (s, 3H); 
0.02 (s, 3H); MS (ESI+) Calcd. For C52H76N4O7Si2+H, 925.53; Found, 925.45. 
 
Benzyl ((1S,2R,3R,4S,5S)-5-((9H-fluoren-2-yl)amino)-2-((S)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(3,3-
dimethylureido)-3,4-dihydroxy-3-methylcyclopentyl)carbamate (2.28f): Isolated from 
2.25 via general procedure B using 2-fluorenyl aniline as the nucleophile in 59% yield. 
Analytical data: 1H NMR (600 MHz, CDCl3): δ 8.17 (d, J = 6.7 Hz, 1H); 7.72 (d, J = 7.1 Hz, 
2H); 7.67 (t, J = 7.0 Hz, 1H); 7.56 (br s, 2H); 7.50 (br s, 2H); 7.39 (t, J = 7.1 Hz, 1H); 7.37-
7.32 (m, 5H); 7.26-7.35 (m, 3H); 7.21 (t, J = 8.1 Hz, 1H); 7.15 (br s, 3H); 6.82 (s, 1H); 6.68 
(d, J = 5.6 Hz, 1H); 6.22 (s, 1H); 5.92 (s, 1H); 5.43 (d, J = 4.4 Hz, 1H); 5.07 (s, 2H); 4.83-4.80 
(m, 1H); 4.44 (d, J = 7.2 Hz, 1H); 4.21 (s, 1H); 3.84(s, 1H); 3.76-3.65 (m, 3H); 3.64 (d, J = 7.2 
Hz, 1H); 3.01 (s, 6H); 1.73 (s, 3H); 1.45 (d, J = 4.4 Hz, 3H); 1.042 (s, 9H); 0.98 (s, 9H); 0.16 
(s, 3H); 0.07  (s, 3H); MS (ESI+) Calcd. For C55H72N4O7Si2+H, 957.50; Found, 957.42. 
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Benzyl ((1S,2R,3R,4S,5S)-5-((4-bromonaphthalen-1-yl)amino)-2-((S)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(3,3-
dimethylureido)-3,4-dihydroxy-3-methylcyclopentyl)carbamate  (2.28g): Isolated from 
2.25 via general procedure B using 4-bromonaphthalen-1-amine as the nucleophile in 87% 
yield. Analytical data: 1H NMR  (400 MHz, CDCl3): δ 8.24 (d, J = 6.4 Hz, 1H); 8.15 (d, J = 
8.4 Hz, 1H); 7.95 (d, J = 8.4 Hz, 1H); 7.67 (d, J = 6.9 Hz, 2H); 7.54 (t, J = 7.1 Hz, 1H); 7.52-
7.07 (m, 15H); 6.61 (d, J = 8.4 Hz, 1H); 6.18 (d, J = 12.4 Hz, 2H); 5.97 (s, 1H); 5.45 (d, J = 
6.8 Hz, 1H); 5.04-4.93 (m, 3H); 4.44 (d, J = 10.4 Hz, 1H); 4.20 (s, 1H); 3.83 (d, J = 10.0 Hz, 
1H); 3.49 (d, J = 10.8 Hz, 1H); 3.00 (s, 6H); 1.74 (s, 3H); 1.46 (d, J = 6.8 Hz, 3H); 1.01 (s, 
9H); 0.99 (s, 9H); 0.17 (s, 3H); 0.11 (s, 3H); MS (ESI+) Calcd. For C52H69BrN4O7Si2+H, 
997.40; Found, 997.48. 
 
Benzyl ((1S,2R,3R,4S,5S)-2-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(((tert-
butyldiphenylsilyl)oxy)methyl)-2-(3,3-dimethylureido)-3,4-dihydroxy-3-methyl-5-((4-
(trifluoromethyl)phenyl)amino)cyclopentyl)carbamate (2.28h): Isolated from 2.25 via 
general procedure B using 4-trifluoromethylaniline as the nucleophile in 47% yield. Analytical 
data: 1H NMR  (600 MHz, CDCl3): δ 8.25 (d, J = 6.6 Hz, 1H); 7.73 (d, J = 7.2 Hz, 2H); 7.53 
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(d, J = 7.8 Hz, 2H); 7.44-7.21 (m, 11H); 6.71 (d, J = 7.8 Hz, 2H); 6.61 (d, J = 8.4 Hz, 2H); 
6.14 (s, 1H); 5.94 (s, 1H); 5.52 (s, 1H); 5.40 (q, J = 6.6 Hz, 1H); 5.05 (s, 2H); 4.81-4.78 (m, 
1H); 4.39 (d, J = 10.8 Hz, 1H); 3.98 (s, 1H); 3.69-3.67 (m, 1H); 3.41 (d, J = 10.8 Hz, 1H); 2.99 
(s, 6H); 1.72 (s, 3H); 1.44 (d, J = 6.6 Hz, 3H); 1.04 (s, 9H); 0.95 (s, 9H); 0.15 (s, 3H); 0.04 (s, 
3H); MS (ESI+) Calcd. For C49H67F3N4O7Si2+H, 937.46; Found, 937.36. 
 
benzyl ((1S,2R,3R,4S,5S) -2-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(((tert-
butyldiphenylsilyl)oxy)methyl)-2-(3,3-dimethylureido)-3,4-dihydroxy-3-methyl-5-((4-
(methylthio)phenyl)amino)cyclopentyl)carbamate (2.28i): Isolated from 2.25 via general 
procedure B using 4-thiomethylaniline as the nucleophile in 77% yield. Analytical data:  1H 
NMR  (600 MHz, CDCl3): δ 8.15 (d, J = 6.6 Hz, 1H); 7.71 (d, J = 7.2 Hz, 2H); 7.55 (d, J = 
7.2 Hz, 2H); 7.41 (t, J = 7.2 Hz, 1H); 7.36-7.23 (m, 10H); 7.13 (d, J = 9.0 Hz, 2H); 6.57 (d, J 
= 7.8 Hz, 2H); 6.14 (s, 1H); 5.86 (s, 1H); 5.37 (d, J = 6.6 Hz, 1H); 5.23 (s, 1H); 5.02 (s, 2H); 
4.75 (dd, J = 9.6, 6.6 Hz, 1H); 4.36 (d, J = 10.8 Hz, 1H); 4.13 (s, 1H); 3.61 (d, J = 9.6 Hz, 1H); 
3.52 (d, J = 10.8 Hz, 1H); 2.96 (s, 6H); 2.39 (s, 3H); 1.67 (s, 3H); 1.14 (d, J = 6.6 Hz, 3H); 
1.01 (s, 9H); 0.92 (s, 9H); 0.11 (s, 3H); 0.01 (s, 3H);  MS (ESI+) Calcd. For 
C49H70N4O7SSi2+Na, 937.46; Found, 937.36. 
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General procedure C for global silyl deprotection. 
 
Benzyl ((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-2-(3,3-dimethylureido)-3,4-
dihydroxy-2-((S)-1-hydroxyethyl)-4-(hydroxymethyl)-3-methylcyclopentyl)carbamate 
(2.26): A 20-mL scintillation vial was charged with silyl ether 2.28 (0.25 g, 0.28 mmol, 1.0 
equiv) and THF (5.5 mL). The resulting solution was cooled to 0 °C, and TBAF (1 M solution 
in THF, 1.1 mL, 1.1 mmol, 4.0 equiv) was added. The reaction was allowed to stir at 0 °C until 
TLC analysis indicated consumption of the starting material, typically 30 min. The reaction 
was diluted with brine (3 mL) and EtOAc (3 mL) and extracted with EtOAc (3 x 7 mL). The 
combined organic extracts were dried with magnesium sulfate and concentrated in vacuo. The 
crude product was purified via flash chromatography (60:40 petroleum ether:acetone) to afford 
tetraol 2.26 as a pale yellow, viscous oil (0.14 g, 90%). Analytical data: [α]D19 +26.0 (c = 0.70, 
CHCl3); 1H NMR (600 MHz, CDCl3): δ 7.36 (s, 4H); 7.29 (br s, 1H); 7.23 (br s, 1H); 7.12 (br 
s, 1H); 6.99 (d, J = 7.8 Hz, 1H); 6.75 (d, J = 6.6 Hz, 1H); 6.02 (d, J = 7.2 Hz, 1H); 5.80 (br s, 
1H); 5.48 (d, J = 7.8 Hz, 1H); 5.27 (br s, 1H); 5.13 (br s, 2H); 4.14-4.10 (m, 1H); 4.06 (br s, 
2H); 3.80 (br s, 2H); 3.74-3.68 (m, 1H); 3.55 (m, 1H); 2.87 (s, 6H); 2.52 (s, 3H); 1.42 (s, 3H); 
1.25 (br s, 3H); 13C NMR (150 MHz, CDCl3): δ 198.7, 158.7, 155.8, 146.6, 138.3, 136.0, 
129.7, 128.6, 128.4, 118.4, 112.0, 88.2, 83.9, 73.2, 71.7, 67.4, 66.9, 64.2, 61.8, 61.2, 36.7, 29.7, 
26.7, 22.7, 21.2, 18.0, 14.1; MS (ESI+) Calcd. For C28H38N4O8+H, 559.2770; Found, 
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559.2800; IR (thin film, cm-1) 3392, 2938, 1716, 1684, 1652, 1635, 1540, 1507, 1473, 1456, 
1361, 1243, 739; TLC (60:40 petroleum ether/acetone): Rf = 0.30. 
 
(Benzyl ((1S,2R,3R,4S,5S)-2-(3,3-dimethylureido)-3,4-dihydroxy-2-((S)-1-hydroxyethyl)-
4-(hydroxymethyl)-5-((4-methoxyphenyl)amino)-3-methylcyclopentyl)carbamate) (S1c): 
Isolated from 2.28 via general procedure C in 94% yield. Analytical data: 1H NMR  (400 MHz, 
CDCl3): δ 7.34-7.26 (m, 5H); 6.85 (br s, 1H); 6.73 (d, J = 8.4 Hz, 2H); 6.5 (d, J = 8.0 Hz, 2H); 
6.06 (br s, 1H); 5.73 (br s, 1H); 5.28 (s, 1H); 5.13-5.10 (m, 2H); 4.95 (br s, 1H); 4.15 (br s, 
1H); 4.04 (d, J =11.2 Hz, 2H); 3.72 (s, 3H); 3.66 (br s, 2H); 2.84 (s, 6H); 1.38 (s, 3H); 1.24 (br 
s, 3H). MS (ESI+) Calcd. For C27H38N4O8+H +H, 547.28; Found, 547.28. 
 
Benzyl ((1S,2R,3R,4S,5S)-2-(3,3-dimethylureido)-3,4-dihydroxy-2-((S)-1-hydroxyethyl)-
4-(hydroxymethyl)-3-methyl-5-((4-(trifluoromethoxy)phenyl) amino)cyclopentyl) 
carbamate H(S1a): Isolated from 2.28a via general procedure C in 68% yield. Analytical 
data: 1H NMR  (400 MHz, CDCl3): δ  7.34-7.26 (m, 5H); 7.00 (d, J = 8.0 Hz, 2H); 6.71 (br s, 
1H); 6.50 (d, J = 8.4 Hz, 2H); 6.05 (br s, 1H); 5.72 (br s, 1H); 5.31 (br s, 1H); 5.26 (s, 1H); 
5.12 (s, 2H); 4.17 (br s, 1H); 4.05 (br s, 1H); 4.01 (d, J=12.0 Hz, 1H); 3.82 (d, J = 11.6 Hz, 
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1H); 3.69 (dd, J = 2.8, 9.0 Hz, 1H); 3.52 (s, 1H); 2.87 (s, 6H); 1.41 (s, 3H); 1.25 (br s, 3H); 
MS (ESI+) Calcd. For C27H35F3N4O8+Na, 623.33; Found, 623.19. 
 
Benzyl ((1S,2R,3R,4S,5S)-2-(3,3-dimethylureido)-5-((3-fluorophenyl)amino)-3,4-
dihydroxy-2-((S)-1-hydroxyethyl)-4-(hydroxymethyl)-3-methylcyclopentyl)carbamate 
(S1b): Isolated from 2.28b via general procedure C in 85% yield. Analytical data: 1H NMR  
(400 MHz, CDCl3): δ 7.34-7.26 (m, 5H); 7.07 (d, J = 7.2 Hz, 1H); 6.85 (br s, 1H); 6.42-6.38 
(m, 1H); 6.32-6.26 (m, 2H); 6.07 (br s, 1H); 5.76 (br s, 1H); 5.39 (d, J = 8.0 Hz, 1H); 5.26 (s, 
1H); 5.13 (d, J = 12.4 Hz, 1H); 5.10 (d, J = 12.4 Hz, 1H); 4.17 (br s, 1H); 4.06 (br s, 1H); 3.98 
(d, J = 11.2 Hz, 1H); 3.80 (d, J = 11.2 Hz, 1H); 3.68 (dd, J = 2.4, 9.0 Hz, 1H); 3.6 (br s, 1H); 
2.86 (s, 6H); 1.40 (s, 3H); 1.25 (d, J = 3.2 Hz, 3H); MS (ESI+) Calcd. For C26H35FN4O7 +H, 
535.26; Found, 535.19. 
 
Benzyl ((1S,2R,3R,4S,5S)-2-(3,3-dimethylureido)-3,4-dihydroxy-2-((S)-1-hydroxyethyl)-
4-(hydroxymethyl)-3-methyl-5-(phenylamino)cyclopentyl)carbamate (S1d): Isolated 
from 2.28d via general procedure C in 91% yield. Analytical data: 1H NMR  (400 MHz, 
CDCl3): δ 7.34 (br s, 5H); 7.16-7.13 (m, 2H); 6.90 (br s, 1H); 6.72 (br s, 1H); 6.56 (br s, 2H); 
6.05 (br s, 1H); 5.78 (s, 1H); 5.28 (br s, 1H); 5.10 (s, 2H); 4.18 (br s, 1H); 4.02 (br s, 2H); 3.78 
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(br s, 2H); 3.63 (s, 1H); 2.85 (s, 6H); 2.61 (br s, 1H); 1.85 (br s, 1H); 1.39 (s, 3H); 1.24 (br s, 
3H); MS (ESI+) Calcd. For C26H36N4O7+Na, 539.25; Found, 539.32. 
 
Benzyl ((1S,2R,3R,4S,5S)-5-((4-(tert-butyl)phenyl)amino)-2-(3,3-dimethylureido)-3,4-
dihydroxy-2-((S)-1-hydroxyethyl)-4-(hydroxymethyl)-3-methylcyclopentyl)carbamate 
(S1e): Isolated from 2.28e via general procedure C in 93% yield. Analytical data: 1H NMR  
(400 MHz, CDCl3): δ7.35 (br s, 5H); 7.18 (d, J = 8.4 Hz, 2H); 6.84 (br s, 1H); 6.51 (d, J = 8.0 
Hz, 2H); 6.06 (br s, 1H); 5.78 (br s, 1H); 5.28 (br s, 1H); 5.15-5.08 (m, 3H); 4.21 (br s, 1H); 
4.06-4.03 (m, 2H); 3.75 (d, J = 11.6 Hz, 1H); 3.70 (d, J = 8.8 Hz, 1H); 3.69 (br s, 1H); 2.86 (s, 
6H); 1.39 (s, 3H); 1.27 (s, 9H); 1.25 (br s, 3H); MS (ESI+) Calcd. For C30H44N4O7 +H, 573.33; 
Found, 573.33. 
 
Benzyl ((1S,2R,3R,4S,5S)-5-((9H-fluoren-2-yl)amino)-2-(3,3-dimethylureido)-3,4-
dihydroxy-2-((S)-1-hydroxyethyl)-4-(hydroxymethyl)-3-methylcyclopentyl)carbamate 
(S1f): Isolated from 2.28f via general procedure C in 85% yield. Analytical data: 1H NMR  
(400 MHz, CDCl3): δ 7.61 (d, J = 7.3 Hz, 1H); 7.55 (br s, 1H); 7.45 (d, J = 7.3 Hz, 1H); 7.42-
7.26 (m, 6H); 7.20-7.17 (m, 1H); 6.97 (br s, 1H); 6.76 (s, 1H); 6.59 (br s, 1H); 6.06 (br s, 1H); 
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5.84 (br s, 1H); 5.35 (br s, 1H); 5.29 (br s, 1H); 5.12 (s, 2H); 4.18-4.06 (m, 3H); 3.82-3.75 (m, 
4H); 3.64 (br s, 1H); 2.86 (s, 6H); 1.41 (s, 3H); 1.24 (s, 3H); MS (ESI+) Calcd. For 
C33H40N4O7+H, 605.30; Found, 605.23. 
 
Benzyl ((1S,2R,3R,4S,5S)-5-((4-bromonaphthalen-1-yl)amino)-2-(3,3-dimethylureido)-
3,4-dihydroxy-2-((S)-1-hydroxyethyl)-4-(hydroxymethyl)-3-methylcyclopentyl) 
carbamate  (S1g): Isolated from 2.28g via general procedure C in 65% yield. Analytical data: 
1H NMR  (400 MHz, CDCl3): δ 8.19 (d, J = 8.4 Hz, 1H); 7.70 (d, J = 7.6 Hz, 1H); 7.59-7.55 
(m, 2H); 7.48-7.45 (m, 1H); 7.27-7.21 (m, 5H); 7.20 (br s, 1H); 6.42 (br s, 1H); 6.32 (br s, 1H); 
6.06 (br s, 2H); 5.25 (s, 1H); 5.14-5.12 (m, 2H); 4.15-4.12 (m, 3H); 3.89-3.82 (m, 2H); 3.64 
(br s, 1H); 2.85 (s, 6H); 1.25 (br s, 3H); MS (ESI+) Calcd. For C30H37BrN4O7+H, 645.19; 
Found, 645.25. 
 
Benzyl ((1S,2R,3R,4S,5S)-2-(3,3-dimethylureido)-3,4-dihydroxy-2-((S)-1-hydroxyethyl)-
4-(hydroxymethyl)-3-methyl-5-((4-(trifluoromethyl)phenyl)amino) cyclopentyl) 
carbamate (S1h): Isolated from 2.28h via general procedure C in 60% yield. Analytical data: 
1H NMR  (400 MHz, CDCl3): δ 7.35-7.26 (m, 8H); 6.87 (br s, 2H); 6.10 (br s, 1H); 5.77 (br s, 
1H); 5.62 (s, 1H); 5.12 (br s, 2H); 4.17 (s, 1H); 4.06 (s, 1H); 3.97 (d, J = 10.4 Hz, 1H); 3.83 
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(d, J = 10.4 Hz, 1H); 3.75 (d, J = 6.8 Hz, 1H); 2.86 (s, 6H); 1.41 (s, 3H); 1.25 (d, J = 4.0 Hz, 
3H); MS (ESI+) Calcd. For C27H35F3N4O7+H, 585.25; Found, 585.24. 
 
benzyl ((1S,2R,3R,4S,5S)-2-(3,3-dimethylureido)-3,4-dihydroxy-2-((S)-1-hydroxyethyl)-
4-(hydroxymethyl)-3-methyl-5-((4-(methylthio)phenyl)amino)cyclopentyl)carbamate 
(S1i): Isolated from 2.28i via general procedure C in 89% yield. Analytical data: 1H NMR  
(400 MHz, CDCl3): δ 7.33 (bs, 5H); 7.16 (d, J = 7.6 Hz, 2H); 6.90 (bs, 1H); 6.49 (d, J = 7.2 
Hz, 2H); 6.11 (bs, 1H); 5.74 (bs, 1H); 5.27 (bs, 2H); 5.11 (d, J = 12.4 Hz, 1H); 5.07 (s, J = 
12.4 Hz, 1H); 4.15 (bs, 1H); 4.03 (bs, 1H); 3.97 (d, J = 11.6 Hz, 1H); 3.76 (d, J = 12.0 Hz, 
1H); 3.69 (d, J = 8.8 Hz, 1H); 2.84 (s, 6H); 2.39 (s, 3H); 1.38 (s, 3H); 1.24 (d, J = 5.6 Hz, 
13H); MS (ESI+) Calcd. For C27H38N4O7S +H, 563.25; Found, 563.27. 
General procedure D for salicylate ester formation. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-
hydroxy-6-methylbenzoate (2.61): A flame-dried 20-mL scintillation vial was charged with 
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cyanomethyl ester 2.27 (0.0075 g, 0.044 mmol, 1.1 equiv) and dimethylacetamide (DMA) (0.3 
mL). K2CO3 (0.005 g, 0.04 mmol, 1.0 equiv) was added, and the resulting mixture was stirred 
for 1 h.  The in situ generated ketene solution was transferred to a stirred solution of tetraol 
2.26 (0.02 g, 0.04 mmol, 1.0 equiv) in DMA (0.7 mL). The reaction was stirred until TLC 
analysis indicated full consumption of the tetraol starting material, typically 3 h. The reaction 
was cooled to 0 °C and quenched by the dropwise addition of saturated NH4Cl(aq.) (1.5 mL). 
The resulting mixture was extracted with EtOAc (3 x 5 mL), washed with H2O (10 ml), brine 
(10 mL), dried with magnesium sulfate, and concentrated in vacuo. The crude product was 
purified via flash chromatography (50:50 hexanes:EtOAc) to afford an inseparable mixture of 
salicylate 2.61 (0.02 g, 80%) and an unknown impurity (15% by NMR analysis) as a pale 
yellow, viscous oil. Analytical data: [α]D19 +33.6 (c = 0.70, CHCl3); 1H NMR  (600 MHz, 
CDCl3): δ 10.87 (s, 1H), 7.52 (br s, 1H), 7.36 (br s, 5H), 7.30-7.22 (m, 4H), 7.10 (s, 1H), 6.81 
(d, J = 8.4 Hz, 1H), 6.63 (d, J = 7.2 Hz, 1H), 6.13 (s, 1H), 5.79 (d, J = 9.0 Hz, 1H), 5.72 (d, J 
= 9.6 Hz, 1H), 5.23-5.10 (m, 3H), 4.91-4.84 (m, 2H), 4.06 (br s, 2H), 3.80 (d, J = 9.6 Hz, 1H), 
3.69 (s, 1H), 2.85 (s, 7H), 2.30 (s, 3H), 1.42 (s, 3H), 1.26 (s, 3H); 13C NMR (150 MHz, CDCl3): 
δ 198.3, 173.4, 162.9, 158.5, 155.3, 146.0, 141.6, 138.3, 135.0, 129.7, 128.6, 128.5, 123.2, 
119.4, 118.4, 115.8, 111.9, 111.6, 99.7, 88.6, 85.0, 73.9, 72.3, 67.5, 66.8, 66.6, 65.4, 62.7, 36.7, 
23.9, 21.0, 18.0, 17.4; MS (ESI+) Calcd. For C36H44N4O10+H, 693.3137; Found, 693.3172; IR 
(thin film, cm-1) 3392, 2965, 1867, 1698, 1670, 1541, 1456, 1374, 1249, 874, 737; TLC (50:50 
EtOAc:hexanes): Rf = 0.30. 
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(((1S,2R,3R,4S,5S)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-dimethylureido)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)-5-((4-methoxyphenyl)amino)-2-methylcyclopentyl) 
methyl 2-hydroxy-6-methylbenzoate) (S2c): Isolated from S1c via general procedure D in 
80% yield. Analytical data: 1H NMR  (400 MHz, CDCl3): δ 10.95 (s, 1H); 7.58 (d, J = 7.2 Hz, 
1H); 7.36 (br s, 4H); 7.28 (d, J = 8.8 Hz, 1H); 6.82 (d, J = 8.4 Hz, 1H); 6.74 (d, J = 8.8 Hz, 
2H); 6.66 (d, 7.6 Hz, 1H); 6.48 (d, J = 8.8 Hz, 2H); 6.04 (s, 1H); 5.90 (d, J = 8.0 Hz, 1H); 5.27 
(d, J = 10.4 Hz, 1H); 5.23 (s, 1H); 5.17 (d, J = 12.0 Hz, 1H); 5.11 (d, J = 12.0 Hz, 1H); 4.88 
(d, J = 12.8 Hz, 1H); 4.84 (d, J = 12.0 Hz, 1H); 4.07 (br s, 2H); 3.75 (s, 3H); 2.86 (s, 6H); 2.44 
(s, 3H); 1.50 (s, 3H); 1.27 (br s, 3H). MS (ESI+) Calcd. For C35H44N4O10+H, 681.31; Found, 
681.26. 
 
 ((1S,2R,3R,4S,5S)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-dimethylureido)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)-2-methyl-5-((4-(trifluoromethoxy)phenyl)amino) 
cyclopentyl)methyl 2-hydroxy-6-methylbenzoate (S2a): Isolated from S1a via general 
procedure D in 63% yield. Analytical data: 1H NMR  (400 MHz, CDCl3): δ 10.90 (br s, 1H); 
7.37-7.28 (m, 8H); 7.01 (d, J = 8.4 Hz, 2H); 6.84 (d, J = 8.4 Hz, 1H); 6.67 (d, J = 7.6 Hz, 1H); 
6.48 (d, J = 8.8 Hz, 2H); 5.84 (d, J = 8.0 Hz, 1H); 5.64 (br s, 1H); 5.22-5.51 (m, 2H); 4.93 (d, 
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J = 12.4 Hz, 1H); 4.05 (d, J = 7.6 Hz, 1H); 3.82 (br s, 1H); 3.72 (s, 1H); 3.00 (s, 1H); 2.88 (s, 
6H); 2.31 (s, 3H); 1.52 (s, 3H); 1.29 (d, J = 6.8 Hz, 3H); MS (ESI+) Calcd. For 
C35H41F3N4O10+H, 735.29; Found, 735.20. 
 
((1S,2R,3R,4S,5S)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-dimethylureido)-5-((3-
fluorophenyl)amino)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 
2-hydroxy-6-methylbenzoate (S2b): Isolated from S1b via general procedure D in 80% yield. 
Analytical data: 1H NMR  (400 MHz, CDCl3): δ 11.91 (s, 1H); 7.54 (br s, 1H); 7.34 (br s, 4H); 
7.27 (d, J = 8.0 Hz, 1H); 7.25 (d, J = 6.4 Hz, 1H); 7.07 (q, J = 7.2 Hz, 1H); 6.81 (d, J = 8.0 Hz, 
1H); 6.65 (d, J = 7.6 Hz, 1H); 6.39 (dd, J = 2.0, 8.0 Hz, 1H); 6.29 (dd, J = 1.6, 8.0 Hz, 1H); 
6.21 (d, J = 11.6 Hz, 1H); 6.12 (s, 1H); 5.79 (d, J = 8.8 Hz, 1H); 5.69 (d, J = 10.0 Hz, 1H); 
5.17-5.10 (m, 3H); 4.90 (d, J = 12.4 Hz, 1H); 4.80 (d, J = 12.4 Hz, 1H); 4.03 (d, J = 8.4 Hz, 
1H); 3.74 (s, 1H); 3.70 (d, J = 9.6 Hz, 1H); 2.84 (s, 6H); 2.33 (s, 3H); 1.48 (s, 3H); 1.24 (d, J 
= 7.2 Hz, 3H); MS (ESI+) Calcd. For C34H41FN4O9+H, 669.15; Found, 669.15. 
 
((1S,2R,3R,4S,5S)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-dimethylureido)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)-2-methyl-5-(phenylamino)cyclopentyl)methyl 2-
hydroxy-6-methylbenzoate (S2d): Isolated from S1d via general procedure D in 69% yield. 
Analytical data: 1H NMR  (400 MHz, CDCl3): δ 10.93 (s, 1H); 7.57 (br s, 1H); 7.35 (br s, 4H); 
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7.27-7.20 (m, 2H); 7.14 (t, J = 7.6 Hz, 2H); 6.80 (d, J = 8.4 Hz, 1H); 6.72 (t, J = 7.2 Hz, 1H); 
6.65 (d, J = 7.2 Hz, 1H); 6.52 (d, J = 7.6 Hz, 2H); 6.05 (s, 1H); 5.84 (d, J = 9.6 Hz, 1H); 5.50 
(d, J = 10.0 Hz, 1H); 5.21 (s, 1H); 5.17-5.07 (m, 2H); 4.91-4.81 (m, 2H); 4.28 (s, 1H); 4.05 (d, 
J = 8.0 Hz, 1H); 3.75 (br s, 2H); 2.83 (s, 6H); 2.34 (s, 3H); 1.48 (s, 3H); 1.13 (br s, 3H); MS 
(ESI+) Calcd. For C34H42N4O9  +H, 651.30; Found, 651.39. 
 
((1S,2R,3R,4S,5S)-4-(((benzyloxy)carbonyl)amino)-5-((4-(tert-butyl)phenyl)amino)-3-
(3,3-dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 
2-hydroxy-6-methylbenzoate  (S2e): Isolated from S1e via general procedure D in 76% yield. 
Analytical data: 1H NMR  (400 MHz, CDCl3): δ 10.95 (br s, 1H); 7.49 (br s, 1H); 7.54 (br s, 
5H); 7.27-7.24 (m, 2H); 7.15 (d, J = 8.4 Hz, 2H); 6.81 (d, J = 8.4 Hz, 1H) 6.65 (d, J = 7.6 Hz, 
1H); 6.06 (s, 1H); 5.83 (d, J = 8.4 Hz, 1H); 5.37 (d, J = 10.4 Hz, 1H); 5.20-5.15 (m, 2H); 5.09 
(d, J = 12.0 Hz, 1H); 485-4.80 (m, 2H); 4.31 (s, 1H); 4.05 (d, J = 7.6, 1H); 3.75 (d, J  =9.2 Hz, 
1H); 3.66 (br s, 1H); 2.83 (s, 6H); 2.33 (s, 3H); 1.47 (s, 3H); 1.27-1.23 (m, 12H); MS (ESI+) 
Calcd. For C38H50N4O9+H, 707.37; Found, 707.24. 
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((1S,2R,3R,4S,5S)-5-((9H-fluoren-2-yl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-
hydroxy-6-methylbenzoate (S2f): Isolated from S1f via general procedure D in 83% yield. 
Analytical data: 1H NMR  (400 MHz, CDCl3): δ 10.92 (s, 1H); 7.61 (d, J = 7.2 Hz, 1H); 7.54 
(d, J = 8.0 Hz, 2H); 7.45 (d, J = 7.2 Hz, 1H); 7.42 (m, 4H); 7.31 (t, J = 7.5 Hz, 2H); 7.26-7.18 
(m, 3H); 6.79 (d, J = 8.4 Hz, 1H); 6.71 (s, 1H); 6.61 (d, J = 7.6 Hz, 1H); 6.54 (d, J = 8.0 Hz, 
1H); 6.16 (s, 1H); 5.82 (d, J = 8,4 Hz, 1H); 5.63 (d, J = 10.0 Hz, 1H); 5.21-5.14( m, 3H); 4.91-
4.88 (m, 2H); 3.82 (br s, 1H); 3.71 (br s, 2H); 2.85 (s, 6H); 2.32 (s, 3H); 1.50 (s, 3H); 1.24 (br 
s, 3H); LRMS (ESI+) Calcd. For C41H46N4O9+H, 739.33; Found, 739.21.   
 
((1S,2R,3R,4S,5S)-4-(((benzyloxy)carbonyl)amino)-5-((4-bromonaphthalen-1-yl)amino)-
3-(3,3-dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl) 
methyl 2-hydroxy-6-methylbenzoate (S2g): Isolated from S1g via general procedure D in 
97% yield. Analytical data: 1H NMR  (400 MHz, CDCl3): δ 10.88 (br s, 1H); 8.21 (d, J = 8.4 
Hz, 1H); 7.73 (d, J = 8.0 Hz, 1H); 7.62-7.58 (m, 2H); 7.50 (t, J = 7.2 Hz, 2H); 7.36 (br s, 5H); 
7.27-7.23 (m, 2H); 6.80 (d, J = 8.0 Hz, 1H); 6.64-6.59 (m, 2H); 6.36 (s, 1H); 6.20 (d, J = 8.0 
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Hz, 1H); 5.81 (br s, 1H); 5.20-5.18 (m, 3H); 5.00-4.98 (m, 2H); 4.05 (br s, 1H); 3.89 (d, J = 
9.2 Hz,1H); 3.81 (s, 1H); 2.86 (s, 6H); 2.21(s, 3H); 1.65 (s, 3H) 1.22 (br s, 3H); MS (ESI+) 
Calcd. For C38H43BrN4O9+H, 779.23; Found, 779.20. 
 
((1S,2R,3R,4S,5S)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-dimethylureido)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)-2-methyl-5-((4-(trifluoromethyl) phenyl)amino) 
cyclopentyl)methyl 2-hydroxy-6-methylbenzoate (S2h): Isolated from S1h via general 
procedure D in >99% yield. Analytical data: 1H NMR  (400 MHz, CDCl3): δ 10.89 (br s, 1H); 
7.52 (br s, 1H); 7.36-7.26 (m, 8H); 6.82 (d, J = 8.4 Hz,1H); 6.65 (d, J = 7.6 Hz, 1H); 6.51 (d, 
J = 8.0 Hz, 2H); 6.16 (s, 1H); 5.92 (d, J = 9.6 Hz, 1H); 5.81 (br s, 1H); 5.17-5.11(m, 3H); 4.93 
(d, J = 12.4 Hz, 1H); 4.81 (d, J = 12.8 Hz, 1H); 2.27 (s, 3H); 1.50 (s, 3H); 1.26 (br s, 3H); MS 
(ESI+) Calcd. For C35H41F3N4O9+H, 719.29; Found, 719.23. 
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General procedure E for Carboxybenzyl group hydrogenolysis. 
 
Pactamycin (2.1): A 4-mL vial was charged with salicylate 2.61 (0.0075 g, 0.01 mmol, 1.0 
equiv), and Pd(OH)2/C (20 wt.%, 0.005 g). MeOH (1 mL) was added and the vial was sealed 
with a Teflon cap. The atmosphere was replaced by H2 (balloon, ~1 atm.) and stirred until TLC 
analysis indicated complete consumption of the starting material, typically 20 min. The 
resulting suspension was filtered through a pad of celite and washed with MeOH. The 
homogeneous solution was concentrated in vacuo. The crude residue was purified by flash 
chromatography (98:2 CH2Cl2:MeOH) affording pactamycin (0.005 g, 82%) as a pale yellow 
solid. Analytical data: [α]D19 +27.4 (c = 0.40, CHCl3); 1H NMR  (600 MHz, CDCl3): δ  10.98 
(br s, 1H), 7.91 (d, J = 10.8 Hz, 1H), 7.26-7.23 (m, 4H), 7.18-7.16 (m, 2H), 6.81-6.78 (m, 2H), 
6.64 (d, J = 7.2 Hz, 1H), 5.78 (br s, 1H), 5.67 (d, J = 10.8 Hz, 1H), 4.84 and 4.79 (ABq, J = 
12.6 Hz, 2H), 3.93 (m, 1H), 3.80 (d, J = 10.2 Hz, 1H), 2.99 (s, 6H), 2.95 (s, 1H), 2.55 (s, 3H), 
2.38 (s, 3H), 1.55 (s, 3H), 1.04 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 198.5, 
172.6, 162.8. 159.2, 146.6, 141.2, 138.3, 134.6, 129.6, 123.0, 118.7, 118.4, 115.7, 112.0, 110.8, 
88.8, 84.9, 74.3, 71.5, 68.7, 65.4, 63.2, 36.9, 29.7, 26.7, 24.1, 21.1, 18.1; MS (ESI+) Calcd. for 
C28H38N4O8+H, 559.2762; Found, 559.2763; IR (thin film, cm
-1) 3393, 2938, 2359, 2341, 
1698, 1652, 1520, 1473, 1418, 1338, 873, 668; TLC (95:5 CH2Cl2/MeOH): Rf = 0.30. 
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(((1S,2R,3R,4S,5S)-4-amino-3-(3,3-dimethylureido)-1,2-dihydroxy-3-((S)-1-
hydroxyethyl)-5-((4-methoxyphenyl)amino)-2-methylcyclopentyl)methyl 2-hydroxy-6-
methylbenzoate) (2.29c): Isolated from S2c via general procedure E in 72% yield. Analytical 
data: [α]D19 +20.9 (c = 0.63, CHCl3); 1H NMR  (400 MHz, CDCl3): δ 10.80 (br s, 1H); 7.93 
(br s, 1H); 7.28-7.24 (m, 2H); 7.21-7.18 (m, 2H); 6.83 (d, J = 8.4 Hz, 1H); 6.78 (d, J = 8.8 Hz, 
2H); 6.68 (d, J = 7.2 Hz, 1H); 6.57 (d, J = 8.4 Hz, 2H); 5.68 (br s, 1H); 5.18 (br s, 1H); 4.85 
(d, J = 12.4 Hz, 1H); 4.80 (d, J = 12.0 Hz, 1H); 3.97 (br s, 1H); 3.76 (s, 3H); 3.00 (s, 7H); 2.91 
(s, 1H); 2.47 (s, 3H); 2.38 (s, 1H); 1.55 (s, 3H); 1.06 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ 172.3, 162.5, 159.2, 152.1, 141.3, 140.5, 134.3, 129.0, 128.2, 125.2, 122.9, 115.6, 
115.1, 114.5, 112.40, 88.7, 84.7, 74.0, 71.3, 69.9, 65.4, 62.6, 55.7, 36.80, 23.9, 21.4, 18.1; MS 
(ESI+) Calcd. for C27H38N4O8+H, 547.28; Found, 547.22; IR (thin film, cm
-1) 3774, 3406, 
2935, 2359, 2069, 1610, 1511, 1377, 1251, 1105, 943; TLC (95:5 CH2Cl2:MeOH): Rf =  0.30. 
 
((1S,2R,3R,4S,5S)-4-amino-3-(3,3-dimethylureido)-1,2-dihydroxy-3-((S)-1-
hydroxyethyl)-2-methyl-5-((4-(trifluoromethoxy)phenyl)amino)cyclopentyl)methyl 2-
hydroxy-6-methylbenzoate (2.29a): Isolated from S2a via general procedure E in 96% yield. 
Analytical data: [α]D19 +34.4 (c = 0.70, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 11.02 (br s, 
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1H); 7.94 (d, J = 11.4 Hz, 1H); 7.31-7.27 (m, 2H); 7.17 (br s, 1H); 7.05 (d, J = 9.0 Hz, 2H); 
6.85 (d, J = 7.8 Hz, 1H); 6.69 (d, J = 7.2 Hz, 1H); 6.58 (d, J = 8.4 Hz, 1H); 5.84 (br s, 1H); 
5.62 (d, J = 10.2 Hz,1H); 4.87 (d, J = 12.6 Hz, 1H); 4.83 (d, J = 12.6 Hz, 1H); 3.99 (br s, 1H); 
3.74 (d, J = 10.2 Hz, 1H); 3.02 (s, 6H); 2.40 (s, 3H); 1.58 (s, 3H); 1.10 (d, J = 6.6 Hz, 3H); 13C 
NMR (150 MHz, CDCl3): δ 172.7, 162.8, 159.2, 145.2, 141.4, 140.6, 134.7, 123.1, 122.8, 
115.7, 113.3, 112.1, 84.9, 65.4, 36.9, 24.0, 21.1, 18.1; MS (ESI+) Calcd. For C27H35F3N4O8+H, 
601.25; Found, 601.28; IR (thin film, cm-1) 3774, 3398, 2935, 2359, 2056, 1723, 1612, 1513, 
1378, 1253, 1163, 1106, 1044, 977, 805; TLC (95:5 CH2Cl2:MeOH): Rf = 0.29. 
 
((1S,2R,3R,4S,5S)-4-amino-3-(3,3-dimethylureido)-5-((3-fluorophenyl)amino)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-hydroxy-6-methyl 
benzoate (2.29b): Isolated from S2b via general procedure E in >99% yield. Analytical data:  
[α]D19 +34.8 (c = 0.90, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 11.04 (br s, 1H); 7.99 (d, J = 
5.2 Hz, 1H); 7.30-7.28 (m, 2H); 7.27-7.18 (m, 2H); 7.12 (dd, J = 5.2, 10.0 Hz, 1H); 6.85 (d, J 
= 5.2 Hz, 1H); 6.70 (d, J = 5.2 Hz, 1H); 6.43 (dd, J = 1.2, 5.6 Hz, 1H); 6.39 (dd, J = 1.2, 11.6 
Hz, 1H); 6.29 (d, J = 7.6 Hz, 1H); 5.83 (s, 1H); 5.69 (d, J = 6.8 Hz, H); 4.87 (d, J = 7.2 Hz, 
1H); 4.82 (d, J = 8.4 Hz, 1H); 3.95 (br s, 1H); 3.72 (d, J = 7.2 Hz, 1H); 3.01 (s, 6H); 2.97 
(s,1H); 2.43 (s, 3H); 1.57 (s, 3H); 1.07 (d, J = 4.0 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 
172.7, 162.8, 159.2, 148.1, 141.3, 134.6, 130.7,  129.0, 128.2,  123.1, 115.7, 112.0, 109.4, 
104.1,  99.4, 88.7, 84.8, 74.2, 71.4, 68.7, 65.2, 63.0, 36.8, 24.0, 21.1, 18.1; MS (ESI+) Calcd. 
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For C26H37FN4O7+H, 535.26; Found, 535.19; IR (thin film, cm
-1) 3397, 2933, 2359, 1724, 
1655, 1617, 1513, 1495, 1377, 1291, 1213, 1091, 943; TLC (95:5 CH2Cl2:MeOH): Rf = 0.29. 
 
((1S,2R,3R,4S,5S)-4-amino-3-(3,3-dimethylureido)-1,2-dihydroxy-3-((S)-1-
hydroxyethyl)-2-methyl-5-(phenylamino)cyclopentyl)methyl 2-hydroxy-6-
methylbenzoate (2.29d): Isolated from S2d via general procedure E in 83% yield. Analytical 
data: [α]D19 -8.9 (c = 0.40, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 10.94 (br s, 1H); 7.90 (dd, 
J = 5.4 Hz, 1H); 7.26 (t, J = 7.8 Hz, 2H); 7.22-7.16 (m, 3H); 6.82 (d, J = 8.4 Hz, 1H); 6.71 (t, 
J = 7.8 Hz, 1H); 6.66 (d, J = 7.2 Hz,1H); 6.59 (d, J = 7.8 Hz, 2H); 5.76 (s, 1H); 5.47 (d, J = 
11.4 Hz, 1H); 4.84 (d, J = 12.6 Hz, 1H); 4.82 (d, J = 12.0 Hz, 1H); 3.94 (dd, J = 6.0, 10.2 Hz, 
1H); 3.76 (d, J = 10.8 Hz, 1H); 2.98 (s, 6H); 2.94 (s, 1H); 2.42 (s, 3H); 1.54 (s, 3H); 1.03 (d, J 
= 6. Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 172.7, 162.8, 159.2, 146.3, 141.4, 134.5, 129.5, 
123.0, 117.7, 115.7, 113.2, 112.1, 89.8, 88.8, 84.9, 74.2, 71.5, 68.9, 65.3, 63.0, 36.8, 36.8, 29.7, 
24.1, 21.2, 18.1; MS (ESI+) Calcd. For C26H38N4O7+H, 517.27; Found, 517.29; IR (thin film, 
cm-1) 3876, 3846, 3774, 3398, 2929, 2359, 1724, 1603, 1460, 1305, 1213, 977; TLC (95:5 
CH2Cl2:MeOH): Rf = 0.26. 
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((1S,2R,3R,4S,5S)-4-amino-5-((4-(tert-butyl)phenyl)amino)-3-(3,3-dimethylureido)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-hydroxy-6-
methylbenzoate  (2.29e): Isolated from S2e via general procedure E in 88% yield. Analytical 
data: [α]D19 +35.9 (c = 0.50, CHCl3); 1H NMR  (400 MHz, CDCl3): δ 11.03 (br s, 1H);7.89 (d, 
J = 10.8 Hz, 1H); 7.28 (t, J = 6.0 Hz, 2H); 7.22-7.19 (m, 4H); 6.84 (d, J = 8.4 Hz, 1H); 6.69 
(d, J = 7.6, 1H); 6.56 (d, J = 8.4 Hz, 2H); 5.70 (s, 1H); 5.33 (d, J = 11.2 Hz, 1H); 4.85 (d, J = 
12.0 Hz, 1H); 4.81 (d, J = 12.4 Hz, 1H); 3.98 (dd, J = 6.4, 1.2 Hz, 1H); 3.76 (d, J = 10.8 Hz, 
1H); 3.01 (s, 6H); 2.46 (s, 3H); 2.38 (s, 1H); 1.56 (s, 3H); 1.29 (s, 9H) 1.06 (d, J = 6.4 Hz, 3H); 
13C NMR (125 MHz, CDCl3): δ 172.5, 167.7, 159.2, 143.8, 141.3, 140.4, 134.4, 126.2, 122.9, 
115.7, 112.9, 112.2, 88.7, 84.8, 74.0, 71.4, 69.3, 65.3, 63.2, 36.8, 33.8, 31.5, 29.7, 24.1, 21.2, 
18.1; MS (ESI+) Calcd. For C30H44N4O7+H, 573.33; Found, 573.33; IR (thin film, cm
-1) 3379, 
3204, 2961, 2360, 1723, 1607, 1518, 1364, 1255, 1082; TLC (90:10 CH2Cl2/MeOH): Rf = 
0.92. 
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((1S,2R,3R,4S,5S)-5-((9H-fluoren-2-yl)amino)-4-amino-3-(3,3-dimethylureido)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-hydroxy-6-
methylbenzoate (2.29f): Isolated from S2f via general procedure E in 40% yield. Analytical 
data: [α]D19 +21.4 (c = 0.23, CHCl3); 1H NMR  (600 MHz, CDCl3): δ (400 MHz, CDCl3): δ 
11.02 (br s, 1H); 7.95 (d, J = 10.8 Hz, 1H); 7.64 (d, J = 7.6 Hz, 1H); 7.59 (d, J = 8.4 Hz, 1H); 
7.48 (d, J = 7.6 Hz, 1H); 7.33 (t, J = 7.2 Hz, 1H); 7.29-7.19 (m, 3H); 6.81 (d, J = 8.0 Hz, 2H); 
6.66-6.63 (m, 2H); 5.83 (s, 1H); 5.60 (d, J = 10.8 Hz, 1H); 4.90 (d, J = 12.4 Hz, 1H); 4.86 (d, 
J = 12.4 Hz, 1H); 4.01 (dd, J = 6.4, 10.4 Hz, 1H); 3.85 (d, J = 10.8 Hz, 2H); 3.81 (d, J = 7.6 
Hz, 1H); 3.06 (s, 1H); 3.02 (s, 6H); 2.44 (s, 3H); 1.59 (s, 3H); 1.07 (d, J = 6.4 Hz, 3H); 13C 
NMR (150 MHz, CDCl3): δ 172.6, 162.7, 159.2, 145.8, 145.4, 142.1, 142.1, 141.3, 134.5, 
132.3, 126.6, 125.0, 124.7, 123.0, 120.9, 118.4, 115.6, 122.1, 110.0, 88.8, 85.0, 74.2, 71.4, 
69.2, 65.4, 65.1, 36.9, 36.8, 24.1, 21.2, 18.1; MS (ESI+) Calcd. For C33H40N4O7+H, 605.30; 
Found, 605.29. IR (thin film, cm-1) 3397, 2925, 1653, 1616, 1519, 1457, 1375, 1290, 1256, 
1096, 804; TLC (95:5 CH2Cl2:MeOH): Rf = 0.37. 
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((1S,2R,3R,4S,5S)-4-amino-3-(3,3-dimethylureido)-1,2-dihydroxy-3-((S)-1-
hydroxyethyl)-2-methyl-5-(naphthalen-1-ylamino)cyclopentyl)methyl 2-hydroxy-6-
methylbenzoate  (2.29g): Isolated from S2g via general procedure E in 48% yield. Analytical 
data: [α]D19 +28.1 (c = 0.82, CHCl3) 1H NMR  (600 MHz, CDCl3): δ 10.98 (s, 1H); 7.97 (br s, 
1H); 7.79 (d, J = 6.0 Hz, 1H); 7.74 (d, J = 12.0 Hz, 1H); 7.46 (m, 2H); 7.31 (t, J = 6.0 Hz, 1H); 
7.27-7.21 (m, 4H); 6.79 (d, J =  8.4 Hz, 1H); 6.61 (d, J = 7.2 Hz, 1H); 6.51 (m, 2H); 5.98 (s, 
1H); 4.95 (dd, J = 12.0, 7.2 Hz, 2H); 3.97 (m, 2H); 3.06 (br s, 1H); 2.98 (s, 6H); 2.96 (m, 2H); 
2.33 (s, 3H); 1.61 (s, 3H); 0.98 (d, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 172.7, 
162.7, 159.3, 141.7, 141.4, 134.6, 134.5, 128.5, 126.3, 126.1, 125.2, 123.7, 123.0, 120.1, 117.3, 
115.6, 122.1, 103.3, 88.9, 85.1, 74.5, 71.6, 68.5, 65.4, 62.9, 36.8, 23.9, 21.2, 18.0; MS (ESI+) 
Calcd. For C30H38N4O7+H, 567.28; Found, 567.28; IR (thin film, cm
-1) 3756, 3398, 3053, 
2984, 2935, 2410, 2304, 1949, 1725, 1656, 1582, 1486, 1265, 1120, 943; TLC (95:5 
CH2Cl2:MeOH): Rf = 0.33. 
 
((1S,2R,3R,4S,5S)-4-amino-3-(3,3-dimethylureido)-1,2-dihydroxy-3-((S)-1-
hydroxyethyl)-2-methyl-5-((4-(trifluoromethyl)phenyl)amino)cyclopentyl)methyl 2-
hydroxy-6-methylbenzoate (2.29h): Isolated from S2h via general procedure E in 96% yield. 
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Analytical data: [α]D19 +30.0 (c = 0.15, CHCl3) 1H NMR  (600 MHz, CDCl3): δ 10.98 (br s, 
1H); 7.93 (d, J = 10.8 Hz, 1H); 7.39 (d, J = 8.4 Hz, 2H); 7.27 (m, 2H); 7.16 (s, 1H); 6.82 (d, J 
= 8.4 Hz, 1H); 6.66 (d, J = 7.2 Hz, 1H); 6.59 (d, J = 8.4 Hz, 2H); 5.91 (d, J = 9.6 Hz, 1H); 5.84 
(s, 1H); 4.85 (d, J = 12.0 Hz, 1H); 4.79 (d, J = 12.0 Hz, 1H); 3.91 (m, 1H); 3.76 (d, J = 12.0 
Hz, 1H); 2.99 (s, 6H); 2.36 (s, 3H); 2.17 (s, 3H); 2.07 (s, 3H); 1.55 (s, 3H); 1.05 (d, J = 6.0 Hz, 
3H); 13C NMR (100 MHz, CDCl3): δ 172.5, 170.7, 162.7, 159.2, 148.5, 141.2, 134.6, 126.9, 
126.9, 123.0, 115.7, 112.2, 112.1, 88.9, 84.7, 74.3, 71.5, 68.3, 65.3, 63.4, 38.0, 36.8, 35.2, 23.9, 
21.5, 21.1, 18.1; MS (ESI+) Calcd. For C27H35F3N4O7+H, 585.25; Found, 585.18; IR (thin 
film, cm-1) 3413, 2359, 1617, 1524, 1457, 1375, 1321, 1255, 1213, 1160, 1106, 1064, 737; 
TLC (95:5 CH2Cl2:MeOH): Rf = 0.17. 
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Enantioselective Mannich reaction to provide enantioenriched material. 
 
(R,E)-benzyl (4-acetyl-4-(3,3-dimethylureido)-5-oxo-1-phenylhex-1-en-3-yl)carbamate 
(2.60): A flame-dried 250-mL round-bottomed flask was charged with urea 2.58 (2.38 g, 12.28 
mmol, 1.0 equiv), cinchonidine (0.72 g, 2.46 mmol, 0.2 equiv), and CH2Cl2 (65 mL). The 
resulting suspension was cooled to -78 °C and a cold solution of imine 2.59 (5.1 g, 19.24 mmol, 
1.5 equiv) in CH2Cl2 (35 mL) was added via cannula transfer. The reaction was warmed to -65 
°C and stirred until complete consumption of urea 2.58 was indicated by TLC analysis, 
typically 14-36 h (scale-dependent). The crude reaction was filtered through a short silica plug 
and rinsed with EtOAc (300 mL). The filtrate was concentrated in vacuo to give a pale yellow 
foam with a 84:16 enantiomeric ratio. Crystalline racemic product was isolated via trituration 
with 60:40 (v/v) hexanes:EtOAc (300 mL). The analytically-pure white solid was removed by 
filtration (1.33 g, 24%) and the filtrate was concentrated in vacuo to give a yellow oil. The 
crude oil was purified by flash chromatography (60:40 to 50:50 hexanes:EtOAc) affording 
diketone 2.60 as a pale yellow foam (3.87 g, 70%, 97:3 er). The enantiomeric ratio was 
determined by SFC analysis (Chiralcel, OD, 9.0% MeOH, 1.5 mL/min, 150 bar, 210 nm; tR-
minor 12.8 min, tR-major 14.7 min). Analytical data: [α]D19 +16.5 (c = 1.00, CHCl3); mp 
(racemate) 130-134 °C; 1H NMR  (600 MHz, CDCl3): δ 7.37-7.21 (m, 10H), 7.07 (br d, J = 
6.0 Hz, 1H), 6.59 (d, J = 16.2 Hz, 1H), 6.50 (s, 1H), 5.96 (dd, J = 16.2 Hz, 7.2, 1H), 5.40 (t, J 
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= 7.2 Hz, 1H), 5.14 (d, J = 12.0 Hz, 1H), 5.11 (d, J = 12.0 Hz, 1H), 2.97 (s, 6H), 2.28 (s, 3H), 
2.14 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 200.9, 200.4, 157.6, 156.7, 136.9, 136.5, 133.2, 
128.7, 128.6, 128.2, 128.2, 128.1, 126.9, 124.6, 81.7, 67.0, 57.2, 36.8, 26.2, 25.4; MS (ESI+) 
Calcd. For C25H29N3O5+H, 452.2187; Found, 452.2212; IR (thin film, cm
-1) 3418, 2243, 1702, 
1635, 1507, 1371, 1249, 1066, 912, 693; TLC (60:40 hexanes:EtOAc): Rf = 0.20.  
 
ent-pactamycin (ent-2.1): When cinchonidine is replaced by cinchonine in the above reaction, 
a crude enantiomeric ratio of 84:16 is obtained.  Upon the analogous trituration protocol, ent-
2.60 is isolated in 68% yield and 96.5:3.5 er (See SFC assay comparison below).  When this 
material is carried forward in the synthesis, ent-pactamycin is obtained.  The optical rotation 
was measured: [α]D19 -23.2 (c = 0.40, CHCl3). 
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SFC analysis of racemic Mannich product 2.60 (20 mol % NIPr2Et) 
 
 
 
 
 
Mannich product for natural pactamycin enantiomer synthesis 
                  Cinchonidine: Crude reaction mixture  (16:84 e.r.)                after purification/trituration (2:98 er) 
ere.r.) 
 
 
 
Mannich product for ent-pactamycin synthesis 
    Cinchonine: Crude reaction mixture (84:16 e.r.)              after trituration/purification (96.5:3.5 e.r.) 
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General procedure F for isocycanate formation/trapping. 
 
Benzyl (1aR,1bR,4aR,5R,5aR)-4a-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5a-(((tert-
butyldiphenylsilyl)oxy)methyl)-5-hydroxy-5-methyl-3-oxohexahydro oxireno 
[2',3':3,4]cyclopenta[1,2-d]imidazole-2(1aH)-carboxylate (2.31).  A 20-mL scintillation 
vial was charged with urea 2.25 (0.06 g, 0.077 mmol, 1.00 equiv) and an 8:1 mixture of 
MeOH:H2O (6.0 mL), and NH4Cl (0.123 g, 2.31 mmol, 30.0 equiv) was added. The vial was 
sealed with a screw-cap and the mixture was heated to 85 °C with vigorous stirring until TLC 
analysis indicated full conversion of the starting material, generally 16 h. The resulting mixture 
was concentrated and the remaining residue was dissolved in water (10 mL).  The solution was 
extracted with EtOAc (3 x 8 mL) and the combined organics were washed with brine (10 mL), 
dried with magnesium sulfate, and concentrated in vacuo. The product was purified via flash 
chromatography (70:30 hexanes:EtOAc), obtaining 2.31 as a pale yellow solid (0.056 g, 73%).  
Analytical Data:   1H NMR  (400 MHz, CDCl3): δ 7.67-7.65 (m, 4H); 7.44-7.33 (m, 12H); 
5.35 (s, 1H); 5.30 (s, 2H); 4.23 (br s, 2H); 3.99 (br s, 2H); 3.75 (s, 1H); 1.60 (s, 3H); 1.17 (d, 
J = 6.0 Hz, 3H); 1.16 (s, 9H); 0.87 (s, 9H); 0.10 (s, 3H); 0.08 (s, 3H);  MS (ESI+) Calcd. For 
C40H54N2O7Si2+H, 731.35; Found, 731.23. 
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General procedure G for selective TBS deprotection of C7 alcohol. 
 
Benzyl ((1R,2R,3R,4R,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(3,3-
dimethylureido)-4-hydroxy-3-((S)-1-hydroxyethyl)-4-methyl-6-oxabicyclo[3.1.0]hexan-
2-yl)carbamate (2.32)  A 20-mL scintillation vial was charged with silyl ether 2.28 (0.067 g, 
0.073 mmol, 1.00 equiv), and a 9:1 mixture of CH3CN:H2O (5 mL).  To the resulting solution 
was added Oxone ® (0.022 g, 0.15 mmol, 2.00 equiv), and the reaction was vigorously stirred 
until full conversion of 2.28 was observed by TLC analysis, typically 3 h.  The mixture was 
diluted with H2O (3 mL) and EtOAc (3 mL), and the layers were partitioned in a separatory 
funnel and extracted with EtOAc (3 x 10 mL).  The combined organic extracts were washed 
with brine (10 mL), dried with magnesium sulfate, and concentrated in vacuo.  The product 
was purified via flash chromatography (70:30 hexanes:EtOAc) to afford triol 2.32 (0.049 g, 
84%) as a clear, viscous oil. Analytical data: 1H NMR  (400 MHz, CDCl3): δ 7.63 (d, J = 6.4 
Hz, 2H); 7.50 (d, J = 8.0 Hz, 2H); 7.43-7.30 (m, 11H); 7.25 (d J = 8.4 Hz,2H); 7.19 (t, J = 7.2 
Hz, 2H); 7.05 (s, 1H); 6.66 (d, J = 7.2 Hz, 1H); 5.92 (d, J = 9.6 Hz, 1H); 5.55 (br s, 1H); 5.22-
5.13 (m, 3H); 4.02-3.99 (m, 3H); 3.92 (d, J = 10.0 Hz,1H); 3.74 (d, J = 9.6 Hz, 1H); 2.87 (s, 
6H); 2.53 (s, 3H); 1.43 (s, 3H); 1.25 (d, J = 8.4 Hz, 3H); 1.02 (s, 9H); MS (ESI+) Calcd. For 
C44H56N4O8Si+H, 797.39; Found, 797.34. 
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Benzyl ((1S,2R,3R,4S,5S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(3,3-
dimethylureido)-5-((3-fluorophenyl)amino)-3,4-dihydroxy-2-((S)-1-hydroxyethyl)-3-
methylcyclopentyl)carbamate (S3a): Isolated from 2.28b via general procedure G in 87% 
yield. Analytical data:  1H NMR  (400 MHz, CDCl3): δ 7.64 (d, J = 6.8 Hz, 2H); 7.51 (d, J = 
7.2 Hz, 2H); 7.46-7.37 (m, 9H); 7.23-7.19 (m, 2H); 7.10 (br s, 1H); 6.44-6.41 (m, 1H); 6.25 
(d, J = 8.0 Hz, 1H); 6.18 (d, J = 11.6 Hz, 1H); 5.95 (br s, 2H); 5.55 (d, J = 9.6 Hz,1H); 5.20-
5.17 (m, 3H); 4.12 (br s, 3H); 4.01 (d, J = 10.4 Hz, 1H); 3.69 (br s, 2H); 2.87 (s, 6H); 1.41 (s, 
3H); 1.25 (br s, 3H); 1.03 (s, 9H); MS (ESI+) Calcd. For C42H53FN4O7Si+H, 773.37; Found, 
773.46. 
 
Benzyl ((1S,2R,3R,4S,5S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(3,3-
dimethylureido)-3,4-dihydroxy-2-((S)-1-hydroxyethyl)-5-((4-methoxyphenyl)amino)-3-
methylcyclopentyl)carbamate (S3b): Isolated from 2.28c via general procedure G in 62% 
yield. Analytical data: 1H NMR  (600 MHz, CDCl3): δ 7.65 (d, J = 7.8 Hz, 2H); 7.58 (br s, 
1H); 7.55 (d, J = 7.8 Hz, 2H); 7.44-7.34 (m, 8H); 7.22 (t, J = 7.8 Hz, 2H); 6.76 (d, J = 8.4 Hz, 
2H); 6.42 (d, J = 7.8 Hz, 2H); 5.95 (s, 1H); 5.89 (br s, 1H); 5.20-5.18 (m, 2H); 5.14-5.11 (m, 
2H); 4.00 (br s, 2H); 3.92 (d, J = 9.6 Hz, 1H); 3.76 (s, 3H); 3.68 (s, 1H); 3.64 (d, J = 6.6 Hz, 
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1H); 2.86 (s, 6H); 1.41 (s, 3H); 1.25 (br s, 3H); 1.03 (s, 9H); MS (ESI+) Calcd. For 
C43H56N4O8Si+H, 785.39; Found, 785.49. 
 
Benzyl ((1S,2R,3R,4S,5S)-5-((4-(tert-butyl)phenyl)amino)-4-(((tert-butyldiphenylsilyl) 
oxy)methyl)-2-(3,3-dimethylureido)-3,4-dihydroxy-2-((S)-1-hydroxyethyl)-3-
methylcyclopentyl)carbamate (S3c): Isolated from 2.28e via general procedure G in 77% 
yield.  Analytical data:  1H NMR  (400 MHz, CDCl3): δ 7.64 (d, J = 6.8 Hz, 2H); 7.58 (d, J = 
9.8 Hz, 1H); 7.51 (d, J = 6.8 Hz, 2H); 7.43-7.32 (m, 9H); 7.20-7.17 (m, 4H); 6.42 (d, J = 8.4 
Hz, 2H); 5.96-5.92 (m, 2H); 5.27 (dd, J = 4.4, 14.4 Hz, 1H); 5.23-5.20 (m, 2H); 5.13 (d, J = 
12.0 Hz, 1H); 4.15-4.10 (m, 3H); 3.72 (s, 1H); 3.67 (d, J = 8.8 Hz, 1H); 2.87 (s, 6H); 1.43 (s, 
3H); 1.29 (s, 9H); 1.27 (d, J = 7.2 Hz, 3H); 1.03 (s, 9H); MS (ESI+) Calcd. For 
C46H62N4O7Si+H, 811.45; Found, 811.53. 
 
Synthesis of De 6-MSA Pactamycate: 
 
Benzyl ((4R,5R,6S,7S,8S,9R)-7-((3-acetylphenyl)amino)-8-(((tert-butyldiphenylsilyl) 
oxy)methyl)-8,9-dihydroxy-4,9-dimethyl-2-oxo-3-oxa-1-azaspiro[4.4]nonan-6-
yl)carbamate (2.33): Isolated from 2.32 via general procedure F in 73% yield. Analytical data: 
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1H NMR  (400 MHz, CDCl3): δ 7.53 (d, J = 6.8 Hz, 2H); 7.45-7.44 (m, 3H); 7.37-7.34 (m, 
4H); 7.28-7.26 (m, 6H); 7.14-7.10(m, 3H); 6.68 (d, J = 6.4 Hz, 1H); 5.69 (s, 1H); 5.34 (d, J = 
6.4 Hz, 1H); 5.69 (s, 1H); 5.34 (d, J = 10,4 Hz, 1H); 5.07 (d, J = 12,4 Hz, 1H); 5.00 (d, J = 
12.4 Hz, 1H); 4.80 (q, J = 6.4 Hz, 1H); 3.51-3.47 (m, 1H), 3.34 (s, 1H); 2.46 (s, 3H); 2.45(s, 
1H); 2.04 (s, 1H); 1.45 (s, 3H); 143 (br s, 3H); 1.02 (s, 9H); MS (ESI+) Calcd. For 
C42H49N3O8Si +H, 752.34; Found, 752.48. 
 
Benzyl ((4R,5R,6S,7S,8S,9R)-7-((3-acetylphenyl)amino)-8,9-dihydroxy-8-
(hydroxymethyl)-4,9-dimethyl-2-oxo-3-oxa-1-azaspiro[4.4]nonan-6-yl)carbamate (S4): 
Isolated from 2.33 via general procedure C in >95% yield. Analytical data: : 1H NMR  (400 
MHz, CDCl3): δ 7.26-7.03 (m, 7H); 6.49 (br s, 2H); 6.30 (d, J = 8.0 Hz , 1H); 5.04 (d, J = 12.8 
Hz , 1H); 4.95 (d, J = 12.4 Hz, 1H); 8.21 (br s, 1H); 4.53 (br s, 1H); 4.45 (s, 1H); 4.32 (br s, 
1H); 4.24 (br s, 1H); 4.04 (d, J = 12.0 Hz, 1H); 3.59-3.56 (m, 3H); 2.35 (s, 1H); 2.27 (s, 3H); 
1.39 (d, J=6.0, 3H); 1.36 (s, 3H); MS (ESI+) Calcd. For C26H31N3O8+H, 514.22; Found, 
514.27. 
 
De-6-MSA Pactamycate (2.34): Isolated from S4 via general procedure E in 46% yield. 
Analytical data: [α]D19 +4.4 (c = 0.11, CHCl3); 1H NMR  (400 MHz, MeOD): δ 7.38 (br s, 1H); 
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7.21-7.19 (m, 2H); 7.01 (dt, J = 2.0, 6.8 Hz, 1H); 4.82 (q; J = 6.4 Hz, 1H); 3.91 (d, J = 11.6 
Hz, 1H); 3.58-3.56 (m, 2H); 3.53 (m, 2H); 3.53 (d, J = 7.6 Hz; 1H); 2.55 (s, 3H); 1.54 (d, J = 
6.8 Hz, 3H); 1.35 (s, 3H); 13C NMR (150 MHz, MeOD): δ 201.5, 161.0, 150.9, 139.2, 130.3, 
119.2, 118.0, 113.2, 84.1, 83.1, 78.4, 72.5, 70.7, 63.5, 60.7, 26.9, 17.5, 17.3; MS (ESI+) Calcd. 
For C18H25N3O6+H, 380.18; Found, 380.23; IR (thin film, cm
-1) 2921, 2846, 2359, 1861, 1785, 
1738, 1710, 1641, 1598, 1512, 1409, 1380, 1252, 1095; TLC (95:5 CH2Cl2:MeOH): Rf = 0.13. 
 
Synthesis of Pactamycate Derivatives: 
 
Benzyl ((4R,5R,6S,7S,8S,9R)-8-(((tert-butyldiphenylsilyl)oxy)methyl)-7-((3-
fluorophenyl)amino)-8,9-dihydroxy-4,9-dimethyl-2-oxo-3-oxa-1-azaspiro[4.4]nonan-6-
yl)carbamate (S5a): Isolated from S3a via general procedure F in 88% yield. Analytical data: 
1H NMR  (400 MHz, CDCl3): δ 7.55 (dd, J = 1.27, 8.31 Hz, 2H); 7.50 (dd, J = 1.21, 8.29, 2H); 
7.36-7.10 (m, 11H); 6.93 (dd, J = 7.6, 14.8 Hz, 1H); 6.35-6.30 (m ,1H); 6.24 (d, J = 8.8 Hz, 
2H); 6.08 (s, 1H); 5.57 (d, J = 10.0 Hz, 1H); 5.05 (d, J = 12.4 Hz, 1H); 4.92 (d, J = 12.0 Hz, 
1H); 4.79 (q, J = 6.4 Hz, 1H); 4.49-4.45 (m, 1H); 4.31 (d, J = 6.8 Hz, 1H); 4.02 (d, J = 11.2 
Hz, 1H);  3.67 (d, J = 11. Hz, 1H) 3.48-3.44 (m, 1H); 3.43 (s, 1H); 2.91 (s, 1H); 1.42 (s, 3H); 
1.39 (d, J = 6.0 Hz, 3H); 1.03 (s, 9H); MS (ESI+) Calcd. For C40H46FN3O7Si+H, 728.32; 
Found, 728.35. 
 
161 
 
 
Benzyl ((4R,5R,6S,7S,8S,9R)-8-(((tert-butyldiphenylsilyl)oxy)methyl)-8,9-dihydroxy-7-
((4-methoxyphenyl)amino)-4,9-dimethyl-2-oxo-3-oxa-1-azaspiro[4.4]nonan-6-
yl)carbamate (S5b): Isolated from S3b via general procedure F in 73% yield. Analytical data: 
1H NMR  (400 MHz, CDCl3): δ 7.55 (d, J = 7.2 Hz, 2H); 7.51 (d, J = 7.2 Hz, 2H); 7.45.7.22 
(m, 12H); 6.62 (d, J = 8.8 Hz, 2H); 6.45 (d, J = 8.8 Hz, 2H); 5.83 (s, 1H); 5.34 (d, J = 10.4 Hz, 
1H); 5.05 (d, J = 12.0 Hz, 1H); 4.97 (d, J = 12.0 Hz, 1H); 4.78 (q, J = 6.4 Hz, 1H); 4.45-4.40 
(m, 1H); 4.06 (d, J = 11.6 Hz, 1H); 3.81 (br s, 1H); 3.71 (s, 3H); 3.36 (d, J = 7.2 Hz, 1H); 3.26 
(s, 1H); 2.56 (s, 1H); 1.41 (br s, 6H); 0.87 (s, 9H); MS (ESI+) Calcd. For C41H49N3O8Si+H, 
740.34; Found, 740.38. 
 
Benzyl ((4R,5R,6S,7S,8S,9R)-7-((4-(tert-butyl)phenyl)amino)-8-(((tert-
butyldiphenylsilyl)oxy)methyl)-8,9-dihydroxy-4,9-dimethyl-2-oxo-3-oxa-1-
azaspiro[4.4]nonan-6-yl)carbamate (S5c): Isolated from S3c via general procedure F in 80% 
yield. Analytical data: 1H NMR  (400 MHz, CDCl3): δ 7.55 (d, J = 6.8 Hz, 2H); 7.49 (d, J = 
6.8 Hz, 2H); 7.42-7.22 (m, 12H); 7.06 (d, J = 8.4 Hz, 2H); 6.46 (d, J = 8.4 Hz, 2H); 5.93 (s, 
1H); 5.39 (d, J = 10.0 Hz, 1H); 5.02 (d, J = 12.0 Hz, 1H); 4.98 (d, J = 12.4 Hz, 1H); 4.80 (dd, 
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J = 6.4, 13.2 Hz, 1H); 4.50-4.77 (m, 1H); 4.05 (br s, 1H); 3.74 (d, J = 11.2 Hz, 1H); 3.47 (br 
s, 1H); 3.42 (s, 1H); 2.75 (s, 1H); 1.42 (d, J = 9.2 Hz, 1H); 1.30 (s, 3H); 1.27 (s, 9H); 1.03 (s, 
9H); MS (ESI+) Calcd. For C44H55N3O7Si+H, 766.39; Found, 766.42. 
 
Benzyl ((4R,5R,6S,7S,8S,9R)-7-((3-fluorophenyl)amino)-8,9-dihydroxy-8-
(hydroxymethyl)-4,9-dimethyl-2-oxo-3-oxa-1-azaspiro[4.4]nonan-6-yl)carbamate 
(2.35a): Isolated from S5a via general procedure C in 78% yield. Analytical data: 1H NMR  
(400 MHz, d6-Acetone): δ 7.26 (br s, 5H); 7.05 (d, J = 8.0 Hz, 1H); 6.65 (d, J = 10.4 Hz, 1H); 
6.57 (d, J = 8.4 Hz, 2H); 6.52 (s, 1H); 6.33-6.29 (m, 1H); 6.08 (s, 1H); 5.15 (d, J = 8.8 Hz, 
1H); 5.08 (d, J = 12.4 Hz, 1H); 5.00 (d, J = 12.4 Hz, 1H); 4.78 (q, J = 6.4 Hz, 1H); 4.74 (s, 
1H); 4.57-4.52 (m, 1H); 4.45 (s, 1H); 4.05 (d, J = 11.2 Hz, 1H); 3.85 (t, J = 8.8 Hz, 1H); 3.67 
(d, J = 11.2 Hz, 1H); 1.44-1.43 (m, 6H); MS (ESI+) Calcd. For C24H28FN3O7+H, 490.20; 
Found, 490.26. 
 
Benzyl ((4R,5R,6S,7S,8S,9R)-8,9-dihydroxy-8-(hydroxymethyl)-7-((4-
methoxyphenyl)amino)-4,9-dimethyl-2-oxo-3-oxa-1-azaspiro[4.4]nonan-6-yl)carbamate  
(2.35b): Isolated from S5b via general procedure C in 76% yield. Analytical data: 1H NMR  
(400 MHz, CDCl3): δ 7.29 (br s, 2H); 7.26 (br s, 3H); 6.77 (d, J = 8.4 Hz, 2H); 6.70 (d, J = 8.4 
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Hz, 2H); 5.72 (s, 1H); 5.32 (d, J = 9.6 Hz, 1H); 5.09 (d, J = 12.4 Hz, 1H); 5.02 (d, J = 12.4 Hz, 
1H); 4.86 (q, J = 6.4 Hz, 1H); 4.60-4.56 (m, 1H); 3.94 (d, J = 12.0 Hz, 1H); 3.88 (br s, 1H); 
3.81 (d, J = 12.4 Hz, 1H); 3.75 (s, 3H); 3.44 (d, J = 8.4 Hz, 1H); 2.63 (s, 1H); 1.47 (d, J = 6.8 
Hz, 3H); 1.38 (s, 3H); MS (ESI+) Calcd. For C25H31N3O8+H, 502.22; Found, 502.17. 
 
Benzyl ((4R,5R,6S,7S,8S,9R)-7-((4-(tert-butyl)phenyl)amino)-8,9-dihydroxy-8-
(hydroxymethyl)-4,9-dimethyl-2-oxo-3-oxa-1-azaspiro[4.4]nonan-6-yl)carbamate 
(2.35c): Isolated from S5c via general procedure C in 80% yield. Analytical data: 1H NMR  
(400 MHz, CDCl3): δ 7.28-7.26 (m, 5H); 7.22 (d, J = 8.4 Hz, 2H); 6.69 (d, J = 8.4 Hz, 2H); 
5.77 (br s, 1H); 5.33 (d, J = 9.2 Hz, 1H); 5.10 (d, J = 12.4 Hz, 1H); 5.04 (d, J = 12.4 Hz, 1H); 
4.86 (d, J = 6.4 Hz, 1H); 4.35 (br s, 1H); 3.98 (d, J = 12.0 Hz, 1H); 3.85 (br s, 1H); 3.78 (d, J 
= 12.4 Hz, 1H); 3.50 (d, J = 7.2 Hz, 1H); 3.35 (s, 1H); 3.11 (br s, 1H); 1.46 (d, J = 6.8 Hz, 3H); 
1.38 (s, 3H); 1.28 (s, 9H); MS (ESI+) Calcd. For C28H37N3O7+H, 528.27; Found, 528.34. 
 
((4R,5R,6R,7S,8S,9S)-9-(((benzyloxy)carbonyl)amino)-8-((3-fluorophenyl)amino)-6,7-
dihydroxy-4,6-dimethyl-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)methyl 2-hydroxy-6-
methylbenzoate (2.36a): Isolated from 2.35a via general procedure D in 89% yield. Analytical 
data: 1H NMR  (400 MHz, CDCl3): δ 10.33 (br s, 1H); 7.26-7.17 (m, 5H); 7.05 (br s, 1H); 6.92 
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(q, J = 7.6 Hz, 1H); 6.78 (d, J = 8.4 Hz, 1H); 6.66 (d, J = 7.2 Hz, 1H); 6.37-6.29 (m, 3H); 5.78 
(d, J = 10.0 Hz, 1H); 5.05 (d, J = 12.0 Hz, 1H); 4.92 (d, J = 11.6 Hz,1H); 4.8 (d, J = 6.0 Hz, 
1H); 4.57 (t, J = 8.8 Hz, 1H); 4.53 (d, J = 12.0 Hz, 1H); 4.43 (d, J = 12.4 Hz, 1H); 4.02 (s, 1H); 
3.76 (s, 1H); 3.65 (br s, 1H); 2.37 (s, 3H); 1.43 (d, J = 6.0 Hz, 3H); 1.24 (br s, 3H); MS (ESI+) 
Calcd. For C32H34FN3O9+H, 624.24; Found, 624.30. 
 
((4R,5R,6R,7S,8S,9S)-9-(((benzyloxy)carbonyl)amino)-6,7-dihydroxy-8-((4-
methoxyphenyl)amino)-4,6-dimethyl-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)methyl 2-
hydroxy-6-methylbenzoate (2.36b): Isolated from 2.35b via general procedure D in 76% 
yield. Analytical data: 1H NMR  (400 MHz, CDCl3): δ 10.46 (s, 1H); 7.31-7.23 (m, 6H); 6.83 
(d, J = 8.0 Hz, 1H); 6.70-6.68 (m, 3H); 6.62 (d, J = 8.4 Hz, 2H); 5.96 (s, 1H); 5.48 (d, J = 10.8 
Hz, 1H); 5.08 (d, J = 12.4 Hz, 1H); 5.00 (d, J = 12.4 Hz, 1H); 4.80 (br s1H); 4.60-4.56 (m, 
1H); 4.45 (d, J = 12.4 Hz, 1H); 4.08 (br s, 1H); 3.76 (s, 1H); 3.69 (s, 3H); 3.55 (br s, 1H); 2.45 
(s, 3H); 1.45 (d, J = 6.4 Hz, 3H); 1.26 (s, 3H); MS (ESI+) Calcd. For C33H37N3O10+H, 636.26; 
Found, 636.27. 
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((4R,5R,6R,7S,8S,9S)-9-(((benzyloxy)carbonyl)amino)-8-((4-(tert-butyl)phenyl)amino)-
6,7-dihydroxy-4,6-dimethyl-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)methyl 2-hydroxy-6-
methylbenzoate (2.36c): Isolated from 2.35c via general procedure D in 95% yield. Analytical 
data: 1H NMR  (400 MHz, CDCl3): δ 10.42 (s, 1H); 7.23 (br s, 6H); 7.09 (d, J = 8.0 Hz, 2H); 
6.81 (d, J = 8.0 Hz, 1H); 6.67 (d, J = 7.2 Hz, 1H); 6.60 (d, J = 8.4 Hz, 1H); 6.24 (s, 1H); 5.66 
(d, J = 9.6 Hz, 1H); 5.07-4.97 (m, 2H); 4.82 (br s, 1H); 4.61 (m, 1H); 4.46 (d, J = 12.8 Hz, 
1H); 4.28 (s, 1H); 4.10 (s, 1H); 3.67 (s, 1H); 3.36 (d, J = 6.8 Hz, 1H); 2.40 (s, 3H); 1.46 (d, J 
= 6.4 Hz, 3H); 1.28 (br s, 3H); 1.23 (s, 9H); MS (ESI+) Calcd. For C36H43N3O9+H, 662.31; 
Found, 662.38. 
 
((4R,5R,6R,7S,8S,9S)-9-amino-8-((3-fluorophenyl)amino)-6,7-dihydroxy-4,6-dimethyl-2-
oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)methyl 2-hydroxy-6-methylbenzoate (2.37a): 
Isolated from 2.36a via general procedure E in 66% yield. Analytical data: [α]D19 +37.3 (c = 
0.8, CHCl3); 1H NMR (600 MHz, MeOD): δ 7.16 (t, J = 7.8 Hz, 1H), 6.94 (q, J = 7.2 Hz, 1H), 
6.69 (m, 2H), 6.51 (m, 2H), 6.17 (m, 1H), 4.81 (q, J = 6.6 Hz, 1H), 4.55 (d, J = 11.4 Hz, 1H), 
4.50 (d, J = 11.4 Hz, 1H), 3.54 (s, 2H), 2.29 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H), 1.35 (s, 3H); 
13CNMR (150 MHz, CDCl3): δ 170.6, 164.7, 161.0, 158.4, 152.0, 140.3, 133.0, 131.1, 123.1, 
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119.3, 114.9, 109.9, 103.9, 103.7, 100.5, 100.4, 83.9, 82.7, 78.5, 72.7, 71.4, 67.1, 21.3, 17.2; 
IR (thin film, cm-1) 3895, 3582, 3388, 3054, 2986, 2520, 2410, 2305, 1736, 1550, 1422, 1333, 
1265, 1115; MS (ESI+) Calcd. For C24H28FN3O7+H, 490.20; Found, 490.26; TLC (95:5 
CH2Cl2:MeOH): Rf = 0.08. 
 
((4R,5R,6R,7S,8S,9S)-9-amino-6,7-dihydroxy-8-((4-methoxyphenyl)amino)-4,6-
dimethyl-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)methyl 2-hydroxy-6-methylbenzoate 
(2.37b): Isolated from 2.36b via general procedure E in 85% yield. Analytical data: [α]D19 
+18.8 (c = 0.95, CHCl3); 1H NMR  (500 MHz, MeOD): δ 7.17 (t, J = 8.0 Hz, 1H); 6.69-6.68 
(m, 4H); 6.62 (t, J = 3.5 Hz, 1H); 6.60 (t, J = 2.0 Hz, 1H); 4.82 (q, J = 7.0 Hz, 1H); 4.57 (d, J 
= 12.0 Hz, 1H); 4.51 (d, J = 12.0 Hz, 1H); 3.63 (s, 3H); 3.54 (s, 2H); 2.31 (s, 3H); 1.52 (d, J = 
6.5 Hz, 3H); 1.41 (s, 3H); 13C NMR (150 MHz, CD3OD): δ 170.7, 160.9, 158.9, 153.2, 143.8, 
140.6, 133.2, 123.1, 118.8, 115.6, 115.5, 115.0, 84.2, 82.8, 78.5, 72.9, 72.3, 66.9, 61.3, 56.1, 
21.6, 17.4, 17.0, 15.4; MS (ESI+) Calcd. For C25H31N3O8+H, 502.22; Found, 502.22; IR (thin 
film, cm-1) 3828, 3740, 3389, 3054, 2986, 2521, 2359, 2305, 1735, 1550, 1441, 1265, 1114; 
TLC (95:5 CH2Cl2:MeOH): Rf = 0.07. 
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((4R,5R,6R,7S,8S,9S)-9-amino-8-((4-(tert-butyl)phenyl)amino)-6,7-dihydroxy-4,6-
dimethyl-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)methyl 2-hydroxy-6-methylbenzoate 
(2.37c): Isolated from 2.36c via general procedure E in 48% yield. Analytical data: [α]D19 +27.0 
(c = 0.85, CHCl3); 1H NMR  (400 MHz, MeOD): δ 7.17 (t, J = 7.6 Hz, 1H); 7.05 (d, J = 8.4 
Hz, 2H); 6.71-6.67 (m, 4H); 4.82 (q, J = 6.8 Hz, 1H); 4.54 (s, 2H); 3.57 (d, J = 6.8 Hz, 1H); 
3.52 (d, J = 6.8 Hz, 1H); 2.29 (s, 3H); 1.53 (d, J = 6.8 Hz, 3H); 1.35 (s, 3H); 1.20 (s, 9H); 13C 
NMR (100 MHz, MeOD): δ 170.7, 161.0, 158.8, 147.3, 140.7, 140.6, 133.1, 126.7, 123.1, 
119.0, 115.0, 114.0, 84.1, 82.8, 78.6, 72.9, 72.00, 67.0, 61.4, 34.5, 32.0, 21.5, 17.4, 17.1; IR 
(thin film, cm-1) 3390, 2960, 2359, 1707, 1649, 1552, 1482, 1385, 1303, 1198, 1071, 737; MS 
(ESI+) Calcd. For C28H37N3O7+H, 528.27; Found, 528.34; TLC (95:5 CH2Cl2:MeOH): Rf = 
0.13. 
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General procedure H for addition of nucleophiles to ketone 2.24.  
 
Benzyl ((1R,2R,3R,4R,5R)-3-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-(((tert-
butyldiphenylsilyl)oxy)methyl)-3-(3,3-dimethylureido)-4-hydroxy-4-methyl-6-
oxabicyclo [3.1.0]hexan-2-yl)carbamate (2.25): A flame-dried 25-mL round-bottomed flask 
was charged with ketone 2.24 (1.7 g, 2.3 mmol, 1.0 equiv) and THF (23 mL). The solution was 
cooled to 0 °C and MeMgBr (3M in THF, 7.6 mL, 22.9 mmol, 10.0 equiv) was added dropwise. 
The reaction was stirred at 0 °C until TLC analysis indicated complete ketone consumption, 
typically 2 h.  Saturated NH4Cl(aq.) (20 mL) was carefully added dropwise and the resulting 
mixture was extracted with EtOAc (3 x 15 mL). The combined organic extracts were washed 
with brine (20 mL), dried with magnesium sulfate, and concentrated in vacuo. The crude 
product was purified via flash chromatography (90:10 to 70:30 hexanes:EtOAc) to afford 
carbinol 2.25 as a clear, viscous oil with >10:1 diastereoselection (1.3 g, 75%). Analytical data: 
[α]D19 +7.2 (c = 0.70, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.73 (d, J = 7.8 Hz, 2H), 7.70 
(d, J = 7.2 Hz, 2H), 7.45-7.30 (m, 12H), 5.55 (br s, 1H), 5.21 (d, J = 12.6 Hz, 1H), 5.17 (br s, 
1H), 5.07 (d, J = 12.0 Hz, 1H), 4.77 (br s, 1H), 4.64 (dd, J = 8.4, 3.6 Hz, 1H), 4.21 (d, J = 12.6 
Hz, 1H), 4.12 (d, J = 12.6 Hz, 1H), 3.90 (s, 1H), 2.75 (s, 6H), 1.30 (s, 3H), 1.25 (d J = 6.0 Hz, 
3H), 1.07 (s, 9H), 0.97 (s, 9H), 0.11 (s, 3H), -0.01 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 
158.8, 156.5, 136.3, 135.6, 135.5, 134.7, 133.3, 132.9, 129.6, 129.4, 128.4, 128.2, 128.1, 127.7, 
127.6, 127.6, 67.1, 66.8, 62.1, 58.3, 36.1, 26.7, 26.5, 25.7, 23.8, 19.6, 19.2, 17.8, -4.2, -5.5; 
MS (ESI+) Calcd. for C42H61N3O7Si2+H, 776.4128; Found, 776.4179; IR (thin film, cm
-1) 
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3430, 2429, 2359, 1716, 1635, 1506, 1456, 1112, 831, 700; TLC (90:10 hexanes/EtOAc): Rf 
= 0.35. 
 
Benzyl ((1R,2R,3R,4R,5R)-3-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-(((tert-
butyldiphenylsilyl)oxy)methyl)-3-(3,3-dimethylureido)-4-ethyl-4-hydroxy-6-
oxabicyclo[3.1.0]hexan-2-yl)carbamate  (2.38a): Isolated from 2.24 via general procedure H 
using EtMgBr as the nucleophile in 75% yield. Analytical data: 1H NMR  (500 MHz, CDCl3): 
δ 7.66-7.63 (m, 4H); 7.42-7.33 (m, 11H); 5.31 (br s, 1H); 5.24 (br s, 1H); 5.16 (d, J=12.0 Hz, 
1H); 5.04 (d, J = 12.5 Hz, H); 4.66 (s, 1H); 4.61-4.57 (m, 2H); 4.33 (d, J = 12.5 Hz, 1H); 3.98 
(s, 1H); 3.95-3.94 (m, 1H); 2.68 (s, 6H); 1.44-1.41 (m, 1H); 1.36-1.32(m, 1H); 1.27-1.25 (m, 
3H); 1.01 (s, 9H); 0.95 (s, 9H); 0.81 (t, J = 7.5 Hz, 3H); 0.08 (s, 3H); 0.07 (s, 3H); MS (ESI+) 
Calcd. For C43H63N3O7Si2+H, 790.43; Found, 790.43. 
 
Benzyl ((1R,2R,3R,4R,5R)-3-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-(((tert-
butyldiphenylsilyl)oxy)methyl)-3-(3,3-dimethylureido)-4-hexyl-4-hydroxy-6-
oxabicyclo[3.1.0]hexan-2-yl)carbamate (2.38b): Isolated from 2.24 via general procedure H 
using (nHexyl)MgBr as the nucleophile in 73% yield. Analytical data: 1HNMR (400 MHz, 
CDCl3): δ 7.67-7.63 (m, 4H), 7.40-7.31 (m, 12H), 5.32 (d, J = 6.8 Hz, 1H), 5.23 (br s, 1H), 
5.18 (d, J = 12.4 Hz, 1H), 5.07 (d, J = 12.4 Hz, 1H), 4.72 (s, 1H), 4.59 (m, 2H), 4.34 (d, J = 
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13.2 Hz, 1H), 3.97 (m, 2H), 2.70 (s, 6H), 1.26 (m, 4H), 1.30-1.26 (m, 8H), 1.18 (m, 4H), 1.02 
(s, 9H), 0.96 (s, 9H), 0.09 (s, 3H), 0.06 (s, 3H); MS (ESI+) Calcd. For C47H71N3O7Si2+H, 
846.49; Found, 846.59. 
 
Benzyl ((1R,2R,3R,4R,5R)-3-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-(((tert-
butyldiphenylsilyl)oxy)methyl)-3-(3,3-dimethylureido)-4-hydroxy-4-vinyl-6-
oxabicyclo[3.1.0]hexan-2-yl)carbamate (2.38c): Isolated from 2.24 via general procedure H 
using (vinyl)MgBr as the nucleophile in 43% yield. Analytical data: 1H NMR  (400 MHz, 
CDCl3): δ 7.65-7.64 (m, 4H); 7.40-7.35 (m, 11H); 5.93 (dd, J = 10.8, 17.20 Hz, 1H); 5.70 (br 
s, 1H); 5.35 (d, J = 17.2 Hz, 1H); 5.19 (d, J = 12.0 Hz, 1H); 5.11-5.06 (m, 3H); 4.93 (br s, 1H); 
4.19 (d, J = 12.8 Hz, 1H); 4.02 (s, 1H); 3.97 (d, J = 12.4 Hz, 1H); 2.72 (s, 6H); 1.23 (d, J = 6.4 
Hz, 3H); 1.01 (s, 9H); 0.93 (s, 9H); 0.09 (s, 3H); 0.01 (s, 3H); MS (ESI+) Calcd. For 
C43H61N3O7Si2+Na, 810.39; Found, 810.24. 
 
Benzyl ((1R,2R,3S,4R,5S)-3-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-(((tert-
butyldiphenylsilyl)oxy)methyl)-3-(3,3-dimethylureido)-4-hydroxy-6-
oxabicyclo[3.1.0]hexan-2-yl)carbamate (2.38d): A flame-dried 100 mL round bottomed 
flask was charged with ketone 2.24 (0.280 g, 0.369 mmol, 1.0 equiv) and MeOH (20 mL) 
under an atmosphere of nitrogen. The solution was cooled to -45 °C and NaBH4 (0.056 g, 1,47 
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mmol, 4.0 equiv) was added in one portion. The reaction was allowed to stir at this temperature 
until TLC analysis indicated full conversion of the starting material, generally 1 h. Saturated 
NH4Cl(aq.) (10 mL) was added slowly followed by EtOAc (20 mL) and the mixture was allowed 
to warm to r.t. The mixture was partitioned and the aqueous layer was extracted with EtOAc 
(3 x 30 mL). The combined organic layers were washed with H2O (2 x 20 mL), brine (15 mL), 
dried with magnesium sulfate and concentrated in vacuo. The crude product was purified via 
flash chromatography (90:10 hexanes:EtOAc) to obtain the title compound as a white foam 
(249 mg, 88%). Analytical Data:  1H NMR  (400 MHz, CDCl3): δ  7.67-7.64 (m, 4H); 7.39-
7.34 (m, 11H); 5.49 (br s, 1H); 5.28 (br s, 1H); 5.20 (d, J = 12.0 Hz, 1H); 5.02 (d, J = 12.0 Hz, 
1H); 4.97 (s, 1H); 4.61(dd, J = 2.8, 8.8 Hz, 1H); 4.48 (bs, 1H); 4.16 (s, 1H); 4.15 (d, J = 12.4 
Hz, 1H); 4.09 (d, J = 12.4 Hz, 1H); 3.92 (br s, 1H); 2.70(s, 6H); 1.18 (d, J = 6.4 Hz, 3H); 1.02 
(s, 9H); 0.92 (s, 9H); 0.06 (s, 3H); -0.07 (s, 3H); MS (ESI+) Calcd. For  C41H59N3O7Si2+Na, 
784.38; Found, 784.44. 
 
Benzyl ((1S,2R,3R,4S,5S)-2-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(((tert-
butyldiphenylsilyl)oxy)methyl)-2-(3,3-dimethylureido)-3-ethyl-3,4-dihydroxy-5-((3-
(prop-1-en-2-yl)phenyl)amino)cyclopentyl)carbamate (2.40a): Isolated from 2.38a via 
general procedure B using 3-isopropenylaniline as the nucleophile in 71% yield. Analytical 
data: 1HNMR (400 MHz, CDCl3): δ 8.07 (d, J = 6.8 Hz, 1H), 7.66 (d, J = 6.8 Hz, 2H), 7.47 
(d, J = 6.8 Hz, 2H), 7.39 (d, J = 7.6 Hz, 1H), 7.34-7.19 (m, 10H), 7.05 (t, J = 8.0 Hz, 1H), 6.80 
172 
 
(m, 2H), 6.57 (d, J = 7.6 Hz, 1H), 6.15 (s, 1H), 5.47 (s, 1H), 5.36 (s, 1H), 5.27 (q, J = 6.4 Hz, 
1H), 5.17 (d, J = 3.6 Hz, 1H), 5.02 (br s, 3H), 4.72 (dd, J = 7.2, 2.8 Hz, 1H), 4.36 (s, 1H), 4.13 
(d, J = 10.8 Hz, 1H), 3.75 (d, J = 10.8 Hz,  1H), 3.66 (dd, J = 4.0, 6.0 Hz, 1H), 2.95 (s, 6H), 
2.12 (s, 3H), 1.88 (m, 1H), 1.35 (d, J = 6.8 Hz, 3H), 0.96 (s, 9H), 0.898 (br s, 12H), 0.09 (s, 
3H), 0.01 (s, 3H); MS (ESI+) Calcd. For C52H74N4O7Si2+H, 923.52; Found, 923.54. 
 
Benzyl ((4S,5S)-2-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(((tert-butyldiphenyl 
silyl)oxy)methyl)-2-(3,3-dimethylureido)-3-hexyl-3,4-dihydroxy-5-((3-(prop-1-en-2-
yl)phenyl)amino)cyclopentyl)carbamate (2.40b): Isolated from 2.38b via general procedure 
B using 3-isopropenylaniline as the nucleophile in 63% yield. Analytical data: 1HNMR (400 
MHz, CDCl3): δ 8.07 (d, J = 6.8 Hz, 1H), 7.66 (d, J = 6.4 Hz, 2H), 7.48 (d, J = 6.8 Hz, 2H), 
7.40(m, 1H), 7.35-7.19 (m, 10H), 7.05 (t, J = 7.6 Hz, 1H), 6.79 (m, 2H), 6.57 (d, J = 7.6 Hz, 
1H), 6.18 (s, 1H), 5.49 (s, 1H), 5.37 (s, 1H), 5.28 (q, J = 6.4 Hz, 1H), 5.16 (s, 1H), 5.01 (s, 
3H), 4.73 (dd, J = 7.2, 2.4 Hz, 1H), 4.38 (s, 1H), 4.13 (d, J = 10.8 Hz, 1H), 3.76 (d, J = 10.8 
Hz, 1H), 3.67 (dd, J = 3.6, 2 Hz, 1H), 2.96 (s, 6H), 2.12 (s, 3H), 1.75 (m, 1H), 1.45 (m, 1H), 
1.34 (d, J = 6.4 Hz 3H), 1.22 (br s, 4H), 0.97 (s, 9H), 0.91 (s, 11H), 0.10 (s, 3H), 0.01 (s, 3H); 
MS (ESI+) Calcd. for C56H82N4O7Si2+H, 979.58; Found, 979.58. 
173 
 
 
Benzyl ((1S,2S,3R,4S,5S)-2-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(((tert-
butyldiphenylsilyl)oxy)methyl)-2-(3,3-dimethylureido)-3,4-dihydroxy-5-((4-
methoxyphenyl)amino)cyclopentyl)carbamate (2.43): Isolated from 2.38d via general 
procedure B using p-anisidine as the nucleophile in 83% yield. Analytical data: 1H NMR  (400 
MHz, CDCl3): δ 8.27 (d, J = 6.0 Hz, 1H); 7.74 (d, J = 6.8 Hz, 2H); 7.68(d, J = 6.8 Hz, 2H); 
7.40-7.26 (m, 12H); 6.69 (d, J = 8.8 Hz, 2H); 6.60 (d, J = 8.40 Hz, 2H); 6.02 (s, 1H); 5.33 (s, 
1H); 5.31 (d, J = 6.8 Hz, 1H); 5.02 (s, 2H); 4.67 (dd, J = 6.4, 9.6 Hz, 1H); 4.38 (d, J = 10.8 
Hz, 1H); 3.92 (s, 1H); 3.83 (s, 1H); 3.74 (s, 3H); 3.64 (d, J = 10.0 Hz, 1H); 3.59 (d, J = 10.8 
Hz, 1H); 2.93 (s, 6H); 1.39 (d, J = 6.0 Hz, 3H); 1.04 (s, 9H); 0.91 (s, 9H); 0.12 (s, 3H); 0.01 
(s, 3H); MS (ESI+) Calcd. For C48H68N4O8Si2+H, 885.47; Found, 885.53. 
 
Benzyl ((1S,2S,3R,4S,5S)-2-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(((tert-
butyldiphenylsilyl)oxy)methyl)-2-(3,3-dimethylureido)-3,4-dihydroxy-5-((3-(prop-1-en-
2-yl)phenyl)amino)cyclopentyl)carbamate (2.40d): Isolated from 2.38d via general 
procedure B using m-isopropenylaniline as the nucleophile in 63% yield. Analytical data: 1H 
NMR  (400 MHz, CDCl3): δ 8.28 (d, J=6.4 Hz, 1H); 7.75 (d, J=6.8 Hz, 2H); 7.60 (d, J=6.8 Hz, 
2H); 7.38 (d, J = 7.2 Hz, 2H); 7.33-7.25 (m, 8H); 7.12 (t, J = 7.6 Hz, 1H); 7.05 (t, J = 7.6 Hz, 
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1H); 6.88 (d, J = 7.6 Hz, 1H); 6,84 (s, 1H); 6.80 (br s, 1H); 6.61 (d, J  =8.0 Hz, 1H); 6.58 (d, J 
= 8.0 Hz, 1H); 6.03 (s, 1H); 5.37-5.29 (m, 3H); 5.04-5.01 (m, 2H); 4.69 (dd, J = 6.4,10.0 Hz, 
1H); 4.40 (d, J = 10.8Hz, 1H); 3.93 (s, 1H); 3.84 (s, 1H); 3.74(d, J = 8.0 Hz, 1H); 3.58 (d, J = 
10.8 Hz, 1H); 2.94 (s, 6H); 2.12 (s, 3H); 1.40 (d, J = 6.4 Hz, 3H); 1.02 (s, 9H); 0.91 (s, 9H); 
0.13 (s, 3H); 0.00 (S, 3H); MS (ESI+) Calcd. For C50H70N4O7Si2+H, 895.49; Found, 895.59. 
 
General procedure I for isopropenyl group oxidative cleavage: 
 
Benzyl ((4S)-5-((3-acetylphenyl)amino)-2-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-
(((tert-butyldiphenylsilyl)oxy)methyl)-2-(3,3-dimethylureido)-3-ethyl-3,4-
dihydroxycyclopentyl)carbamate (2.41a). A 20 mL scintillation vial was charged with olefin 
2.40a (0.154 g, 0.17 mmol, 1.00 equiv) and THF (2 mL), Acetone (2 mL), and H2O (0.4 mL) 
were added. The solution was cooled to 0 °C and NMO (0.101 g, 0.860 mmol, 5.00 equiv) was 
added followed by two flakes of OsO4.  The resulting mixture and stirred for 1 h at r.t. Saturated 
NaHSO3(aq)  (3 mL) was added, and the mixture was stirred 30 min. The mixture was then 
extracted with EtOAc (3 x 30 mL) and the combined organic layers were washed with water 
(10 mL), brine (10 mL), dried with magnesium sulftate and concentrated in vacuo. The crude 
diol was judged clean by 1H NMR spectroscopy and was submitted to the next step without 
further purification. 
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The crude diol was added to a 20 mL scintillation vial and dissolved in THF (3 mL) and water 
(3 mL). NaIO4 (0.065 g, 0.30 mmol, 2.40 equiv) was added at rt and the reaction was allowed 
to stir for 3h. The reaction mixture was partitioned between EtOAc (5 mL) and H2O (5 mL), 
and the mixture was extracted with EtOAc (3 x 30 mL) and the combined organic layers were 
washed with water (10 mL), brine (10 mL), dried with magnesium sulfate and concentrated in 
vacuo.  The crude product was purified via flash chromatography (90:10 to 80:20 
hexanes:EtOAc) to give acetophenone 2.41a as a  pale yellow foam (98 mg, 65% over two 
steps) Analytical data: 1HNMR (400 MHz, CDCl3): δ 8.18 (d, J = 6.8 Hz, 1H), 7.63 (d, J = 8.0 
Hz, 2H), 7.44 (d, J = 6.8 Hz, 2H), 7.38 (d, J = 7.2 Hz, 1H), 7.33-7.12 (m, 13H), 6.81 (d, J = 
8.8 Hz, 1H), 6.11 (s, 1H), 5.45 (s, 1H), 5.33 (d, J = 4.0 Hz, 1H), 5.26 (q, J = 6.8 Hz, 1H), 5.02 
(d, J = 1.2 Hz, 2H), 4.72 (dd, J = 6.8, 2.8 Hz, 1H), 4.32 (s, 1H), 4.06 (d, J = 10.8 Hz, 1H), 6.68 
(d, J = 10.8 Hz, 1H), 3.64 (d, J = 4.0 Hz, 1H), 2.96 (s, 6H), 2.50 (s, 3H), 2.09 (m, 1H), 2.05 (s, 
3H), 1.85 (m, 1H), 1.34 (d, J = 6.8 Hz, 3H), 0.92 (br s, 11H), 0.89 (br s, 10H), 0.09 (s, 3H), 
0.00 (s, 3H); MS (ESI+) Calcd. for C51H72N4O8Si2+H, 925.50; Found, 925.52. 
 
Benzyl ((4S,5S)-5-((3-acetylphenyl)amino)-2-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-
4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(3,3-dimethylureido)-3-hexyl-3,4-
dihydroxycyclopentyl)carbamate (2.41b): Isolated from 2.40b via general procedure I in 
63% yield. Analytical data: 1HNMR (400 MHz, CDCl3): δ 8.17 (d, J = 6.4Hz, 1H), 7.62 (d, J 
= 6.8Hz, 2H), 7.43 (d, J = 6.8Hz, 2H), 7.38 (d, J = 7.2Hz, 1H), 7.33-7.12 (m, 13H), 6.80 (d, J 
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= 8.0Hz, 1H), 6.13 (s, 1H), 5.47 (s, 1H), 5.31 (d, J = 3.6 Hz, 1H), 5.26 (q, J = 6.4 Hz, 1H), 
5.02 (s, 1H), 4.34 (s, 1H), 4.07 (J = 10.8 Hz, 1H), 3.69 (d, J = 10.8 Hz, 1H), 3.65 (dd, J = 4.0, 
6.0 Hz, 1H), 2.96 (s, 6H), 2.50 (s, 3H), 1.74 (m, 1H), 1.42 (br s, 2H), 1.33 (d, J = 6.4 Hz, 3H), 
1.20 (br s, 4H), 0.95-0.86 (m, 24H), 0.09 (s, 3H), 0.00 (s, 3H); MS (ESI+) Calcd. for 
C55H80N4O8Si2+H, 981.56; Found, 981. 55. 
 
Benzyl ((1S,2S,3R,4S,5S)-5-((3-acetylphenyl)amino)-2-((S)-1-((tert-
butyldimethylsilyl)oxy)ethyl)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(3,3-
dimethylureido)-3,4-dihydroxycyclopentyl)carbamate (2.41d): Isolated from 2.40d via 
general procedure I in 65% yield. Analytical data: 1H NMR  (400 MHz, CDCl3): δ  8.36 (br s, 
1H); 7.72 (d, J = 7.2 Hz, 2H); 7.56 (d, J = 6.8 Hz, 2H); 7.38 (d, J = 7.6 Hz, 1H); 7.33-7.20 (m 
12H); 5.99 (s, 1H); 5.46 (s, 1H); 5.39 (s, 1H); 5.05 (d, J = 12.0 Hz, 1H); 4.99 (d, J = 12.0 Hz, 
1H); 4.69 (dd, J = 6.4, 10.0 Hz, 1H); 4.34 (d, J = 10.4 Hz, 1H), 3.94 (s, 1H); 3.86 (s, 1H); 3.74 
(d, J = 10.4 Hz, 1H); 3.47 (d, J = 10.8 Hz, 1H); 2.94 (s, 6H); 2.50 (S, 3h); 1.4 (d, J = 6.4 Hz, 
3H); 1.00 (s, 9H); 0.93 (s, 9H); 0.13 (s, 3H); 0.00 (s, 3H); MS (ESI+) Calcd. For 
C49H68N4O8Si2+H, 897.47; Found, 897.56. 
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Benzyl ((4S)-5-((3-acetylphenyl)amino)-2-(3,3-dimethylureido)-3-ethyl-3,4-dihydroxy-2-
((S)-1-hydroxyethyl)-4-(hydroxymethyl)cyclopentyl)carbamate (S6a): Isolated from 2.41a 
via general procedure C in 88% yield. Analytical data:  1HNMR (400 MHz, CDCl3): δ 7.33-
7.15 (m, 5H), 6.96 (br s, 1H), 6.78 (d, J = 7.2 Hz, 2H), 6.56 (br s, 2H), 6.06 (br s, 1H), 5.58 (s, 
1H), 5.47 (br s, 1H), 5.37-5.25 (m, 3H), 5.11 (br s, 2H), 4.33 (br s, 1H), 4.07 (br s, 1H), 3.85 
(s, 2H), 3.71 (s, 1H), 2.87 (s, 6H), 2.50 (s, 3H), 1.86 (m, 2H), 1.25 (br s, 5H); MS (ESI+) Calcd. 
for C29H40N4O8+H, 573.29; Found, 573.27. 
 
Benzyl ((4S,5S)-5-((3-acetylphenyl)amino)-2-(3,3-dimethylureido)-3-hexyl-3,4-
dihydroxy-2-((S)-1-hydroxyethyl)-4-(hydroxymethyl)cyclopentyl)carbamate  (S6b): 
Isolated from 2.41b via general procedure C in 78% yield. Analytical data: 1HNMR (400 MHz, 
CDCl3): δ 7.32-7.05 (m, 10H), 6.94 (br s, 1H), 6.77 (br s, 2H), 6.14 (d, J = 7.6 Hz, 1H), 5.43 
(br s, 1H), 5.25 (s, 1H), 5.10 (br s, 2H), 4.23 (br s, 1H), 4.10 (br s, 1H), 3.86-3.73 (m, 3H), 
2.87 (s, 6H), 2.49 (s, 3H), 1.93 (br s, 2H), 1.56 (t, J = 12.0 Hz, 1H), 1.50 (br s, 1H), 1.26 (br s, 
9H), 1.00 (br s, 1H); MS (ESI+) Calcd. for C33H48N4O8+H, 629.36; Found, 629.36. 
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Benzyl ((1S,2R,3R,4S,5S)-2-(3,3-dimethylureido)-3,4-dihydroxy-2-((S)-1-hydroxyethyl)-
4-(hydroxymethyl)-5-((4-methoxyphenyl)amino)cyclopentyl)carbamate (S8): Isolated 
from 2.43 via general procedure C in 73% yield. Analytical data: 1H NMR  (400 MHz, CDCl3): 
δ 7.33-7.26 (m, 8H); 6.72 (d, J = 8.4 Hz, 2H); 6.64 (br s, 2H); 6.00 (br s, 1H); 5.72 (br s, 1H); 
5.61 (br s, 1H); 5.10 (d, J = 11.2 Hz, 1H); 5.04 (d, J = 12.0 Hz, 1H); 4.40 (s, 1H); 4.10 (br s, 
1H); 4.04-3.97 (m, 3H); 3.80 (d, J = 11.8 Hz, 1H); 3.73 (s, 3H); 3.59 (br s, 1H); 2.90 (s, 6H); 
1.19 (d, J = 4.4 Hz, 3H); MS (ESI+) Calcd. For C26H36N4O8+H, 533.26; Found, 533.26. 
 
Benzyl ((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-2-(3,3-dimethylureido)-3,4-
dihydroxy-2-((S)-1-hydroxyethyl)-4-(hydroxymethyl)cyclopentyl)carbamate (S6d): 
Isolated from 2.41d via general procedure C in 91% yield. Analytical data: 1H NMR  (400 
MHz, CDCl3): δ 7.29-7.22 (m, 7H); 7.15 (t, J = 8.0 Hz, 1H); 6.84 (d, J = 6.4 Hz, 1H); 6.32 (d, 
J = 8.4 Hz, 1H); 5.85 (s, 1H); 5.60 (br s, 1H); 5.04 (d, J = 12.0 Hz, 1H); 4.97 (d, J = 12.4 Hz, 
1H); 4.78 (br s, 1H); 4.43 (s, 1H); 4.22-4.15 (m, 2H); 4.03-3.97 (m, 2H); 3.73 (d, J = 11.6 Hz, 
1H); 2.87 (s, 6H); 2.47 (s, 3H); 1.16 (d, J = 5.2 Hz, 3H); MS (ESI+) Calcd. For C27H36N4O8+H, 
545.26; Found, 545.31. 
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((1S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-2-ethyl-1,2-dihydroxy-3-((S)-1-hydroxyethyl)cyclopentyl)methyl 2-
hydroxy-6-methylbenzoate (S7a): Isolated from S6a via general procedure D in 80% yield. 
Analytical data: 1HNMR (400 MHz, CDCl3): δ 10.89 (s, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.35 
(br s, 4H), 7.27-7.20 (m, 4H), 7.05 (s, 1H), 6.79 (d, J = 8.0 Hz, 1H), 6.68 (d, J = 6.8 Hz, 1H), 
6.58 (d, J = 7.2 Hz, 1H), 5.88 (s, 1H), 5.83 (m, 1H), 5.16 (s, 2H), 5.107-5.063 (m, 2H), 4.88 
(d, J = 12.8 Hz, 1H), 4.04 (br s, 2H), 3.71 (d, J = 9.2 Hz, 1H), 2.84 (s, 6H), 2.49 (s, 3H), 2.19 
(s, 3H), 2.12 (m, 1H), 1.97 (m, 1H), 1.24 (d, J = 7.2 Hz, 3H), 1.04 (t, J = 7.6 Hz, 3H); MS 
(ESI+) Calcd. for C37H46N4O10+H, 707.33; Found, 707.36. 
 
((1S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-2-hexyl-1,2-dihydroxy-3-((S)-1-hydroxyethyl)cyclopentyl)methyl 2-
hydroxy-6-methylbenzoate (S7b): Isolated from S6b via general procedure D in 84% yield. 
Analytical data: 1HNMR (400 MHz, CDCl3): δ 10.90 (s, 1H), 7.44-7.18 (m, 9H), 7.06 (s, 1H), 
6.80 (d, J = 8.4 Hz, 1H), 6.69, (d, J = 7.6 Hz, 1H), 6.59 (d, J = 7.2 Hz, 1H), 5.90 (s, 2H), 5.78 
(d, J = 9.6 Hz, 1H), 5.16-5.04 (m, 4H), 4.87 (d, J = 12.8 Hz, 1H), 4.03 (s, 2H), 2.85 (s, 6H), 
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2.49 (s, 3H), 2.20 (s, 3H), 1.83 (m, 1H), 1.61 (m, 2H), 1.28 (br s, 12H); MS (ESI+) Calcd. for 
C41H54N4O10+H, 763.39; Found, 763.46. 
 
((1S,2R,3R,4S,5S)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-dimethylureido)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)-5-((4-methoxyphenyl)amino)cyclopentyl)methyl 2-
hydroxy-6-methylbenzoate  (S9): Isolated from S8 via general procedure D in 56% yield. 
Analytical data: 1H NMR  (400 MHz, CDCl3): δ 10.78 (br s, 1H); 7.34-7.24 (m, 5H); 7.17 (d, 
J = 7.6 Hz, 1H); 6.83 (d, J = 8.4 Hz, 2H); 6.75-6.69 (m, 4H); 6.53 (br s, 2H); 5.88 (br s, 2H); 
5.50 (s, 1H); 5.15-5.09 (m, 3H); 4.93 (d, J = 12.0 Hz, 1H); 4.75 (d, J = 12.4 Hz, 1H); 4.31 (s, 
1H); 4.09 (br s, 1H); 3.88 (br s, 1H); 3.74 (s, 3H); 2.96 (s, 1H); 2.86 (s, 6H); 2.47 (s,3H); 1.21 
(br s, 1H); MS (ESI+) Calcd. For C34H42N4O10+H, 667.30; Found, 667.31. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)cyclopentyl)methyl 2-hydroxy-6-
methylbenzoate (S7d): Isolated from S6d via general procedure D in 66% yield. Analytical 
data: 1H NMR  (400 MHz, CDCl3): δ 10.61 (br s, 1H); 7.29 (m, 10H); 6.77 (d, J = 8.4 Hz, 
2H); 6.64 (d, J = 7.2 Hz, 1H); 6.37 (br s, 1H); 6,21 (br s, 1H); 5.64 (br s, 2H); 5.19-4.09 (m, 
3H); 4.86 (d, J = 12.0 Hz, 1H); 4.67 (d, J = 12.0 Hz, 1H); 4.41 (s, 1H); 4.13-4.08 (m, 1H); 3.86 
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(br s, 1H); 2.85 (s, 6H); 2.46 (s, 3H); 1.18 (br s, 3H); MS (ESI+) Calcd. For C35H42N4O10+H, 
679.30; Found, 679.35. 
 
((1S,5S)-5-((3-acetylphenyl)amino)-4-amino-3-(3,3-dimethylureido)-2-ethyl-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)cyclopentyl)methyl 2-hydroxy-6-methylbenzoate 
(2.42a): Isolated from S7a via general procedure E in 48% yield. Analytical data: [α]D19 +39.3 
(c = 0.25, CHCl3); 1HNMR (400 MHz, CDCl3): δ 10.99 (s, 1H), 7.84 (d, J = 10.8 Hz, 1H), 
7.25-7.21 (m, 5H), 7.11 (s, 1H), 6.79 (d, J =8.0 Hz, 1H), 6.75 (m, 1H), 6.60 (d, J = 7.6 Hz, 
1H), 5.75 (d, J = 10.0 Hz, 1H), 5.63 (s, 1H), 4.99 (d, J = 12.8 Hz, 1H), 4.88 (d, J = 12.4 Hz, 
1H), 3.98 (m, 1H), 3.76 (d, J = 10.4 Hz, 1H), 2.99 (s, 6H), 2.91 (s, 1H), 2.53(s, 3H), 2.29 (s, 
3H), 2.16 (m, 1H), 2.05 (m, 1H), 1.05 (m, 6H). 13C NMR (150 MHz, CDCl3): δ 198.5, 173.0, 
162.8, 159.2, 146.5, 141.5, 138.2, 134.6, 129.6, 129.0, 128.2, 125.3, 123.0, 118.2, 115.6, 111.9, 
90.4, 86.0, 73.8, 72.8, 68.4, 66.8, 62.2, 36.90, 26.7, 25.8, 23.8, 18.1, 8.6; IR (thin film, cm-1) 
3381, 2926, 1724, 1667, 1604, 1522, 1485, 1464, 1389, 1253, 1115, 1074, 735; MS (ESI+) 
Calcd. for C29H40N4O8+H, 573.29; Found, 573.33; TLC (95:5 CH2Cl2:MeOH): Rf = 0.18. 
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((1S,5S)-5-((3-acetylphenyl)amino)-4-amino-3-(3,3-dimethylureido)-2-hexyl-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)cyclopentyl)methyl 2-hydroxy-6-methylbenzoate 
(2.42b): Isolated from S7b via general procedure E in 61% yield. Analytical data:  [α]D19 +28.8 
(c = 0.15, CHCl3); 1HNMR (400 MHz, CDCl3): δ 10.98 (br s, 1H), 7.85 (br s, 1H), 7.25-7.11 
(m, 5H), 6.79 (d, J = 8.4 Hz, 1H), 6.75 (m, 1H), 6.60 (d, J = 7.2 Hz, 1H), 5.73 (d, J = 10.0 Hz, 
1H), 5.67 (s, 1H), 4.94 (d, J = 12.4 Hz, 1H), 4.86 (d, J = 12.4 Hz, 1H), 3.98 (br s, 1H), 3.76 (d, 
J = 10.0 Hz, 1H), 3.64 (s, 1H), 2.99 (s, 6H), 2.95 (s, 1H), 2.53 (s, 3H), 2.29 (s, 3H), 2.07 (m, 
1H), 1.93 (m 2H), 1.62 (m, 2H), 1.31 (br s, 7H), 1.04 (d, J = 6.0 Hz, 3H). 13C NMR (150 MHz, 
CDCl3): δ 198.59, 172.88, 162.73, 159.17, 146.49, 141.47, 138.15, 134.52, 129.58, 122.98, 
118.46, 118.20, 115.61, 111.96, 110.52, 90.22, 86.00, 73.67, 72.82,  68.23, 66.68, 62.31, 36.93, 
33.40, 31.84, 30.51, 29.68,  26.68, 24.05, 23.84, 22.66, 18.13, 14.15; IR (thin film, cm-1) 3413, 
2928, 2359, 1653, 1604, 1509, 1438, 1378, 1252, 1213, 1095, 736; MS (ESI+) Calcd. for 
C33H48N4O8+H,629.36; Found, 629.42; TLC (95:5 CH2Cl2:MeOH): Rf = 0.21. 
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((1S,2R,3R,4S,5S)-4-amino-3-(3,3-dimethylureido)-1,2-dihydroxy-3-((S)-1-
hydroxyethyl)-5-((4-methoxyphenyl)amino)cyclopentyl)methyl 2-hydroxy-6-
methylbenzoate (2.44): Isolated from S9 via general procedure E in 67% yield. Analytical 
data:  [α]D19 +4.4 (c = 0.25, CHCl3); 1HNMR (400 MHz, CDCl3): δ 10.92 (br s, 1H); 7.46 (br 
s, 1H); 7.29-7.25 (m, 2H); 6.99 (br s, 1H); 6.82 (d, J = 8.0 Hz, 1H); 6.79 (d, J = 8.8 Hz, 2H);6.70 
(d, J = 7.2 Hz, 1H); 6.60 (d, J = 8.8 Hz, 2H); 5.52 (br s, 1H); 4.87 (d, J = 12.4 Hz, 1H); 4.75 
(d, J = 12.0 Hz, 1H); 4.70 br s, 1H); 4.32 (s, 1H); 3.84 (br s, 1H); 3.74 (s, 3H); 3.13 (br s, 1H); 
2.96 (s, 6H); 2.51 (s, 3H); 1.06 (d, J = 6.4 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 171.5, 
158.6, 152.4, 141.1, 140.7, 134.2, 122.9, 115.6, 115.0, 114.5, 64.4, 55.7, 50.9, 36.7, 31.9, 29.7, 
29.6, 24.8, 23.6, 22.7, 17.7, 14.1; IR (thin film, cm-1) 3939, 3389, 3054, 2931, 2359, 2054, 
1640, 1512, 1442, 1382, 1265, 1119, 736; MS (ESI+) Calcd. for C26H36N4O8+H, 533.26; 
Found, 533.26; TLC (95:5 CH2Cl2:MeOH): Rf = 0.05. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-amino-3-(3,3-dimethylureido)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)cyclopentyl)methyl 2-hydroxy-6-methylbenzoate  
(2.42d): Isolated from S7d via general procedure E in 72% yield. Analytical data: [α]D19 +39.3 
(c = 0.25, CHCl3); 1H NMR  (400 MHz, CDCl3): δ 10.86 (br s, 1H); 7.55 (br s, 1H); 7.52-7.54 
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(m, 4H); 7.20 (s, 1H); 7.10 (s, 1H); 6.83-6.79 (m, 2H); 6.67 (d, J = 7.6 Hz, 1H); 5.61 (br s, 
1H); 5.11 (s, 1H); 4.84 (d, J = 12.4 Hz, 1H); 4.76 (d, J = 12.4 Hz, 1H); 4.81 (s, 1H); 3.85 (d, J 
= 10.4 Hz, 1H); 3.80 (br s, 1H); 3.48 (s, 1H); 3.07 (s, 6H); 2.55 (s, 3H); 2.47 (s, 3H); 1.04 (d, 
J = 6.4 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 198.6, 171.7, 162.3, 159.0, 146.6, 141.2, 
138.2, 134.3, 129.7, 123.0, 118.7, 118.6, 115.6, 112.5, 111.0, 83.9, 82.9, 74.1, 69.7, 68.5, 65.9, 
63.4, 36.6, 29.7, 26.7, 23.9, 17.9; IR (thin film, cm-1) 3381, 2926, 1724, 1667, 1604, 1522, 
1485, 1464, 1389, 1253, 1115, 1074, 735; MS (ESI+) Calcd. For C27H36N4O8+H, 545.26; 
Found, 545.32; TLC (90:10 CH2Cl2:MeOH): Rf = 0.90 
 
C6 Hydroxymethylene Derivatives 
 
5-methoxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (2.49): A flame dried 250-mL 
round bottomed flask was charged with  2.45 (0.50 g, 2.57 mmol, 1.00 equiv), acetone (70 mL) 
and anhydrous K2CO3 (0.53 g, 3.85 mmol, 1.50 equiv). The mixture was cooled to 0 °C and  
MeI (0.239 mL, 3.85 mmol, 1.50 equiv) was added slowly, and then warmed slowly to rt. After 
1 h the reaction was poured into H2O (20 mL) and exctracted with EtOAc (3 x 20 mL). The 
combined organic layers were washed with brine (15 mL),  dried with magnesium sulfate, and 
concentrated in vacuo. The crude product was purified via flash chromatography  (60:40 
hexanes:EtOAc), affording  ether 2.49 (400 mg, 74% yield) as a pale yellow solid. Analytical 
Data: 1H NMR  (400 MHz, CDCl3): δ 7.45 (t, J = 8.4 Hz, 1H); 6.63 (d, J = 8.4 Hz, 1H); 6.56 
(d, J = 9.6 Hz, 1H); 3.96 (s, 3H); 1.70 (s, 6H). 
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cyanomethyl 2-hydroxy-6-methoxybenzoate (2.50): Methyl ether 2.49 (0.40 g, 1.90 mmol, 
1.00 equiv) was dissolved in THF (2 mL) and a solution of KOH (0.53 g, 9.50 mmol, 5.00 
equiv) in 2 mL of H2O was added. The mixture was refluxed overnight, subsequently cooled 
to rt, acidified to pH 1 with 6M HCl(aq.) (10 mL), and extracted with EtOAc (3 x 10 mL). The 
combined organic layers were washed with brine (10 mL), dried with magnesium sulfate, and 
concentrated in vacuo, to afford the crude acid, which was carried on to the next step without 
further purification. 
The crude product was dissolved distilled acetone (7 mL). Et3N (379 µl, 2.85 mmol, 1.50 
equiv) and chloroacetonitrile (181 µl, 2.85 mmol, 1.50 equiv) were added to the solution and 
the mixture was refluxed for 3 h. The solvent was removed via rotary evaporator and pH 4 
buffer (10 mL) was added. The aqueous layer was extracted with EtOAc (3 x 15mL). The 
organic layers were combined, washed with brine (10 mL), dried with magnesium sulfate, and 
concentrated in vacuo. The crude product was purified with flash chromatography (80:20 
Hexane:EtOAc) to afford ester 2.50 as a pale yellow solid (113 mg, 29% yield). Analytical 
Data: 1H NMR  (400 MHz, CDCl3): δ 10.86 (s, 1H); 3.40 (t, J = 8.4 Hz, 1H); 6.62 (d, J = 9.2 
Hz, 1H); 6.44 (d, J = 8.4 Hz, 1H); 4.96 (s, 2H); 3.87 (s, 3H). 
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2,2-Dimethyl-5-phenyl-4H-benzo[d][1,3]dioxin-4-one (2.47): A 100-mL round-bottomed 
flask was charged with 2.46  (0.948 g, 2.91 mmol, 1.00 equiv), phenyl boronic acid (0.531 g, 
4.36 mmol, 1.5 equiv), KBr (0.346 g, 2.91 mmol, 1equiv), K3PO4 (0.928g, 4.36 mmol, 1.50 
equiv) and dioxane (12 mL). Pd(PPh3)4 (0.169 g, 0.15 mmol, 0.05 equiv) was added as a 
suspension in dioxane (3 mL) and the mixture was stirred at 100°C for 12 h. The mixture was 
cooled to room temperature, diluted with H2O (10 mL), and the aqueous layer was extracted 
with EtOAc (3 x 30 mL). The combined organic layers were washed with water (20 mL), brine 
(20 mL), dried with magnesium sulfate, and concentrated in vacuo.  The product was purified 
via flash chromatography  (60:40 hexanes:EtOAc), affording the desired product 2.47 (413 
mg, 55%) as a pale yellow solid. Analytical Data: 1H NMR  (400 MHz, CDCl3): δ 7.52 (t, J = 
8.0 Hz, 1H); 7.42-7.37 (m, 3H); 7.34-7.32 (m, 2H); 7.01 (d, J = 6.4 Hz, 1H); 6.98 (d, J = 7.2, 
1H); 1.79 (s, 6H).  MS (ESI+) Calcd. For C16H14O3+Na, 277.08; Found, 277.11. 
 
 
Cyanomethyl 3-hydroxybiphenyl-2-carboxylate (2.48): 2.47 (0.40 g, 1.90 mmol, 1.00 
equiv) was dissolved in THF (2 mL), and a solution of KOH (0.53 g, 9.50 mmol, 5.00 equiv) 
in 2 mL H2O was added. The mixture was heated at reflux for 12 h.  The resulting mixture was 
cooled to room temperature and acidified with 6M HCl(aq.) (10 mL) and extracted with EtOAc 
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(3 x 10 mL). The combined organic layers were washed with brine, dried with magnesium 
sulfate and concentrated in vacuo to afford crude the crude acid, which was used in the next 
step without further purification. 
The crude acid was dissolved in acetone (7 mL), and triethylamine (379 µL, 2.85 mmol, 1.50 
equiv) and chloroacetonitrile (181 µL, 2.85 mmol, 1.50 equiv) were added to the solution. The 
mixture was refluxed for 3h, upon which the solvent was removed in vacuo. A pH = 4 buffer 
solution (10 mL) was then added to the residue, and the mixture was extracted with EtOAc (3 
x 15 mL). The organic layers were combined, washed with brine, dried with magnesium 
sulfate, and concentrated in vacuo. The product was purified via flash chromatography (80:20 
hexanes:EtOAc) to afford ester 2.48 as a pale yellow solid (113 mg, 29%). 1H NMR  (400 
MHz, CDCl3): δ 10.11 (br s, 1H); 7.50-7.40 (m, 1H); 7.39-7.37 (m, 3H); 7.36-7.23 (m, 2H); 
7.05 (d, J = 9.6 Hz, 1H); 6.86 (d, J = 8.4 Hz, 1H); 4.52 (s, 2H). MS (ESI+) Calcd. For 
C15H11NO3+Na, 276.06; Found, 276.49. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-
hydroxy-6-methoxybenzoate (S10a): Isolated from 2.26 via general procedure D using 
cyanomethyl ester 2.50 as the electrophile in 57% yield. Analytical data: 1H NMR  (400 MHz, 
CDCl3): δ 11.08 (s, 1H); 7.37-7.20 (m, 8H); 7.12 (s, 1H); 6.73 (d, J = 6.4 Hz, 1H); 6.59 (d, J 
= 6.0 Hz, 1H); 6.39 (d, J = 8.4 Hz, 1H); 6.04 (s, 1H); 5.89 (br s, 1H); 5.59 (d, J = 7.9 Hz, 1H); 
5.27 (s, 1H); 5.20 (d, J = 13.5 Hz, 1H); 5.14 (d, J = 11.8 Hz, 1H); 4.72 (d, J = 12.0 Hz, 1H); 
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4.66 (d, J = 11.6 Hz, 1H); 4.07 (br s, 1H); 3.84 (d, J = 9.6 Hz, 1H); 3.79 (s, 1H); 3.75 (s, 3H); 
2.88 (s, 6H); 2.50 (s, 3H); 1.48 (s, 3H); 1.23 (br s, 3H); MS (ESI+) Calcd. For C36H44N4O11+H, 
709.31; Found, 709.15. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 3-
hydroxy-[1,1'-biphenyl]-2-carboxylate (S10b): Isolated from 2.26 via general procedure D 
using S17 as the electrophile in 43% yield. Analytical data:  1H NMR  (400 MHz, CDCl3): δ 
11.04 (s, 1H); 7.51-7.46 (m, 6H); 7.40-7.32 (m, 3H); 7.26-7.23 (m, 4H); 7.19-7.17 (m, 1H); 
7.04 (s, 1H); 6.98 (d, J = 8.0 Hz, 1H); 6.61 (t, J = 8.4 Hz, 2H); 5.86 (s, 1H); 5.38-5.34 (m, 1H); 
5.30 (s, 1H); 5.20 (d, J = 11.2 Hz, 1H); 5.05 (d, J = 8.0 Hz, 1H); 5.00 (s, 1H); 4.56 (d, J = 11.6 
Hz, 1H); 4.08 (d, J = 12.0 Hz, 1H); 3.91 (br s, 1H); 3.82 (d, J = 8.4 Hz, 1H); 2.91 (d, J = 10.4 
Hz, 1H); 2.85 (s, 6H); 2.25 (s, 3H); 1.261.22 (m, 6H); MS (ESI+) Calcd. For C41H46N4O10+H, 
755.33; Found, 755.19. 
 
((1S,2R,3R,4S,5S)-5-(3-acetylphenylamino)-4-(benzyloxycarbonylamino)-3-(3,3-
dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-
methylbenzoate (S10c): A flame-dried 20-mL scintillation vial was charged with  tetraol 2.26 
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(0.041 g, 0.073 mmol, 1.00 equiv) and CH2Cl2 (3.3 mL) was added under an atmosphere of 
N2. The solution was cooled to -78 °C and 2,4,6-collidine (0.02 mL, 0.47 mmol, 2.00 equiv) 
and DMAP (0.001 g, 0.01 mmol, 0.10 equiv)  were added sequentially. The mixture was stirred 
for 30 min, and 2-methylbenzoyl chloride was added. The reaction was allowed to stir for 1 
hour, warmed to room temperature and stirred until TLC analysis indicated full conversion of 
the starting material, generally 8 h. A 1:1 mixture of saturated NH4Cl(aq.): 1 M HCl(aq.) (3 mL) 
was added, followed by EtOAc (4 mL). The mixture was partitioned in a separatory funnel, 
and the aqueous layer was extracted with EtOAc (3 x 6 mL), and the combined organic layers 
were washed with saturated NaHCO3(aq.) (5 mL), water (5 mL), brine (5 mL) and dried with 
magnesium sulfate. The crude product was concentrated in vacuo and purified via flash 
chromatography (60:40 to 50:50 hexanes:EtOAc) to give the ester S10c (0.03 g, 60%) as a pale 
yellow foam. Analytical Data: 1H NMR  (400 MHz, CDCl3): δ 7.31 (d, J = 7.6 Hz, 1H); 7.51 
(br s, 1H); 7.38-7.12 (m, 11H); 6.74 (d, J = 7.6 Hz, 1H); 6.07 (s, 1H); 5.87 (d, J = 9.2 Hz, 1H); 
5.74 (d, J = 10.0 Hz, 1H); 5.20 (s, 1H); 5.16 (d, J = 12.4 Hz, 1H); 5.10 (d, J = 12.0 Hz, 1H); 
4.8 (d, J = 12.8 Hz, 1H); 4.73 (d, J = 12.4 Hz, 1H); 4.12-4.05 (m, 2H); 3.97 (s, 1H); 3.81 (d, J 
= 9.6 Hz, 1H); 2.85 (s, 6H); 2.50 (s, 3H); 2.49 (s, 3H); 1.51 (s, 3H); 1.25 (br s, 3H); MS (ESI+) 
Calcd. For C36H44N4O9+H, 677.32; Found, 677.25. 
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General Procedure J for primary alcohol esterification using aliphatic electrophiles.  
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-
phenylacetate  (S10e): A flame-dried scintillation vial was charged with  tetraol 2.26 (0.032 
g, 0.056 mmol, 1.00 eq.) and CH2Cl2 (2.5 mL) under an atmosphere of N2. The solution was  
cooled to -78 °C and 2,4,6-collidine (15 µL, 0.112 mmol, 2.00 eq.) was added. The resulting 
mixture was stirred for 30 min, and phenylacetyl chloride was added.  The reaction was 
allowed to stir at this temperature until TLC analysis indicated full conversion of the starting 
material, typically 1 h. A mixture of saturated NH4Cl(aq.):1M HCl(aq.) (1:1) (3 mL) was added 
followed by EtOAc (4 mL) and the reaction was allowed to warm to rt. The mixture was 
partitioned in a separatory funnel and the aqueous layer was extracted with EtOAc (3 x 6 mL). 
The combined orgaic layers were washed with saturated NaHCO3(aq.) (5 mL), water (5 mL), 
brine (5 mL), dried with magnesium sulfate, and concentrated in vacuo. The crude product was 
purified via flash chromatography (60:40 to 50:50 hexanes:EtOAc) to give the title compound 
S10e as a pale yellow foam (0.033 g mg, 87%).  Analytical data: 1H NMR  (400 MHz, CDCl3): 
δ 7.39-7.34 (m, 5H); 7.32 (d, J = 7.6Hz, 1H); 7.26-7.23 (m, 5H); 7.17 (d, J = 6.4 Hz, 2H); 6.67 
(d, J = 7.6 Hz, 1H); 5.98 (s, 1H); 5.65 (d, J = 9.2 Hz, 1H); 5.59 (d, J = 10.4 Hz, 1H); 5.15-5.13 
(m, 3H); 4,53 (s, 2H); 4.01 (br s, 1H); 3.96 (d, J = 8.4 Hz; 1H); 3.59 (s, 2H); 3.55 (d, J = 9.6 
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Hz, 1H); 3.21 (s, 1H); 2.84 (s, 6H); 2.54 (s, 3H); 1.37 (s, 3H); 1.20 (d, J = 7.2 Hz, 3H); MS 
(ESI+) Calcd. For C36H44N4O9+H, 677.32; Found, 677.31. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 
cyclohexanecarboxylate (S10d): Isolated from 2.26 via general procedure J using 
cyclohexoyl chloride as the electrophile in 83% yield. Analytical data: : 1H NMR  (400 MHz, 
CDCl3): δ 7.37 (br s, 1H); 7.31-7.23 (m, 6H); 7.10 (s, 1H); 6.71 (d, J = 6.4 Hz, 1H); 6.02 (s, 
1H); 5.82 (d, J = 8.0 Hz, 1H); 5.64 (d, J = 10.0 Hz, 1H); 5.16-5.10 (m, 3H); 4.52 (d, J = 12.0 
Hz, 1H); 4.51 (d, J = 12.4 Hz, 1H); 4.02 (br s, 1H); 3.72-3.68 (m, 2H); 2.85 (s, 6H); 2.54 (s, 
3H); 2.29-2.35 (m, 1H); 1.83-1.74 (m, 2H): 1.67-1.63 (m, 4H); 1.44 (s, 3H); 1.36-1.27 (m, 
2H); 1.25-1.18 (m, 5H); MS (ESI+) Calcd. For C35H48N4O9 +H, 669.35; Found, 669.35. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 
methanesulfonate (S10f): Isolated from 2.26 via general procedure J using cyclohexoyl 
chloride as the electrophile in 54% yield. Analytical data: 1H NMR  (400 MHz, CDCl3): δ  
7.34-7.24 (m, 7H); 7.14 (s, 1H); 6.75 (d, J = 7.6 Hz; 1H); 5.96 (d, J = 9.6 Hz, 1H); 5.55 (bs, 
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1H); 5.25 (s, 1H); 5.12 (bs, 2H); 4.65 (d, J = 11.2 Hz, 1H); 4.53 (d, J = 11.2 Hz, 1H); 4.09 (bs, 
1H); 3.85 (bs, 1H); 2.90 (s, 3H); 2.85 (s, 6H); 2.53 (s, 3H); 1.46 (s, 3H); 1.25 (bs, 3H);  MS 
(ESI+) Calcd. For C29H40N4O10S +H, 637.25; Found, 669.14. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-amino-3-(3,3-dimethylureido)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 3-hydroxy-[1,1'-
biphenyl]-2-carboxylate (2.51b): Isolated from S10b via general procedure E in 62% yield. 
Analytical data: [α]D19 +8.4 (c = 0.3, CHCl3); 1H NMR  (400 MHz, CDCl3): δ  11.05 (br s, 
1H); 7.85 (d, J = 10.8 Hz, 1H); 7.57 (t, J = 7.4 Hz, 2H); 7.44-7.33 (m, 5H); 7.18-7.15 (m, 2H); 
7.10 (s, 1H); 7.02 (s, 1H); 6.97 (d, J=8.4 Hz, 1H); 6.67 (d, J = 7.2 Hz, 1H); 6.62 (d, J = 7.6 Hz, 
1H); 5.48 (s, 1H); 5.32 (d, J = 10.4 Hz, 1H); 5.11 (br s, 1H); 4.09 (d, J = 12.0 Hz, 1H); 3.80 
(br s, 1H); 2.98 (s, 6H); 2.95 (s, 1H); 2.91-2.83 (m, 2H); 2.75 (s, 1H); 2.54 (s, 3H); 1.30 (s, 
3H): 0.97 (d, J = 6.4 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 198.6, 170.7, 162.4, 159.1, 
146.7, 144.6, 143.8, 137.9, 133.9, 130.9, 129.5, 128.8, 128.7, 128.5, 127.1, 123.1, 119.8, 118.7, 
117.3, 110.7, 110.00, 88.5, 83.1, 74.0, 71.2, 68.2, 68.2, 66.3, 65.9, 65.4, 36.8, 31.9, 29.7, 28.9, 
26.7, 23.7, 21.0, 18.1, 15.3, 14.2, 11.00; IR (thin film, cm-1) 3376, 2925, 2853, 2359, 1727, 
1672, 1602, 1520, 1438, 1267, 1216; MS (ESI+) Calcd. For C33H40N4O8+H, 621.29; Found, 
621.22; TLC (95:5 CH2Cl2:MeOH): Rf = 0.24. 
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((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-amino-3-(3,3-dimethylureido)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-methylbenzoate  
(2.51c): Isolated from S10c via general procedure E in 73% yield. Analytical data: [α]D19 +9.9 
(c = 0.28, CHCl3); 1H NMR  (400 MHz, CDCl3): δ 7.75 (d, J = 8.0 Hz, 1H); 7.39 (t, J = 7.6 
Hz, 1H); 7.26-7.25 (m, 6H); 6.83 (d, J = 6.8 Hz, 1H); 5.8 (br s, 1H); 5.68 (d, J = 10.4 Hz, 1H): 
4.74 (s, 2H); 4.01 (br s, 1H); 3.86 (d, J = 10.4 Hz, 1H); 3.01 (s, 6H); 2.55 (s, 3H); 2.52 (s, 3H); 
1.58 (s, 3H); 1.08 (d, J = 6.4 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 198.6, 168.7, 159.2, 
146.8, 140.4, 138.2, 132.3, 131.7, 131.5, 130.7, 129.6, 128.8, 125.7, 118.7, 118.1, 110.7, 89.8, 
88.6, 85.1, 84.9, 64.7, 36.8, 29.7, 26.7, 21.7, 21.1, 18.1; IR (thin film, cm-1) 3408, 2925, 2360, 
1716, 1636, 1520, 1375, 1252, 1082; MS (ESI+) Calcd. For C28H38N4O7+H, 543.28; Found, 
543.21; TLC (95:5 CH2Cl2:MeOH): Rf = 0.32. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-amino-3-(3,3-dimethylureido)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-phenylacetate (2.51e): 
Isolated from S10e via general procedure E in 61% yield. Analytical data:   [α]D19 +48.9 (c = 
0.45, CHCl3); 1H NMR  (400 MHz, CDCl3): δ  7.88 (d, J = 11.2 Hz, 1H); 7.29-7.24 (m,6H); 
7.18-7.24 (m, 4H); 6.74 (d, J = 7.6 Hz, 1H); 5.55 (d, J = 10.4 Hz, 1H); 4.53 (d, J = 12.4 Hz, 
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1H); 4.44 (d, J = 12.4 Hz, 1H); 3.87 (br s, 1H); 3.58 (s, 2H); 3.55 (s, 1H); 2.96 (s, 6H); 2.85 
(s, 1H); 1.41 (s, 3H); 1.01 (d, J = 6.4 Hz, 3H).  13C NMR (150 MHz, CDCl3): δ 198.7, 172.4, 
159.2, 146.6, 138.3, 133.7, 129.6, 129.2, 129.1, 128.6, 127.2, 118.9, 118.2, 110.5, 88.5, 84.6, 
74.2, 71.4, 68.3, 64.6, 63.1, 41.3, 36.8, 29.7, 26.8, 21.0, 18.1; IR (thin film, cm-1) 3398, 2928, 
2359, 1733, 1671, 1602, 1519, 1455, 1373, 1327, 1266, 1094, 780;  MS (ESI+) Calcd. For 
C28H38N4O7+H, 543.28; Found, 543.21; TLC (95:5 CH2Cl2: MeOH): Rf = 0.15. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-amino-3-(3,3-dimethylureido)-1,2-
dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl cyclohexanecarboxylate 
(2.51d): Isolated from S10d via general procedure E in 76% yield. Analytical data:  [α]D19 
+22.3 (c = 0.3, CHCl3); 1H NMR  (400 MHz, CDCl3): δ  7.86 (br s, 1H); 7.24-7.21 (m, 3H); 
7.16-7.13 (m, 2H); 6.77 (d, J = 6.8 Hz, 1H); 5.69 (br s, 1H); 5.57 (d, J = 10.4 Hz, 1H); 4.48 (d, 
J = 12.0 Hz, 1H); 4.43 (d, J = 12.0 Hz, 1H); 3.95 (br s, 1H); 3.72 (d, J = 10.4 Hz, 1H); 2.98 (s, 
6H); 2.57 (br s, 1H); 1.83-1.60 (m, 5H); 1.49 (s, 3H); 1.36-1.15 (m, 5H); 1.03 (d, J = 6.0 Hz, 
3H); 13C NMR (150 MHz, CDCl3): δ 198.7, 177.3, 159.2, 146.8, 138.2, 129.6, 118.8, 118.2, 
110.5, 84.6, 65.9, 64.2, 43.0, 36.8, 29.0, 28.8, 26.7, 25.6, 25.3, 25.2, 21.1, 18.1, 15.3; IR (thin 
film, cm-1) 3380, 3054, 2986, 2935, 2410, 1727, 1679, 1603, 1514, 1440, 1265, 738; MS 
(ESI+) Calcd. For C27H42N4O7+H, 535.31; Found, 535.37; TLC (95:5 CH2Cl2:MeOH): Rf = 
0.36. 
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General Procedure K for C6,C7 bis acylation: 
 
((1S,2R,3R,4S,5S)-3-((S)-1-acetoxyethyl)-5-((3-acetylphenyl)amino)-4-(((benzyloxy) 
carbonyl)amino)-3-(3,3-dimethylureido)-1,2-dihydroxy-2-methylcyclopentyl)methyl 
acetate (S11a): A flame-dried 20-mL scintillation vial was charged with  tetraol 2.26 (0.020 
g, 0.036 mmol, 1.00 equiv) and CH2Cl2 (1 mL) under an atmosphere of N2. The solution was 
cooled to 0 °C and NEt3 (0.01 mL, 0.07 mmol, 2.00 equiv) and DMAP (0.001 g, 0.01 mmol, 
0.27 equiv) were added followed lastly by Ac2O (0.01 mL, 0.11 mmol, 3.00 equiv).  The 
mixture was allowed to warm to rt and stirred until full conversion of the starting material was 
observed by TLC analysis, typically 12 h.  The reaction was quenched via addition of saturated 
NaHCO3(aq.) (5 mL), and the layers were partitioned in a separatory funnel.  The aqueous layer 
was extracted with CH2Cl2 (3 x 5 mL), and the combined organics were washed with brine (5 
mL), dried with magnesium sulfate, and concentrated in vacuo.  The product was purified via 
flash chromatography (70:30 to 60:40 petroleum ether:acetone) to afford diester S11a (0.02 g, 
86%) as a colorless foam. Analytical Data: 1H NMR  (400 MHz, CDCl3): δ  7.67 (d, J = 8.0 
Hz, 1H), 7.25-7.23 (m, 8H), 6.20 (q, J = 6.4 Hz, 1H), 5.57 (s, 1H), 5.07 (d, J = 12.4 Hz, 1H), 
5.00 (d, J = 12.8 Hz, 1H), 4.82 (d, J = 5.2 Hz, 1H), 4.59 (m, 3H), 4.21 (d, J = 12.4 Hz, 1H), 
3.85 (m, 1H), 3.62 (s, 1H), 2.96 (s, 6H), 2.55 (s, 3H), 2.06 (s, 3H), 1.91 (s, 3H), 1.48 (s, 3H), 
1.37 (d, J = 6.4 Hz, 3H); MS (ESI+) Calcd. For C32H42N4O10+Na, 665.28; Found, 665.34. 
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((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-1,2-dihydroxy-2-methyl-3-((S)-1-(pivaloyloxy)ethyl)cyclopentyl)methyl 
pivalate (S11b): Isolated from 2.26 via general procedure K using pivaloyl chloride as the 
electrophile in 92% yield. Analytical data: 1H NMR  (400 MHz, CDCl3): δ  7.86 (d, J = 8.0 
Hz, 1H), 7.25-7.19 (m, 8H), 6.88 (d, J = 8.0 Hz, 1H), 6.16 (q, J = 8.0 Hz, 1H), 5.61 (s, 1H), 
5.03 (dd, J = 4.8, 12.0 Hz, 2H), 4.95 (d, J = 5.2 Hz, 1H), 4.66 (m, 2H), 4.57 (t, J = 12.5 Hz, 
1H), 4.17 (d, J = 12.4 Hz, 1H), 3.86 (m, 1H), 3.64 (s, 1H), 2.96 (s, 6H), 2.55 (s, 3H), 2.17 (s, 
3H), 1.46 (s, 3H), 1.38 (d, J = 6.8 Hz, 3H), 1.19 (s, 9H), 1.14 (s, 9H); MS (ESI+) Calcd. For 
C38H54N4O10 +Na, 749.37; Found, 749.45. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-((S)-1-
((cyclohexanecarbonyl)oxy)ethyl)-3-(3,3-dimethylureido)-1,2-dihydroxy-2-
methylcyclopentyl)methyl cyclohexanecarboxylate (S11c): Isolated from 2.26 via general 
procedure K using cyclohexylacetyl chloride as the electrophile in 76% yield. Analytical data: 
1H NMR  (400 MHz, CDCl3): δ  7.85 (d, J = 8.0 Hz, 1H), 7.28-7.20 (m, 8H), 6.88 (d, J = 8.4 
Hz, 1H), 6.23 (q, J = 6.8 Hz, 1H), 5.64 (s, 1H), 5.04 (dd, J = 5.6, 12.4 Hz, 2H), 4.96 (d, J = 5.2 
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Hz, 1H), 4.64 (m, 3H), 4.22 (d, J = 12.4 Hz, 1H), 3.84 (dd, J = 4.0, 5.2 Hz, 1H), 3.79 (s, 1H), 
2.97 (s, 6H), 2.56 (s, 3H), 2.27 (m, 1H), 2.16 (t, J = 10.8 Hz, 1H), 1.96-1.62 (m, 11H), 1.48 (s, 
3H), 1.38 (d, J = 6.4 Hz, 3H), 1.32-1.13 (m, 9H); MS (ESI+) Calcd. For C42H58N4O10 +H, 
801.41; Found, 801.54. 
 
((1S,2R,3R,4S,5S)-3-((S)-1-acetoxyethyl)-5-((3-acetylphenyl)amino)-4-amino-3-(3,3-
dimethylureido)-1,2-dihydroxy-2-methylcyclopentyl)methyl acetate (2.57a): Isolated 
from S11a via general procedure E in 38% yield. Analytical data: :   [α]D19 +5.6 (c = 0.17, 
CHCl3); 1H NMR  (600 MHz, CDCl3): δ  7.27-7.21 (m, 4H), 6.95 (d, J = 6.6 Hz, 1H), 6.10 (q, 
J = 6.6 Hz, 1H), 5.54 (s, 1H), 4.51 (d, J = 12.0 Hz, 2H), 4.21 (d, J = 12.0 Hz, 1H), 4.06 (br s, 
1H), 3.44 (br s, 1H), 2.99 (s, 7H), 2.55 (s, 3H), 2.11 (s, 1H), 1.82 (s, 1H), 1.44 (m, 6H); 13C 
NMR (150 MHz, CDCl3): δ 198.9, 172.2, 169.7, 158.7, 148.2, 138.0, 129.3, 117.8, 112.1, 
85.7, 81.7, 72.1, 69.3, 65.6, 36.7, 29.7, 26.8, 21.5, 20.8, 20.2, 16.6, 1.0; IR (thin film, cm-1) 
3421, 2926, 2846, 1637, 1541, 1246, 1066; MS (ESI+) Calcd. For C24H36N4O8 +H; Found, 
509.33; TLC (98:2 CH2Cl2:MeOH): Rf = 0.10. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-amino-3-(3,3-dimethylureido)-1,2-
dihydroxy-2-methyl-3-((S)-1-(pivaloyloxy)ethyl)cyclopentyl)methyl pivalate (2.57b): 
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Isolated from S11b via general procedure E in 53% yield. Analytical data: :   [α]D19 +21.8 (c = 
0.45, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.29-7.22 (m, 4H), 6.95 (d, J = 6.6 Hz, 1H), 
6.08 (q, J = 6.6 Hz, 1H), 5.55 (s, 1H), 4.60 (d, J = 12.0 Hz, 1H), 4.33 (br s, 1H), 4.17 (d, J = 
12.0 Hz, 1H), 4.04 (t, J = 7.8 Hz, 1H), 3.34 (d, J = 6.8 Hz, 1H), 2.98 (s, 6H), 2.55 (s, 3H), 1.43 
(d, J = 6.6 Hz, 3 H), 1.38 (s, 3H), 1.23 (s, 9H), 1.09 (s, 9H); 13C NMR (150 MHz, CDCl3): δ 
198.7, 179.9, 177.0, 158.6, 148.2, 138.1, 129.5, 117.7, 117.4, 112.2, 85.5, 81.5, 69.6, 66.0, 
38.9, 38.8, 36.7, 27.1, 26.8, 20.2, 16.6; IR (thin film, cm-1) 3895, 3399, 2972, 2359, 1710, 
1642, 1530, 1461, 1367, 1284, 1165; MS (ESI+) Calcd. For C30H48N4O8 +H, 593.36; Found, 
593.38; TLC (90:10 CH2Cl2:MeOH): Rf = 0.34. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-amino-3-((S)-1-((cyclohexanecarbonyl) 
oxy)ethyl)-3-(3,3-dimethylureido)-1,2-dihydroxy-2-methylcyclopentyl)methyl 
cyclohexanecarboxylate (2.57c): Isolated from S11c via general procedure E in 72% yield. 
Analytical data: :   [α]D19 +22.6 (c = 0.85, CHCl3); 1H NMR  (600 MHz, CDCl3): δ  7.28-7.20 
(m, 4H),  6.93 (d, J = 7.2 Hz, 1H), 6.14 (q, J = 6.6 Hz, 1H), 5.55 (s, 1H), 4.53 (d, J = 12.6 Hz, 
1H), 4.34 (s, 1H), 4.18 (d, J = 16.2 Hz, 1H), 3.98 (t, J = 7.8 Hz, 1H), 3.30 (d, J = 7.2 Hz, 1H), 
2.98 (s, 6H), 2.55 (s, 3H) 2.30 (m, 1H), 2.05 (m, 1H), 1.91 (m, 2H), 1.76 (m, 3H), 1.66-1.57 
(m, 5H), 1.42 (d, J = 6.6 Hz, 3H), 1.38 (s, 3H), 1.28-1.10 (m, 10H);  13C NMR (150 MHz, 
CDCl3): δ 198.7, 177.4, 174.5, 158.5, 148.4, 138.0, 129.3, 117.6, 117.5, 112.2, 85.6, 81.6, 
69.5, 65.5, 43.4, 43.1, 36.7, 28.7, 26.8, 25.8, 25.6, 25.5, 25.4, 25.3, 20.3, 16.6; IR (thin film, 
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cm-1) 3390, 3055, 2935, 2857, 2305, 2054, 1723, 1642, 1538, 1450, 1332, 1247, 1132, 737; 
MS (ESI+) Calcd. For C34H52N4O8+H, 645.39; Found, 645.47; TLC (90:10 CH2Cl2:MeOH): 
Rf = 0.36. 
 
Nanoparticle Fabrication and Characterization    
PRINT-pactamycin NPs were fabricated with solutions of P(d,l-lactide) and docetaxel 
dissolved in chloroform as previously described.14b,27 Particle size and shape were determined 
by Dynamic Light Scattering (DLS, Malvern Instruments) and confirmed by Scanning 
Electron Microscopy (SEM; Hitachi model 2-4700). Drug loadings were determined by 
dissolving the NPs and analyzing solutions by reverse-phase HPLC using validated 
concentration curves. NP fabrication was conducted, molds were filled with a pre-particle 
polymer solution prepared with 2 percent by weight PLGA and quantum dots (28:1) in 
chloroform as previously described.14b,27 Particle size and shape were determined by DLS and 
SEM. Particle concentration was determined using Thermogravimetric Analysis correcting for 
the supernatant (TA Instruments). Excitation, emission, and absorbance wavelength scans of 
PLGA Quantum Dot NPs were performed on a 96 well plate reader (Molecular Devices 
SpectraMax M5). QD concentrations were determined by inductively coupled plasma mass 
spectroscopy (ICP-MS). 
 
High Pressure Liquid Chromatography Analysis and Drug Loading  
HPLC analysis of PRINT-therapeutics was performed with an analytical Agilent 1200 HPLC 
system equipped with a variable wavelength absorbance detector using a reverse phase C18 
column (Agilent, Zorbax Eclipse XDB-C18, 5 Å, 4.6 x 150mm). A binary gradient of water 
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(10% isopropyl alcohol), acetonitrile (10% isopropyl alcohol), 1 mL min-1 was used and the 
eluent was monitored by UV absorbance at 205 and 210 nm. 
 
In vitro cytotoxicity assays  
A549 (ATCC® CCL-185™), MDAMB231 (ATCC® HTB-26™), SK-OV-3 (ATCC® HTB-
77™), MRC-5 (ATCC® CCL-171™), were purchased directly from and authenticated by 
ATCC immediately prior to initiation of these studies. All cell-based assays were performed 
utilizing passage number for each cell line ranging from 6-16.  Each cell line was seeded in 
200 μL of media [RPMI1640 (A549), Leibovitz’s L-15 medium (MDAMB231), McCoy’s 5A 
(SK-OV-3), and EMEM (MRC-5) with 10% fetal bovine serum] at a density of 5000 cells per 
cm2 into a 96-well microtiter plate. Cells were allowed to adhere for 24 h and subsequently 
incubated with PRINT particles at drug concentrations ranging from 4uM to 0.05 nM for 72 h 
at 37 °C in a humidified 5% CO2 atmosphere. After the incubation period, all medium/particles 
were aspirated off cells. 100 μL fresh medium was added back to cells followed by the addition 
of 100 μL CellTiter-Glo® Luminescent Cell Viability Assay reagent. Plates were placed on a 
microplate shaker for 2 min, then incubated at room temperature for 10 minutes to stabilize 
luminescent signal. The luminescent signal was recorded on a SpectraMax M5 plate reader 
(Molecular Dynamics). The viability of the cells exposed to PRINT particles was expressed as 
a percentage of the viability of cells grown in the absence of particles. 
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Table 2-8. Physical Characteristics of 80x320 nm PRINT-Therapeutic NPs as Measured by 
DLS and ζ-Potential.  
NP containing 
therapeutic# 
Hydrodynamic 
size (nm) 
Polydisdersity 
Index 
Zetapotential 
(mV) 
Drug 
Loading 
(wt%) 
1 253 ± 8 0.07 ± 0.02 -9 10 
2.29e 262 ± 5 0.09 ± 0.02 -9 9 
2.42dc 243 ± 2 0.09 ± 0.02 -9 9 
 
Figure 2-8. Scanning electron microscope (SEM) images of 80x320 nm PRINT-therapeutic 
NPs containing derivative (A) 2.1, (B) 2.29e, and (C) 2.42d, show that the particles are 
monodisperse and uniform in size and shape despite containing different therapeutics. 
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Figure 2-9.  NCI-60 Screening Results for Derivative 2.51c 
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Figure 2-10.  NCI-60 Screening Results for Derivative 2.42d 
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Figure 2-11.  NCI-60 Screening Results for Derivative ent-Pactamycin 
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Figure 2-12.  NCI-60 Screening Results for Derivative 2.29f 
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Figure 2-13.  NCI-60 Screening Results for Derivative 2.57a 
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CHAPTER THREE: 
INCEPTION AND DEVELOPMENT OF A GLOBAL AND LOCAL 
DESYMMETRIZATION APPROACH TO THE SYNTHESIS OF STEROIDAL 
ALKALOIDS: STEREOCONTROLLED TOTAL SYNTHESIS OF PASPALINE‡ 
 
3.1 Introduction 
  The total synthesis of terpene alkaloid natural products has received significant 
attention from the synthetic community in the last half-century.  In recent years, however, 
synthetic interest in these targets has been reignited, in no small part due to the continued 
discovery of natural molecules bearing deviations from the classical steroid arhitecture.  These 
findings have challenged the organic chemist toward new innovations in the preparation of 
these molecules.  In this final chapter, we detail the design and implementation of a series of 
new synthetic disconnetions in the arena of terpene alkaloid synthesis, specifically applied to 
the total synthesis of paspaline. These studies culminated in the further application of 
symmetry-breaking techniques (both “global” and “local”) in the rapid assembly of 
stereochemical information, providing the title compound with exceptional stereochemical 
fidelity. 
 
 
                                                          
‡Reprinted in part with permission from Sharpe, R. J.; Johnson, J. S. J. Am. Chem. Soc. 2015, 
137, 4968, Sharpe, R. J.; Portillo, M.; Vélez, R. A.; Johnson, J. S. Synlett 2015, 26, 2293, and 
Sharpe, R. J.; Johnson, J. S. J. Org. Chem. 2015, 80, 9740. 
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3.2  Background 
3.2.1  Historical Perspective on Ergot Alkaloids 
Production of novel metabolites by the ergot fungus has been well-documented.1 Most 
notably, those produced by Claviceps purpurea have long been implicated in the contamination 
of various grains.2   Claviceps paspali, another species in this genus, has been linked to 
“paspalum stagger” poisoning, most commonly in livestock.3 This infection is typically 
marked by sustained tremors, discoordination, limb weakness, and severe convulsions, which 
may ultimately result in death. Near the middle of the twentieth century, the source of these 
toxins was identified in a series of alkaloid small molecules.4 Among these compounds were 
the tremorgenic indole diterpenoid family of structures (Figure 3-1).  
Figure 3-1. Paspaline and Related Indole Diterpenoid Natural Products 
 
 Arigoni and co-workers first reported the isolation of paspaline (3.1) and paspalicine 
(3.4) in 1966,4 the first of what has become an extensive family of natural products.  Since this 
initial report, the related structures including paspaline B (3.2),5 paspalinine (3.3),6  JBIR-03 
(3.6),7 paxilline (3.7),8 and others have also been reported.9  
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The varied biological profiles of these compounds have rendered them particularly attractive 
targets. The recently discovered JBIR-03 has displayed significant inhibition of V. 
ceratosperma (MIC = 128 μg/mL) while showing no cytotoxic effects to the human 
fibrosarcoma cell line HT-1080 at 100 μM.7 Moreover, paspalinine and its derivatives have 
demonstrated marked activity as Maxi-K channel antagonists, and as a result, are under 
examination as treatments for Alzheimer’s disease and other neurological disorders.10 Paxilline 
is currently under study for its properties as a BK-channel antagonist toward the suppression 
of seizures in postnatal mammals.11  From a standpoint of structure-activity, prior work by 
Cole has underscored the significance of the axial tert-hydroxyl functionality (C4b, paspaline 
numbering) as an important source of activity for these structures, evidenced by the lack of 
tremorgenicity demonstrated by paspaline and paspalicine.12  
3.2.2  Structure Analysis and Biosynthetic Proposal for Paspaline   
 The absolute structure of 3.1 was confirmed in 1980 by Springer and Clardy on the 
basis of X-ray diffraction studies.12a  Paspaline and its related compounds are characterized 
principally by their unique departures from the classical steroid architecture; these features are 
contrasted with the archetypal steroid motif in  Figure 3-2.  While the core 6,6,6,5 ring system 
is retained in 3.1, the presence of a fused indole functional group (A,B rings) replaces the more 
standard oxygenation pattern observed in steroids such as testosterone (3.9) and cholesterol 
(3.10).  Additional oxygenation is present in the terminal 6-ring in the form of a 
tetrahydropyran (or derivatives thereof).   Furthermore, grafted onto the D/E decalin core one 
encounters three all-carbon quaternary carbons. This so-called “angular functionality,” while 
non-distinct from classical steroid architecture, is of note due to its proximal arrangement in  
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Figure 3-2. Divergence of Paspaline from Classical Steroidal Structures 
 
paspaline, particularly the vicinal C12b,C12c methyl groups and the syn-diaxial C12c, C4a 
methyl groups.   
 The biosynthesis for paspaline was first proposed by Arigoni in 197713 and has since 
been confirmed by Hull and Oikawa (Scheme 3-1).14 Synthesis of 3.1 arises from building 
Scheme 3-1.  Biosynthetic Pathway for Paspaline 
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blocks geranylgeranyl diphosphate (GGDP, 3.11) and indole phosphate 3.12.15  A 
prenyltransferase enzyme facilitates the union of 3.11 and 3.12 to install the needed carbon 
skeleton. Stereoselective epoxidation of the C4a,C14a double bond in 3.13 and subsequent 
polycyclization ensues to construct rings A-E, and a second epoxidation/etherification 
sequence affords paspaline.  3.1 is also a biosynthetic intermediate to a number of its related 
structures including paxilline (3.7) as illustrated.15  While an approach such as this one would 
be challenging in a laboratory setting, this synthesis provides insight into how nature addresses 
the preparation of the indole, tetrahydropyran, and angular methyl groups. 
3.2.3  Smith Synthesis of Paspaline 
 The salient features of 3.1 necessitate careful planning for endeavors in total synthesis; 
outside of significant contributions from the Smith laboratory,16 whose thirty-year research 
program in this field has defined the state of the art for this class of molecule, synthetic interest 
in this subset of alkaloids has been limited.17  Smith’s twenty-three-step synthesis of 3.1, the 
single published total synthesis of paspaline prior to our work, was reported in 1985.16a His 
approach to the core stereochemistry is described in Scheme 3-2. Beginning from Wieland-
Miescher ketone 3.17, ketalization, thiomethylation, and reductive alkylation installed the C4a, 
C12c diaxyl methyl groups in 69% yield (3.18).  Reduction of the ketone in 3.18 with 
preferential hydride approach opposite the C12c and C4a axial methyl groups delivered alcohol 
3.19 in 72% yield and 4:1 dr following removal of the dioxolane protecting group.  A four-
step sequence provided access to enone 3.20.  As the centerpiece to their strategy, Smith 
envisioned stereoselective reductive alkylation of the enone to give the desired trans-
hydrindanone 3.21.  However, treatment of 3.20 with Li0, NH3, and MeI furnished exclusively  
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Scheme 3-2. Smith Synthesis of Paspaline: Angular Methyl Group Installation 
 
the undesired cis adduct 3.22 in 50% yield.  An extensive screen of conditions for this reaction 
resulted in only marginal improvement in diastereoselectivity as modification of the reaction 
temperature and order of addition of the enolate furnished a 50% yield of the diastereomeric 
ketones with the desired isomer 3.21 isolated in 17% yield.  The allyl group was then extended 
in a four-step sequence to provide advanced ketone intermediate 3.23 poised for synthesis 
completion. 
 From ketone 3.23, two challenges remained: i) installation of the tetrahydropyran and 
C2 stereocenter, and ii) incorporation of the indole moiety (Scheme 3-3).  Toward this goal, 
Smith elected to perform a nonstereoselective epoxidation on alkene 3.23, which upon silyl 
deprotection and ring closure gave the secondary alcohol 3.24.  Oxidation of the alcohol 
provided a configurationally-labile C2 methine proton, wherein base mediated epimerization 
installed the final stereocenter in 3.1.  Addition of a methyl nucleophile gave tertiary alcohol 
3.25 in 64% over five steps.  While at first a Fisher indolization of ketone 3.25 to paspaline 
seemed obvious, this indolization proved to be a significant issue in synthesis completion,  
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Scheme 3-3.  Smith Synthesis of Paspaline: Tetrahydropyran and Indole Synthesis 
 
primarily due to the steric encumbrance associated with the ketone in 3.25 (a problem that will 
be further elaborated upon in Section 3.3.21).16d Ultimately, the Gassman four-step 
indolization protocol proved successful in incorporating the indole moiety and completing their 
synthesis.18 
 In a second generation approach, Smith looked to circumvent the problematic reductive 
alkylation protocol (3.20 → 3.21).16b,c  Beginning from dioxolane 3.26, Robinson annulation 
delivered enone 3.27 with complete control of the C6a stereocenter (Scheme 3-4).  This set the 
stage for an alternative reductive alkylation in which electrophile approach was projected to 
occur opposite the C12c angular methyl group.  Treatment of enone 3.27 with ZnMe2 and 
Ni(acac)2 followed by trapping with TMSCl afforded enol-silane 3.28 with complete 
selectivity for the desired trans-fused bicycle in 90% yield.  The cyclohexene was then cleaved 
via ozonolysis, which after esterification and intramolecular aldol cyclization, gave alcohol 
3.30.  Oxidation of the alcohol, elimination of the ester, and cleavage of the dioxolane gave 
diketone 3.31 in 38% yield from 3.29. Diketone 3.31 is converted to paspaline in twenty steps 
using the previously described route.16e In addition, Smith demonstrated the applicability of 
3.31 as a common intermediate in the synthesis of diterpenoids paspalinine and paspalicine.  
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Scheme 3-4.  Second Generation Approach to Paspaline and C12b Stereocenter 
 
 In summary, the Smith work illustrates marked creativity in the midst of a highly rigid 
chemical environment but also highlights the major challenges we were led to anticipate at the 
genesis of our endeavors.  Namely, stereocontrolled incorporation of the three angular methyl 
groups and the tetrahydropyranyl D-ring would require a well-designed approach in which the 
3-D environment of each synthetic intermediate is carefully planned and manipulated. 
3.2.4 Desymmetrization Analysis for Paspaline 
Following our successful use of symmetry-breaking transformations applied to the 
pactamycin problem (described in Chapter One),19 we identified paspaline and its family of 
compounds for further investigation in this area (Figure 3-3).  Specifically, we noted the 
applicability of stereoselective desymmetrizations in the remote stereocontrol of highly 
congested quaternary atoms.  In the symmetry-breaking transformation used for pactamycin 
(3.32 → 3.33), a diketone monoreduction was employed.  This reaction established the identity 
of the C7 secondary alcohol with indirect stereochemical assignment of the C1 fully-
substituted carbon.  As applied to paspaline, we envisioned that this mode of stereocontrol 
could be employed to quaternary carbons C12b and C4a via the manifolds of ketone reduction 
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and C−H activation (3.34).  It is important to note, however, that while this synthetic analysis 
proved fruitful in the end, it was not the strategy we envisioned for paspaline at the outset.  The 
discussion that follows details chronologically the foundation and evolution of this approach 
in route to a highly stereocontrolled preparation of paspaline and its core architecture. 
Figure 3-3.  Desymmetrization Applied to Pactamycin and Paspaline 
 
3.3  Results and Discussion 
3.3.1 Transannular Cyclization Strategy 
Our preliminary synthetic plan for paspaline identified the C,D,E ring fusion as the 
product of a complex transannular cyclization (Scheme 3-5).20  Accordingly, we envisioned 
simplification of 3.1 to hydroxyalkene 3.35.  This intermediate could arise from a Lewis acid 
mediated cyclization of cyclodecenone 3.36, establishing the vicinal C12b, C12c quaternary 
centers in a single operation. Enone 3.36 presented a particularly stimulating challenge in that 
stereoselective construction of trans-tetrasubstituted alkene within a ten-membered ring would 
be required.  At the outset, we proposed that this alkene could be prepared via a complex ring-
closing metathesis from diene 3.3821 or McMurry coupling reaction from dicarbonyl 3.37,22  
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Scheme 3-5. Initial Retrosynthetic Analysis for Paspaline 
 
both of which would provide avenues for new methods development.  Synthesis of this ketone 
would rely on the union of fragments 3.39 and 3.40 to assemble the C6a, C6, and C5 carbon 
carbon bonds.  This left only preparation of pyran 3.40, for which we initially hoped to 
construct via a Lewis acid catalyzed donor-acceptor cyclobutane annulation according to 
chemistry previously developed in our laboratory.23 
3.3.2  Donor-Acceptor Cyclobutane Annulation Studies 
 Initial focus was placed on probing the feasibility of uniting the known aldehyde 3.4124 
and cyclobutane 3.42 (Scheme 3-6).  Prior art suggested that vinyl cyclobutane 3.42 could be 
prepared via SN2’ cyclization of the appropriately-selected allylic electrophile.25 Accordingly, 
cross metathesis of alkene 3.43 with methacrolein proceeded in 71% yield.  Reduction of the 
resulting aldehyde 3.44 and acylation afforded carbonate 3.45 in 49% yield over the two-step 
sequence.  However, upon subjection of 3.45 to a variety of basic conditions, only starting 
material recovery or decomposition was observed.  It seems reasonable that this poor reactivity 
is the result of an undesirable conversion of trisubstituted alkene 3.45 to a less substituted form; 
consequently, we set out to prepare cyclobutane 3.49, which was also viable in our synthetic  
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Scheme 3-6.   Synthesis of Cyclobutane [4+2] Annulation Precursor 
 
approach and would obviate the alkene substitution problem.  Carbonate 3.48 was prepared in 
three steps in a manner similar to 3.45.  Gratifyingly, subjection of the secondary carbonate 
3.48 to NaH in C7H8 furnished cyclobutane 3.49 in 55% yield. 
 With both coupling partners in hand, we began screening conditions for our proposed 
cycloaddition (Table 3-1).  Previous work in our laboratory had demonstrated the applicability 
of strained ring cycloadditions to stereoselective tetrahydropyran synthesis.23  Specifically, 
vinyl cyclobutane 3.50 was reacted with aliphatic aldehyde 3.51 using catalytic MADNTf2
26 
(3.53) to give pyran 3.52 in 72% yield and 77:23 dr.  When we applied these conditions to 
aldehyde 3.41 and our prepared cyclobutane 3.49, we were disappointed to observe only 
decomposition of the cyclobutane and recovery of the aldehyde.  Screening other Lewis acids 
such as Sc(OTf)3 and Hf(OTf)2 resulted in complex mixtures or decomposition of 3.49.  In a 
final case, we employed the conditions used in our previously reported annulation of 
cyclopropanes and aldehydes (Sn(OTf)2, MgI2(pybox));
27 however, these reactions also failed 
to provide any amounts of 3.54.  In light of the observed instability of 3.49 to the reaction  
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Table 3-1. Summary of Attempted Strained Ring Cycloaddition for Paspaline 
 
Lewis Acid 
(mol %) 
Conditions Result 
MADNTf2  (5) (CH2)2Cl2, rt decomposition of 3.49 
MADNTf2  (20) CH2Cl2, rt decomposition of 3.49 
Sc(OTf)3 (20) CH2Cl2, rt complex mixture 
Hf(OTf)4 (20) CH2Cl2, rt decomposition of 3.49 
Sn(OTf)2 (20) (CH2)2Cl2, rt complex mixture 
MgI2(pybox) (10) CCl4, rt no reaction 
 
conditions examined, we began to doubt the applicability of this protocol in our synthesis and 
proceeded to evaluate contingency plans with which to prepare pyran 3.40. 
3.3.3  Tetrahydropyran Synthesis via Tandem Alkylation/Michael Addition 
 A survey of the literature led to the identification of a protocol by Gharpure for 
stereoselective tetrahydropyran synthesis derived from malonates and vinylogous esters 
bearing a tethered primary iodide;28 a tandem alkylation/Michael addition reaction provided 
products bearing exactly the substitution pattern needed for our synthetic strategy, although 
our required substrate was not reported (Scheme 3-7).  In our hands, tosylation of diol 3.55 
proceeded uneventfully (79% yield),29 and a subsequent oxy-Michael addition reaction gave 
vinyl ether 3.57.  Iodination of the tosylate gave the key precursor 3.58 in 72% yield, and  
222 
 
Scheme 3-7. Tandem Alkylation/Cyclization Approach to Tetrahydropyran Synthesis 
 
subjection of this material to Gharpure’s conditions (dimethylmalonate, Cs2CO3) furnished 
pyran 3.59 in 99% yield and >20:1 dr, completing F-ring synthesis for 3.1.  The desired cis-
pyran configuration was confirmed on the basis of nOesy analysis.  To intercept intermediate 
3.40 required for our strategy, the ethyl ester in 3.59 was selectively reduced with DIBAL-H, 
giving thence the iodide 3.60 upon treatment with I2 and PPh3.   Finally, alkylation of the iodide 
3.60 was accomplished upon treatment with (isopropenyl)2CuLi to give diene 3.40 in 99% 
yield. 
3.3.4  Access to the C4a Stereocenter 
 With pyran 3.40 in our possession, we sought to further elaborate the available 
functional handles towards preparation of cyclodecenone 3.36. Access to the C4a stereocenter 
was envisioned via desymmetrization of the gem-diester (Scheme 3-8).  Previous work by 
Deslongchamps had shown that equatorial-selective manipulations of cyclohexane diesters 
were feasible;30 in our system, this selectivity would deliver exactly the relative configuration 
needed for synthesis completion.  In a first trial, monohydrolysis of 3.40 (KOH, THF:MeOH) 
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gave exclusively the carboxylic acid diastereomer 3.61 in 96% yield (as determined by nOesy 
analysis).  Anticipating that this selectivity might be general for other addition reactions, we 
next examined incorporation of carbon nucleophiles.  Toward this aim, careful addition of 
MeLi to 3.40 also proceeded with complete stereoselectivity to give methyl ketone 3.62 in 62% 
yield.  In a final case, 3.40 was treated with EtLi, giving the ethyl ketone 3.63 in 89% yield 
and >20:1 dr.  This compound provided entry into a valuable unsaturated ketone handle 3.64 
via α-selenide addition/elimination.  Since an approach could be devised for synthesis 
completion using any of the three illustrated products, we envisioned these compounds would 
give us maximum flexibility in construction of the remaining carbon skeleton of 3.1. 
Scheme 3-8. Desymmetrization of the C14a Stereocenter 
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3.3.5  Indole/Pyran Fragment Coupling: a Non-Trivial Operation 
 With the pyran stereochemistry in place, the next challenge was assembly of the 
C5/C6/C6a carbon skeleton concomitant with incorporation of the indole fragment.  This 
transformation could take many forms depending on the identities of the reactive functional 
groups employed on both the pyran and indole segments  However; we found this union to be 
a significantly greater challenge than first expected.  A brief summary of these screenings is 
given in Figure 3-4 (see Section 3.5 for synthesis of the indole fragments).  At the outset, 
Figure 3-4.  Attempts at Coupling of the Indole and Pyran Fragments 
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we envisioned a stereocontrolled ene reaction of unsaturated ketone 3.64 and prenylated indole 
3.65.   Unfortunately, this approach failed to deliver triene 3.66 as strong Lewis acids such as 
MeAlCl2 and TiCl4 quickly resulted in decomposition of enone 3.64.  Milder Lewis acids gave 
only starting material recovery.  In our first contingency, we attempted the reaction of methyl 
ketone 3.62 and indole enone 3.67 via a Michael addition reaction.  This addition could occur 
either via an anionic pathway or under Mukaiyama conditions using the enol-silane of 3.62; 
however, enone 3.67 lacked sufficient reactivity to interact with the enolate of 3.62 under any 
basic conditions examined as only recovered starting material was observed in all cases.  
Notably, ketone 3.62 was unreactive to methyl vinyl ketone under basic conditions during a 
model study.  Mukaiyama conditions also failed to produce sufficient reactivity, primarily due 
to premature deprotection of the enol-silane of 3.62.  A final contingency examined the reversal 
of nucleophile and electrophile identities in a Mukaiyama addition of enol-silane 3.69 to the 
enone 3.64.  This approach, perhaps expectedly, was also met with failure due to the previously 
described instability of enone 3.64 to acidic conditions and premature deprotection of enol-
silane 3.69.  Collectively, these failed efforts led us to conclude that direct intermolecular 
coupling methodologies of these fragments to 3.1 from the C4a functionality were 
prohibitively challenging.  Furthermore, the inability to access diene 3.38 or diketone 3.37 thus 
far had prevented us from even attempting the critical cyclodecenone synthesis (3.36).  
Concluding that the route in its current formed lacked feasibility, this approach was abandoned. 
3.3.6   Decarboxylative Annulation Approach to D,E Rings  
In an effort to circumvent the issues associated with the above strategy, we postulated 
that an intramolecular approach to the critical bond disconnection might be more facile 
(Scheme 3-9).  This process would be enabled via appendage of the appropriate functionality 
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to the iodide 3.60.  We selected 2-methyl-1,3-cyclohexanedione 3.72 as this nucleophile 
anticipating that an intramolecular aldol addition process might result from Krapcho product 
3.70 to assemble the D,E-ring decalin moiety in 3.1 as well as the C12c and C4b stereocenters 
(3.71).  In practice, alkylation of iodide 3.60 with 3.72 gave a ~1:2 mixture of diketone 3.73 
and the undesired O-alkylation product 3.74 in 34% and 56% yields, respectively. While this 
issue of regiochemistry rendered material throughput challenging, we carried on in the  
Scheme 3-9.  Cyclohexanedione Alkylation and Decarboxylative Annulation Strategy 
 
interest of validating the proposed downstream reactivity.  Operating first on small scale (15 
mg), treatment of diketone 3.73 with NaCl in DMSO afforded a ~1:1 ratio of the diastereomeric 
Krapcho product 3.70 and tricycle 3.75 as a single diastereomer.  However, a single crystal X-
ray diffraction study revealed 3.75 to be the undesired cis-decalinone product (e.g. epimeric at 
C12c).  Fortunately, formation of 3.75 was suppressed when the reaction was further scaled 
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(70 mg), giving exclusively the monoester 3.70 in 43% yield. In hopes that a stepwise 
Krapcho/aldol process might proceed with selectivity orthogonal to 3.75, we began an 
extensive screen of conditions in an attempt to access 3.71.   A summary of our screenings is 
given in Table 3-2. Exposure of diketone 3.70 to Brønsted or Lewis acidic conditions failed to 
produce any observable amounts of 3.71, often giving starting material recovery 
Table 3-2.  Intramolecular Aldol Reaction Screenings 
 
Conditions Result 
Yb(OTf)3, C7H8, rt to 70 °C no reaction 
Sc(OTf)3, C7H8, rt to 70 °C decomposition 
TMSI, CH2Cl2, -78 °C to rt decomposition 
TMSOTf, CH2Cl2, 0 °C decomposition 
BF3•OEt2, CH2Cl2, 0 °C decomposition 
CSA, C7H8, rt to 70 °C no reaction 
TFA, CH2Cl2, rt no reaction 
NEt3, DMSO, rt to 80 °C no reaction 
K2CO3, DMSO, rt to 80 °C decomposition 
DBU, THF, rt to 80 °C decomposition 
DMAP, DMF, rt to 70 °C no reaction 
K2CO3, MeOH, rt 3.76 
NaOtBu, MeOH, rt 3.76 
NaOtBu, THF, rt decomposition 
CeCl3•NaI, CH3CN, rt to 80 °C no reaction 
 
or decomposition when the reaction temperature was increased.   Basic conditions also failed 
promote any desirable reactivity.  When 3.70 was treated with bases in protic media, only 
conversion to the retro-Dieckmann adduct 3.76 was observed as a diastereomeric mixture.   
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3.3.7   Development of an Enantioselective Desymmetrization Strategy 
 Having arrived at another impasse, we began to question the viability of this initial 
route in providing access to 3.1.  While the alkylation/Michael cascade sequence (3.58  3.59) 
provided expedient access to the F-ring tetrahydropyran stereochemistry and 
desymmetrization of the C4a stereocenter proceeded as planned, further elaboration of this 
material to 3.1 seemed an unlikely venture.  At this stage in our studies, we began to examine 
alternative points of initiation for our synthesis (Scheme 3-10).  Guided by our previous work 
in developing symmetry-breaking processes to enable rapid construction of complex natural 
products,19 we surmised that a synthesis beginning from desymmetrization of a paspaline E-
ring precursor might circumvent the problems associated with our initial strategy.  It is 
important to note at this juncture that Smith’s synthesis of 3.1 also commences via a symmetry-
breaking process;16a namely, the Wieland-Miescher ketone synthesis (3.723.17) assembles 
the D-E ring fusion of paspaline concomitant with the C12c quaternary stereocenter.  While 
this reaction is a classic “single stereocenter” desymmetrization, we envisioned an alternative 
E-ring desymmetrization arising from stereoselective mono-reduction of functionalized 
diketone 3.77.  Reduction of this compound would establish the stereochemical identity of C4a 
and C14a in 3.78 in a single operation while supplying the needed functional handles for 
tetrahydropyran assembly and synthesis completion.  Armed with this new hypothesis, we 
refocused our efforts in the synthesis of 3.1 via this approach. 
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Scheme 3-10.  Revised Approach to Paspaline via Enantioselective Desymmetrization 
 
3.3.8   Enantioselective Desymmetrization: Substrate Preparation 
The first challenge in our revised synthesis plan was preparation of the 
desymmetrization precursor 3.77 via alkylation of dione 3.72 or its derivatives (Scheme 3-11).  
In practice, deprotonation of 3.72 with NaH followed by addition of iodide 3.79 provided the 
desired cycloalkanone 3.77 in 7% yield along with 26% of the undesired O-alkylation product 
3.80.  A screen of alternative bases and conditions provided no enhancement in the yield or 
selectivity of this reaction.  These results were not entirely unexpected: challenges associated 
with regioselective C-alkylation of cyclic α-dicarbonyls have been well-documented (see 
Section 3.3.9).31 In hopes of enhancing the C-nucleophilicity of this structure, we prepared 
hydrazone 3.81.32 A screen of conditions revealed that enolization of 3.81 with KH followed 
by addition of iodide 3.79 provided exclusively the corresponding C-alkylation adduct which, 
following hydrazone deprotection, afforded functionalized diketone 3.77 in 76% yield over 
two steps.  Of particular importance is the scalability of this process: diketone 3.77 can be 
prepared using this route in >10 g scale in a single batch.   
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Scheme 3-11.  Scalable Preparation of Diketone Desymmetrization Precursor 
 
3.3.9   Substrate Scope of Hydrazone Alkylation Reaction 
 The utility and scalability of the preparation of 3.77 prompted us to further explore 
substrate generality in the C-selective alkylation of cyclic diketones.  While alkylation of 3.72 
with activated electrophiles (e.g. MeI, H2C=CHCH2Br, BnBr, etc.) or π-electrophiles (e.g. α,β-
unsaturated carbonyls) is efficient, alkylation with unactivated sp3 electrophiles is a significant 
challenge due to preferential O-alkylation in these cases,31 limiting the effectiveness of this 
method in target-oriented synthesis.  Piers and others have described a preparation of 2,2-
dialkyl-1,3-cyclohexanediones via alkylation and hydrolysis of 1,5-dimethoxy-1,4-
cyclohexadienes;33 however, the stoichiometric requirements of tBuLi and HMPA limit 
scalability and practicality of this protocol. 
 To examine the substrate scope of our developed reaction, hydrazone 3.81 was treated 
with KH in THF followed by addition of the electrophile at -78 °C and warming to rt (Table 
3-3).  Hydrolysis of the intermediate alkylation products was completed via Corey’s method 
Cu(OAc)2, aq. THF)
34 or upon treatment with Oxone® in aqueous acetone.35  In our model case, 
we were pleased to find that alkylation of 3.81 with 1-iodooctane followed by hydrolysis gave 
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diketone 3.82a in 89% yield over the two-step sequence (entry 1).  Extending the carbon chain 
in the alkyl iodide (entries 2-3) gave the same C-alkylation selectivity in slightly decreased 
yields.  Alkenyl halides (entries 4-5) also performed well (78% and 92%, respectively), which 
upon hydrolysis, provided diketones 3.77 and 3.82d bearing valuable functional handles. 
Alkylation of 3.81 with an iodide bearing a protected hydroxyl group (entry 6) also underwent 
efficient alkylation (73%, two steps), although the analogous protected aminoiodide (entry 7) 
failed to react with 3.81 under any conditions examined.  Secondary alkyl halides (entry 8)  
Table 3-3.  Substrate Scope of the C-Selective Alkylation of Methyl Cyclohexanedionesa 
 
Entry Alkyl Halide Product 
Akylation 
Yieldb 
Hydrolysis Method 
(Yield)c 
1  3.82a 92% 1
d (97%) 
2  3.82b 81% 1 (81%) 
3  3.82c 90% 1 (81%) 
4 
 
3.77 78% 1 (91%) 
5 
 
3.82d 92% 1 (80%) 
6  3.82e 90% 1 (81%) 
7  3.82f 0% -- 
8 
 
3.82g 67% 2e (63%) 
9  3.82h 68% 1 (78%) 
10 
 
3.82i 94% 2 (80%) 
11 
 
3.82j 67% 1 (77%) 
 
 
aYields refer to isolated analytically pure material. Yields are reported as averages of at 
least two experiments. 
bReactions were carried out with 1.0 mmol alkyl halide, 1.5 mmol 4, and 1.5 mmol of KH. 
cReactions were carried out with 0.5 mmol of intermediate ketohydrazone. 
dMethod 1: Cu(OAc)2 (2.0 equiv), THF:H2O (1:1), rt. 
eMethod 2: Oxone® (4.0 equiv), Acetone:H2O (1:3), rt. 
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also proceeded with complete C-regioselectivity, albeit in decreased yields (42%, two steps) 
to give diketone 3.82g.  Furthermore, alkyl bromides (entries 9-11) participated in C-selective 
alkylation.  The alkyl bromide bearing an electrophilic epoxide functionality (entry 11) 
underwent C-alkylation (and not the undesired epoxide opening) to give the corresponding 
diketone upon hydrolysis (52%, two steps).  The development of this methodology, particularly 
the demonstrated scalability (3.81 → 3.77), may be useful to the synthetic community in the 
preparation of “quaternized” building blocks for natural product synthesis. 
3.3.10 Development of a “Global” Enantioselective Desymmetrization   
 With the key desymmetrization precursor in our possession, we began investigating 
selective monoreduction of 3.77 to access the C4a/C14a stereodiad (Scheme 3-12).  Operating 
first in a racemic sense, treatment of 3.77 with NaBH4 in MeOH provided the monoreduction 
product 3.83 with excellent yield and diastereoselectivity (19:1).  However, nOesy analysis 
revealed that 3.83 was the opposite diastereomer to that required.  It is reasonable to expect 
Scheme 3-12.  Enantioselective Desymmetrization Studies  
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formation of this diastereomer under strictly substrate-controlled conditions, although we were 
surprised by the magnitude of selectivity for this diastereomer.  We were encouraged, however, 
by the recent reports of Nakada36 and Node37 which demonstrated access to the diastereomer 
needed for our synthesis on similar cyclic diketones using biocatalytic reducing conditions.  In 
experimenting with our compound, we were pleased to find monoreduction of 3.77 with 
Saccharomyces cerevisiae (YSC-2) proceeded with virtually complete reagent control, giving 
the desired alcohol diastereomer 3.78 in 10:1 dr and >99:1 er.  While only minimal 
optimization was required to achieve suitable levels of selectivity and conversion in this 
reaction, the chemical yield initially suffered (~10-20%) due to material loss from the workup 
procedure.  A series of modifications to this protocol (see Section 3.5 for the optimized workup 
procedure) improved the yield to suitable levels of 3.78 for material throughput (65%).  The 
success of this transformation provided encouragement to the viability of our revised synthesis 
plan and set the stage for further manipulation to paspaline. 
3.3.11 F-Ring Synthesis and C2 Stereocenter: an Unexpected Stereocontrol Element 
From hydroxy olefin 3.78, we anticipated assembly of the tetrahydropyranyl F-ring via 
an oxidative cyclization sequence (Scheme 3-13).  With this goal in mind, treating the alkene 
in 3.78 with m-CPBA provided the corresponding epoxide 3.84 in 93% yield and poor 
diastereoselectivity (2:1).  While any number of asymmetric epoxidation methods could likely 
enhance this selectivity, of greater concern was that treatment of this diastereomeric mixture 
3.84 with conditions requisite for ring closure (PPTS) gave an inseparable 5:1 mixture of 
products with the desired tetrahydropyran 3.85 as the minor product.  The major material was 
identified as alcohol 3.86, the result of epoxide trapping by the enol tautomer of the ketone in 
3.84.  To circumvent this issue, we envisaged that masking the ketone in 3.78 would preclude 
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this undesired mode of ring closure.  Since it translated well to our downstream strategy for D-
ring construction, 3.78 was converted to the corresponding tosyl hydrazone 3.87 in 97% yield.  
To our surprise, the reaction of this compound with m-CPBA followed by PPTS initiated an 
epoxidation/cyclization cascade, providing the desired tetrahydropyran 3.88 directly in 77% 
yield and >20:1 dr.  This reaction gave expedient preparation of the paspaline F-ring in a single 
operation.  Notably, the cyclization step in the conversion of 3.87 to 3.88 takes place in the 
absence of PPTS; in the optimized system, this additive was included as it promoted formation 
of 3.88 in the absence of hydrazone hydrolysis decomposition, which was found to be 
competitive with the desired ring closure event when promoters were not employed. 
Scheme 3-13.  Unexpected Stereoselective Access to Tetrahydropyran and C2 Stereocenter 
 
We were unaware of any previously reported directing effects of tosyl hydrazones on 
analogous systems (Figure 3-5).  To provide understanding to this difference in reactivity 
between hydroxyketone 3.78 and hydrazone 3.87, we carried out the following experiments.  
First, the alkene in hydrazone 3.87 was removed via hydrogenation to give alcohol 3.89. 
Treatment of 3.89 with the exact reaction conditions used in the epoxidation of 3.87 resulted 
in quantitative starting material recovery.  This datum excluded the possibility of 
intramolecular oxygen delivery in the reaction via a transient oxazidirine such as 3.90.   
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Figure 3-5.  Mechanistic Investigations in the “Hydrazone Directed” Epoxidation 
 
Concluding that the reactivity may be a consequence of underlying conformational 
differences between 3.78 and 3.87, we calculated both structures using density functional 
theory (DFT) at the level of B3LYP/6-311G(d).38  Interestingly, the optimized structures of 
3.78 and 3.87 showed a significant  difference in the dihedral angle about the C14a C−OH 
bond and the C4a C−CH2R bond (69 ° for 3.78 and 85 ° for 3.87). On the basis of these facts, 
we hypothesize that the observed selectivity is a consequence of the hydrazone in 3.87 
imposing a favorable reactive conformation (3.91) on the cyclohexane such that the C14a 
hydroxyl is in close proximity to the alkene during the oxidation.  It follows that this would 
enhance transfer of the substrate’s chiral information to C2 during the oxidation, giving the 
observed pyran 3.88 following ring closure.  To the best of our knowledge, this reaction is the 
first example of an alkene epoxidation stereoselectivity being influenced by the presence of a 
tosyl hydrazone.39 
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3.3.12  Synthesis of Paspaline via “D-Ring First” Approach 
With assembly of the E- and F-rings complete, attention was directed toward 
construction of the sterically congested D-ring and C12c stereocenter (Scheme 3-14).  A 
critical decision we faced at this juncture was whether to install the C12c methyl group first 
followed by cyclization (D-ring in paspaline) or vice versa.  Either option would invariably 
have a significant impact on downstream stereochemical outcomes.  At the outset, we elected 
to pursue installation of the D-ring first followed by a downstream C12c methylation.  We 
believed that the tosyl hydrazone in 3.88 would be engaged via the Shapiro reaction to produce 
a transient vinyllithium which, upon trapping with the appropriate electrophile, would provide 
the functionality required to incorporate the remaining paspaline core.40  Thus, TBS protection 
of the tert-alcohol in 3.88 proceeded to give silyl ether 3.92 in 77% yield.  Shapiro reaction of 
3.92 followed by DMF trapping furnished unsaturated aldehyde 3.93 in 62% yield, which upon 
olefination, gave diene 3.94 poised for a Diels-Alder cycloaddition.   
Scheme 3-14.  Synthesis of Paspaline D-Ring via Diels-Alder Reaction/Isomerization 
 
 
237 
 
To be compatible in our synthesis manifold, a ketene surrogate would be needed in this 
transformation.  Gratifyingly, nitroethylene proved to be an excellent dienophile in this 
reaction, giving the annulation product 3.95 in 94% yield and with complete regioselectivity 
under thermal conditions.  Subsequent Nef reaction and alkene isomerization afforded the 
ketone 3.96.  We surmised that the enone functional handle in 3.96 would allow for the 
investigation of multiple approaches for installing the C12c methyl group and C4b methine 
stereocenter. 
3.3.13 Attempts to Install C12c Quaternary Stereocenter  
We first pursued manipulation of the alkene functional handle in 3.96 via a Birch 
alkylation, simultaneously establishing both the C4b and C12c stereocenters (Scheme 3-15).  
Accordingly, Birch reduction (Li0, liq. NH3) of 3.96 followed by electrophilic trapping with 
MeI furnished decalinone 3.97 in 67% yield and high stereoselectivity (>20:1).  We 
immediately set out to determine the stereochemical identity of this compound, whereupon 
TBS deprotection of 3.97 afforded a derivative that crystallized readily. Unfortunately, X-ray 
diffraction analysis of 3.98 identified the product as the undesired cis-decalinone (bearing 
desired C4b stereochemistry and undesired C12c stereochemistry).  A subsequent screen of 
Scheme 3-15. Attempted Birch Alkylation Approach to C12c and C4b Stereocenters 
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reducing metals, solvents, and addition methods gave no promise for overriding this selectivity.     
It is rational to expect that this diastereomer might be formed as prior art by Stork suggests 
that the kinetically-favored cis decalin is preferentially generated in related systems.41 
 We then began investigating auxiliary methods for stereoselective introduction of the 
C12c methyl group.   First, we surmised that if the Birch reduction product could be isolated 
and exposed to thermodynamic methylation conditions, the stereochemical outcome might 
differ from that observed in 3.97 (Table 3-4).  To this end, Birch reduction of 3.96 followed 
by protic quenching gave a 1:1 mixture of crude diastereomeric ketones 3.99.  Subjection of 
this mixture to thermodynamic enolization conditions (DBU, C7H8) provided exclusively  
 
Table 3-4. Birch Reduction and Thermodynamic Methylation Studies 
 
Conditions Result 
tBuOK, tBuOH:THF, MeI, 60 °C polymethylation 
NaOtBu, THF, MeI, rt to 60 °C no reaction 
LDA, THF, then MeI no reaction 
NaHMDS, THF, then MeI no reaction 
KOH, THF:MeOH, CH2O(aq.) decomposition 
NaOMe, THF, CH2O(aq.) polymethylation 
tBuOK, 18-crown-6, then CH2I2 
THF, rt 
no reaction 
K2CO3, (HCHO)n, DMF, 90 °C no reaction 
tBuOK, THF, 18-crown-6 
 MeI, 60 °C 
polymethylation 
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trans-decalinone 3.100 in 75% yield over the two-step sequence.  We then screened a variety 
of conditions for thermodynamic introduction of the requisite carbon functionality.  In the first 
case, typical conditions for thermodynamic methylation (tBuOK, THF:tBuOH, then MeI)  
failed to give any desired product as polymethylated products were isolated as the major 
material.  Kinetic deprotonation and treatment with MeI resulted only in starting material 
recovery.  Additionally, attempts at thermodynamic hydroxymethylation with CH2O(aq.) or 
(HCHO)n  gave either no reaction or alkylation at the less-substituted α-position.   
Met with these failures in delivering the methyl group directly, we next examined 
whether the C12c methyl group could be introduced stereospecfically via an 
epoxidation/semipinacol reaction sequence (Scheme 3-16).  This would be enabled by a 
stereoselective epoxidation of the alkene in 3.96.  Toward this aim, epoxidation of 3.96 with 
the electrophilic p-NPBA42 afforded ketoepoxide 3.102 in 46% yield as a single diastereomer.  
X-ray diffraction analysis indicated that the correct epoxide had been formed for semi-pinacol 
studies.  Ketone 3.102 was then treated with MeMgBr to provide the carbinol envisioned to 
undergo rearrangement; unfortunately, all conditions examined failed to initiate the desired 
semi-pinacol process.  
In a final attempt to install the methyl group from this route, the ketone in 3.96 was 
reduced upon treatment with LiAl(OtBu)3H to give alcohol 3.104 in 95% yield and 10:1 dr.  
From this compound, we pursued radical delivery of the C12c methyl group via tethering from 
the secondary hydroxyl.43  However, while functionalization of the alcohol was realized with 
a number of known radical precursors, the alkene in 3.105 failed to engage all of these radical 
tethers, ultimately returning starting material or unidentified reduction products. 
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Scheme 3-16. C12c Incorporation Attempts via Semi-Pinacol and Radical Cyclization 
 
3.3.14 Paspaline “Methyl Group-First” Approach via Diels Alder Reaction 
 Collectively, these reactions indicated that the inherent bias of enone 3.96 for the α-
face of the D-E-ring fusion (presumably influenced by the C4a angular methyl group) would 
preclude all attempts at late-stage introduction of the C12c methyl group.  At this juncture in 
our studies, we decided that if D-ring assembly was preceded by introduction of this methyl 
group, then the subsequent annulation step might also proceed with α-face selectivity to give 
the needed syn-diaxial methyl group relationship.  Thus, methylation of hydrazone 3.92 upon 
treatment with n-BuLi and MeI proceeded smoothly to give the monomethylated product 3.106 
in 95% yield (Scheme 3-17).  In accordance with our Diels-Alder strategy, Shapiro reaction of 
3.106 followed by trapping with DMF afforded aldehyde 3.107 in 61% yield, giving thence 
the diene 3.108 upon olefination.  While we at first anticipated that the [4+2] annulation of 
3.108 with nitroethylene would proceed in a manner similar to the previously-described des-
methyl cycloaddition (3.943.95), we quickly found the steric impact of the newly-introduced 
methyl group to be much greater than expected.  In our initial trials, the reaction of 3.108 with 
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nitroethylene failed to produce the desired cycloadduct under both thermal and Lewis acidic 
conditions.  An extensive screen of thermal dienophiles including acrolein, acrylonitriles, 
enones, and functionalized nitroalkenes also gave no promise for efficient reactivity.   Photo-
induced Diels-Alder pathways were also pursued using the illustrated dienophiles, although 
these cycloaddition partners showed no improvement in reactivity with diene 3.108.   
Scheme 3-17. Attempts to Install D-Ring and C12c Methyl Group via Diels-Alder Reaction 
 
3.3.15 Investigation of Alternative Methyl Group-First Annulation Modes 
 Having encountered this lack of reactivity, we turned to alternative annulation modes, 
making use of the flexibility of electrophile choice in the Shapiro reaction step and its 
subsequent intermediates (Scheme 3-18).  To bypass an intermolecular cycloaddition, we 
pursued an electrocyclization pathway to form the requisite D-ring.  Operating first in the 
simplest case, olefination of aldehyde 3.107 with the ylide derived from 
allyltriphenylphosphonium bromide gave the simplified triene 3.109 in 36% yield.  Irradiation 
of 3.109 (Hg vapour lamp) gave complete conversion to a single product after one hour, 
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Scheme 3-18. Electrocyclization Approach to D-Ring Synthesis 
 
although the product did not match the expected 1H NMR spectrum.  Further spectroscopic 
analysis revealed the identity of the material as the sigmatropic rearrangement product 3.111 
and not the desired cyclization adduct 3.110.  Suspecting that this rearrangement might 
predominate using any analog of this triene, this pathway was abandoned. 
 Having arrived at another impasse, we continued exploring alternative electrophiles in 
the Shapiro reaction of 3.106 (Scheme 3-19).  We first returned to our [4+2] cycloaddition 
strategy, envisioning that a suitable diene bearing additional electron density relative to 3.108 
might engage dienophiles more readily.  Accordingly, Shapiro reaction of 3.106 followed by 
trapping with acetaldehyde gave the resulting sec-alcohol, which after Dess-Martin oxidation 
and enol-silane formation gave silyloxydiene 3.113 in 42% yield over the three-step sequence.  
The reaction of this diene with nitroethylene (among other dienophiles) was then studied; 
however, 3.113 showed no improvement in reactivity as a Diels-Alder counterpart over 
simplified diene 3.108.   
In another contingency, Shapiro reaction of 3.106 followed by trapping with (E)-
crotonaldehyde followed by oxidation gave dienone 3.114 in 46% yield.  This substrate could  
be employed in our synthesis via its action as a Nazarov reaction substrate.  A subsequent 
ozonolysis/condensation sequence from 3.115 would generate the D-Ring.  While dienone 
3.114 seemed ideally-poised for rearrangement, exposure of this compound to a variety of 
acidic promoters failed to induce the desired cyclization.   
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Scheme 3-19. Alternative Shapiro Adducts Explored in D-Ring Synthesis 
 
We next employed I2 as the electrophilic trap in the Shapiro reaction, giving vinyl 
iodide 3.116 in 67% yield from which we aimed to incorporate the necessary functionality for 
ring closure via cross coupling methods.  Gratifyingly, iodide 3.116 reacted readily with alkyl 
borane 3.117 to give the tethered ester 3.118 in 44% yield.  Unfortunately, this ester (or its 
derivatives) could not be further manipulated to access the D-ring of 3.1.   
3.3.16 Development of an Ireland-Claisen Rearrangement Approach to Paspaline 
Our options diminishing, we prepared primary alcohol 3.119 via trapping the Shapiro 
intermediate of 3.106 with (HCHO)n (Note: this reaction could also be performed in a one pot 
protocol from des-methyl hydrazone 3.92, see Scheme 3-20).  We surmised that the 
appropriately-selected ester of 3.119 would participate in an Ireland-Claisen rearrangement,44 
influenced by the C4a stereocenter, to install the C12c (and potentially C12b) quaternary 
methyl group(s) while providing functional handles for D-ring construction.   In an initial 
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model case, acylation of alcohol 3.119 with isobutyric acid (mediated by DCC) gave the 
corresponding isobutyrate 3.120 in 73% yield.  Gratifyingly (and perhaps also to our relief!), 
enolization of isobutyrate 3.120 followed by trapping with TMSCl, heating and hydrolysis 
afforded rearrangement product 3.121 in 80% yield and 6:1 dr.  The presence of the correct 
C12c relative configuration was confirmed via X-ray crystallographic evidence of a later 
intermediate (vide infra).  While entry into the C12b quaternary stereocenter from α-dimethyl 
Scheme 3-20. Discovery of an Ireland-Claisen Rearrangement for Paspaline 
 
carboxylic acid 3.121 was not immediately clear, access to D-ring synthesis completion from 
the available functional handles was palpable and subsequently studied from this compound as 
proof-of-concept.   
Esterification of 3.121 proceeded uneventfully to give ester 3.122 in 98% yield 
(Scheme 3-21).  While we initially imagined conversion of the ester to its methyl ketone might 
be challenging, we were surprised to find that ketone 3.123 was readily accessed in 86% yield 
upon treatment of ester 3.122 with excess MeLi at rt (!).  Hydroboration/oxidation of the alkene 
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in 3.123 established the identity of the C4b methine carbon with complete stereofidelity (3.124, 
74% yield) concomitant with non-stereoselective reduction of the ketone.   
 From diol 3.124, only oxidation of both alcohols and intramolecular condensation 
remained to complete D-ring construction.  This oxidation was complicated, however, by 
intramolecular interception of the initially-formed aldehyde by the secondary hydroxyl, 
ultimately forming a lactone upon oxidation of the lactol.  Indeed, numerous oxidative 
conditions (Dess-Martin, TPAP, PCC) gave only starting material decomposition with trace 
amounts of the lactone side product.  Fortunately, global Swern oxidation proved viable in 
producing the crude ketoaldehyde 3.125 in the absence of unwanted cyclization side products.  
Exposure of ketoaldehyde 3.125 to basic conditions furnished cyclohexenone 3.126 in 74% 
yield from diol 3.124.  This sequence confirmed the viability of this route in completing our 
synthesis of 3.1.  At this juncture, we returned to the Ireland-Claisen rearrangement stage to 
find a suitable ester for incorporation of the C12b quaternary stereocenter. 
Scheme 3-21. D-Ring Synthesis Completion with Model Ireland-Claisen Substrate 
 
 
 
 
246 
 
3.3.17 Investigation of Higher Order Esters in the Ireland-Claisen Rearrangement 
 Our goal at the outset of these screenings was to identify an ester of 3.119 that i) 
participated efficiently in the Ireland-Claisen rearrangement to assemble (at very least) the 
C12c stereocenter and ii) provided accommodating functionality for immediate or downstream 
incorporation of the C12b quaternary center (Table 3-5).  To these aims, the simplified acetate 
3.127a and propionate 3.127b (entries 1-2) were prepared and examined in the rearrangement.  
However, these substrates failed to rearrange as the intermediate silyl ketene acetals of     
3.127a-b were labile to the required reaction temperatures.  We subsequently focused our  
Table 3-5. Alternative Ester Screenings in Ireland-Claisen Rearrangement 
 
entry carboxylic acid ester (yield)a acid (yield, dr)a 
1 Ac2O 3.127a (82%)
b no reaction 
2 
 
3.127b (83%) no reaction 
3 
 
3.127c (73%) no reaction 
4 
 
3.127d (93%) no reaction 
5 
 
3.127e (74%) no reaction 
6 
 
3.127f (54%) no reaction 
7 
 
3.127g (87%) 3.128g (57%, 6.6:1.1:1 dr) 
 aIsolated yields.  
b Conditions: Ac2O, NEt3, DMAP (10 mol %), CH2Cl2, rt.  
c Determined by 1H NMR analysis of crude mixtures. 
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search on more functionalized esters.  Indole ester 3.127c (entry 3) and its protected 
derivatives, perhaps ideally suited for our synthesis manifold, also failed to rearrange as the 
additional steric encumbrance precluded any observable silyl ketene acetal generation.  
Unfortunately, the same issue was true for esters 3.127d-f.  We were pleased to find promising 
reactivity in the case of silyl functionalized isobutyrate 3.127g (entry 7), which readily 
underwent rearrangement to give carboxylic acid 3.128g in 52% yield and 6.6:1.1:1 dr.  The 
stereochemistry at C12c of this compound was assigned by analogy to rearrangement product 
3.121.  The identity of the C12b stereocenter could not be determined at this juncture. 
 With carboxylic acid 3.128g in our possession, we envisioned direct translation of our 
ring closure strategy (3.121 → 3.126) would complete D-ring assembly and set the stage for 
synthesis completion (Scheme 3-22).  The phenyldimethylsilyl group was purposed to be 
revealed downstream as a primary alcohol via Tamao-Fleming oxidation.45  Along these lines, 
esterification of 3.128g with TMSCHN2 provided ester 3.129 in 85% yield, setting the stage 
for conversion to the resulting methyl ketone.  However, ester 3.129 was found to be unreactive 
to all conditions examined for nucleophilic methylation, even at elevated temperatures.  In 
order to circumvent this challenging addition, the ester in 3.129 was reduced with DIBAL-H 
to give the corresponding alcohol.  Dess-Martin oxidation subsequently gave the aldehyde 
3.131 in 46% yield over two steps.  We surmised that aldehyde 3.131 would be more accessible 
to methide nucleophiles. Unfortunately, this approach was also met with failure due to 
unsuitable reactivity of the aldehyde to nucleophilic addition.   
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Scheme 3-22.  Failed Advancement of Silyl-Functionalized I-C Product to Paspaline 
 
3.3.18 Development of a “Local” Desymmetrization of C12b Dimethyl Group 
The studies on carboxylic acid 3.128g seemed to suggest that further elaboration of this 
compound to paspaline would be significantly impaired by the challenging manipulation of the 
carbonyl, a problem that would inevitably be encountered in any variant of this substrate. 
Moreover, early returns on elaboration of the dimethyl carboxylic acid 3.121 to complete D-
ring synthesis (3.126) had been successful; elaboration of this compound to 3.1 would require 
a late-stage C−H activation reaction to desymmetrize the C12b stereocenter for synthesis 
completion (Scheme 3-23). For a C−H activation of this compound to be successful, a selective 
functionalization of the equatorial methyl group over its axial counterpart would be required 
to achieve the diastereomer needed.  We were aware that the lowest energy conformer of 3.126 
places the C−O double bond in the same plane as the equatorial methyl group and anticipated 
that the appropriate catalytic system would operate selectively if a suitable directing group 
were employed.  In the event, we selected the catalytic C−H oxidation reaction developed by 
Sanford and co-workers,46 which had demonstrated applicability to substituted cyclohexanone  
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Scheme 3-23.  Development of a Local Desymmetrization for C12b Stereocenter 
 
oximes.  Toward this aim, hydrogenation of enone 3.126 followed by amine condensation 
provided oxime 3.133 in 82% yield.  In the key experiment, the direct application of Sanford’s 
conditions to oxime 3.133 provided monoacetate 3.135 (via transition structure 3.134) in 79% 
yield and >20:1 dr.  This “local” desymmetrization completed assembly of the final quaternary 
center in 3.1 and provided a functional handle for completion of our synthesis. 
 The yield and selectivity of this transformation is noteworthy; examples for the 
successful execution of this reaction as a platform for desymmetrization of achiral quaternary 
centers are scarce in recent literature (Figure 3-6).  In 2008, Yu and co-workers reported a 
stoichiometric desymmetrization of dimethyl oxime 3.136, proceeding in 72% yield and 
complete selectivity en route to the synthesis of lobatoside E.47 Six years later, the Sorenson 
laboratory described the first symmetry-breaking implementation of Sanford’s catalytic 
reaction in their synthesis of jiadifenolide.48 In this reaction, treating oxime 3.138 with 
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Pd(OAc)2 and PhI(OAc)2 afforded the desired acetate 3.139 in 22% yield and 1:1 dr.  In our 
case, exposure of oxime 3.133 to Sanford’s conditions provided the desired acetate 
diastereomer 3.135 in 79% yield and >20:1 dr.  That this reaction (3.1333.135) provided the 
desired product diastereomer in such high yield illustrates the viability of this and related 
transformations in the late-stage pursuit of challenging quaternary stereocenters.   
Figure 3-6. Examples of Substrate-Directed sp3 C−H Oxidation/Desymmetrization 
 
3.3.19  Synthesis of Paspaline C-Ring and Incorrect C6a Stereocenter 
With acetate 3.135 in hand, we faced the remaining challenges of C-ring installation, 
C6a reduction, and indolization to complete our synthesis (Scheme 3-24).  Acetate 3.135 was 
subjected to global hydrolysis to remove the acetate, oxime, and silyl ether functionalities.  The 
resulting primary alcohol was oxidized with Dess-Martin periodinane (DMP) to give 
ketoaldehyde 3.140 in 70% yield over two steps.  From 3.140, we envisioned bis-vinylation 
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followed by ring-closing metathesis (RCM) would install the remaining carbon skeleton. To 
our surprise, treatment of 3.140 with vinylmagnesium bromide at -78 °C gave predominantly 
the retro-aldol decomposition product 3.141.  After some experimentation, we found that the 
CeCl3·2LiCl complex recently reported by Knochel aided in suppressing the retro-aldol 
product completely,49 giving diol 3.142 in 95% yield.   
Scheme 3-24.  Access to bis-Allylic Alcohol Substrate for Ring-Closing Metathesis 
 
Treatment of 3.142 with Grubb’s second Generation catalyst provided allylic alcohol 
3.143 in 71% yield (Scheme 3-25). While an alcohol oxidation/hydroxyl elimination pathway 
was first pursued for the conversion of diol 3.143 to enone 3.144, we found that simply 
subjecting 3.143 to acidic conditions (TFA) resulted in direct elimination of the tert-hydroxyl 
to give nonconjugated enone 3.144 in 71% yield.  This set the stage for hydrogenation of the 
resultant alkene to install the final stereocenter in 3.1.  In the event, catalytic hydrogenation of 
alkene 3.144 with Pd/C provided ketone 3.145 in 87% yield and >20:1 dr.  However, 1H NMR 
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Scheme 3-25.  Access to Non-Conjugated Enone and Undesired Convex-Face Reduction 
 
spectral data of this compound were not consistent with that of the desired compound 
previously synthesized by Smith and co-workers,16d leading to the conclusion that this 
hydrogenation had delivered the opposite diastereomer to that required.  In order to better 
rationalize this result, we calculated the structure of non-conjugated enone 3.144.  As 
anticipated, the DFT-optimized structure of 3.144 revealed a marked puckering of the C-D ring 
fusion; catalytic hydrogenation of this alkene to give the desired diastereomer at C6a would 
necessitate approach of H2 to the concave Re face of 3.144.  This result is in accord with prior 
studies on similar steroidal systems50 which also describe convex surface hydrogenation on 
related enones. 
3.3.20 Substrate Directed Hydrogenation for Access to C6a Stereocenter 
 Upon assessing our available functional handles, we surmised that selective reduction 
of the ketone in 3.144 might alter the outcome of the ensuing alkene hydrogenation by virtue 
of directing ability of the nascent hydroxyl group (Scheme 3-26).  The use of Crabtree’s 
catalyst in alcohol-directed alkene hydrogenations has been well-documented51 and would 
presumably engage the alkene on the same face as the hydroxyl.  To this end, treatment of 
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ketone 3.144 with LiAlH4 afforded the desired (S)-alcohol 3.146 in 60% yield >20:1 dr over 
two steps from diol 3.143.  The steric impact of the C12c methyl group on the outcome of this 
reaction cannot be overstated; ketone reduction in analogous steroidal systems not bearing this 
methyl group generally proceed with the opposite sense of selectivity in ketone reduction.50,52 
With this alcohol in hand, catalytic hydrogenation of 3.146 using Crabtree’s catalyst 
completely overrode the inherent substrate bias, giving the corresponding alcohol 3.148 (via 
3.147) in >20:1 dr and subsequently the ketone 3.25 in 86% over two steps after re-oxidation 
of the alcohol.  The stereochemistry of 3.25 was confirmed via 1H NMR comparison with 
Smith’s intermediate and an X-ray diffraction study.16d 
Scheme 3-26. Directed Alkene Hydrogenation and Completion of Paspaline Core 
 
 
 
 
  
3.25 
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3.3.21 Indolization and Synthesis Completion 
With ketone 3.25 in hand, only indolization of the ketone functionality remained to 
complete our synthesis.  As in Smith’s synthesis,16a we anticipated significant difficulty 
associated with direct incorporation of the indole via the ketone.  In the present case, we 
envisioned incorporation of the necessary functionality via ketone enolate arylation.  A 
summary of our attempts is given in Table 3-6.  Treatment with o-amino electrophiles using  
Table 3-6.  Summary Attempts at Ketone Indolization via Enolate Arylation  
 
Aryl Electrophile Conditions Result 
 
Pd(OAc)2 (cat.) 
JohnPhos, Cs2CO3, DMF 
no reaction 
 
Pd(OAc)2 (cat.) 
XantPhos, NaOtBu, C7H8 
no reaction 
 
Pd(OAc)2 (cat.) 
JohnPhos, Cs2CO3, DMF 
no reaction 
 
Pd2dba3 (cat.)                  
4-methoxyphenol, 
NaHMDS, DavePhos 
no reaction 
 
Pd2dba3 (cat.)     
XantPhos, NaHMDS 
C7H8  
no reaction 
 
LDA, CuCN, then 
electrophile 
no reaction 
 
LDA, THF, HMPA 
then electrophile 
no reaction 
 
KNH2, liq. NH3, hν decomposition 
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Pd-catalyzed arylation failed to give any desired product as 3.25 was recovered in all cases.  
As a control experiment, 2-bromobenzene also failed under these conditions. We then moved 
on to SnAr electrophiles such as aryliodonium and aryl lead reagents.  Unfortunately, these 
electrophiles were also unreactive to the ketone enolate 3.25.  In a final iteration, 3.25 was 
reacted with 2-bromoaniline under conditions suited for radical arylation.  This trial only 
resulted in starting material decomposition. 
Determined to complete our synthesis, we turned to the Gassman protocol which 
proved successful in the hands of Smith and co-workers (Scheme 3-27).18 This approach  
Scheme 3-27.  Gassman Indole Synthesis and Completion of the Synthesis of Paspaline 
 
 
3.1 
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installs the requisite aryl portion via an intramolecular [2,3] rearrangement, obviating 
intermolecular functionalization of the ketone.  Thus, enolization of 3.25 followed by addition 
of Me2S2 gave thioether 3.150 in 84% yield as a mixture of diastereomers.  Treatment of this 
compound with N-chloroaniline led to SN2 displacement of the chloride by the thioether, which 
upon treatment with base, initiated a Sommelet-Hauser type rearrangement and assembled the 
critical C−C bond.  The thioether was then reduced with Raney Ni to give ketoaniline 3.151 in 
61% yield over two steps.  Exposure of this compound to acidic conditions (PTSA, 50 °C) 
resulted in intramolecular condensation to give paspaline in 89% yield (46% yield from ketone 
3.25).  In addition to matching the reported analytical data, an X-ray diffraction study of 
synthetic paspaline provided secondary confirmation of the final structure6b and the sense of 
enantioinduction imposed in the biocatalytic desymmetrization of diketone 3.77. 
3.4 Conclusion 
In conclusion, we have described a global and local symmetry-breaking approach to 
the total synthesis of the indole diterpene alkaloid paspaline.  After initial approaches for the 
assembly of 3.1 via a cationic transannular cyclization were unsuccessful, a symmetry-
breaking biocatalytic monoreduction was devised to establish the initial C4a/C14a 
stereocenters.  A novel tosyl hydrazone-influenced epoxidation enabled excellent control of 
the C2 stereocenter (>20:1), and an Ireland-Claisen rearrangement provided access to the D-
ring and C12c stereocenter of 3.1.  A substrate-directed symmetry-breaking C−H acetoxylation 
inspired by Sanford and co-workers provided excellent control of the C12b stereocenter 
(>20:1). To override the inherent facial bias in the hydrogenation of enone 3.144, 
stereoselective reduction of the ketone followed by hydrogenation with Crabtree’s catalyst 
provided the final stereocenter in 3.1 with excellent selectivity at C6a (>20:1) The route and 
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methods described in this work present a number of complimentary conceptual disconnections 
in the arena of steroid total synthesis. 
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3.5  Experimental Details 
Methods: General. Infrared (IR) spectra were obtained using a Jasco 460 Plus Fourier 
transform infrared spectrometer. Proton and carbon magnetic resonance spectra (1H NMR and 
13C NMR) were recorded on a Bruker model Avance 400 (1H NMR at 400 MHz and 19F NMR 
at 376 MHz), Bruker Avance III 500 (1H NMR at 500 MHz), Varian INOVA600 (1H NMR at 
600 MHz), or a Bruker Avance III 600 (1H NMR at 600 MHz and 13C NMR at 150 MHz) 
spectrometer with solvent resonance as the internal standard (1H NMR: CDCl3 at 7.26 ppm 
and C6D6 at 7.16 ppm; 
13C NMR: CDCl3 at 77.0 ppm). 
1H NMR data are reported as follows: 
chemical shift, multiplicity (s = singlet, br s = broad singlet, d = doublet, br d = broad doublet, 
t = triplet, q = quartet, m = multiplet), coupling constants (Hz), and integration. Mass spectra 
were obtained using a Thermo LTqFT mass spectrometer with electrospray introduction and 
external calibration. All samples were prepared in methanol. Analytical thin layer 
chromatography (TLC) was performed on Sorbent Technologies 0.20 mm Silica Gel TLC 
plates. Visualization was accomplished with UV light, KMnO4, and/or Seebach’s stain 
followed by heating. Purification of the reaction products was carried out by flash 
chromatography using Siliaflash-P60 silica gel (40-63 μm) purchased from Silicycle. Unless 
otherwise noted, all reactions were carried out under an atmosphere of dry nitrogen in flame-
dried glassware with magnetic stirring. Yield refers to isolated yield of analytically pure 
material unless otherwise noted. Yields are reported for a specific experiment and as a result 
may differ slightly from those found in figures, which are averages of at least two experiments.   
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Materials: General. Tetrahydrofuran (THF), diethyl ether (Et2O), dichloromethane (CH2Cl2), 
and toluene (C7H8) were dried by passage through a column of neutral alumina under nitrogen 
prior to use. Aniline, Hexamethylphosphoramide (HMPA), and Diisopropylamine were freshly 
distilled from calcium hydride prior to use. Compounds 3.55,53 S2,54 S5,55 S7,56 3.79,57 
nitroethylene,57  p-NPBA,
42 S10,58  S12,59 S13,60 and S1461 were prepared according to known 
procedures. All other reagents were purchased from commercial sources and were used as 
received unless otherwise noted. 
Computation Analysis: High-level density functional theory (DFT) calculations using the 
B3LYP38a,,b approximate exchange-correlation energy density functional were performed with 
the standard Pople triple-zeta basis set 6-311G(d)38c,d for all elements when stable structures 
are optimized. Calculations were performed in the gas phase at 0K with tight SCF convergence 
and ultrafine integration grids. All calculations were performed with the package of Gaussian 
09 version D01.62 Cartesian coordinates of the studied systems are provided below. 
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Experimental Procedures: 
 
dimethyl (E)-2-(but-2-en-2-yl)cyclobutane-1,1-dicarboxylate (3.49):  NaH (60% dispersion 
in oil, 0.084 g, 2.10 mmol, 1.90 equiv) was washed free of oil with hexanes and transferred to 
a flame-dried 20-mL scintillation vial.  C7H8 (2 mL) was added followed by a solution of 
carbonate 3.48 (0.40 g, 1.10 mmol, 1.00 equiv).  The resulting mixture was warmed to 50 °C 
and stirred until complete conversion of 3.48 was observed by TLC analysis, typically 4 h.  
The mixture was cooled to rt, diluted with H2O (5 ml), and partitioned in a separatory funnel.  
The aqueous layer was extracted with Et2O (3 x 10 mL), and the combined organic extracts 
were washed with 1 M NaOH(aq.) (2 x 5 mL), dried with magnesium sulfate, and concentrated 
in vacuo.  The product was purified via flash chromatography (95:5 to 90:10 hexanes:EtOAc) 
to afford volatile cyclobutane 3.49 (0.139 g, 55% yield) as a clear oil.  Analytical data: 1H 
NMR (400 MHz, CDCl3): δ 5.27 (d, J = 6.4 Hz, 1H), 3.73 (s, 3H), 3.63 (s, 3H), 2.51 (t, J = 9.6 
Hz, 1H), 2.29 (m, 1H), 2.08 (m, 1H), 1.79 (m, 1H), 1.62 (s, 3H), 1.59 (d, J = 6.8 Hz, 3H). 
 
3-hydroxy-4-methylpent-4-en-1-yl 4-methylbenzenesulfonate (3.56): A flame-dried, 1000 
mL round bottomed flask was charged with diol 3.55 (4.67 g, 40.2 mmol, 1.00 equiv) and 
CH2Cl2 (300 mL) under an atmosphere of N2.  The solution was cooled to 0 °C and NEt3 (14.0 
mL, 100.5 mmol, 2.50 equiv), DMAP (0.49 g, 4.00 mmol, 0.10 equiv), and lastly TsCl (8.43 
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g, 44.2 mmol, 1.10 equiv) were added sequentially.  The resulting mixture was allowed to stir 
at this temperature until complete conversion of the starting material was observed by TLC 
analysis, typically 12 h.  The mixture was then diluted with H2O (150 mL) and partitioned in 
a separatory funnel.  The organic layer was separated and the aqueous layer was extracted with 
CH2Cl2 (3 x 40 mL). The combined organic extracts were dried with sodium sulfate and 
concentrated in vacuo.  The product was purified via flash chromatography (70:30 to 60:40 
hexanes:EtOAc) to afford the tosylate 3.56 (8.75 g, 81% yield) as a pale yellow oil. Analytical 
data: 1H NMR  (600 MHz, CDCl3): δ 7.79 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 4.91 
(s, 1H), 4.82 (s, 1H), 4.22 (m, 1H), 4.16 (m, 1H), 4.09 (m, 1H), 2.44 (s, 3H), 1.91 (m, 1H), 
1.79 (m, 1H), 1.75 (br s, 1H), 1.68 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 146.4, 144.8, 
132.9, 129.8, 127.9, 111.4, 71.5, 67.6, 34.1, 21.6, 17.6; HRMS (ESI+) Calcd. For 
C13H18O4S+Na, 293.0824; Found, 293.0815; IR (thin film, cm
-1) 3545, 3055, 2984, 2686, 
1652, 1616, 1456, 1360, 1266, 1189; TLC (80:20 hexanes:EtOAc): Rf = 0.14. 
 
Ethyl (E)-3-((2-methyl-5-(tosyloxy)pent-1-en-3-yl)oxy)acrylate (3.57): A flame-dried, 500 
mL round bottomed flask was charged with alcohol 3.56 (8.75 g, 32.0 mmol, 1.00 equiv) and 
CH2Cl2 (160 mL) under an atmosphere of N2 at rt.  N-methylmorpholine (3.60 mL, 35.7 mmol, 
1.10 equiv) and ethyl propiolate (3.92 mL, 35.7 mmol, 1.10 equiv) were added sequentially, 
and the mixture was allowed to stir until complete conversion of the starting material was 
observed by TLC analysis, typically 4 h.  The reaction mixture was concentrated on a rotary 
evaporator, and the crude product was purified via flash chromatography (80:20 to 70:30 
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hexanes:EtOAc) to give the vinyl ether 3.57 (11.4 g, 97% yield) as a clear oil.  Analytical data: 
1H NMR  (600 MHz, CDCl3): δ 7.77 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 7.28 (d, J 
= 12.6 Hz, 1H), 5.14 (d, J = 12.6 Hz, 1H), 4.97 (s, 1H), 4.93 (s, 1H), 4.31 (dd, J = 4.8, 4.2 Hz, 
1H), 4.16-4.06 (m, 4H), 2.43 (s, 3H), 1.97 (m, 2H), 1.61 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H); 13C 
NMR (150 MHz, CDCl3): δ 167.6, 160.5, 145.0, 141.5, 132.6, 129.9, 127.9, 115.4, 98.6, 81.5, 
66.2, 59.8, 32.7, 21.6, 16.7, 14.3; HRMS (ESI+) Calcd. For C18H24O6S+Na, 391.1191; Found, 
391.1181; IR (thin film, cm-1) 2980, 2916, 2849, 1706, 1644, 1488, 1362, 1189, 1097, 923; 
TLC (80:20 hexanes:EtOAc): Rf = 0.32.  
 
Ethyl (E)-3-((5-iodo-2-methylpent-1-en-3-yl)oxy)acrylate (3.58): To a solution of tosylate 
3.57 (11.4 g, 30.8 mmol, 1.00 equiv) in acetone (300 mL) at rt was added NaI (40.0 g, 308.0 
mmol, 10.0 equiv) portionwise with vigorous stirring.  The resulting suspension was allowed 
to stir 12 h at which point TLC analysis confirmed complete consumption of the starting 
material.  The reaction mixture was diluted with brine (150 mL) and transferred to a separatory 
funnel.  The aqueous layer was extracted with EtOAc (3 x 60 mL), and the combined organic 
extracts were dried with magnesium sulfate and concentrated in vacuo.  The product was 
purified via flash chromatography (90:10 to 80:20 hexanes:EtOAc) to afford the alkyl iodide 
3.58 (8.67 g, 87% yield) as a pale yellow oil.  Analytical data: 1H NMR  (600 MHz, CDCl3): 
δ 7.46 (d, J = 12.6 Hz, 1H), 5.27 (d, J = 12.6 Hz, 1H), 5.05 (s, 1H), 5.04 (s, 1H), 4.39 (dd, J = 
4.8, 3.0 Hz, 1H), 4.14 (m, 2H), 3.17 (m, 2H), 2.21 (m, 1H), 2.07 (m, 1H), 1.67 (s, 3H), 1.25 (t, 
J = 7.2 Hz, 1H); 13C NMR (150 MHz, CDCl3): δ 167.7, 160.8, 141.5, 115.3, 98.6, 85.5, 59.8, 
36.7, 17.0, 14.3, 0.9; HRMS (ESI+) Calcd. For C11H17IO3+Na, 347.0120; Found, 347.0111; 
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IR (thin film, cm-1) 3078, 2978, 2916, 1707, 1644, 1456, 1322, 1171, 1006, 834; TLC (80:20 
hexanes:EtOAc): Rf = 0.64. 
 
Dimethyl 2-(2-ethoxy-2-oxoethyl)-6-(prop-1-en-2-yl)dihydro-2H-pyran-3,3(4H)-
dicarboxylate (3.59): A 500 mL round bottomed flask was charged with the iodide 3.58 (8.75 
g, 27.00 mmol, 1.00 equiv) and DMF (130 mL) at rt.  Dimethyl malonate (6.20 mL, 54.0 mmol, 
2.00 equiv) and Cs2CO3 (26.4 g, 81.0 mmol, 3.00 equiv) were added sequentially, whereupon 
a bright orange color was observed.  The resulting mixture was allowed to stir for 14 h and 
was subsequently diluted with H2O (50 mL) and Et2O (50 mL).  The layers were partitioned in 
a separatory funnel, and the aqueous layer was extracted with Et2O (3 x 30 mL).  The combined 
organic extracts were washed with brine (40 mL), dried with magnesium sulfate and 
concentrated in vacuo to give the crude pyran as a single diastereomer (as determined by 1H 
NMR spectroscopic analysis of the crude mixture, which revealed a single compound). The 
product was purified via flash chromatography (90:10 to 80:20 hexanes:EtOAc) to afford 
tetrahydropyran 3.59 (8.85 g, 99% yield) as a clear, viscous oil.  Analytical data: 1H NMR  
(600 MHz, CDCl3): δ 4.86 (s, 1H), 4.75 (s, 1H), 4.31 (dd, J = 9.0, 6.0 Hz, 1H), 4.11 (m, 2H), 
3.83 (d, J = 12.0 Hz, 1H), 3.72 (s, 3H), 3.67 (s, 3H), 2.77 (m, 2H), 2.54 (m, 1H), 1.92 (m, 1H), 
1.82 (m, 1H), 1.67 (br s, 1H), 1.65 (s, 3H), 1.20 (t, J = 6.6 Hz, 3H); 13C NMR (150 MHz, 
CDCl3): δ 171.4, 170.7, 169.0, 144.6, 110.7, 81.1, 77.3, 60.3, 55.8, 52.5, 52.2, 38.0, 31.7, 26.0, 
18.8, 14.1; HRMS (ESI+) Calcd. For C16H24O7+Na, 351.1420; Found, 351.1409; IR (thin film, 
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cm-1) 3446, 2955, 2849, 1733, 1652, 1455, 1267, 1186, 1072, 904; TLC (80:20 
hexanes:EtOAc): Rf = 0.43.  
Crude 1H NMR spectrum of 17 
 
 
Dimethyl-2-(2-hydroxyethyl)-6-(prop-1-en-2-yl)dihydro-2H-pyran-3,3(4H)-
dicarboxylate (S1): A flame-dried, 500 mL round bottomed flask was charged with ester 3.59 
(6.00 g, 18.3 mmol, 1.00 equiv) and THF (150 mL) under an atmosphere of N2.  The solution 
was cooled to 0 °C, and DIBAL-H (1 M solution in hexane, 18.3 mL, 18.3 mmol, 1.00 equiv) 
was added slowly.  The reaction was then analyzed for reaction completion via TLC analysis, 
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which indicated incomplete starting material conversion.  Another 1.00 equiv DIBAL-H was 
added, whereupon TLC analysis indicated incomplete starting material conversion.  Another 
1.00 equiv DIBAL-H was added, whereupon TLC analysis indicated complete conversion of 
the starting material.  The reaction mixture was quenched via addition of acetone (30 mL), and 
the mixture was stirred 5 min at 0 °C.  Saturated Rochelle’s salt(aq.) (40 mL) was then added, 
and the mixture was transferred to a separatory funnel.  The aqueous layer was extracted with 
Et2O (3 x 40 mL), and the combined organic extracts were washed with 1 M HCl(aq.) (40 mL) 
and brine (40 mL), dried with magnesium sulfate and concentrated in vacuo.  The product was 
purified via flash chromatography (60:40 to 50:50 to 40:60 hexanes:EtOAc) to afford alcohol 
S1 (3.78 g, 72% yield) as a clear, viscous oil.  Analytical data: 1H NMR  (600 MHz, CDCl3): 
δ 4.92 (s, 1H), 4.81 (s, 1H), 4.01 (dd, J = 8.4, 1.8 Hz, 1H), 3.88 (m, 1H), 3.79-3.76 (m, 5H), 
3.71 (s, 3H), 2.54 (m, 1H), 2.42 (d, J = 5.4 Hz, 1H), 2.14 (m, 1H), 1.93-1.88 (m, 3H), 1.70 (s, 
3H), 1.67 (m, 1H); 13C NMR (150 MHz, CDCl3): δ 171.2, 169.3, 144.7, 111.1, 81.5, 81.1, 
62.1, 56.2, 52.6, 52.1, 34.7, 31.9, 26.6, 18.7; HRMS (ESI+) Calcd. For C14H22O6+Na, 
309.1314; Found, 309.1305; IR (thin film, cm-1) 3446, 3055, 2954, 2883, 1731, 1455, 1266, 
1078, 906, 737; TLC (75:25 hexanes:EtOAc): Rf = 0.05. 
 
Dimethyl-2-(2-iodoethyl)-6-(prop-1-en-2-yl)dihydro-2H-pyran-3,3(4H)-dicarboxylate 
(3.60): A 500 mL round bottomed flask was charged with CH2Cl2 (96 mL), and the solution 
was cooled to 0 °C.  Imidazole (3.22 g, 47.4 mmol, 4.96 equiv) and PPh3 (5.14 g, 19.0 mmol, 
2.05 equiv) were added followed by I2 (4.83 g, 19.0 mmol, 2.00 equiv).  The mixture was 
allowed to stir at 0 °C for 10 min whereupon a pale yellow suspension was observed.  The 
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alcohol S1 (2.73 g, 9.55 mmol, 1.00 equiv) was then added as a solution in CH2Cl2 (20 mL), 
and the mixture was allowed to warm to rt and stirred until complete consumption of the 
starting material was observed by TLC analysis, typically 12 h.  The mixture was then 
quenched via addition of saturated Na2S2O3(aq.) (50 mL) and transferred to a separatory funnel. 
The aqueous layer was extracted with CH2Cl2 (3 x 30 mL), and the combined organic extracts 
were washed with brine (30 mL), dried with magnesium sulfate, and concentrated in vacuo. 
The product was purified via flash chromatography (95:5 to 90:10 hexanes:EtOAc) to afford 
primary iodide 3.60 (2.64 g, 70% yield) as a white solid.  Analytical data: mp 61-65 °C; 1H 
NMR  (600 MHz, CDCl3): δ 4.93 (s, 1H), 4.83 (s, 1H), 3.88 (d, J = 10.2 Hz, 1H), 3.84 (d, J = 
11.4 Hz, 1H), 3.75 (s, 3H), 3.72 (s, 3H), 3.36 (m, 1H), 3.28 (m, 1H), 2.56 (dt, J = 6.6, 3.0 Hz, 
1H), 2.37 (m, 1H), 2.13 (m, 1H), 1.95 (m, 1H), 1.84 (m, 1H), 1.73 (s, 3H), 1.69 (m, 1H); 13C 
NMR (150 MHz, CDCl3): δ 171.0, 169.3, 144.8, 110.9, 81.4, 80.9, 56.4, 52.6, 52.2, 35.8, 32.0, 
26.3, 19.0, 4.3; HRMS (ESI+) Calcd. For C14H21IO5+Na, 419.0326; Found, 419.0320; IR (thin 
film, cm-1) 2917, 2849, 1731, 1652, 1540, 1455, 1265, 1083, 905; TLC (75:25 
hexanes:EtOAc): Rf = 0.50. 
 
Dimethyl-2-(3-methylbut-3-en-1-yl)-6-(prop-1-en-2-yl)dihydro-2H-pyran-3,3(4H)-
dicarboxylate (3.40): A flame-dried, 50 mL round bottomed flask was charged with 2-
bromopropene (0.67 mL, 7.57 mmol, 3.00 equiv) and Et2O (13 mL) under an atmosphere of 
N2.  The mixture was cooled to -78 °C, and 
tBuLi (1.70 M solution in pentane, 8.91 mL, 15.14 
mmol, 6.00 equiv) was added dropwise.  The reaction mixture was allowed to stir 30 min at -
78 °C, then warmed to rt and stirred for 1 h.  During this time period, a second flame-dried, 
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100 mL round bottomed flask was charged with CuI (0.72 g, 3.79 mmol, 1.50 equiv) and Et2O 
(12 mL) and was cooled to -78 °C.  The isopropenyllithium solution was then cooled to -78 °C 
and transferred via cannula to the CuI suspension over a period of ~ 1 min.  The resulting 
suspension was then warmed to -45 °C and stirred 1 h, upon which a color change from pale 
brown to dark gray to dark yellow-green was observed.  The mixture was cooled to -78 °C, 
and a solution of iodide 3.60 (1.00 g, 2.52 mmol, 1.00 equiv) in Et2O (5 mL) was added.  The 
reaction was then warmed to 0 °C and stirred until complete conversion of the starting material 
was observed by TLC analysis, typically 30 min.  The reaction was then quenched via addition 
of saturated NH4Cl(aq.) (20 mL), and the mixture was transferred to a separatory funnel.  The 
aqueous layer was extracted with Et2O (3 x 20 mL), and the combined organic extracts were 
washed with saturated NH4Cl(aq.) (20 mL), dried with magnesium sulfate, and concentrated in 
vacuo.  The product was purified via flash chromatography (100:0 to 95:5 to 90:10 
hexanes:EtOAc) to afford the alkene 3.40 (0.77 g, 99% yield) as a clear oil. Analytical data: 
1H NMR  (600 MHz, CDCl3): δ 4.93 (s, 1H), 4.81 (s, 1H), 4.72 (s, 1H), 4.69 (s, 1H), 3.75 (br 
s, 4H), 3.70 (br s, 4H), 2.53 (m, 1H), 2.21 (m, 1H), 2.12 (m, 1H), 1.94-1.78 (m, 4H), 1.74 (s, 
3H), 1,72 (s, 3H), 1.67 (m, 1H); 13C NMR (150 MHz, CDCl3): δ 171.6, 169.7, 154.4, 145.1, 
110.6, 110.3, 81.0, 80.5, 56.6, 52.4, 52.0, 34.9, 32.2, 30.1, 26.2, 22.2, 19.2; HRMS (ESI+) 
Calcd. For C17H26O5+Na, 333.1678; Found, 333.1669; IR (thin film, cm
-1) 3446, 3056, 2953, 
2849, 1731, 1669, 1636, 1520, 1455, 1203, 1266; TLC (75:25 hexanes:EtOAc): Rf = 0.52. 
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3-(methoxycarbonyl)-2-(3-methylbut-3-en-1-yl)-6-(prop-1-en-2-yl)tetrahydro-2H-
pyran-3-carboxylic acid (3.61): A 20 mL scintillation vial was charged with diester 3.40 (0.10 
g, 0.32 mmol, 1.00 equiv) and THF (3 mL) with stirring at rt.  KOH (1 M in MeOH, 1.70 mL, 
1.70 mmol, 5.27 equiv) was added, and the resulting mixture was allowed to stir at rt until 
complete consumption of the starting material was observed by TLC analysis.  This time period 
varied widely for each experiment (from 12 h to 6 d dependent on scale; in this iteration, 5 
days were required to reach complete conversion).  Once complete, the reaction mixture was 
concentrated on a rotary evaporator.  The residue was diluted with H2O (10 mL), transferred 
to a separatory funnel, and extracted with Et2O (2 x 5 mL).  The aqueous layer was acidified 
to pH=1 with 1 M HCl(aq.) and extracted with EtOAc (3 x 5 mL).  The combined EtOAc extracts 
were dried with magnesium sulfate and concentrated in vacuo to afford the crude mono-acid 
3.61 (0.094 g, >99% crude yield) as a pale yellow, viscous oil.  The diastereomeric ratio was 
determined via 1H NMR spectroscopic analysis of this crude material, which revealed a single 
compound.  Analytical data: 1H NMR  (600 MHz, C6D6): δ 10.56 (br s, 1H), 5.02 (s, 1H), 4.90 
(s, 1H), 4.84 (s, 1H), 4.80 (s, 1H), 3.84 (dd, J = 7.2, 1.8 Hz, 1H), 3.58 (d, J = 11.4 Hz, 1H), 
3.31 (s, 3H), 2.56 (d, J = 13.2 Hz, 1H), 2.33 (m, 2H), 2.17 (m, 2H), 2.08 (m, 1H), 1.71 (s, 3H), 
1.68-1.67 (m, 4H), 1.34 (d, J = 1.8 Hz, 1H); 13C NMR (150 MHz, CDCl3): δ 177.1, 169.6, 
145.3, 145.0, 110.8, 110.4, 81.1, 80.3, 56.6, 52.2, 34.8, 32.2, 30.1, 26.1, 22.2, 19.2; HRMS 
(ESI+) Calcd. For C16H24O5+Na, 319.1521; Found, 319.1513; IR (thin film, cm
-1) 3566, 3074, 
2952, 2857, 2633, 1732, 1650, 1438, 1268, 1080, 891; TLC (75:25 hexanes:EtOAc): Rf = 0.32. 
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Crude 1H NMR Spectrum of 3.61 
 
nOesy Spectrum of 3.61 (C6D6) 
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Methyl-3-acetyl-2-(3-methylbut-3-en-1-yl)-6-(prop-1-en-2-yl)tetrahydro-2H-pyran-3-
carboxylate (3.62): A flame-dried, 25 mL round bottomed flask was charged with diester 3.40 
(0.35 g, 1.13 mmol, 1.00 equiv) and THF (11 mL) under an atmosphere of N2.  The solution 
was cooled to -78 °C, and MeLi (1.60 M in Et2O, 0.6 mL, 0.97 mmol, 2.00 equiv) was added 
over 5 sec.  The reaction was then checked via TLC analysis, which showed incomplete 
conversion of the starting material.  Another 2.00 equiv MeLi was added, whereupon TLC 
analysis showed incomplete conversion of the starting material.  Another 1.00 equiv MeLi was 
added, whereupon TLC analysis showed complete conversion of the starting material.  The 
reaction mixture was then quenched via addition of saturated NH4Cl(aq.) (5 mL) and 
subsequently warmed to rt.  The mixture was transferred to a separatory funnel, and the 
aqueous layer was extracted with Et2O (3 x 10 mL).  The combined organic extracts were dried 
with magnesium sulfate and concentrated in vacuo to give the crude ketone as a single 
diastereomer  (as determined via 1H NMR spectroscopic analysis of the crude product residue, 
which revealed a single stereoisomer in combination with over-addition products).  The 
product was purified via flash chromatography (100:0 to 98:2 to 95:5 to 90:10 hexanes:EtOAc) 
to afford ketone 3.62 (0.22 g, 65% yield) as a clear, viscous oil. Analytical data: 1H NMR  
(600 MHz, CDCl3): δ 4.94 (s, 1H), 4.82 (s, 1H), 4.71 (s, 1H), 4.69 (s, 1H), 3.78-3.75 (m, 4H), 
3.71 (d, J = 11.4 Hz, 1H), 2.45 (m, 1H), 2.22 (m, 1H), 2.12 (br s, 4H), 1.99 (m, 1H), 1.75 (br 
s, 4H), 1.73 (br s, 4H), 1.68 (m, 2H); 13C NMR (150 MHz, CDCl3): δ 205.1, 171.0, 145.6, 
145.2, 110.6, 110.3, 80.8, 80.3, 62.3, 52.0, 34.9, 31.4, 30.2, 27.1, 26.4, 22.3, 19.3; HRMS 
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(ESI+) Calcd. For C17H26O4+Na, 317.1729; Found, 317.1720; IR (thin film, cm
-1) 3445, 3072, 
2969, 2857, 1708, 1649, 1436, 1356, 1221, 1081; TLC (75:25 hexanes:EtOAc): Rf = 0.45. 
Crude 1H NMR spectrum of 1.62 
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nOesy Spectrum of 3.62 (C6D6) 
 
 
Methyl-2-(3-methylbut-3-en-1-yl)-6-(prop-1-en-2-yl)-3-propionyltetrahydro-2H-pyran-
3-carboxylate (3.63): A flame-dried 20 mL scintillation vial was charged with bromoethane 
(0.13 mL, 1.69 mmol, 3.50 equiv) and THF (5 mL) under an atmosphere of N2.  The solution 
was cooled to -78 °C, and tBuLi (1.70 M in pentane, 1.99 mL, 3.38 mmol, 7.00 equiv) was 
added dropwise.  The mixture was allowed to stir 30 min at -78 °C whereupon a solution of 
the diester 3.40 (0.15 g, 0.48 mmol, 1.00 equiv) was added over ~10 sec.  The reaction progress 
was immediately checked via TLC analysis, which confirmed complete consumption of the 
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starting material.  The reaction was then quenched via addition of saturated NH4Cl(aq.) (5 mL) 
and warmed to rt.  The mixture was transferred to a separatory funnel, and the aqueous layer 
was extracted with Et2O (3 x 10 mL).  The combined organic extracts were dried with 
magnesium sulfate and concentrated in vacuo to afford the crude ketone as a single 
diastereomer (as determined via 1H NMR spectroscopic analysis of the crude product residue, 
which revealed a single stereoisomer in combination with over-addition products).  The 
product was purified via flash chromatography (100:0 to 98:2 to 95:5 to 90:10 hexanes:EtOAc) 
to afford ketone 3.63 (0.13 g, 89% yield) as a clear, viscous oil. Analytical data: 1H NMR  
(600 MHz, CDCl3): δ 4.93 (s, 1H), 4.82 (s, 1H), 4.71 (s, 1H), 4.68 (s, 1H), 3.79-3.77 (m, 4H), 
3.71 (d, J = 3.6 Hz, 1H), 2.42 (m, 3H), 2.21 (m, 1H), 2.12 (m, 1H), 1.95 (m, 1H), 1.78 (m, 1H), 
1.74 (s, 3H), 1.73 (s, 3H), 1.69 (m, 2H), 1.60 (br s, 1H), 1.03 (t, J = 7.2 Hz, H); 13C NMR (150 
MHz, CDCl3): δ 208.0, 171.2, 145.6, 145.2, 110.6, 110.3, 80.8, 80.5, 62.4, 51.9, 34.9, 32.6, 
31.7, 30.2, 26.4, 22.3, 19.3, 7.9; HRMS (ESI+) Calcd. For C18H28O4+Na, 331.1885; Found, 
331.1876; IR (thin film, cm-1) 3446, 3073, 2970, 2855, 1739, 1650, 1455, 1342, 1159, 892; 
TLC (75:25 hexanes:EtOAc): Rf = 0.47. 
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Crude 1H NMR spectrum of 3.63 
 
nOesy Spectrum of 3.63 (C6D6) 
 
275 
 
 
Methyl 3-acryloyl-2-(3-methylbut-3-en-1-yl)-6-(prop-1-en-2-yl)tetrahydro-2H-pyran-3-
carboxylate (3.64): A flame-dried, 20 mL scintillation vial was charged with THF (4 mL) and 
diisopropylamine (0.08 mL, 0.55 mmol, 1.30 equiv) under an atmosphere of N2.  The mixture 
was cooled to 0 °C, and nBuLi (1.74 M in hexanes, 0.32 mL, 0.55 mmol, 1.30 equiv) was added 
dropwise.  After stirring 30 min, the mixture was cooled to -78 °C, and a solution of ketone 
3.63 (0.13 g, 0.42 mmol, 1.00 equiv) in THF (1 mL) was added.  After stirring 45 min at -78 
°C, PhSeBr (0.11 g, 0.51 mmol, 1.10 equiv) was added, and the mixture was allowed to stir 
until complete consumption of the starting material was observed by TLC analysis, typically 
45 min.  The reaction mixture was diluted with H2O (10 mL), warmed to rt, and transferred to 
a separatory funnel.  The organic layer was separated, and the aqueous layer was extracted 
with Et2O (3 x 10 mL).  The combined organic extracts were dried with magnesium sulfate 
and concentrated in vacuo to give the crude α-selenide, which was used in the next step without 
further purification. 
The intermediate selenide was dissolved in CH2Cl2 (2 mL), and the mixture was cooled to 0 
°C.  H2O2 (30% w/w in H2O, 0.80 mL) was added dropwise, and the mixture was stirred at 0 
°C until complete consumption of the starting material was observed by TLC analysis, 
typically 15 min.  The reaction mixture was diluted with H2O (7 mL) and transferred to a 
separatory funnel.  The aqueous layer was extracted with EtOAc (3 x 7 mL), and the combined 
organic extracts were dried with magnesium sulfate and concentrated in vacuo.  The product 
was purified via flash chromatography (100:0 to 98:2 to 95:5 hexanes:EtOAc) to afford 
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unsaturated ketone 3.64 (0.079 g, 56%) as a pale yellow, viscous oil. Analytical data: 1H NMR  
(600 MHz, CDCl3): δ 6.39 (d, J = 3.0 Hz, 1H), 6.38 (s, 1H), 5.71 (dd, J = 4.2, 3.0 Hz, 1H), 
4.95 (s, 1H), 4.84 (s, 1H), 4.72 (s, 1H), 4.70 (s, 1H), 3.84 (d, J = 10.2 Hz, 1H), 3.76 (s, 3H), 
3.72 (d, J = 11.4 Hz, 1H), 2.43 (m, 1H), 2.22 (m, 1H), 2.17 (m, 1H), 2.08 (m, 1H), 1.81 (m, 
1H), 1.77 (s, 3H), 1.74 (s, 3H), 1.72-1.66 (m, 3H); 13C NMR (150 MHz, CDCl3): δ 195.6, 
170.9, 145.6, 145.2, 131.7, 129.7, 110.7, 110.4, 80.7, 79.9, 60.8, 52.0, 34.8, 31.0, 30.2, 26.2, 
22.3, 19.4; HRMS (ESI+) Calcd. For C18H26O4+Na, 329.1729; Found, 329.1720; IR (thin film, 
cm-1) 3420, 3054, 2952, 2852, 1740, 1636, 1455, 1265, 1049, 894; TLC (75:25 
hexanes:EtOAc): Rf = 0.63. 
 
tert-butyl 3-(3-oxopropyl)-1H-indole-1-carboxylate (S3): A flame-dried, 50 mL round 
bottomed flask was charged with 3-(1H-indol-3-yl)propanal S2 (0.37 g, 2.10 mmol, 1.00 
equiv), CH2Cl2 (14 mL), NEt3 (0.44 mL, 3.15 mmol, 1.50 equiv), and lastly DMAP (0.005 g, 
0.21 mmol, 0.10 equiv) at rt under an atmosphere of N2.  Boc2O (0.55 g, 2.52 mmol, 1.20 
equiv) was added in one porition, and the resulting mixture was allowed to stir until complete 
consumption of the starting material was observed by TLC analysis, typically 5 h.  The mixture 
was then diluted with H2O (10 mL) and transferred to a separatory funnel.  The organic layer 
was separated, and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined 
organic extracts were dried with magnesium sulfate and concentrated in vacuo.  The product 
was purified via flash chromatography (100:0 to 90:10 to 80:20 hexanes:EtOAc) to afford the 
protected indole S3 (0.24 g, 42% yield) as a clear, viscous oil.  Analytical data: 1H NMR  (600 
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MHz, CDCl3): δ 9.87 (s, 1H), 8.13 (br s, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.38 (br s, 1H), 7.33 (t, 
J = 7.2 Hz, 1H), 7.25 (t, J = 7.2 Hz, 1H), 3.04 (t, J = 7.2 Hz, 2H), 2.87 (t, J = 7.8 Hz, 2H), 1.67 
(s, 9H); 13C NMR (150 MHz, CDCl3): δ 201.5, 124.5, 122.6, 122.4, 119.1, 118.7, 115.3, 43.1, 
28.2, 17.4; HRMS (ESI+) Calcd. For C16H19NO3+Na, 296.1263; Found, 296.1256; IR (thin 
film, cm-1) 3446, 2977, 2916, 1731, 1670, 1636, 1455, 1373, 1256, 1158, 1018, 746; TLC 
(80:20 hexanes:EtOAc): Rf = 0.53. 
 
tert-butyl 3-(2-formylallyl)-1H-indole-1-carboxylate (S4): A flame-dried, 50 mL round 
bottomed flask was charged with aldehyde S3 (0.16 g, 0.60 mmol, 1.00 equiv) and CH2Cl2 (12 
mL) at rt under an atmosphere of N2.  NEt3 (0.84 mL, 6.00 mmol, 10.0 equiv) was added 
followed lastly by dimethylmethylideneiminium iodide (0.33 g, 1.8 mmol, 3.00 equiv).  The 
mixture was allowed to stir at rt until complete conversion of the starting material was observed 
by TLC analysis, typically 12 h.  The reaction was then concentrated on a rotary evaporator 
and purified via flash chromatography (95:5 to 90:10 hexanes:EtOAc) to afford unsaturated 
aldehyde S4 (0.08 g, 45% yield) as a yellow, viscous oil. Analytical data: 1H NMR  (600 MHz, 
CDCl3): δ 9.67 (s, 1H), 8.13 (br s, 1H), 7.42 (br s, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.32 (t, J = 
8.4 Hz, 1H), 7.22 (t, J = 7.8 Hz, 1H), 3.65 (s, 2H), 1.67 (s, 9H); 13C NMR (150 MHz, CDCl3): 
δ 194.0, 149.7, 147.9, 135.3, 130.1, 124.4, 124.1, 122.5, 119.1, 116.8, 115.3, 83.6, 28.2, 23.3; 
HRMS (ESI+) Calcd. For C17H19NO3+Na, 308.1263; Found, 308.1255; IR (thin film, cm
-1) 
3446, 2916, 1732, 1685, 1488, 1455, 1370, 1255, 1158, 1083, 959; TLC (80:20 
hexanes:EtOAc): Rf = 0.60. 
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tert-butyl 3-(2-methylene-3-oxobutyl)-1H-indole-1-carboxylate (3.67): A flame-dried, 20 
mL scintillation vial was charged with aldehyde S4 (0.04 g, 0.12 mmol, 1.00 equiv) and THF 
(2 mL) under an atmosphere of N2.  The solution was cooled to 0 °C, and MeMgBr (3 M in 
Et2O, 0.12 mL, 0.37 mmol, 3.00 equiv) was added over a period of ~1 min.  The mixture was 
allowed to stir until complete consumption of the starting material was observed by TLC 
analysis, typically 30 min.  The reaction was then quenched via addition of saturated NH4Cl(aq.) 
(5 mL), and the mixture was transferred to a separatory funnel.  The aqueous layer was 
extracted with Et2O (3 x 10 mL), and the combined organic extracts were dried with 
magnesium sulfate and concentrated in vacuo to give the crude alcohol, which was used in the 
next step without further purification. 
The crude residue was dissolved in CH2Cl2 (2 mL) and transferred to a 20 mL scintillation vial. 
Dess-Martin periodinane (0.10 g, 0.25 mmol, 2.00 equiv) was added to the vial, and the 
resulting mixture was allowed to stir until complete consumption of the starting material was 
observed by TLC analysis, typically 20 min.  The reaction mixture was then quenched via a 
1:1 mixture of saturated NaHCO3(aq.) and saturated Na2S2O3(aq.) (5 mL) and allowed to stir 5 
min.  The mixture was then transferred to a separatory funnel, and the aqueous layer was 
extracted with Et2O (3 x 5 mL).  The combined organic extracts were dried with magnesium 
sulfate and concentrated in vacuo.  The product was purified via flash chromatography (95:5 
to 90:10 hexanes:EtOAc) to afford enone 3.67 (0.026 g, 71% yield) as a yellow viscous oil. 
Analytical data: 1H NMR  (600 MHz, CDCl3): δ 8.12 (br s, 1H), 7.41 (d, J = 9.0 Hz, 1H), 7.39 
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(br s, 1H), 7.31 (t, J = 9.0 Hz, 1H), 7.21 (t, J = 9.0 Hz, 1H), 6.10 (s, 1H), 5.72(s, 1H), 3.67 (s, 
2H), 2.39 (s, 3H), 1.67 (s, 9H); 13C NMR (150 MHz, CDCl3): δ 199.4, 146.8, 126.5, 124.3, 
124.0, 122.4, 119.2, 117.8, 115.2, 36.6, 28.2, 25.9; HRMS (ESI+) Calcd. For C18H21NO3+Na, 
322.1419; Found, 322.1411; IR (thin film, cm-1) 3445, 3054, 2980, 2930, 1731, 1680, 1628, 
1454, 1368, 1256, 1158, 1082; TLC (80:20 hexanes:EtOAc): Rf = 0.60. 
 
4-(1-(2,2,2-trifluoroacetyl)-1H-indol-3-yl)butan-2-one (S6): A flame-dried, 100 mL round 
bottomed flask was charged with TFAA (1.51 mL, 10.7 mmol, 4.00 equiv) and CH2Cl2 (25 
mL) under an atmosphere of N2.  4-(1H-indol-3-yl)butan-2-one S5 (0.50 g, 2.67 mmol, 1.00 
equiv) was dissolved in CH2Cl2 (2 mL) and added dropwise to the TFAA solution.  Once the 
addition was complete, the mixture was allowed to stir at rt until complete consumption of the 
starting material was observed by TLC analysis, typically 12 h.  The reaction was quenched 
via addition of saturated NaHCO3(aq.) (10 mL) and transferred to a separatory funnel.  The 
aqueous layer was extracted with EtOAc (3 x 10 mL) and the combined organic extracts were 
dried with sodium sulfate and concentrated in vacuo.  The product was purified via flash 
chromatography (90:10 to 80:20 hexanes:EtOAc) to afford TFA-protected indole S6 (0.54 g, 
71% yield) as a pale yellow solid. Analytical data: mp 55-58 °C; 1H NMR  (600 MHz, CDCl3): 
δ 8.43 (d, J = 7.8 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.42 (m, 2H), 7.25 (br s, 1H), 2.99 (t, J = 
7.8 Hz, 2H), 2.87 (t, J = 7.8 Hz, 2H), 2.20 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 207.0, 
136.2, 130.5, 126.4, 125.5, 125.2, 120.3, 120.2, 119.2, 117.0, 42.2, 30.0, 18.6; HRMS (ESI+) 
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Calcd. For C14H12F3NO2+Na, 306.0718; Found, 306.0709; IR (thin film, cm
-1) 2917, 1717, 
1459, 1419, 1292, 1207, 1155, 880; TLC (80:20 hexanes:EtOAc): Rf = 0.48. 
 
2,2,2-trifluoro-1-(3-(3-((trimethylsilyl)oxy)but-2-en-1-yl)-1H-indol-1-yl)ethan-1-one 
(3.69): a flame-dried, 20 mL scintillation vial was charged with ketone S6 (0.05 g, 0.267 mmol, 
1.00 equiv) and CH2Cl2 (3 mL) under an atmosphere of N2.  The mixture was cooled to -10 
°C, and HMDS (0.17 mL, .801 mmol, 3.00 equiv) was added followed by TMSI (0.02 mL, 
0.267 mmol, 1.00 equiv) dropwise.  The reaction mixture was warmed to rt and stirred until 
TLC analysis confirmed complete consumption of the starting material, typically 45 min.  The 
reaction mixture was then quenched via addition of saturated NaHCO3(aq.) (5 mL) and 
transferred to a separatory funnel.  The organic layer was separated, and the aqueous layer was 
extracted with CH2Cl2 (3 x 5 mL).  The combined organic extracts were dried with magnesium 
sulfate and concentrated in vacuo to afford the crude enol-silane as a ~3:1 mixture of alkene 
isomers as determined by 1H NMR analysis.  This material was unstable to further purification 
and was used directly in reaction screenings.  The crude 1H NMR spectrum is included below. 
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Crude 1H NMR spectrum of 3.69 
 
 
tert-butyl 3-(3-methylbut-2-en-1-yl)-1H-indole-1-carboxylate (3.65): A flame-dried, 20 mL 
scintillation vial was charged with 3-(3-methylbut-2-en-1-yl)-1H-indole S7 (0.05 g, 0.27 
mmol, 1.00 equiv), NEt3 (0.06 mL, 0.41 mmol, 1.50 equiv), DMAP (0.003 g, 0.027 mmol, 
0.10 equiv), and CH2Cl2 (3 mL) at rt under an atmosphere of N2.  Boc2O (0.07 mL, 0.32 mmol, 
1.20 equiv) was added, and the mixture was allowed to stir at rt until TLC analysis confirmed 
complete consumption of the starting material, typically 12 h.  The mixture was diluted with 
H2O (5 mL) and transferred to a separatory funnel.  The aqueous layer was extracted with 
CH2Cl2 (3 x 5 mL), and the combined organic extracts were washed with H2O (5 mL), dried 
with sodium sulfate, and concentrated in vacuo.  The product was purified via flash 
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chromatography (100:0 to 98:2 hexanes:EtOAc) to afford protected indole 3.67 (0.06 g, 73% 
yield) as a yellow viscous oil. Analytical data: 1H NMR  (600 MHz, CDCl3): δ 8.11 (d, J = 9.0 
Hz, 1H), 7.53 (d, J = 7.8 Hz, 1H), 7.35-7.31 (m, 2H), 7.25 (t, J = 7.8 Hz, 1H), 5,41 (t, J = 7.2 
Hz, 1H), 3.39 (d, J = 7.2 Hz, 2H), 1.78 (br s, 6H), 1.68 (s, 9H); 13C NMR (150 MHz, CDCl3): 
δ 133.0, 124.2, 123.1, 122.3, 122.2, 121.5, 120.6, 120.5, 119.1, 115.2, 107.1, 28.2, 25.7, 23.9, 
17.8; HRMS (ESI+) Calcd. For C18H23NO2+Na, 308.1626; Found, 308.1619; IR (thin film, 
cm-1) 3421, 3053, 2980, 2931, 1730, 1454, 1371, 1265, 1158, 855; TLC (80:20 
hexanes:EtOAc): Rf = 0.95 . 
 
Dimethyl 2-(2-(1-methyl-2,6-dioxocyclohexyl)ethyl)-6-(prop-1-en-2-yl)dihydro-2H-
pyran-3,3(4H)-dicarboxylate (3.73): A flame-dried, 20 mL scintillation vial was charged 
with iodide 3.60 (0.60 g, 1.51 mmol, 1.00 equiv), 2-methyl-1,3-cyclohexanedione (0.27 g, 2.12 
mmol, 1.4 equiv), and DMF (3 mL) at rt under an atmosphere of N2.  Cs2CO3 (0.74 g, 2.27 
mmol, 1.50 equiv) was added, and the mixture was warmed to 65 °C.  The reaction was allowed 
to stir at this temperature until complete consumption of the starting material was observed by 
TLC analysis, typically 5 h.  The reaction mixture was cooled to rt, diluted with H2O (6 mL) 
and Et2O (5 mL), and transferred to a separatory funnel.  The organic layer was separated, and 
the aqueous layer was extracted with Et2O (3 x 10 mL). The combined organic extracts were 
washed with brine (10 mL), dried with magnesium sulfate, and concentrated in vacuo.  The 
mixture was purified via flash chromatography (70:30 to 60:40 to 50:50 hexanes:EtOAc) to 
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afford diketone 3.73 (0.20 g, 34% yield) as a clear, viscous oil and enol ether 3.74 (0.34 g, 56 
% yield) as a clear, viscous oil. Analytical data: O-alkylation product 3.74: 1H NMR  (600 
MHz, CDCl3): δ 4.90 (s, 1H), 4.79 (s, 1H), 4.09 (m, 2H), 3.92 (d, J = 10.8 Hz, 1H), 3.77 (d, J 
= 11.4 Hz, 1H), 3.74 (s, 3H), 3.69 (s, 3H), 2.55-2.51 (m, 3H), 2.31 (t, J = 6.6 Hz, 2H), 2.21 (m, 
1H), 2.09 (m, 1H), 1.96-1.90 (m, 3H), 1.79 (m, 1H), 1.70 (s, 3H), 1.68 (s, 3H), 1.66 (m, 1H); 
13C NMR (150 MHz, CDCl3): δ 198.8, 171.5, 110.9, 169.3, 144.8, 115.0, 110.8, 81.3, 77.1, 
64.6,  56.4, 52.6, 52.1, 36.2, 32.7, 31.9, 26.4, 25.3, 20.9, 18.8, 7.3; HRMS (ESI+) Calcd. For 
C21H30O7+Na, 417.1889; Found, 417.1879; IR (thin film, cm
-1) 2953, 1731, 1635, 1455, 1377, 
1355, 1262, 1095, 921; TLC (75:25 hexanes:EtOAc): Rf = 0.10. C-alkylation product 3.73: 1H 
NMR  (600 MHz, CDCl3): δ 4.90 (s, 1H), 4.79 (s, 1H), 3.73-3.70 (m, 4H), 3.68 (s, 3H), 3.61 
(m, 1H), 2.76 (m, 2H), 2.56-2.48 (m, 3H), 2.12 (m, 1H), 2.04 (m, 1H), 1.85-1.74 (m, 4H), 1.69 
(s, 3H), 1.63 (m, 1H), 1.59 (m, 2H), 1.18 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 210.0, 209.8, 
171.3, 169.2, 145.0, 110.6, 81.1, 80.9, 66.1, 56.2, 52.5, 52.0, 37.5, 35.5, 32.0, 27.6, 26.4, 18.8, 
17.8, 17.0; HRMS (ESI+) Calcd. For C21H30O7+Na, 417.1889; Found, 417.1879; IR (thin film, 
cm-1) 3403, 3057, 2954, 2872, 1729, 1696, 1455, 1266, 1084, 905; TLC (75:25 
hexanes:EtOAc): Rf = 0.13. 
 
Methyl 10a-hydroxy-6a-methyl-7-oxo-3-(prop-1-en-2-yl)decahydro-1H-
benzo[f]chromene-10b(4aH)-carboxylate (3.75):  A 5 mL dram vial was charged with 
diketone 3.73 (0.015 g, 0.04 mmol, 1.00 equiv) and DMSO (2 mL), and NaCl (0.02 g, 0.38 
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mmol, 10.0 equiv) was added in one portion.  The vial was sealed with a screw-cap, and the 
mixture was warmed to 150 °C and stirred 9 h.  The mixture was cooled to rt, diluted with Et2O 
(2 mL) and transferred to a separatory funnel containing H2O (10 mL).  The aqueous layer was 
extracted with Et2O (3 x 5 mL), and the combined organic extracts were washed with brine (5 
mL), dried with magnesium sulfate, and concentrated in vacuo.  Crude 1H NMR analysis 
revealed a ~1:1 mixture of the diastereomeric decarboxylation product 3.70 and annulation 
product 3.75.  This mixture was purified via flash chromatography (70:30 to 60:40 
hexanes:EtOAc) to afford annulation product 3.75 (0.006 g, 47% yield) as a clear, viscous oil 
and Krapcho adduct 3.70 (0.005 g, 39% yield) as a clear, viscous oil.  Slow evaporation of 3.75 
from acetone and hexanes provided crystals suitable for X-ray crystallographic analysis.  
(Note: when this reaction was conducted on 0.07 g, scale, only the Krapcho adduct 3.70 was 
isolated in 43% yield. No cyclization product 3.75 was detected on this scale.) Analytical data: 
decarboxylation product 3.70:  1H NMR  (600 MHz, CDCl3): δ 4.94 (s, 2H), 4.82-4.81 (m, 
2H), 3.73-3.70 (m, 2H), 3.68-6.67 (m, 3H), 3.47-3.41 (m, 2H), 2.80-2.69 (m, 4H), 2.60-2.54 
(m, 4H), 2.24 (m, 1H), 2.14-2.12 (m, 2H), 2.07-1.98 (m, 5H), 1.85-1.77 (m, 3H), 1.74-1.73 (m, 
5H), 1.51-1.39 (m, 5H), 1.21 (s, 3H), 1.18 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 210.3, 
210.1, 210.0, 209.9, 174.3, 172.8, 145.8, 145.5, 110.6, 110.2, 81.5, 80.0, 78.0, 77.3, 66.1, 65.5, 
51.7, 51.3, 46.7, 37.8, 37.7, 37.5, 34.0, 33.5, 29.7, 29.1, 28.9, 28.8, 27.7, 26.2, 25.7, 19.0, 18.8, 
18.3, 17.9, 17.7, 16.4; HRMS (ESI+) Calcd. For C19H28O5+Na, 359.1834; Found, 359.1825; 
IR (thin film, cm-1) 3446, 2917, 2849, 1731, 1652, 1540, 1456, 1200, 901; TLC (75:25 
hexanes:EtOAc): Rf = 0.17.  Annulation product 3.75: 1H NMR  (600 MHz, CDCl3): δ 4.91 
(s, 1H), 4.78 (s, 1H), 3.86 (d, J = 12.0 Hz, 1H), 3.66 (dd, J = 7.8, 4.8 Hz, 1H), 3.59 (s, 3H), 
2.47 (m, 2H), 2.31 (m, 2H), 2.16 (dd, J = 10.8, 6.0 Hz, 1H), 2.10-2.00 (m, 3H), 1.77 (m, 2H), 
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1.68 (s, 3H), 1.62 (m, 1H), 1.52 (br s, 1H), 1.45 (m, 1H), 1.35 (m, 1H), 1.18 (s, 3H); 13C NMR 
(150 MHz, CDCl3): δ 210.0, 172.5, 145.7, 110.9, 82.0, 80.0, 78.2, 53.5, 53.2, 50.5, 34.1, 29.1, 
28.1, 27.5, 26.9, 25.9, 25.4, 18.4, 18.1; HRMS (ESI+) Calcd. For C19H28O5+Na, 359.1834; 
Found, 359.1825; IR (thin film, cm-1) 3446, 3055, 2950, 1718, 1456, 1339, 1265, 1073, 899; 
TLC (75:25 hexanes:EtOAc): Rf = 0.07. 
 
2-methyl-3-((4-methylpent-3-en-1-yl)oxy)cyclohex-2-en-1-one (3.80): A flame-dried, 25 
mL round bottomed flask was charged with 2-methyl-1,3-cyclohexanedione 3.72 (1.00 g, 7.93 
mmol, 100 equiv) and DMF (8 mL) under an atmosphere of N2.  The mixture was cooled to 0 
°C and NaH (60% dispersion in oil, 0.39 g, 10.3 mmol, 1.30 equiv) was added portionwise.  
The mixture was warmed to rt and stirred 10 min whereupon the iodide 3.79 (2.16 g, 10.3 
mmol, 1.30 equiv) was added.  The mixture was allowed to stir 12 h, and the reaction mixture 
was poured into a separatory funnel containing H2O (20 mL).  CH2Cl2 (20 mL) was added, and 
the aqueous layer was extracted with CH2Cl2 (3 x 10 mL).  The combined organic extracts 
were washed with brine (20 mL), dried with magnesium sulfate, and concentrated in vacuo.  
The products were purified via flash chromatography (90:10 to 80:20 to 60:40 hexanes:EtOAc) 
to afford cycloalkanedione 3.77 (0.12 g, 7% yield) as a yellow oil and vinyl ether 3.80 (0.43 
g, 26% yield) as a clear, viscous oil.  Analytical data: O-alkylation product 3.80: 1H NMR  
(600 MHz, CDCl3): δ 5.11 (m, 1H), 3.93 (t, J = 6.6 Hz, 2H), 2.51 (m, 2H), 2.36 (q, J = 7.2 Hz, 
2H), 2.30 (t, J = 6.6 Hz, 2H), 1.93 (m, 2H), 1.68 (s, 3H), 1.66 (t, J = 1.2 Hz, 3H), 1.61 (s, 3H); 
13C NMR (150 MHz, CDCl3): δ 198.8, 171.4, 134.8, 118.9, 115.0, 67.4, 36.2, 28.7, 25.7, 25.4, 
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20.9, 17.7, 7.29; HRMS (ESI+) Calcd. For C13H20O2+Na, 231.1361; Found, 231.1354; IR 
(thin film, cm-1) 3446, 2926, 1732, 1646, 1472, 1376, 1238, 1096; TLC (70:30 
hexanes:EtOAc): Rf = 0.26. C-alkylation product 3.77: 1H NMR  (600 MHz, CDCl3): δ 4.99 
(br s, 1H), 2.70 (m, 2H), 2.60 (m, 2H), 2.01 (m, 1H), 1.86-1.80 (m, 5H), 1.64 (s, 3H), 1.55 (s, 
3H), 1.23 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 210.3, 132.9, 122.9, 65.6, 37.9, 37.5, 25.6, 
23.3, 18.9, 17.7, 17.6; HRMS (ESI+) Calcd. For C13H20O2+H, 209.1542; Found, 209.1537; IR 
(thin film, cm-1) 3400, 2967, 2929, 1725, 1695, 1602, 1451, 1280, 1169, 1026; TLC (80:20 
hexanes:EtOAc): Rf = 0.40. 
 
(E)-3-(2,2-dimethylhydrazono)-2-methylcyclohexan-1-one (3.81): A 250 mL round 
bottomed flask was charged with 2-methyl-1,3-cyclohexanedione 3.72 (12.0 g, 95.1 mmol, 
1.00 equiv), C6H6 (150 mL), H2NNMe2 (8.70 mL, 114.2 mmol, 1.20 equiv), and TsOH (0.50 
g, 2.63 mmol, 0.03 equiv).  A Dean-Stark apparatus was connected to the flask, and the mixture 
was heated to 100 °C with vigorous stirring for 6 h.   The mixture was cooled to rt and 
concentrated on a rotary evaporator.  The crude residue was then recrystallized from C7H8 to 
afford ketohydrazone 3.81 (16.00 g, 99% yield) as a yellow powder.  Analytical data for this 
compound matched that reported in the literature.32 1H NMR  (600 MHz, CDCl3): δ 5.05 (br 
s, 1H), 2.64 (m, 2H), 2.53 (s, 6H), 2.32 (t, J = 7.2 Hz, 2H), 1.90 (m, 2H), 1.66 (s, 3H). 
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2-methyl-2-(4-methylpent-3-en-1-yl)cyclohexane-1,3-dione(3.77): A flame-dried, 500-mL 
round-bottomed flask was charged with THF (250 mL) under an atmosphere of N2.  KH (10.40 
g, 30% dispersion in oil, 78.50 mmol, 1.20 equiv) was washed free of oil three times with 
petroleum ether, suspended in THF (20 mL) and added to the flask with stirring.  The reaction 
mixture was cooled to -78 ºC, and a solution of ketohydrazone 3.72 (11.00 g, 65.42 mmol, 1.00 
equiv) in THF (25 mL) was slowly added.  The reaction was warmed to 0 ºC and allowed to 
stir 4.5 h.  The resulting dark-brown mixture was re-cooled to -78 ºC, and iodide 3.79 (17.3 g, 
78.50 mmol, 1.20 equiv) was added.  The reaction mixture was allowed to stir while slowly 
warming to rt overnight, producing a cream-white suspension.  The reaction was then quenched 
with saturated NH4Cl(aq.) (50 mL), and the resulting mixture was partitioned in a separatory 
funnel.  The aqueous layer was extracted with Et2O (3 x 50 mL), and the combined organic 
extracts were washed with brine (40 mL), dried with magnesium sulfate, and concentrated in 
vacuo to give the intermediate alkylation product, which was used in the next step without 
further purification. 
Cu(OAc)2•H2O (26.00 g, 130.9 mmol, 2.00 equiv) was dissolved in H2O (300 mL) in a 1000-
mL round-bottomed flask with vigorous stirring.  The crude hydrazone was then dissolved in 
THF (300 mL) and added to the Cu(OAc)2•H2O solution, and the reaction mixture was allowed 
to stir until TLC analysis confirmed complete conversion of the starting material, typically 12 
h.  The resulting mixture was concentrated on a rotary evaporator to remove the THF, and the 
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solution was then diluted with saturated NH4Cl(aq.) (100 mL) and CH2Cl2 (100 mL).  This 
mixture was transferred to a separatory funnel and extracted with CH2Cl2 (3 x 50 mL).  The 
combined organic extracts were washed with brine (2 x 50 mL), dried with magnesium sulfate, 
and concentrated in vacuo.  The product was purified via flash chromatography (90:10 to 80:20 
hexanes:EtOAc) to afford diketone 3.77 (10.34 g, 76% yield) as an orange, viscous oil.  
General procedure A for the regioselective alkylation of hydrazone 3.72: 
 
(E)-3-(2,2-dimethylhydrazono)-2-methyl-2-octylcyclohexan-1-one (S8a): KH (30% 
dispersion in oil, 0.20 g, 1.50 mmol, 1.50 equiv) was washed free of oil with petroleum ether 
and suspended in anhydrous THF (3.0 mL).  The suspension was transferred to a flame-dried, 
10 mL round bottomed flask under an atmosphere of N2, and the suspension was cooled to -78 
°C.   Hydrazone 3.81 (0.25 g, 1.50 mmol, 1.50 equiv) was dissolved in THF (1.0 mL) and 
added dropwise to the KH suspension.  The resulting solution was warmed to 0 °C and stirred 
4.5 h.  The reaction was re-cooled to -78 °C, and 1-iodooctane (0.18 mL, 1.00 mmol, 1.00 
equiv) was added dropwise.  The mixture was allowed to stir overnight, allowing the reaction 
to slowly warm to rt as the dry ice bath evaporated.  After 14 h, the reaction was quenched via 
addition of saturated NH4Cl(aq.) (4.0 mL), and the mixture was partitioned in a separatory 
funnel.  The organic layer was separated, and the aqueous layer was extracted with ether (3 x 
10 mL).  The combined organic extracts were washed with brine (10 mL), dried with 
magnesium sulfate and concentrated in vacuo. The product was purified via flash 
chromatography (80:20 to 70:30 hexanes:EtOAc) to afford the product ketohydrazone S8a 
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(0.25 g, 91% yield) as a yellow oil. Analytical data: 1H NMR  (600 MHz, CDCl3): δ 3.07 (dt, 
J = 5.4, 4.2 Hz, 1H),  2.51 (m, 1H), 2.41 (m, 8H), 1.88 (m, 1H), 1.66 (m, 3H), 1.24-1.16 (m, 
14H), 1.08 (m, 2H), 0.82 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 212.8, 169.6, 
57.7, 47.2, 38.9, 38.3, 31.7, 29.9, 29.2, 29.1, 24.7, 24.1, 22.5, 20.5, 20.1, 14.0; HRMS (ESI+) 
Calcd. For C17H32N2O+H, 281.2593; Found, 281.2588; IR (thin film, cm
-1) 3411, 2925, 2855, 
2713, 1714, 1645, 1620, 1466, 971; TLC (80:20 hexanes:EtOAc): Rf = 0.36. 
 
(E)-2-decyl-3-(2,2-dimethylhydrazono)-2-methylcyclohexan-1-one (S8b): Isolated via 
general procedure A (0.26 g, 84% yield). Analytical data: 1H NMR  (600 MHz, CDCl3): δ 3.07 
(dt, J = 5.4, 3.6 Hz, 1H), 2.50 (m, 1H), 2.45 (m, 1H), 2.40 (br s, 7H), 1.89 (m, 1H), 1.68 (m, 
3H), 1.24-1.17 (m, 18H), 1.09 (m, 2H), 0.83 (t, J = 6.6  Hz, 3H); 13C NMR (150 MHz, CDCl3): 
δ 212.8, 169.6, 57.7, 47.2, 38.9, 38.3, 31.8, 29.9, 29.5, 29.4, 29.3, 29.2, 24.7, 24.1, 22.6, 20.5, 
20.1, 14.0; HRMS (ESI+) Calcd. For C19H36N2O+H, 309.2906; Found, 309.2901; IR (thin 
film, cm-1) 3411, 2925, 2854, 2773, 1713, 1645, 1618, 1466, 972; TLC (80:20 
hexanes:EtOAc): Rf = 0.52. 
 
(E)-3-(2,2-dimethylhydrazono)-2-dodecyl-2-methylcyclohexan-1-one (S8c): Isolated via 
general procedure A (0.32 g, 94% yield).  Analytical data:1H NMR  (600 MHz, CDCl3): δ 3.08 
(dt, J = 5.4, 3.6 Hz, 1H), 2.52 (m, 1H), 2.44 (m, 1H), 2.40 (br s, 7H), 1.89 (m, 1H), 1.68 (m, 
3H), 1.21-1.19 (m, 22H), 1.09 (m, 2H), 0.84 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): 
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δ 212.8, 169.6, 57.7, 47.2, 38.9, 38.3, 31.8, 29.9, 29.6, 29.5, 29.4, 29.3, 29.2, 24.7, 24.1, 22.6, 
20.6, 20.1, 14.0; HRMS (ESI+) Calcd. For C21H40N2O+H, 337.3219; Found, 337.3218; IR 
(thin film, cm-1) 3437, 3054, 2927, 2855, 2776, 1707, 1466, 1265, 895; TLC (70:30 
hexanes:EtOAc): Rf = 0.46. 
 
(E)-3-(2,2-dimethylhydrazono)-2-methyl-2-(4-methylpent-3-en-1-yl)cyclohexan-1-one 
(S8d): Isolated via general procedure A (0.20 g, 79%).  Analytical data: 1H NMR  (600 MHz, 
CDCl3): δ 5.03 (br s, 1H), 3.06 (m, 1H), 2.53 (m, 2H), 2.43 (br s, 7H), 1.91-1.70 (m, 6H), 1.64 
(br s, 3H), 1.55 (br s, 3H), 1.24 (br s, 3H); 13C NMR (150 MHz, CDCl3): δ 212.7, 169.3, 132.0, 
123.7, 57.6, 47.3, 38.6, 38.4, 25.6, 24.7, 23.1, 21.1, 20.1, 17.5; HRMS (ESI+) Calcd. For 
C15H26N2O+H, 251.2123; Found, 251.2120; IR (thin film, cm
-1) 3401, 2953, 2857, 1711, 1618, 
1455, 1375, 1288, 971; TLC (80:20 hexanes:EtOAc): Rf = 0.43. 
 
(E)-3-(2,2-dimethylhydrazono)-2-methyl-2-(4-methylpent-4-en-1-yl)cyclohexan-1-one 
(S8e): Isolated via general procedure A (0.24 g, 94% yield).  Analytical data: 1H NMR (600 
MHz, CDCl3): δ 4.62 (s, 1H), 4.57 (s, 1H), 3.00 (dt, J = 5.4, 3.6 Hz, 1H), 2.47 (m, 2H), 2.41-
2.38 (m, 7H), 1.90 (t, J = 7.8 Hz, 3H), 1.85 (m, 1H), 1.66 (m, 3H), 1.60 (s, 3H), 1.27 (m, 1H), 
1.21-1.16 (m, 4H); 13C NMR (150 MHz, CDCl3): δ 212.6, 169.3, 145.1, 110.1, 57.5, 47.2, 
38.3, 37.9, 37.8, 24.7, 22.1, 22.0, 21.6, 20.0; HRMS (ESI+) Calcd. For C15H26N2O+H, 
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251.2123; Found, 251.2119; IR (thin film, cm-1) 3420, 3073, 2951, 2857, 2773, 1714, 1648, 
1455, 972; TLC (70:30 hexanes:EtOAc): Rf = 0.45. 
 
(E)-2-(4-((tert-butyldimethylsilyl)oxy)butyl)-3-(2,2-dimethylhydrazono)-2-
methylcyclohexan-1-one (S8f): Isolated via general procedure A (0.31 g, 91% yield).  
Analytical data: 1H NMR  (600 MHz, CDCl3): δ 3.53 (t, J = 6.6 Hz, 1H), 3.06 (dt, J = 5.4, 4.2 
Hz, 1H), 2.49 (m, 2H), 2.40 (br s, 7H), 1.88 (m, 1H), 1.73-1.66 (m, 3H), 1.42 (m, 2H), 1.20 
(br s, 4H), 1.13 (m, 1H), 0.84 (s, 9H), -0.01 (s, 6H); 13C NMR (150 MHz, CDCl3): δ 212.8, 
169.4, 62.8, 57.7, 47.2, 38.6, 38.3, 33.1, 25.9, 24.7, 20.8, 20.7, 20.1, 18.2, -5.4; HRMS (ESI+) 
Calcd. For C19H38N2O2Si+H, 355.2781; Found, 355.2777; IR (thin film, cm
-1) 3421, 2952, 
2896, 2773, 1771, 1713, 1621, 1470, 1255; TLC (70:30 hexanes:EtOAc): Rf = 0.44. 
 
(E)-3-(2,2-dimethylhydrazono)-2-isopropyl-2-methylcyclohexan-1-one (S8g): Isolated via 
general procedure A (0.15 g, 71% yield).  Analytical data: 1H NMR  (600 MHz, CDCl3): δ 
3.42 (m, 1H), 2.63 (m, 1H), 2.38 (br s, 7H), 2.31 (m, 1H), 2.13 (m, 1H), 1.99 (m, 1H), 1.50 (m, 
1H), 1.02 (s, 3H), 0.76 (d, J = 7.2 Hz, 3H), 0.74 (d, J = 6.6 Hz, 3H);13C NMR (150 MHz, 
CDCl3): δ 212.6, 169.3, 145.1, 110.1, 57.5, 47.2, 38.3, 37.9, 37.8, 24.7, 22.1, 22.0, 21.2, 20.0; 
HRMS (ESI+) Calcd. For C12H22N2O+H, 211.1810; Found, 211.1806; IR (thin film, cm
-1) 
3902, 2966, 2856, 2773, 1710, 1619, 1466, 1437, 971; TLC (80:20 hexanes:EtOAc): Rf = 0.28. 
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(E)-2-butyl-3-(2,2-dimethylhydrazono)-2-methylcyclohexan-1-one (S8h): Isolated via 
general procedure A (0.24 g, 71% yield).  Analytical data: 1H NMR  (600 MHz, CDCl3): δ 
3.07 (dt, J = 4.8, 3.6 Hz, 1H), 2.50 (m, 1H), 2.44 (m, 1H), 2.39 (br s, 7H), 1.88 (m, 1H), 1.69-
1.65 (m, 3H), 1.22-1.17 (m, 5H), 1.07 (m, 2H), 0.81 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, 
CDCl3): δ 212.8, 169.5, 57.7, 47.2, 38.6, 38.3, 26.3, 24.7, 23.0, 20.5, 20.1, 13.8; HRMS (ESI+) 
Calcd. For C13H24N2O+H, 225.1967; Found, 225.1962; IR (thin film, cm
-1) 3400, 2955, 2859, 
2773, 1714, 1646, 1456, 972, 737; TLC (80:20 hexanes:EtOAc): Rf = 0.68. 
 
ethyl (E)-2-(2-(2,2-dimethylhydrazono)-1-methyl-6-oxocyclohexyl)acetate (S8i): Isolated 
via general procedure A (0.24 g, 96% yield).  Analytical data: 1H NMR  (600 MHz, CDCl3): 
δ 4.02 (m, 2H), 3.19 (dt, J = 5.4, 4.2 Hz, 1H), 3.09 (dd, J = 16.8, 11.4 Hz, 2H), 2.58 (m, 2H), 
2.43 (m, 1H), 2.37 (s, 6H), 1.93 (m, 2H), 1.22 (s, 3H), 1.20 (t, J = 6.6 Hz, 3H);13C NMR (150 
MHz, CDCl3): δ 212.1, 172.1, 169.6, 60.2, 53.9, 47.0, 41.2, 38.3, 26.4, 25.1, 18.9, 14.2; HRMS 
(ESI+) Calcd. For C13H22N2O3+H, 255.1709; Found, 255.1708; IR (thin film, cm
-1) 3437, 
2980, 2953, 1731, 1715, 1624, 1466, 1340, 1192; TLC (60:40 hexanes:EtOAc): Rf = 0.43. 
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(E)-3-(2,2-dimethylhydrazono)-2-(2-(3,3-dimethyloxiran-2-yl)ethyl)-2-methylcyclohexan 
-1-one (S8j): Isolated via general procedure A (0.18 g, 67% yield).  Analytical data: 1H NMR  
(600 MHz, CDCl3): δ 2.92 (m, 1H), 2.67 (m, 2H), 2.50 (m, 2H), 2.43 (s, 3H), 2.00 (m, 1H), 
1.86-1.77 (m, 3H), 1.48-1.36 (m, 2H), 1.29 (s, 3H), 1.26 (s, 3H), 1.23 (s, 3H); 13C NMR (150 
MHz, CDCl3): δ 212.5, 168.9, 64.1, 58.5, 57.1, 47.3, 38.5, 34.0, 24.9, 24.3, 22.9, 22.8, 19.9, 
19.8, 18.6; HRMS (ESI+) Calcd. For C15H26N2O2+H, 267.2073; Found, 267.2073; IR (thin 
film, cm-1) 3448, 2963, 2860, 1708, 1625, 1377, 1125, 917, 735; TLC (60:40 hexanes:EtOAc): 
Rf = 0.38. 
General procedure B for hydrazone hydrolysis (Method 1): 
 
2-methyl-2-octylcyclohexane-1,3-dione (3.82a):  A 10 mL round bottomed flask was charged 
with Cu(OAc)2•H2O (0.20 g, 1.00 mmol, 2.00 equiv) and H2O (3.3 mL), and the solution was 
allowed to stir until complete dissolution of Cu(OAc)2•H2O was observed, typically 2 min.  
The Ketohydrazone S8a (0.14 g, 0.50 mmol, 1.00 equiv) was dissolved in THF (3.3 mL) and 
added to the Cu(OAc)2•H2O solution.  The resulting reaction mixture was allowed to stir until 
complete conversion of the starting material was observed by TLC analysis, typically 12 h.  
The reaction mixture was concentrated on a rotary evaporator to remove THF, and the 
remaining solution was quenched with saturated NH4Cl(aq.) (5 mL) and diluted with CH2Cl2 (5 
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mL).  The mixture was partitioned in a separatory funnel, the organic layer was separated, and 
the aqueous layer was extracted with CH2Cl2 (3 x 10 mL).  The combined organic extracts 
were dried with sodium sulfate and concentrated in vacuo.  The product was purified via flash 
chromatography (90:10 to 80:20 hexanes:EtOAc) to afford diketone 3.82a (0.12 g, 99% yield) 
as a yellow oil. Analytical data: 1H NMR  (600 MHz, CDCl3): δ 2.69 (m, 2H), 2.58 (m, 2H), 
2.01 (m, 1H), 1.82 (m, 1H), 1.74 (m, 2H), 1.25 (m, 2H), 1.21-1.19 (m, 11H), 1.09 (m, 2H), 
0.85 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 210.4, 65.8, 37.9, 37.8, 31.7, 29.8, 
29.2, 29.1, 24.6, 22.6, 18.5, 17.7, 14.0; HRMS (ESI+) Calcd. For C15H26O2+Na, 261.1831; 
Found, 261.1829; IR (thin film, cm-1) 3403, 3056, 2925, 2855, 1726, 1697, 1458, 1132,1024; 
TLC (60:40 hexanes:EtOAc): Rf = 0.67. 
 
2-decyl-2-methylcyclohexane-1,3-dione (3.82b): Isolated via general procedure B (method 
1) (0.11 g, 83% yield). Analytical data: 1H NMR  (600 MHz, CDCl3): δ 2.71 (m, 2H), 2.59 
(m, 2H), 2.03 (m, 1H), 1.84 (m, 1H), 1.76 (m, 2H), 1.27 (m, 2H), 1.22-1.21 (m, 15H), 1.01 (m, 
2H), 0.87 (t, J =  6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 210.5, 65.8, 37.9, 31.9, 29.9, 
29.5, 29.4, 29.3, 24.6, 22.7, 18.5, 17.7, 14.1; HRMS (ESI+) Calcd. For C17H30O2+Na, 
289.2144; Found, 289.2144; IR (thin film, cm-1) 3404, 2124, 2853, 1726, 1697, 1458, 1426, 
1132, 1024; TLC (60:40 hexanes:EtOAc): Rf = 0.70. 
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2-dodecyl-2-methylcyclohexane-1,3-dione (3.82c): Isolated via general procedure B (method 
1) (0.123 g, 84% yield).  Analytical data: 1H NMR  (600 MHz, CDCl3): δ 2.70 (m, 2H), 2.57 
(m, 2H), 2.02 (m, 1H), 1.82 (m, 1H), 1.74 (m, 2H), 1.23-1.19 (m, 21H), 1.09 (m, 2H), 1.86 (m, 
3H); 13C NMR (150 MHz, CDCl3): δ 210.4, 65.8, 37.9, 31.9, 29.8, 29.6, 29.5, 29.4, 29.3, 29.2, 
24.6, 22.6, 18.5, 17.7, 14.1; HRMS (ESI+) Calcd. For C19H34O2+Na, 317.2457; Found, 
317.2460; IR (thin film, cm-1) 3405, 2923, 2853, 1726, 1697, 1457, 1024, 909, 721; TLC 
(60:40 hexanes:EtOAc): Rf = 0.71. 
 
2-methyl-2-(4-methylpent-4-en-1-yl)cyclohexane-1,3-dione (3.82d): Isolated via general 
procedure B (method 1) (0.08 g, 83% yield).  Analytical data: 1H NMR  (600 MHz, CDCl3): 
δ 4.68 (s, 1H), 4.61 (s, 1H), 2.68 (m, 2H), 2.59 (m, 2H), 2.00 (m, 1H), 1.95 (t, J = 7.8 Hz, 2H), 
1.84 (m, 1H), 1.73 (m, 2H), 1.65 (s, 3H), 1.24 (m, 2H), 1.21 (s, 3H); 13C NMR (150 MHz, 
CDCl3): δ 210.3, 144.7, 110.5, 65.6, 37.9, 37.6, 36.9, 22.3, 22.1, 18.9, 17.7; HRMS (ESI+) 
Calcd. For C13H20O2+Na, 231.1361; Found, 231.1361; IR (thin film, cm
-1) 3403, 2938, 1725, 
1696, 1648, 1456, 1025, 735, 628; TLC (60:40 hexanes:EtOAc): Rf = 0.63. 
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2-(4-((tert-butyldimethylsilyl)oxy)butyl)-2-methylcyclohexane-1,3-dione (3.82e): Isolated 
via general procedure B (method 1) (0.13 g, 81% yield).  Analytical data: 1H NMR  (600 MHz, 
CDCl3): δ 3.54 (t, J = 6.6 Hz, 2H), 2.69 (m, 2H), 2.57 (m, 2H), 2.00 (m, 1H), 0.85 (m, 1H), 
1.77 (m, 2H), 1.44 (m, 2H), 1.19 (s, 3H), 1.15 (m, 2H), 085 (s, 9H), 0.00 (s, 6H); 13C NMR 
(150 MHz, CDCl3): δ 210.3, 65.8, 62.5, 37.9, 37.5, 32.8, 25.9, 21.1, 18.5, 17.7, -5.4; HRMS 
(ESI+) Calcd. For C17H32O3Si+Na, 335.2018; Found, 335.2021; IR (thin film, cm
-1) 3404, 
2953, 2857, 1726, 1697, 1472, 1255, 1099, 835; TLC (60:40 hexanes:EtOAc): Rf = 0.63. 
General procedure B for hydrazone hydrolysis (Method 2): 
 
2-isopropyl-2-methylcyclohexane-1,3-dione (3.82g): A 20 mL scintillation vial was charged 
with acetone (2.0 mL), and Oxone® (1.20 g, 2.00 mmol, 4.00 equiv) with magnetic stirring.  
Ketohydrazone S8g (0.11 g, 0.50 mmol, 1.00 equiv) was dissolved in acetone (0.7 mL) and 
transferred to the Oxone® solution at rt, producing a white suspension.  The resulting mixture 
was stirred 2 h, whereupon the solution was concentrated on a rotary evaporator to remove the 
acetone.  The remaining solution was diluted with H2O (5 mL), and transferred to a separatory 
funnel.  The aqueous layer was extracted with EtOAc (2 x 7 mL) and CH2Cl2 (2 x 7 mL), and 
the combined organic extracts were dried with magnesium sulfate and concentrated in vacuo.  
The product was purified via flash chromatography (90:10 to 80:20 hexanes:EtOAc) to afford 
diketone 3.82g (0.051 g, 65% yield) as a yellow oil.  Analytical data: 1H NMR  (600 MHz, 
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CDCl3): δ 2.81 (m, 2H), 2.54 (m, 1H), 2.47 (m, 1H), 2.09 (m, 1H), 1.64 (m, 1H), 1.04 (s, 3H), 
0.82 (d, J = 6.6 Hz, H); 13C NMR (150 MHz, CDCl3): δ 209.6, 71.7, 37.5, 34.6, 18.2, 17.1, 
8.99; HRMS (APCI-) Calcd. For C10H16O2-H, 167.1072; Found, 167.1081; IR (thin film, cm
-
1) 3400, 3057, 2951, 2877, 1721, 1692, 1497, 1428, 1267; TLC (60:40 hexanes:EtOAc): Rf = 
0.50. 
 
2-butyl-2-methylcyclohexane-1,3-dione (3.82h): Isolated via general procedure B (method 
1) (0.072 g, 79% yield).  Analytical data: 1H NMR  (600 MHz, CDCl3): δ 2.71 (m, 2H), 2.59 
(m, 2H), 2.03 (m, 1H), 1.84 (m, 1H), 1.77 (m, 2H), 1.25 (m, 2H), 1.21 (s, 3H), 1.10 (m, 2H), 
0.86 (t, J = 7.8 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 210.5, 65.8, 38.0, 37.6, 26.8, 23.0, 
18.6, 17.7, 13.8; HRMS (ESI+) Calcd. For C11H18O+Na, 205.1204; Found, 205.1200; IR (thin 
film, cm-1) 3401, 2958, 2872, 1725, 1697, 1457, 1132, 1068, 1024; TLC (60:40 
hexanes:EtOAc): Rf = 0.53. 
 
ethyl 2-(1-methyl-2,6-dioxocyclohexyl)acetate (3.82i): Isolated via general procedure B 
(method 2) (0.085 g, 80% yield). Analytical data: 1H NMR  (600 MHz, CDCl3): δ 4.01 (q, J = 
7.2 Hz, 2H), 3.00 (s, 2H), 2.71-2.67 (m, 4H), 2.08 (m, 2H), 1.23 (s, 3H), 1.18 (t, J = 7.2 Hz, 
3H); 13C NMR (150 MHz, CDCl3): δ 210.3, 171.9, 60.9, 60.7, 39.3, 37.6, 23.4, 17.3, 14.0; 
HRMS (ESI+) Calcd. For C11H16O4+Na, 235.0946; Found, 235.0946; IR (thin film,  cm
-1) 
3446, 2917, 2849, 2253, 1771, 1731, 1636, 907, 732; TLC (60:40 hexanes:EtOAc): Rf = 0.37. 
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2-(2-(3,3-dimethyloxiran-2-yl)ethyl)-2-methylcyclohexane-1,3-dione (3.82j): Isolated via 
general procedure B (method 1) (0.09 g, 79% yield).  Analytical data: 1H NMR  (600 MHz, 
CDCl3): δ 2.71-2.63 (m, 5H), 2.06 (m, 1H), 1.99 (m, 1H), 1.92 (m, 1H), 1.84 (m, 1H), 1.40 (m, 
1H), 1.32 (m, 1H), 1.28 (s, 3H), 1.26 (s, 3H), 1.22 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 
210.1, 64.9, 63.7, 58.6, 37.9, 37.8, 32.9, 24.8, 24.5, 20.7, 18.6, 17.6; HRMS (ESI+) Calcd. For 
C13H20O3+Na, 247.1310; Found, 247.1311; IR (thin film, cm
-1) 3503, 2964, 2929, 1725, 1696, 
1487, 1377, 1127, 1025; TLC (60:40 hexanes:EtOAc): Rf = 0.33. 
 
3-hydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)cyclohexan-1-one (3.83): A 20 mL 
scintillation vial was charged with diketone 3.77 (0.1 g, 0.48 mmol, 1.00 equiv) and MeOH 
(10 mL), and the solution was cooled to 0 °C.  NaBH4 (0.005 g, 0.12 mmol, 0.25 equiv) was 
added, and the mixture was allowed to stir at this temperature until complete consumption of 
the starting material was observed by TLC analysis, typically 10 min.  The reaction was diluted 
with brine (5 mL) and CH2Cl2 (5 mL), and the mixture was transferred to a separatory funnel.  
The aqueous layer was extracted with CH2Cl2 (3 x 5 mL), and the combined organic extracts 
were dried with sodium sulfate and concentrated in vacuo to give the crude alcohol as a 19.4:1 
mixture of diastereomers.  The diastereomeric ratio was determined by 1H NMR spectroscopic 
analysis of the crude reaction mixture by comparison of the integration of the resonances at δ 
1.14 (major diastereomer) and δ 1.09 (minor diastereomer).  The product was purified via flash 
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chromatography (80:20 to 70:30 hexanes:EtOAc) to afford hydroxyketone 3.83 (0.093 g, 93% 
yield) as a clear, viscous oil. Analytical data: 1H NMR  (600 MHz, CDCl3): δ 5.05 (t, J = 6.0 
Hz, 1H), 3.65 (d, J = 7.8 Hz, 1H), 2.39 (m, 1H), 2.32 (m, 1H), 1.99-1.88 (m, 5H), 1.73 (m, 
1H), 1.66-1.63 (m, 4H), 1.55 (br s, 4H), 1.15 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 214.1, 
132.1, 123.9, 77.5, 54.7, 37.6, 31.5, 28.7, 25.6, 21.9, 20.7, 18.7, 17.6; HRMS (ESI+) Calcd. 
For C13H22O2+Na, 233.1518; Found, 233.1510; IR (thin film, cm
-1) 3420, 2939, 2871, 1698, 
1455, 1375, 1161, 1059, 993, 831; TLC (70:30 hexanes:EtOAc): Rf = 0.32. 
 
Crude 1H NMR Spectrum of 3.83 
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(2R,3S)-3-hydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)cyclohexan-1-one(3.78): A 1000-
mL round-bottomed flask was charged with H2O (320 mL), and YSC-2 (77 g, purchased from 
Sigma Aldrich) was added portion-wise with vigorous stirring.  Diketone 3.77 (2.00 g, 9.60 
mmol, 1.00 equiv) was dissolved in DMSO (32 mL) and added to the YSC-2 suspension, and 
the mixture was warmed to 30 ºC and vigorously stirred for 24 h.  The reaction mixture was 
then cooled to rt, diluted with Et2O (50 mL), and celite (10 g) was added.  The stirring was 
stopped, and the mixture was allowed to let stand at rt for 12 h.  The resulting mixture was 
then filtered through a pad of celite in a Buchner funnel.  Once the filter cake was dry, the 
celite pad was then washed with Et2O (100 mL), CH2Cl2 (100 mL), acetone (100 mL), Et2O 
(100 mL), and EtOAc (100 mL), ensuring that the filter cake was loosened with a spatula 
between each wash.  The filtrate was transferred to a separatory funnel, and the organic layer 
was separated.  The aqueous layer was extracted with EtOAc (50 mL), and the combined 
organic extracts were dried with sodium sulfate and concentrated in vacuo, giving crude 
alcohol 3.78 as a 10:1 mixture of diasteromers.  The diastereomeric ratio was determined by 
1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the integration 
of the resonances at δ 1.15 (minor diastereomer) and δ 1.10 (major diastereomer).  The product 
was purified via flash chromatography (80:20 to 70:30 hexanes:EtOAc) to afford alcohol 3.78 
(1.32 g, 67% yield) as a yellow, viscous oil.  (Note:  for purposes of material throughput, the 
crude residue may be stored indefinitely with no deleterious effects to yield.  In practice, up to 
8 iterations of this procedure were carried out, and the crude residues were combined and 
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purified simultaneously). The enantioselectivity (>99:1) was determined via 19F NMR analysis 
of the resulting Mosher ester S9 (vide infra). Analytical data: [α]D28 –74.7 (c = 0.30, CHCl3); 
1H NMR  (600 MHz, CDCl3): δ 5.04 (m, 1H), 3.89 (dd, J = 3.0, 2.4 Hz, 1H), 2.41 (m, 1H), 
2.31 (m, 1H), 2.08 (m, 1H), 2.02 (m, 1H), 1.93 (m, 1H), 1.87-1.79 (m, 4H), 1.65 (br s, 4H), 
1.56 (s, 3H), 1.53 (m, 1H), 1.10 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 214.4, 132.2, 123.7, 
76.3, 54.3, 37.8, 36.2, 28.1, 25.6, 22.6, 20.7, 17.6, 17.3; HRMS (ESI+) Calcd. For 
C13H22O2+Na, 233.1518; Found, 233.1514; IR (thin film, cm
-1) 3434, 3054, 2985, 2305, 1703, 
1630, 1442, 1265, 738; TLC (80:20 hexanes:EtOAc): Rf = 0.23. 
 
Crude 1H NMR spectrum of 3.78. 
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(1S,2R)-2-methyl-2-(4-methylpent-3-en-1-yl)-3-oxocyclohexyl(R)-3,3,3-trifluoro-2-
methoxy-2-phenylpropanoate (S9):  A flame-dried, 20 mL scintillation vial was charged with 
(R)-(+)-α-methoxy-α-trifluoromethylphenylacetic acid (0.45 g, 1.90 mmol, 2.00 equiv) and 
CH2Cl2 (8 mL) with magnetic stirring at rt under an atmosphere of N2.  DCC (0.39 g, 1.90 
mmol, 2.00 equiv) was added followed by DMAP (0.01 g, 0.10 mmol, 0.10 equiv) and lastly 
a 10:1 diastereomeric mixture of alcohol 3.78 (0.20 g, 0.95 mmol, 1.00 equiv) in CH2Cl2 (2 
mL).  The reaction mixture was allowed to stir at rt until complete conversion of the starting 
material was observed by TLC analysis, typically 12 h.  The resulting mixture was filtered 
through cotton and concentrated in vacuo.  The product was purified via flash chromatography 
(95:5 to 90:10 hexanes:EtOAc) to provide Mosher ester S9 (0.40 g, 99% yield) as an 
inseparable 10:1 mixture of diastereomers (as determined by integration of the resonances at 
dd 5.33 (major diastereomer) and dd 5.06 (minor diastereomer)).  19F NMR analysis revealed 
only a 10:1 mixture of diastereomers at     δ -71.1 ppm (minor diastereomer) and δ -71.2 ppm 
(major diastereomer).  Analytical data: [α]D28 +22.6 (c = 0.50, CHCl3); 1H NMR  (600 MHz, 
CDCl3): δ 7.50 (m, 2H), 7.39 (m, 3H), 5.33 (dd, J = 3.0, 3.0 Hz, 1H), 3.50 (s, 3H), 2.45 (m, 
1H), 2.35 (m, 1H), 2.22 (m, 1H), 1.96-1.74 (m, 5H), 1.66 (s, 3H), 1.57 (s, 3H), 1.54 (m, 2H), 
0.96 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 211.5, 165.8, 132.5, 131.9, 129.6, 128.4, 127.2, 
123.2, 80.3, 55.3, 52.6, 37.4, 35.9, 25.6, 25.5, 22.4, 20.4, 17.8, 17.6; HRMS (ESI+) Calcd. For 
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C23H29F3O4+Na, 449.1916; Found, 449.1923; IR (thin film, cm
-1) 3423, 2949, 2855, 1746, 
1713, 1451, 1270, 1168, 1019, 807, 721; TLC (80:20 hexanes:EtOAc): Rf = 0.51. 
19F NMR spectrum of S9. 
 
 
(2R,3S)-2-(2-(3,3-dimethyloxiran-2-yl)ethyl)-3-hydroxy-2-methylcyclohexan-1-one 
(3.84): A 20 mL scintillation vial was charged with hydroxyketone 3.78 (0.10 g, 0.48 mmol, 
1.00 equiv) and CH2Cl2 (5 mL), and the mixture was cooled to 0 °C.  m-CPBA (70% dispersion 
in H2O, 0.19 g, 0.76 mmol, 1.60 equiv) was added in one portion, and the mixture was stirred 
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until complete consumption of the starting material was observed by TLC analysis, typically 
20 minutes.  The reaction was quenched via saturated Na2S2O3 (5 mL), and the mixture was 
transferred to a separatory funnel.  The aqueous layer was extracted with CH2Cl2 (3 x 5 mL), 
and the combined organic extracts were dried with sodium sulfate and concentrated in vacuo 
to give the crude epoxide as a 2:1 mixture of diastereomers. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of 
the integration of the resonances at δ 1.13 (major diastereomer) and δ 1.12 (minor 
diastereomer).  The product was purified via flash chromatography (60:40 to 50:50 to 40:60 
hexanes:EtOAc) to afford epoxide 3.84 (0.10 g, 93% yield) as a clear oil in an inseparable 
mixture of diastereomers.  Analytical data: [α]D25 +1.9 (c = 1.25, CHCl3); 1H NMR  (600 MHz, 
CDCl3): δ 3.83 (dd, J = 4.2, 3.0 Hz, 1H), 2.68 (m, 1H), 2.33 (m, 2H), 2.01 (m, 2H), 1.84-1.54 
(m, 5H), 1.48-1.40 (m, 1H), 1.27 (m, 3H), 1.23 (m, 3H), 1.09 (m, 3H); 13C NMR (150 MHz, 
CDCl3): δ 214.2, 214.1, 75.6, 74.4, 64.7, 64.3, 59.1, 58.7, 54.3, 54.0, 37.6, 37.5, 32.0, 31.7, 
28.4, 28.3, 24.8, 23.6, 23.5, 20.4, 20.3, 18.6, 18.5, 18.0, 17.1; HRMS (ESI+) Calcd. For 
C13H22O3+Na, 249.1467; Found, 249.1459; IR (thin film, cm
-1) 3446, 3054, 2982, 2874, 1732, 
1702, 1497, 1422, 1266, 1156, 1016, 895; TLC (80:20 hexanes:EtOAc): Rf = 0.07. 
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Crude 1H NMR spectrum of 3.84 
 
 
(4aR,8aS)-2-(2-hydroxypropan-2-yl)-4a-methyloctahydro-5H-chromen-5-one (3.85) and 
(4aR,5S)-2-(2-hydroxypropan-2-yl)-4a-methyloctahydro-2H-chromen-5-ol (3.86): A 20 
mL scintillation vial was charged with keto-epoxide 3.84 (0.05 g, 0.22 mmol, 1.00 equiv) and 
CH2Cl2 (2 mL), and PPTS (0.01 g, 0.04 mmol, 0.20 equiv) was added.  The mixture was 
allowed to stir at rt until TLC analysis indicated complete consumption of the starting material, 
typically 30 min.  The reaction mixture was diluted with saturated NaHCO3(aq.) (5 mL) and 
transferred to a separatory funnel.  The aqueous layer was extracted with CH2Cl2 (3 x 5 mL), 
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and the combined organic extracts were dried with sodium sulfate and concentrated in vacuo.  
Crude 1H NMR analysis revealed an inseparable ~1:5 mixture of diastereomeric 
tetrahydropyrans 3.85 and diastereomeric vinyl ethers 3.86.  The crude 1H NMR spectrum and 
mass spectral data are included below: HRMS (ESI+) Calcd. For +Na, 249.1467; Found, 
249.1459. 
Crude 1H NMR spectrum of 3.85 and 3.86 
 
 
 
 3.86 
 
3.85 
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N'-((2S,3S,E)-3-hydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)cyclohexylidene)-4-
methylbenzenesulfonohydrazide(3.87): The alcohol 3.78 (8.20 g, 38.99 mmol, 1.00 equiv) 
was dissolved in wet C7H8 (195 mL) in a 500-mL round-bottomed flask, and p-
toluenesulfonylhydrazine (8.71 g, 46.79 mmol, 1.20 equiv) was added with magnetic stirring.  
The mixture was placed in a preheated oil bath at 70 ºC and allowed to stir for 50 min.  (Note: 
product decomposition was observed if the reaction was allowed to stir for longer than this 
time period).  The resulting mixture was cooled to rt and concentrated on a rotary evaporator.  
The product was purified via flash chromatography (70:30 to 60:40 to 50:50 hexanes:EtOAc) 
to provide the hydrazone 3.87 (14.75 g, >99% yield) as a pale yellow, viscous foam. Analytical 
data: [α]D28 –144.6 (c = 0.50, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.82 (d, J = 8.4 Hz, 
2H), 7.64 (br s, 1H), 7.28 (d, J = 7.8 Hz, 2H), 4.93 (t, J = 6.6 Hz, 1H), 3.63 (dd, J = 3.0, 2.4 
Hz, 1H), 2.39 (s, 3H), 2.35 (m, 1H), 2.00 (m, 1H), 1.90 (m, 1H), 1.75-1.66 (m, 3H), 1.64 (s, 
3H), 1.57-1.49 (m, 2H), 1.46 (s, 3H), 1.37 (m, 2H), 1.04 (s, 3H); 13C NMR (150 MHz, CDCl3): 
δ 163.3, 143.9, 135.1, 131.5, 129.3, 128.2, 124.1, 75.4, 47.6, 36.5, 25.6, 22.0, 21.5, 19.8, 19.1, 
17.5; HRMS (ESI+) Calcd. For C20H30N2O3S+Na, 401.1875; Found, 401.1892; IR (thin film, 
cm-1) 3516, 3212, 2933, 2872, 1914, 1725, 1598, 1447, 1329, 1185, 1165, 1091, 736; TLC 
(80:20 hexanes:EtOAc): Rf = 0.17. 
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N'-((2S,4aS,8aS,E)-2-(2-hydroxypropan-2-yl)-4a-methyloctahydro-5H-chromen-5-
ylidene)-4-methylbenzenesulfonohydrazide(3.88): Hydrazone 3.87 (14.76 g, 38.99 mmol, 
1.00 equiv) was dissolved in CH2Cl2 (320 mL) in a 1000-mL round-bottomed flask with 
stirring.  The mixture was cooled to 0 ºC, and m-CPBA (14.42 g, 70% dispersion in H2O, 58.49 
mmol, 1.50 equiv) was added.  The reaction was allowed to stir at this temperature until TLC 
analysis showed full conversion of the starting material, typically 10 min.  The reaction was 
quenched via addition of saturated Na2S2O3(aq.) (70 mL), and the mixture was partitioned in a 
separatory funnel.  The mixture was extracted with CH2Cl2 (3 x 50 mL), and the combined 
organic extracts were washed with brine (50 mL), dried with magnesium sulfate, and 
concentrated to a volume of ~300 mL on a rotary evaporator.  A stir bar was added followed 
by PPTS (0.98 g, 3.90 mmol, 0.10 equiv), and the mixture was allowed to stir 12 h at rt.  The 
reaction mixture was then concentrated in vacuo to give the crude tetrahydropyran 3.88 as a 
single diastereomer (as determined by 1H NMR spectroscopic analysis of the crude reaction 
mixture, which revealed a single stereoisomer).  The product was purified via flash 
chromatography (60:40 to 50:50 to 40:60 hexanes:EtOAc) to afford pyran 3.88 (11.63 g, 76% 
yield) as a pale yellow, viscous foam. Analytical data: [α]D28 –63.2 (c = 0.40, CHCl3); 1H NMR  
(600 MHz, CDCl3): δ 7.82 (d, J = 7.8 Hz, 2H), 7.73 (br s, 1H), 7.30 (d, J = 7.8 Hz, 2H), 3.11 
(t, J = 3.6 Hz, 1H), 3.09 (t, J = 2.4 Hz, 1H), 2.52 (dd, J = 12.0, 3.0 Hz, 1H), 2.45-2.40 (m, 4H), 
1.94 (m, 1H), 1.82 (m, 2H), 1.67 (m, 2H), 1.59-1.50 (m, 3H), 1.33-1.26 (m, 2H), 1.15 (s, 3H), 
1.14 (s, 3H), 0.96 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 164.5, 143.9, 135.1, 129.3, 128.1, 
309 
 
84.5, 82.0, 71.8, 42.4, 32.1, 26.3, 21.6, 17.2; HRMS (ESI+) Calcd. For C20H30N2O4S+Na, 
417.1824; Found, 417.1840; IR (thin film, cm-1) 3451, 3216, 2946, 2870, 1630, 1598, 1450, 
1333, 1166, 1089, 925; TLC (80:20 hexanes:EtOAc): Rf = 0.11. 
 
Crude 1H NMR spectrum of 3.88. 
 
 
N'-((2S,3S,E)-3-hydroxy-2-methyl-2-(4-methylpentyl)cyclohexylidene)-4-
methylbenzenesulfonohydrazide (3.89): A 20-mL scintillation vial was charged with alkene 
3.87 (0.05 g, 0.13 mmol, 1.00 equiv) and MeOH (4 mL).  Pd/C (0.025 g, 0.50 mass equiv) was 
added, and the resulting suspension was placed under 1 atm H2 (balloon) and allowed to stir 1 
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h whereupon TLC analysis indicated complete consumption of the starting material.  The 
suspension was filtered through a pad of celite and concentrated on a rotary evaporator to 
afford hydrazone 3.89 (0.05 g, >99% crude yield) as a single diastereomer (as determined by 
1H NMR analysis of the crude mixture, which revealed a single stereoisomer).  When this 
material was subjected to the reaction conditions used in the conversion of 3.87 to 3.88, no 
reaction was observed, and the starting material was recovered quantitatively. Analytical data: 
[α]D28  51.9 (c = 1.25, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.83 (d, J = 8.2 Hz, 2H), 7.65 
(br s, 1H), 7.28 (d, J = 7.8 Hz, 2H), 3.63 (dd, J = 3.0, 1.8 Hz, 1H), 2.40 (s, 3H), 2.36 (m, 1H), 
1.93 (m, 2H), 1.79-1.64 (m, 3H), 1.56 (m, 1H), 1.46 (m, 1H), 1.34 (m, 1H), 1.27 (m, 1H), 1.02 
(s, 3H), 1.00-0.98 (m, 3H), 0.77 (d, J = 6.6 Hz, 3H), 0.76 (d, J = 6.6 Hz, 3H); 13C NMR (150 
MHz, CDCl3): δ 163.5, 143.8, 135.2, 129.3, 128.2, 75.6, 47.6, 39.5, 36.8, 27.7, 27.6, 22.6, 
22.5, 21.5, 21.1, 19.7, 19.2; HRMS (ESI+) Calcd. For C20H32N2O3S+Na, 403.2031; Found, 
403.2022; IR (thin film, cm-1) 3503. 3214, 2951, 2868, 1670, 1470, 1329, 1165, 1092, 1001, 
924; TLC (80:20hexanes:EtOAc): Rf = 0.07. 
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Crude 1H NMR Spectrum of 3.89 
 
 
N'-((2S,4aS,8aS,E)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a-methyloctahydro-
5H-chromen-5-ylidene)-4-methylbenzenesulfonohydrazide(3.92): A flame-dried, 150-mL 
round-bottomed flask was charged with pyran 3.88 (9.41 g, 23.88 mmol, 1.00 equiv) and 
CH2Cl2 (120 mL) under an atmosphere of N2.  The reaction mixture was cooled to -50 ºC 
(CO2(s)/acetonitrile bath), and 2,6-lutidine (5.50 mL, 47.46 mmol, 2.00 equiv) and TBSOTf 
(9.87 mL, 42.99 mmol, 1.8 equiv) were added sequentially.  The reaction was allowed to stir 
at this temperature until TLC analysis confirmed complete consumption of the starting 
material, typically 30 min.  The reaction was quenched via addition of saturated NaHCO3(aq.) 
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(40 mL), and the mixture was warmed to rt and partitioned in a separatory funnel.  The aqueous 
layer was extracted with EtOAc (3 x 30 mL), and the combined organic extracts were washed 
with brine (40 mL), dried with magnesium sulfate, and concentrated in vacuo.  The product 
was purified via flash chromatography (100:0 to 95:5 to 90:10 to 80:20 hexanes:EtOAc) to 
remove silanol byproducts then purified a second time (90:10 to 80:20 hexanes:EtOAc) to 
afford silyl ether 3.92 (9.46 g, 79% yield) as a pale yellow, viscous foam. Analytical data: 
[α]D28 –75.5 (c = 0.35, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.84 (d, J = 8.4 Hz, 2H), 7.57 
(br s, 1H), 7.31 (d, J = 7.8 Hz, 2H), 3.04 (dd, J = 7.8, 3.6 Hz, 1H), 2.99 (d, J = 11.4 Hz, 1H), 
2.50 (d, J = 14.4 Hz, 1H), 2.43 (s, 3H), 1.93 (m, 1H), 1.83-1.76 (m, 2H), 1.68-1.50 (m, 6H), 
1.19 (s, 3H), 1.15 (s, 3H), 0.95 (s, 3H), 0.84 (s, 9H), 0.07 (s, 3H), 0.04 (s, 3H); 13C NMR (150 
MHz, CDCl3): δ 165.0, 143.8, 135.2, 129.3, 128.1, 85.3, 82.0, 76.8, 74.7, 42.5, 32.4, 27.2, 
25.1, 21.6, 21.3, 17.3, -2.1, -2.2; HRMS (ESI+) Calcd. For C26H44N2O4SSi+Na, 531.2689; 
Found, 531.2704; IR (thin film, cm-1) 3433, 3054, 2985, 2855, 2305, 1630, 1422, 1167, 1092, 
835, 739; TLC (80:20 hexanes:EtOAc): Rf = 0.37. 
 
(2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a-methyl-3,4,4a,7,8,8a-
hexahydro-2H-chromene-5-carbaldehyde (3.93): A flame-dried, 100 mL round bottomed 
flask was charged with hydrazone 3.92 (2.00 g, 3.93 mmol, 1.00 equiv) and THF (39 mL) 
under an atmosphere of N2.  The mixture was cooled to -50 °C, and 
nBuLi (1.64 M in hexane, 
12.0 mL, 19.7 mmol, 5.00 equiv) was added dropwise, producing a dark orange color.  The 
mixture was allowed to stir 30 min at -50 °C.  The flask was fitted with a venting needle, and 
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the mixture was warmed to 0 °C and stirred 5 min, then warmed to rt and stirred until complete 
consumption of the starting material was observed by TLC analysis, typically 20 min (scale 
dependent).  The venting needle was removed, and DMF (3.02 mL, 39.3 mmol, 10.0 equiv) 
was added.  Following this addition, the reaction was stirred 20 min, diluted with H2O (20 mL) 
and Et2O (20 mL) and transferred to a separatory funnel. The organic layer was separated, and 
the aqueous layer was extracted with Et2O (3 x 20 mL).  The combined organic extracts were 
washed with brine (20 mL), dried with magnesium sulfate, and concentrated in vacuo.  The 
product was purified via flash chromatography (100:0 to 95:5 to 90:10 hexanes:EtOAc) to 
afford unsaturated aldehyde 3.93 (0.92 g, 66% yield) as a yellow, viscous oil. Analytical data: 
[α]D28  -138.0 (c = 0.55, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 9.38 (s, 1H), 6.55 (t, J = 3.0 
Hz, 1H), 3.22 (dd, J = 8.4, 3.6 Hz, 1H), 3.15 (dd, J = 9.0, 3.0 Hz, 1H), 2.70 (m, 1H), 2.46 (m, 
2H), 1.68 (m, 2H), 1.57 (m, 2H), 1.28 (m ,1H), 1.23 (s, 3H), 1.18 (s, 3H), 1.14 (s, 3H), 0.84 (s, 
9H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 193.8, 151.0, 148.3, 85.9, 
80.9, 74.9, 35.4, 32.6, 27.2, 26.4, 25.8, 25.1, 23.2, 21.3, 17.9, -2.2; HRMS (ESI+) Calcd. For 
C20H36O3Si+Na, 375.2331; Found, 375.2323; IR (thin film, cm
-1) 3435, 2955, 2855, 1692, 
1635, 1472, 1376, 1251, 1173, 1042; TLC (90:10 hexanes:EtOAc): Rf = 0.49. 
 
tert-butyldimethyl((2-((2S,4aS,8aS)-4a-methyl-5-vinyl-3,4,4a,7,8,8a-hexahydro-2H-
chromen-2-yl)propan-2-yl)oxy)silane (3.94): A flame-dried, 100 mL round bottomed flask 
was charged with methyltriphenylphosphonium bromide (4.90 g, 13.7 mmol, 6.00 equiv) and 
THF (20 mL) under an atmosphere of N2.  The mixture was cooled to 0 °C and 
nBuLi (1.65 M 
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in hexanes, 7.63 mL, 12.6 mmol, 5.50 equiv) was added dropwise.  The deep yellow mixture 
was allowed to stir 1 h at 0 °C upon which the aldehyde 3.93 (0.81 g, 2.29 mmol, 1.00 equiv) 
was added as a solution in THF (3 mL).  The reaction was allowed to stir until complete 
consumption of the starting material was observed by TLC analysis, typically 15 min.  The 
reaction was diluted with H2O (15 mL) and transferred to a separatory funnel.  The layers were 
separated, and the aqueous layer was extracted with Et2O (3 x 15 mL). The combined organic 
extracts were washed with brine (15 mL), dried with magnesium sulfate, and concentrated in 
vacuo.  The product was purified via flash chromatography (100:0 to 99:1 to 97.5:2.5 
hexanes:EtOAc) to afford diene 3.94 (0.69 g, 86% yield) as a clear oil. Analytical data: [α]D28 
-167.4 (c = 0.35, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 6.24 (dd, J = 10.8, 6.0 Hz, 1H), 5.61 
(t, J = 3.6 Hz, 1H), 5.26 (d, J = 17.4 Hz, 1H), 4.93 (d, J = 10.8 Hz, 1H), 3.23 (dd, J = 5.4, 4.8 
Hz, 1H), 3.12 (m, 1H), 2.20 (m, 1H), 1.93 (dt, J = 6.0, 3.0 Hz, 1H), 1.66 (m, 2H), 1.60 (m, 
2H), 1.35 (m, 1H), 1.24 (s, 3H), 1.18 (s, 3H), 1.07 (s, 3H), 0.85 (s, 9H), 0.09 (s, 3H), 0.06 (s, 
3H); 13C NMR (150 MHz, CDCl3): δ 144.5, 135.4, 121.6, 113.5, 85.5, 81.5, 74.9, 36.1, 34.3, 
27.4, 25.9, 25.0, 23.8, 21.8, 18.9, 18.2, -2.1, -2.2; HRMS (ESI+) Calcd. For C21H38O2Si+Na, 
373.2539; Found, 373.2529; IR (thin film, cm-1) 3053, 2985, 2956, 2854, 2685, 1716, 1636, 
1456, 1265, 1143; TLC (90:10 hexanes:EtOAc): Rf = 0.91. 
 
tert-butyldimethyl((2-((3S,4aS,10bS)-10b-methyl-7-nitro-2,3,4a,5,6,6a,7,8,9,10b-
decahydro-1H-benzo[f]chromen-3-yl)propan-2-yl)oxy)silane (3.95): A 20 mL scintillation 
vial was charged with diene 3.94 (0.66 g, 1.88 mmol, 1.00 equiv) and CH2Cl2 (9 mL).  
315 
 
Nitroethylene (10 M solution in CH2Cl2, 0.75 mL, 7.50 mmol, 4.00 equiv) was added, and the 
vial was sealed with a screw-cap.  The mixture was heated to 65 °C and stirred until complete 
conversion of the starting material was observed by TLC analysis, typically 12 h.  The mixture 
was cooled to rt and concentrated on a rotary evaporator.  The product was purified via flash 
chromatography (100:0 to 97.5:2.5 to 95:5 to 90:10 hexanes:EtOAc) to afford alkene 3.95 
(0.75 g, 95% yield) as a clear, viscous oil in an inseparable mixture of diastereomers.  
Analytical data: [α]D28 -4.7 (c = 0.75, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 5.51 (br s, 1H), 
5.45 (d, J = 4.8 Hz, 1H), 4.79-4.66 (m, 1H), 4.32-4.20 (m, 1H), 3.45 (dd, J = 7.8, 3.0 Hz, 1H), 
3.06-3.01 (m, 4H), 2.96-2.87 (m, 3H), 2.27-1.89 (m, 13H), 1.76-1.72 (m, 3H), 1.66-1.37 (m, 
17H), 1.25 (m, 2H), 1.21-1.19 (m, 8H), 1.17-1.15 (m, 3H), 1.05-1.03 (m, 8H), 0.84 (br s, 25H), 
0.07 (s, 8H), 0.05 (s, 8H); 13C NMR (150 MHz, CDCl3): δ 144.8, 143.9, 143.2, 118.4, 117.9, 
117.7, 90.6, 89.8, 85.6, 85.4, 85.1, 84.9, 83.4, 82.2, 74.8, 39.6, 37.5, 36.8, 36.4, 36.1, 34.4, 
28.0 27.3, 27.1, 27.0, 25.5, 25.2, 25.0, 24.4, 24.0, 23.0, 22.7, 21.9, 21.8, 21.6, 21.5, 18.1, 17.0, 
-2.2; HRMS (ESI+) Calcd. For C23H41NO4Si+Na, 446.2703; Found, 446.2692; IR (thin film, 
cm-1) 3054, 2954, 2930, 2855, 1732, 1670, 1546, 1488, 1362, 1265, 1167, 1046; TLC (90:10 
hexanes:EtOAc): Rf = 0.66. 
 
(3S,4aS,10bS)-3-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-10b-methyl-
1,2,3,4a,5,6,8,9,10,10b-decahydro-7H-benzo[f]chromen-7-one (3.96): A 100 mL round 
bottomed flask was charged with alkene 3.95 (0.753 g, 1.78 mmol, 1.00 equiv) and a 1:1 
mixture of THF:MeOH (35 mL).  The solution was cooled to 0 °C, and KOH (1 M in H2O, 
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5.34 mL, 5.34 mmol, 3.00 equiv) was added dropwise, subsequently warming to rt.  The 
mixture was stirred until complete conversion of the starting material was observed by TLC 
analysis, typically 45 min.  The mixture was cooled to 0 °C, and MsOH was added drop-by-
drop until the reaction pH reached <1 (scale dependent, ~2 mL was required in this iteration), 
resulting in the formation of a white suspension.  The resulting mixture was warmed to rt and 
stirred vigorously for 1 h whereupon the mixture was neutralized with saturated NaHCO3(aq.) 
(20 mL).  The mixture was transferred to a separatory funnel, the layers were separated, and 
the aqueous layer was extracted with Et2O (3 x 15 mL).  The combined organic extracts were 
washed with brine (15 mL), dried with magnesium sulfate, and concentrated in vacuo to give 
the crude non-conjugated enone, which was used in the next step without further purification. 
The crude ketone was transferred to a flame-dried, 50 mL round bottomed flask and dissolved 
in CH2Cl2 (18 mL) under an atmosphere of N2.  DBU (0.52 mL, 3.60 mmol, 2.00 equiv) was 
added, and the mixture was allowed to stir at rt until complete conversion of the starting 
material was observed by TLC analysis, typically 3 h.  The reaction was diluted with H2O (15 
mL) and transferred to a separatory funnel.  The organic layer was separated, and the aqueous 
layer was extracted with CH2Cl2 (3 x 10 mL).  The combined organic extracts were dried with 
sodium sulfate and concentrated in vacuo.  The product was purified via flash chromatography 
(100:0 to 97.5:2.5 to 95:5 to 90:10 hexanes:EtOAc) to afford conjugated enone 3.96 (0.38 g, 
54% yield) as a yellow solid.  Analytical data: mp: 85-89 °C; [α]D28 -118.8 (c = 0.85, CHCl3); 
1H NMR  (600 MHz, CDCl3): δ 3.19 (dd, J = 9.6, 3.0 Hz, 1H), 3.08 (dd, J = 4.2, 4.2 Hz, 1H), 
2.44 (m, 2H), 2.34-2.20 (m, 4H), 2.01 (m, 1H), 1.93 (dt, J = 6.0, 3.0 Hz, 1H), 1.84 (m, 1H), 
1.76 (m, 1H), 1.65-1.59 (m, 3H), 1.40 (m, 1H), 1.24 (s, 3H), 1.19 (s, 3H), 1.10 (s, 3H), 0.84 (s, 
9H), 0.09 (s, 3H), 0.06 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 199.8, 162.7, 129.8, 85.1, 
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80.4, 74.8, 38.0, 37.7, 33.3, 27.5, 25.8, 25.2, 24.9, 23.3, 22.9, 22.4, 21.4, 18.1, 18.0, -2.1, -2.2; 
HRMS (ESI+) Calcd. For C23H40O3Si+Na, 415.2644; Found, 415.2636; IR (thin film, cm
-1) 
3053, 2954, 2887, 2855, 1683, 1616, 1576, 1472, 1362, 1265, 1172, 1045; TLC (90:10 
hexanes:EtOAc): Rf = 0.34. 
 
(3S,4aS,6aR,10aS,10bS)-3-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-6a,10b-
dimethyldodecahydro-7H-benzo[f]chromen-7-one (3.97): An oven-dried, 50 mL two-neck 
round bottomed flask was fitted with a stir bar and an oven-dried cold finger condenser and 
placed under an atmosphere of Ar.  The flask and condenser were cooled to -78 °C, and liq. 
NH3 (5 mL) was allowed to condense into the flask.  Freshly cut Li
0 (0.01 g, 1.43 mmol, 14.3 
equiv) was washed with hexanes and added to the flask, resulting in the formation of a dark 
blue color.  After stirring 5 min at -78 °C, a solution of ketone 3.96 (0.04 g, 0.10 mmol, 1.00 
equiv) in THF (3 mL) was added, and the reaction was warmed to -33 °C and stirred 15 
minutes.  The reaction was the cooled to -78 °C, diluted with THF (5 mL), and a solution of 
MeI (0.38 mL, 6.0 mmol, 60.0 equiv) in THF (2 mL) was added dropwise.  The mixture was 
allowed to warm to rt and stirred until liq. NH3 had completely evaporated.  The residue was 
quenched with saturated NH4Cl(aq.) (10 mL), diluted with Et2O (10 mL) and transferred to a 
separatory funnel.  The organic layer was separated, and the aqueous layer was extracted with 
Et2O (3 x 10 mL).  The combined organic extracts were dried with magnesium sulfate and 
concentrated in vacuo to give the crude ketone 3.97 as a single diastereomer (as determined by 
1H NMR spectroscopic analysis of the crude reaction mixture, which revealed a single 
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compound).  The product was purified via flash chromatography (100:0 to 98:2 to 95:5 to 90:10 
hexanes:EtOAc) to afford ketone 3.97 (0.025 g, 61% yield) as a clear, viscous oil. Analytical 
data: [α]D28 -38.2 (c = 0.75, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 2.98 (dd, J = 8.4, 3.0 Hz, 
1H), 2.84 (dd, J = 7.8, 3.6 Hz, 1H), 2.64 (m, 1H), 2.44 (dt, J = 7.2, 3.0 Hz, 1H), 2.25 (dd, J = 
10.2, 6.0 Hz, 1H), 2.08 (m, 2H), 1.95-1.87 (m, 3H), 1.52-1.44 (m, 5H), 1.25 (m, 1H), 1.24 (s, 
3H), 1.20 (s, 3H), 1.14 (s, 3H), 1.06 (m, 1H), 0.83 (s, 9H), 0.82 (s, 3H) 0.06 (s, 3H), 0.04 (s, 
3H); 13C NMR (150 MHz, CDCl3): δ 216.0, 84.9, 84.3, 74.8, 54.4, 47.9, 37.9, 37.3, 36.4, 32.6, 
29.9, 27.3, 25.8, 25.1, 25.1, 23.8, 21.5, 19.1, 18.2, 16.0, -2.1, -2.2; HRMS (ESI+) Calcd. For 
C24H44O3Si+Na, 431.2957; Found, 431.2949; IR (thin film, cm
-1) 3421, 2954, 2855, 1792, 
1698, 1377, 1265, 1215, 1058; TLC (90:10 hexanes:EtOAc): Rf = 0.54. 
 
Crude 1H NMR spectrum of 54 
 
319 
 
 
(3S,4aS,6aS,10aR,10bS)-3-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-10b-
methyldodecahydro-7H-benzo[f]chromen-7-one (3.100): An oven-dried, 50 mL two-neck 
round bottomed flask was fitted with a stir bar and an oven-dried cold finger condenser and 
placed under an atmosphere of Ar.  The flask and condenser were cooled to -78 °C, and liq. 
NH3 (5 mL) was allowed to condense into the flask.  Freshly cut Li
0 (0.005 g, 0.714 mmol, 
14.3 equiv) was washed with hexanes and added to the flask, resulting in the formation of a 
dark blue color.  After stirring 5 min at -78 °C, a solution of ketone 3.96 (0.02 g, 0.05 mmol, 
1.00 equiv) in THF (2 mL) was added, and the reaction was warmed to -33 °C and stirred 15 
minutes.  The reaction was carefully quenched via portionwise addition of NH4Cl(s), and the 
mixture was allowed to warm to rt and stirred until liq. NH3 had completely evaporated.  The 
residue was diluted with H2O (10 mL) and Et2O (10 mL) and transferred to a separatory funnel.  
The organic layer was separated, and the aqueous layer was extracted with Et2O (3 x 10 mL).  
The combined organic extracts were dried with magnesium sulfate and concentrated in vacuo 
to afford the crude ketone as a 1:1 mixture of diastereomers (3.99),  which was taken on directly 
to the next step without further purification.  A crude 1H NMR spectrum of this reaction is 
included below. 
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Crude 1H NMR spectrum of initial Birch reduction product 3.99 
 
This crude residue was transferred to a flame-dried 20 mL scintillation vial and dissolved in 
C7H8 under an atmosphere of N2.  DBU (0.01 mL, 0.05 mmol, 1.00 equiv) was added, and the 
mixture was warmed to 65 °C and stirred 12 h.  The reaction was cooled to rt, diluted with H2O 
(10 mL) and CH2Cl2 (5 mL) and transferred to a separatory funnel.  The organic layer was 
separated, and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL).  The combined organic 
extracts were dried with magnesium sulfate and concentrated in vacuo.  At this juncture, crude 
1H NMR analysis revealed complete epimerization to a single diastereomer.  The product was 
purified via flash chromatography (100:0 to 97.5:2.5 to 90:10 hexanes:EtOAc) to afford ketone 
3.100 (0.015 g, 75% yield) as a clear, viscous oil.  Analytical data: [α]D28 -72.0 (c = 0.75, 
CHCl3); 1H NMR  (600 MHz, CDCl3): δ 3.03 (dd, J = 7.2, 3.6 Hz, 1H), 2.87 (dd, J = 7.8, 3.6 
Hz, 1H), 2.36 (m, 1H), 2.26 (m, 2H), 2.10 (m, 1H), 1.91-1.83 (m, 3H), 1.63 (m, 1H), 1.57-1.52 
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(m, 4H), 1.43-1.36 (m, 3H), 1.21 (s, 3H), 1.16 (br s, 4H), 0.91 (s, 3H), 0.84 (s, 9H), 0.07 (s, 
3H), 0.05 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 213.2, 85.1, 83.2, 74.8, 52.3, 49.2, 41.8, 
36.7, 36.6, 27.4, 26.5, 26.2, 25.8, 24.9, 24.3, 23.6, 21.8, 18.1, 12.1, -2.1, -2.2; HRMS (ESI+) 
Calcd. For C23H42O3Si+Na, 417.2801; Found, 417.2793; IR (thin film, cm
-1) 3420, 2951, 2854, 
1715, 1652, 1472, 1376, 1251, 1155, 1051, 835; TLC (90:10 hexanes:EtOAc): Rf = 0.40. 
 
Crude 1H NMR spectrum of 3.100 
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(3S,4aS,6aS,10aR,10bR)-3-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-10b-
methyloctahydro-1H-6a,10a-epoxybenzo[f]chromen-7(8H)-one (3.102):  A 20 mL 
scintillation vial was charged with enone 3.96 (0.10 g, 0.26 mmol, 1.00 equiv) and (CH2Cl)2 
(5 mL).  p-NPBA (0.19 g, 0.89 mmol, 3.50 equiv) was added, and the vial was sealed with a 
screw-cap.  The mixture was warmed to 65 °C and stirred until complete consumption of the 
starting material was observed by TLC analysis, typically 3 h.  The reaction mixture was 
warmed to rt, quenched via saturated Na2S2O3(aq.) (5 mL), and transferred to a separatory 
funnel.  The organic layer was separated, and the aqueous layer was extracted with CH2Cl2 (3 
x 7 mL).  The combined organic extracts were dried with sodium sulfate and concentrated in 
vacuo to afford the crude epoxide as a single diastereomer (as determined by 1H NMR 
spectroscopic analysis of the crude reaction mixture, which revealed a single compound).  The 
product was purified via flash chromatography (100:0 to 97.5:2.5 to 95:5 hexanes:EtOAc) to 
afford keto-epoxide 3.102 (0.05 g, 47% yield) as a clear, viscous oil.  Slow evaporation of 
3.102 from HPLC grade methanol afforded crystals suitable for X-ray crystallographic 
analysis. Analytical data: [α]D28 -105.2 (c = 0.70, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 3.43 
(dd, J = 8.4, 4.2 Hz, 1H), 3.06 (m, 1H), 2.58 (m, 1H), 2.08 (m, 2H), 1.91-1.85 (m, 3H), 1.64 
(m, 3H), 1.55-1.49 (m, 3H), 1.37 (m, 1H), 1.20 (s, 3H), 1.15 (s, 3H), 1.03 (s, 3H), 0.84 (s, 9H), 
0.07 (s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 207.2, 84.8, 75.4, 74.7, 64.3, 36.4, 
36.2, 32.0, 27.4, 25.8, 24.9, 22.3, 21.6, 21.3,18.9, 18.8, 18.1, 15.9, -2.1, -2.2; HRMS (ESI+) 
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Calcd. For C23H40O4Si+Na, 431.2594; Found, 431.2585; IR (thin film, cm
-1) 3420, 2955, 2856, 
1704, 1646, 1488, 1396, 1265, 1173, 1072, 835, 739; TLC (90:10 hexanes:EtOAc): Rf = 0.25. 
 
Crude 1H NMR spectrum of 3.102 
 
 
(3S,4aS,7S,10bS)-3-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-10b-methyl-
2,3,4a,5,6,7,8,9,10,10b-decahydro-1H-benzo[f]chromen-7-ol (3.104): A flame-dried, 20 
mL scintillation vial was charged with ketone 3.96 (0.06 g, 0.15 mmol, 1.0 equiv) and THF (2 
mL) under an atmosphere of N2.  The reaction mixture was cooled to -78 °C, and LiAl(O
tBu)3H 
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(1 M solution in THF, 0.31 mL, 0.31 mmol, 2.00 equiv) was added in one portion.  The reaction 
mixture was allowed to stir for 12 h, slowly warming to rt during this time period at which 
point TLC analysis confirmed complete consumption of the starting material.  The reaction 
was quenched via saturated NH4Cl(aq.) (5 mL) and transferred to a separatory funnel.  The 
organic layer was separated, and the aqueous layer was extracted with Et2O (3 x 7 mL).  The 
combined organic extracts were dried with magnesium sulfate and concentrated in vacuo to 
give the crude alcohol as a 10:1 mixture of diastereomers.  The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of 
the integration of the resonances at δ 3.99 (major diastereomer) and δ 3.82 (minor 
diastereomer).  The product was purified via flash chromatography (90:10 to 80:20 
hexanes:EtOAc) to afford alcohol 3.104 (0.054 g, 90% yield) as a clear, viscous oil. Analytical 
data: [α]D28 -92.7 (c = 1.00, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 3.99 (m, 1H), 3.20 (dd, J 
= 8.4, 3.6 Hz, 1H), 3.08 (dd, J = 7.2, 3.6 Hz, 1H), 2.49 (m, 1H), 1.98 (m, 2H), 1.88 (m, 2H), 
1.82 (m, 1H), 1.71 (m, 2H), 1.65 (m, 2H), 1.57 (m, 2H), 1.52 (m, 2H), 1.29 (m, 1H), 1.23 (s, 
3H), 1.17 (s, 3H), 0.99 (s, 3H), 0.84 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR (150 MHz, 
CDCl3): δ 139.7, 128.2, 85.1, 81.2, 74.9, 70.6, 34.5, 34.0, 32.6, 27.3, 26.8, 25.9, 25.1, 24.0, 
23.8, 21.8, 19.8, 18.4, 18.2, -2.1, -2.2; HRMS (ESI+) Calcd. For C23H42O3Si+Na, 417.2801; 
Found, 417.2791; IR (thin film, cm-1) 3420, 2930, 2855, 1683, 1636, 1507, 1456, 1361, 1264, 
1046, 835; TLC (90:10 hexanes:EtOAc): Rf = 0.25. 
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Crude 1H NMR spectrum of 3.104 
 
 
N'-((2S,4aS,8aS,E)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-
dimethyloctahydro-5H-chromen-5-ylidene)-4-methylbenzenesulfonohydrazide (3.106): 
A flame-dried, 500 mL round bottomed flask was charged with hydrazone 3.92 (6.21 g, 12.2 
mmol, 1.00 equiv) and THF (122 mL) under an atmosphere of N2.  The mixture was cooled to 
-50 °C, and nBuLi (2.60 M in hexanes, 16.4 mL, 42.7 mmol, 3.50 equiv) was added over a 
period of ~2 min, producing a dark orange color.   The reaction mixture was allowed to stir 40 
min whereupon MeI (1.90 mL, 30.5 mmol, 2.50 equiv) was added, resulting in a color change 
326 
 
from orange to yellow.  The reaction was allowed to stir until complete consumption of the 
starting material was observed by TLC analysis, typically 20 min.  The reaction was quenched 
via saturated NH4Cl(aq.) (40 mL) and allowed to warm to rt. The mixture was transferred to a 
separatory funnel, the organic layer was separated, and the aqueous layer was extracted with 
Et2O (3 x 40 mL).  The combined organic extracts were washed with brine (40 mL), dried with 
magnesium sulfate and concentrated in vacuo.  The product was purified via flash 
chromatography (90:10 to 80:20 hexanes:EtOAc) to afford hydrazone 3.106 (6.37 g, 98% 
yield) as a white foam in a 7:1 diastereomeric ratio.  Analytical data: [α]D28 -121.0 (c = 0.60, 
CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.83 (d, J = 7.2 Hz, 2H), 7.72 (br s, 1H), 7.30 (d, J = 
7.8 Hz, 2H), 3.05 (m, 1H), 3.00 (s, 1H), 2.73 (q, J = 7.8 Hz, 1H), 2.43 (s, 3H), 2.01 (d, J = 13.2 
Hz, 1H), 1.69 (m, 1H), 1.57-1.54 (m, 5H), 1.45 (m, 1H), 1.34 (m, 1H), 1.20 (s, 3H), 1.15 (s, 
3H), 1.07 (d, J = 7.2 Hz, 3H), 0.95 (s, 3H), 0.84 (s, 9H), 0.07 (s, 3H), 0.04 (s, 3H); 13C NMR 
(150 MHz, CDCl3): δ 167.1, 143.8, 135.3, 129.3, 128.0, 127.9, 85.2, 82.0, 74.7, 41.9, 33.3, 
28.3, 27.7, 27.2, 25.8, 25.0, 22.8, 21.6, 21.2, 19.1, 18.3, 18.1, -2.1, -2.2; HRMS (ESI+) Calcd. 
For C27H46N2O4SSi+Na, 545.2845; Found, 545.2840; IR (thin film, cm
-1) 3225, 2954, 2855, 
1472, 1396, 1265, 1168, 1090, 1038, 812, 773; TLC (90:10 hexanes:EtOAc): Rf = 0.35. 
 
(2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-3,4,4a,7,8,8a-
hexahydro-2H-chromene-5-carbaldehyde (3.107): A flame-dried, 25 mL round bottomed 
flask was charged with hydrazone 3.106 (0.48 g, 0.92 mmol, 1.00 equiv) and THF (9.5 mL) 
under an atmosphere of N2.  The solution was cooled to -50 °C, and 
nBuLi (1.70 M in hexanes, 
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3.25 mL, 5.52 mmol, 6.00 equiv) was added over a period of ~2 min, producing a dark orange 
color.  The reaction was allowed to stir 30 min whereupon a venting needle was added, and 
the mixture was warmed to 0 °C and stirred 5 min.  The reaction was then warmed to rt and 
stirred until complete consumption of the starting material was observed by TLC analysis, 
typically 20 min. The venting needle was removed, DMF (0.71 mL, 9.2 mmol, 10.0 equiv) was 
added, and the reaction was stirred 20 min.  The mixture was diluted with H2O (15 mL) and 
Et2O (10 mL) and transferred to a separatory funnel.  The organic layer was separated, and the 
aqueous layer was extracted with Et2O (3 x 15 mL).  The combined organic extracts were 
washed with brine (15 mL), dried with magnesium sulfate and concentrated in vacuo.  The 
product was purified via flash chromatography (95:5 to 90:10 hexanes:EtOAc) to afford 
aldehyde 3.107 (0.21 g, 62% yield) as a yellow, viscous oil. Analytical data: [α]D28 -151.8 (c = 
0.80, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 10.05 (br s, 1H), 3.16 (m, 1H), 3.11 (dd, J = 
9.0, 3.0 Hz, 1H), 2.65 (m, 1H), 2.38 (m, 1H), 2.28 (m, 1H), 2.06 (s, 3H), 1.69 (m, 2H), 1.62-
1.53 (m, 3H), 1.22 (s, 3H), 1.17 (s, 3H), 1.14 (s, 3H), 0.84 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H); 
13C NMR (150 MHz, CDCl3): δ 191.9, 153.9, 140.3, 85.8, 80.6, 74.9, 35.7, 34.3, 33.5, 27.1, 
25.8, 25.1, 23.7, 21.6, 18.8, 18.2, 18.1, -2.1, -2.2; HRMS (ESI+) Calcd. For C21H38O3Si+Na, 
389.2488; Found, 389.2481; IR (thin film, cm-1) 2954, 2928, 2855, 1733, 1674, 1472, 1376, 
1251, 1095, 1005, 835; TLC (90:10 hexanes:EtOAc): Rf = 0.50. 
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tert-butyl((2-((2S,4aS,8aS)-4a,6-dimethyl-5-vinyl-3,4,4a,7,8,8a-hexahydro-2H-chromen-
2-yl)propan-2-yl)oxy)dimethylsilane (3.108): A flame-dried, 25 mL round bottomed flask 
was charged with methyltriphenylphosphonium bromide (1.90 g, 5.28 mmol, 8.00 equiv) and 
THF (7 mL) under an atmosphere of N2.  The mixture was cooled to 0 °C and 
nBuLi (1.69 M 
in hexanes, 2.94 mL, 4.95 mmol, 7.50 equiv) was added dropwise.  The deep yellow mixture 
was allowed to stir 1 h at 0 °C upon which the aldehyde 3.107 (0.24 g, 0.66 mmol, 1.00 equiv) 
was added as a solution in THF (2 mL).  The reaction was allowed to stir until complete 
consumption of the starting material was observed by TLC analysis, typically 15 min.  The 
reaction was diluted with H2O (15 mL) and transferred to a separatory funnel.  The layers were 
separated, and the aqueous layer was extracted with Et2O (3 x 15 mL). The combined organic 
extracts were washed with brine (15 mL), dried with magnesium sulfate, and concentrated in 
vacuo.  The product was purified via flash chromatography (100:0 to 99:1 to 97.5:2.5 
hexanes:EtOAc) to afford diene 3.108 (0.20 g, 82% yield) as a clear oil. Analytical data: [α]D28 
-94.4 (c = 1.50, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 6.13 (dd, J = 12.0, 6.0 Hz, 1H), 5.23 
(dd, J = 8.4, 3.0 Hz, 1H), 4.96 (dd, J = 15.6, 2.4 Hz, 1H), 3.19 (dd, J = 7.2, 4.8 Hz, 1H), 3.08 
(dd, J = 6.6, 4.2 Hz, 1H), 2.18 (m, 1H), 2.08 (dd, J = 11.4, 6.6 Hz, 1H), 1.84 (dt, J = 6.0, 4.2 
Hz, 1H), 1.66 (br s, 4H), 1.55 (br s, 3H), 1.28 (m, 1H), 1.23 (s, 3H), 1.17 (s, 3H), 1.02 (s, 3H), 
0.84 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 138.1, 134.3, 127.5, 
118.0, 85.2, 81.4, 75.0, 36.2, 35.2, 31.6, 27.3, 25.9, 25.1, 24.3, 21.8, 20.5, 18.7, 18.2; HRMS 
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(ESI+) Calcd. For C22H40O2Si+Na, 387.2695; Found, 387.2688; IR (thin film, cm
-1) 2954, 
2855, 1717, 1471, 1376, 1253, 1167, 1039, 880, 741; TLC (90:10 hexanes:EtOAc): Rf = 0.93. 
 
((2-((2S,4aS,8aS)-5-((Z)-buta-1,3-dien-1-yl)-4a,6-dimethyl-3,4,4a,7,8,8a-hexahydro-2H-
chromen-2-yl)propan-2-yl)oxy)(tert-butyl)dimethylsilane (3.109): A flame-dried, 20 mL 
scintillation vial was charged with allyltriphenylphosphonium bromide (1.31 g, 3.43 mmol, 
8.00 equiv) and THF (5 mL) under an atmosphere of N2.  The mixture was cooled to 0 °C and 
nBuLi (2.64 M in hexanes, 1.22 mL, 3.21 mmol, 7.50 equiv) was added dropwise.  The deep 
yellow mixture was allowed to stir 1 h at 0 °C whereupon the aldehyde 3.107 (0.16 g, 0.43 
mmol, 1.00 equiv) was added as a solution in THF (2 mL).  The reaction was allowed to stir 
until complete consumption of the starting material was observed by TLC analysis, typically 
12 h.  The reaction was diluted with H2O (15 mL) and transferred to a separatory funnel.  The 
layers were separated, and the aqueous layer was extracted with Et2O (3 x 15 mL). The 
combined organic extracts were washed with brine (15 mL), dried with magnesium sulfate, 
and concentrated in vacuo.  The product was purified via flash chromatography (100:0 to 99:1 
to 97.5:2.5 hexanes:EtOAc) to afford triene 3.109 (0.06 g, 36% yield) as a clear oil. Analytical 
data: [α]D28 -49.8 (c = 1.25, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 6.37 (m, 1H), 6.05 (m, 
2H), 5.15 (d, J = 16.8 Hz, 1H), 5.03 (d, J = 10.2 Hz, 1H), 3.19 (dd, J = 7.2, 4.8 Hz, 1H), 2.20 
(m, 1H), 2.11 (dd, J = 12.6, 5.4 Hz, 1H), 1.88 (dt, J = 6.0, 3.0 Hz, 1H), 1.68 (br s, 5H), 1.56 
(m, 2H), 1.27 (m, 1H), 1.23 (s, 3H), 1.17 (s, 3H), 1.04 (s, 3H), 0.84 (s, 9H), 0.08 (s, 3H), 0.06 
(s, 3H); 13C NMR (150 MHz, CDCl3): δ 137.7, 137.1, 133.9, 130.7, 128.7, 115.4, 85.2, 81.4, 
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74.9, 36.6, 35.3, 31.8, 27.3, 25.8, 25.0, 24.2, 21.8, 20.8, 18.9, 18.2, -2.1, -2.2; HRMS (ESI+) 
Calcd. For C24H42O2Si+Na, 413.2852; Found, 413.2843; IR (thin film, cm
-1) 3420, 2929, 2855, 
1670, 1497, 1457, 1387, 1265, 1165, 1040, 835; TLC (90:10 hexanes:EtOAc): Rf = 0.94. 
 
((2-((2S,4aS,8aS,E)-5-(but-3-en-1-ylidene)-4a-methyl-6-methyleneoctahydro-2H-
chromen-2-yl)propan-2-yl)oxy)(tert-butyl)dimethylsilane (3.111): The triene 3.109 (0.017 
g, 0.043 mmol, 1.00 equiv) was taken up into hexanes and transferred to a toroidal 
photochemical reactor equipped with a water-cooled Pyrex immersion well.  A 450 watt 
Hanovia medium pressure mercury vapor lamp was lowered inside the immersion well, and 
the triene solution was irradiated for 1 h.  The solution was subsequently concentrated in vacuo.  
The product was purified via flash chromatography to give rearrangement product 3.111 (0.009 
g, 53% yield) as a clear, viscous oil. Analytical data: [α]D28 – 11.8 (c = 0.10, CHCl3); 1H NMR 
(600 MHz, CDCl3): δ 5.83 (m, 1H), 5.20 (t, J = 7.8 Hz, 1H), 5.01 (m, 1H), 4.97 (m, 1H), 4.66 
(t, J = 1.8 Hz, 1H), 3.10 (dd, J = 7.8, 4.2 Hz, 1H), 3.05 (m, 1H), 2.90 (m, 2H), 2.33 (m, 1H), 
2.06 (m, 1H), 1.70 (m, 2H), 1.66-1.55 (m, 6H), 1.22 (s, 3H, 1.17 (s, 3H), 0.94 (s, 3H), 0.85 (s, 
9H), 0.08 (s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 148.0, 144.1, 138.3, 119.1, 
114.3, 112.8, 85.2, 82.5, 74.9, 39.8, 34.5, 33.8, 33.2, 28.5, 27.2, 25.8, 25.1, 21.9, 18.2, 17.9, -
2.1, -2.2; HRMS (ESI+) Calcd. For C24H42O2Si+Na, 413.2852; Found, 413.2843; IR (thin 
film, cm-1) 3053, 2956, 2855, 1749, 1670, 1540, 1456, 1265, 1046, 835; TLC (90:10 
hexanes:EtOAc): Rf = 0.97. 
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1-((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-
3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)ethan-1-one (3.112): A flame-dried, 25 mL 
round bottomed flask was charged with hydrazone 3.106 (0.30 g, 0.57 mmol, 1.00 equiv) and 
THF (6 mL) under an atmosphere of N2.  The solution was cooled to -50 °C, and 
nBuLi (2.64 
M in hexanes, 1.30 mL, 3.44 mmol, 6.00 equiv) was added over a period of ~2 min, producing 
a dark orange color.  The reaction was allowed to stir 30 min whereupon a venting needle was 
added, and the mixture was warmed to 0 °C and stirred 5 min.  The reaction was then warmed 
to rt and stirred until complete consumption of the starting material was observed by TLC 
analysis, typically 20 min. The venting needle was removed, the mixture was cooled to -78 °C, 
and acetaldehyde (0.32 mL, 5.74 mmol, 10.0 equiv) was added dropwise.  The reaction was 
allowed to stir 25 min whereupon H2O (5 mL) and Et2O (5 mL) were added, and the mixture 
was warmed to rt and transferred to a separatory funnel.  The organic layer was separated, and 
the aqueous layer was extracted with Et2O (3 x 10 mL).  The combined organic extracts were 
washed with brine (10 mL), dried with magnesium sulfate, and concentrated in vacuo to give 
the crude alcohol, which was taken on to the next step without further purification 
The crude residue was taken up into CH2Cl2 (5 mL) and transferred to a 20 mL scintillation 
vial.  Dess-Martin periodinane (0.29 g, 0.68 mmol, 2.00 equiv) was added to the vial, and the 
mixture was allowed to stir until TLC analysis indicated complete consumption of the starting 
material, typically 15 min.  The mixture was then quenched via a 1:1 solution of saturated 
NaHCO3(aq.) and saturated Na2S2O3(aq.) (5 mL), and the mixture was stirred 5 min.  The reaction 
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mixture was then diluted with Et2O (10 mL) and partitioned in a separatory funnel.  The organic 
layer was separated, and the aqueous layer was extracted with Et2O (3 x 10 mL). The combined 
organic extracts were dried with magnesium sulfate and concentrated in vacuo. The product 
was purified via flash chromatography (100:0 to 97.5:2.5 to 95:5 hexanes:EtOAc) to afford 
ketone 3.112 (0.09 g, 43% yield) as a yellow, viscous oil. Analytical data: [α]D28 -31.6 (c = 
0.50, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 3.21 (dd, J = 6.0, 3.6 Hz, 1H), 3.09 (dd, J = 5.4, 
3.6 Hz, 1H), 2.25 (s, 3H), 2.16 (m, 1H), 2.08 (m, 1H), 1.67 (m, 2H), 1.56-1.54 (m, 6H), 1.44 
(m, 1H), 1.21 (s, 3H), 1.17-1.15 (m, 6H), 0.83 (s, 9H), 0.07 (s, 3H), 0.04 (s, 3H); 13C NMR 
(150 MHz, CDCl3): δ 208.2, 143.5, 128.5, 85.4, 80.4, 74.8, 35.4, 34.4, 33.3, 30.6, 27.3, 25.8, 
25.0, 23.8, 21.3, 20.1, 19.6, 18.1, -2.1, -2.2; HRMS (ESI+) Calcd. For C22H40O3Si+Na, 
403.2644; Found, 403.2636; IR (thin film, cm-1) 2955, 2854, 1829, 1686, 1488, 1361, 1249, 
1095, 835, 739; TLC (90:10 hexanes:EtOAc): Rf = 0.38. 
 
tert-butyl((1-((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-
dimethyl-3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)vinyl)oxy)dimethylsilane (3.113): A 
flame-dried, 20 mL scintillation vial was charged with ketone 3.112 (0.06 g, 0.16 mmol, 1.00 
equiv) and THF (2 mL) under an atmosphere of N2.  The reaction was cooled to 0 °C and NEt3 
(0.07 mL, 0.47 mmol, 3.00 equiv) and TBSOTf (0.075 mL, 0.32 mmol, 2.00 equiv) were added 
sequentially.  The reaction mixture was warmed to rt and stirred until TLC analysis showed 
complete consumption of the starting material, typically 3 h.  The reaction was quenched via 
addition of saturated NaHCO3(aq.) (2 mL) and transferred to a separatory funnel.  The organic 
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layer was separated, and the aqueous layer was extracted with pentane (3 x 5 mL).  The 
combined organic extracts were dried with magnesium sulfate and concentrated in vacuo.  The 
product was purified via flash chromatography (100:0 to 98:2 to 97.5:2.5 hexanes:EtOAc) to 
afford silyloxydiene 3.113 (0.077 g, 99% yield) as a clear, viscous oil. Analytical data: [α]D28 
= 20.8 (c = 0.33, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 4.27 (s, 1H), 3.90 (s, 1H), 3.15 (dd, 
J = 7.2, 4.8 Hz, 1H), 3.08 (dd, J = 7.8, 3.0 Hz, 1H), 2.15 (m, 1H), 2.06 (dd, J = 11.4, 6.6 Hz, 
1H), 1.81 (d, J = 13.2 Hz, 1H), 1.66 (br s, 5H), 1.54 (m, 2H), 1.39 (m, 1H), 1.23 (s, 3H), 1.16 
(s, 3H), 1.07 (s, 3H), 0.92 (s, 9H), 0.84 (s, 9H), 0.20 (s, 3H), 0.17 (s, 3H), 0.08 (s, 3H), 0.05 (s, 
3H); 13C NMR (150 MHz, CDCl3): δ 155.6, 138.9, 128.6, 85.3, 81.1, 75.0, 34.7, 30.5, 27.2, 
25.9, 25.8, 25.7, 25.2, 24.1, 21.9, 20.8, 18.2, 18.1, -2.1, -2.2, -4.5, -4.6; HRMS (ESI+) Calcd. 
For C28H54O3Si2+Na, 517.3509; Found, 517.3499; IR (thin film, cm
-1) 2930, 2896, 1611, 1497, 
1376, 1265, 1165, 1038, 835, 775; TLC (90:10 hexanes:EtOAc): Rf = 0.94. 
 
(E)-1-((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-
3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)but-2-en-1-one (3.114): A flame-dried, 25 mL 
round bottomed flask was charged with hydrazone 3.106 (0.30 g, 0.57 mmol, 1.00 equiv) and 
THF (6 mL) under an atmosphere of N2.  The solution was cooled to -50 °C, and 
nBuLi (2.64 
M in hexanes, 1.30 mL, 3.44 mmol, 6.00 equiv) was added over a period of ~2 min, producing 
a dark orange color.  The reaction was allowed to stir 30 min whereupon a venting needle was 
added, and the mixture was warmed to 0 °C and stirred 5 min.  The reaction was then warmed 
to rt and stirred until complete consumption of the starting material was observed by TLC 
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analysis, typically 20 min.  The venting needle was removed, the mixture was cooled to -78 
°C, and (E)-crotonaldehyde (0.48 mL, 5.74 mmol, 10.0 equiv) was added dropwise.  The 
reaction was allowed to stir 25 min whereupon H2O (5 mL) and Et2O (5 mL) were added, and 
the mixture was warmed to rt and transferred to a separatory funnel.  The organic layer was 
separated, and the aqueous layer was extracted with Et2O (3 x 10 mL).  The combined organic 
extracts were washed with brine (10 mL), dried with magnesium sulfate, and concentrated in 
vacuo to give the crude alcohol, which was taken on to the next step without further purification 
The crude residue was taken up into CH2Cl2 (5 mL) and transferred to a 20 mL scintillation 
vial.  Dess-Martin periodinane (0.29 g, 0.68 mmol, 2.00 equiv) was added to the vial, and the 
mixture was allowed to stir until TLC analysis indicated complete consumption of the starting 
material, typically 15 min.  The mixture was then quenched via a 1:1 solution of saturated 
NaHCO3(aq.) and saturated Na2S2O3(aq.) (5 mL), and the mixture was stirred 5 min.  The reaction 
mixture was then diluted with Et2O (10 mL) and partitioned in a separatory funnel.  The organic 
layer was separated, and the aqueous layer was extracted with Et2O (3 x 10 mL). The combined 
organic extracts were dried with magnesium sulfate and concentrated in vacuo. The product 
was purified via flash chromatography (100:0 to 97.5:2.5 to 95:5 hexanes:EtOAc) to afford 
ketone 3.114 (0.10 g, 46% yield) as a yellow, viscous oil. Analytical data: [α]D28 -72.2 (c = 
0.48, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 6.73 (m, 1H), 6.14 (dd, J = 13.8, 1.8 Hz, 1H), 
3.26 (dd, J = 6.6, 5.4 Hz, 1H), 3.09 (dd, J = 7.8, 1.8 Hz, 1H), 2.21 (m, 1H), 2.11 (dd, J = 11.4, 
6.6 Hz, 1H), 1.93 (dd, J = 5.4, 1.8 Hz, 3H), 1.74-1.70 (m, 2H), 1.51-1.47 (m, 6H), 1.38 (m, 
1H), 1.22 (s, 3H), 1.15 (s, 3H), 1.14 (s, 3H), 0.83 (s, 9H), 0.07 (s, 3H), 0.04 (s, 3H); 13C NMR 
(150 MHz, CDCl3): δ 200.7, 146.4, 140.2, 134.6, 130.2, 85.4, 80.4, 74.9, 35.7, 34.5, 30.5, 27.2, 
25.8, 25.0, 23.9, 21.4, 20.7, 19.7, 18.4, 18.1, -2.1, -2.2; HRMS (ESI+) Calcd. For 
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C24H42O3Si+Na, 429.2801; Found, 429.2792; IR (thin film, cm
-1) 2955, 2855, 1671, 1472, 
1361, 1265, 1165, 1041, 835, 739; TLC (90:10 hexanes:EtOAc): Rf = 0.56. 
 
tert-butyl((2-((2S,4aR,8aS)-5-iodo-4a,6-dimethyl-3,4,4a,7,8,8a-hexahydro-2H-chromen-
2-yl)propan-2-yl)oxy)dimethylsilane (3.116): A flame-dried, 20 mL scintillation vial was 
charged with hydrazone 3.106 (0.30 g, 0.57 mmol, 1.00 equiv) and THF (6 mL) under an 
atmosphere of N2.  The solution was cooled to -50 °C, and 
nBuLi (1.70 M in hexanes, 2.00 mL, 
3.42 mmol, 6.00 equiv) was added over a period of ~2 min, producing a dark orange color.  
The reaction was allowed to stir 30 min whereupon a venting needle was added, and the 
mixture was warmed to 0 °C and stirred 5 min.  The reaction was then warmed to rt and stirred 
until complete consumption of the starting material was observed by TLC analysis, typically 
20 min.  The venting needle was removed, the mixture was cooled to 0 °C, and I2 (0.43 g, 1.71 
mmol, 3.00 equiv) was added portionwise.  The reaction was allowed to stir 20 min whereupon 
H2O (5 mL) and Et2O (5 mL) were added, and the mixture was warmed to rt and transferred to 
a separatory funnel.  The organic layer was separated, and the aqueous layer was extracted 
with Et2O (3 x 10 mL).  The combined organic extracts were washed with brine (10 mL) and 
saturated Na2S2O3(aq.), dried with magnesium sulfate, and concentrated in vacuo.  The product 
was purified via flash chromatography (100:0 to 99:1 to 98:2) to afford iodide 3.116 (0.18 g, 
67% yield) containing 17% of the inseparable vinyl C-H compound (arising from protic 
quenching of the transient vinyllithium) by 1H NMR analysis. Analytical data: [α]D28 -248.0 (c 
= 1.00, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 3.32 (dd, J = 7.8, 4.2 Hz, 1H), 3.07 (dd, J = 
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9.0, 3.0 Hz, 1H), 2.30 (m, 1H), 2.22 (dd, J = 11.4, 6.0 Hz, 1H), 1.90 (m, 1H), 185 (s, 3H), 1.70 
(m, 1H), 1.60 (br s, 1H), 1.55 (m, 2H), 1.28 (m, 1H), 1.24 (s, 3H), 1.18 (s, 3H), 0.99 (s, 3H), 
0.84 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 136.2, 131.2, 114.8, 
85.5, 81.1, 74.6, 41.5, 41.3, 32.3, 29.8, 27.4, 25.8, 25.0, 24.2, 22.7, 18.5, 18.1, -2.1, -2.2; 
HRMS (ESI+) Calcd. For C20H37IO2Si+Na, 487.1505; Found, 487.1497; IR (thin film, cm
-1) 
2954, 2854, 1771, 1670, 1488, 1376, 1264, 1162, 1040, 834; TLC (90:10 hexanes:EtOAc): Rf 
= 0.91. 
 
((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-
3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)methanol (3.119):  A flame-dried, 50 mL round 
bottomed flask was charged with hydrazone 3.106 (0.58 g, 1.10 mmol, 1.00 equiv) and THF 
(11 mL) under an atmosphere of N2.  The solution was cooled to -50 °C, and 
nBuLi (1.55 M in 
hexanes, 4.27 mL, 6.62 mmol, 6.00 equiv) was added over a period of ~2 min, producing a 
dark orange color.  The reaction was allowed to stir 30 min whereupon a venting needle was 
added, and the mixture was warmed to 0 °C and stirred 5 min.  The reaction was then warmed 
to rt and stirred until complete consumption of the starting material was observed by TLC 
analysis, typically 20 min. The venting needle was removed, (HCHO)n (0.35 g, 11.0 mmol, 
10.0 equiv) was added to the mixture in one portion, and the reaction was allowed to stir 40 
minutes at rt.  H2O (10 mL) and Et2O (5 mL) were added, and the mixture was transferred to a 
separatory funnel.  The organic layer was separated, and the aqueous layer was extracted with 
Et2O (3 x 10 mL).  The combined organic extracts were washed with brine (10 mL), dried with 
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magnesium sulfate and concentrated in vacuo.  The product was purified via flash 
chromatography (100:0 to 95:5 to 90:10 to 80:20 hexanes:EtOAc) to afford alcohol 3.119 (0.26 
g, 65% yield) as a yellow, viscous oil. Analytical data: : [α]D28 –53.7 (c = 0.70, CHCl3); 1H 
NMR  (600 MHz, CDCl3): δ 4.20 (d, J = 11.4 Hz, 1H), 4.07 (d, J = 11.4 Hz, 1H), 3.18 (dd, J 
= 6.0, 4.2 Hz, 1H), 3.09 (dd, J = 6.6, 3.6 Hz, 1H), 2.17 (m, 1H), 2.06 (m, 1H), 1.98 (dt, J = 6.0, 
3.6 Hz, 1H), 1.71 (s, 3H), 1.66 (m, 2H), 1.60 (m, 2H), 1.44 (m, 1H), 1.23 (s, 3H), 1.17 (s, 3H), 
1.00 (s, 3H), 0.84 (s, 9H), 0.80 (s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 137.4, 
132.2, 85.2, 81.3, 74.9, 58.2, 31.5, 25.8, 25.0, 24.2, 21.7, 19.4, 19.0, 18.1, -2.16, -2.21; HRMS 
(ESI+) Calcd. For C21H40O3Si+Na, 391.2645; Found, 391.2652; IR (thin film, cm
-1) 3409, 
2953, 2855, 1641, 1461, 1377, 1252, 1168, 1092, 834; TLC (85:15 hexanes:EtOAc): Rf = 0.29. 
 
One-pot procedure for the conversion of 3.92 to 3.119 
 
((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-
3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)methanol (3.119): A flame-dried, 250 mL 
round-bottomed flask was charged with hydrazone 3.92 (1.50 g, 2.95 mmol, 1.00 equiv) and 
THF (30 mL) under an atmosphere of N2.  The solution was cooled to -50 ºC, and 
nBuLi (3.97 
mL, 2.6 M in hexanes, 10.32 mmol, 3.50 equiv) was added dropwise, producing a dark orange 
color.  The reaction mixture was allowed to stir 40 min at this temperature, then MeI (0.46 mL, 
7.37 mmol, 2.50 equiv) was added.  The reaction was allowed to stir at -50 ºC until TLC 
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analysis confirmed complete conversion of 3.92, typically 20 min.  An additional charge of 
nBuLi (9.07 mL, 2.6 M in hexanes, 23.6 mmol, 8.00 equiv) was added to the reaction, and the 
resulting mixture was stirred 30 min. The flask was fitted with a venting needle, and the 
reaction mixture was then warmed to 0 ºC, stirred 5 min, then warmed to rt and stirred until 
complete consumption of the intermediate hydrazone was observed by TLC analysis, typically 
15-25 min (scale dependent).  The septum was partially removed, and (HCHO)n (0.89 g, 29.5 
mmol, 10.0 equiv) was added in one portion with vigorous stirring.  The reaction was allowed 
to stir 30 min at rt, at which time the mixture was diluted with H2O (25 mL) and Et2O (20 mL) 
and transferred to a separatory funnel.  The organic layer was separated and the aqueous layer 
was extracted with Et2O (3 x 20 mL).  The combined organic extracts were washed with brine 
(30 mL), dried with magnesium sulfate, and concentrated in vacuo.  The product was purified 
via flash chromatography (100:0 to 95:5 to 90:10 to 80:20 hexanes:EtOAc) to afford alcohol 
3.119 (0.76 g, 66% yield). 
 
((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-
3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)methyl isobutyrate(3.120): A flame-dried, 500 
mL round-bottomed flask was charged with CH2Cl2 (110 mL) and isobutyric acid (2.22 mL, 
24.47 mmol, 2.00 equiv) at rt under an atmosphere of N2.  DCC (5.05 g, 24.47 mmol, 2.00 
equiv) and DMAP (0.15 g, 1.22 mmol, 0.10 equiv) were added followed lastly by a solution 
of alcohol 3.119 (4.51 g, 12.23 mmol, 1.00 equiv) in CH2Cl2 (10 mL), and the reaction was 
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allowed to stir at rt until TLC analysis confirmed complete conversion of the starting material, 
typically 2.5 h.  The reaction mixture was filtered through cotton into a separatory funnel, and 
H2O (40 mL) and EtOAc (100 mL) were added.  The mixture was extracted with EtOAc (3 x 
30 mL), and the combined organic extracts were washed with saturated NaHCO3(aq.) (2 x 30 
mL), dried with magnesium sulfate, and concentrated in vacuo.  The product was purified via 
flash chromatography (100:0 to 97.5:2.5 to 95:5 hexanes:EtOAc) to afford ester 3.120 (4.01 g, 
75%) as a clear, viscous oil. Analytical data: [α]D28      –73.0 (c = 0.75, CHCl3); 1H NMR  (600 
MHz, CDCl3): δ 4.58 (br s, 2H), 3.19 (dd, J = 5.4, 4.8 Hz, 1H), 3.08 (dd, J = 5.4, 4.2 Hz, 1H), 
2.54 (m, 1H), 2.19 (m, 1H), 2.09 (m, 1H), 1.82 (dt, J = 6.0, 3.0 Hz, 1H), 1.67-1.65 (m, 5H), 
1.57 (m, 2H), 1.37 (m, 1H), 1.23 (s, 3H), 1.17 (br s, 6H), 1.15 (d, J = 2.4 Hz, 3H), 0.99 (s, 3H), 
0.84 (s, 3H), 0.08 (s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 177.3, 134.5, 132.3, 
85.1, 81.0, 74.9, 60.3, 25.8, 24.2, 21.7, 19.3, 19.2, 19.1, 19.0, 18.2, -2.1, -2.2; HRMS (ESI+) 
Calcd. For C25H46O4Si+Na, 461.3063; Found, 461.3062; IR (thin film, cm
-1) 2955, 2856, 1721, 
1470, 1378, 1215, 1092, 835, 756; TLC (85:15 hexanes:EtOAc): Rf = 0.66. 
 
2-((2S,4aS,6S,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-5-
methyleneoctahydro-2H-chromen-6-yl)-2-methylpropanoic acid (3.121):  A flame-dried, 
250-mL round-bottomed flask was charged with THF (80 mL) and diisopropylamine (3.84 
mL, 27.42 mmol, 3.00 equiv) under an atmosphere of N2.  The mixture was cooled to 0 ºC and 
nBuLi (1.85 M solution in hexanes, 14.82 mL, 27.42 mmol, 3.00 equiv) was added slowly.  
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After stirring for 30 min at 0 ºC, the mixture was cooled to -78 ºC, and isobutyrate 3.120 (4.01 
g, 9.14 mmol, 1.00 equiv) was added as a solution in THF (15 mL).  The mixture was allowed 
to stir for 45 min at which time TMSCl (3.52 mL, 27.42 mmol, 3.00 equiv) was added.  The 
reaction mixture was then allowed to warm to rt, stirred for 5 min, and subsequently warmed 
to 75 ºC and stirred until TLC analysis indicated complete conversion of the starting material, 
typically 12h.   The reaction mixture was cooled to rt and quenched via 1 M HCl(aq.) (25 mL).  
The mixture was then partitioned in a separatory funnel and extracted with Et2O (3 x 20 mL).  
The combined organic extracts were washed with 6 M HCl (2 x 30 mL), dried with magnesium 
sulfate, and concentrated in vacuo to provide the crude acid as a 6:1 mixture of diastereomers.  
The diastereomeric ratio was determined by 1H NMR spectroscopic analysis of the crude 
reaction mixture by comparison of the integration of the resonances at δ 5.13 (minor 
diastereomer) and δ 5.12 (major diastereomer).  The product was purified via flash 
chromatography (100:0 to 90:10 to 80:20 hexanes:EtOAc) to afford acid 3.121 (3.14 g, 78% 
yield) as a clear, viscous oil in an inseparable 6:1 diastereomeric ratio. Analytical data: [α]D28 
–43.5 (c =0.70, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 5.12 (s, 1H), 5.04 (s, 1H), 3.12 (dd, 
J = 6.6, 2.4 Hz, 1H), 3.04 (m, 1H), 2.09 (m, 1H), 1.95 (m, 1H), 1.66 (m, 2H), 1.59 (m, 2H), 
1.54 (m, 1H), 1.41 (m, 1H), 1.33 (s, 3H), 1.31 (s, 3H), 1.25 (s, 3H), 1.23 (s, 3H), 1.17 (s, 3H), 
1.09 (s, 3H), 0.84 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 184.5, 
161.1, 110.4, 84.7, 81.0, 74.8, 50.2, 44.4, 39.5, 36.9, 33.2, 28.3, 27.4, 25.6, 25.0, 24.6, 23.7, 
23.6, 22.4, 22.1, 18.2, -2.2; HRMS (ESI+) Calcd. For C25H46O4Si+Na, 461.3063; Found, 
461.3063; IR (thin film, cm-1)  3406, 2955, 2856, 1693, 1641, 1471, 1378, 1252, 1170, 1094, 
1042, 835, 760; TLC (85:15 hexanes:EtOAc): Rf = 0.40. 
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Crude 1H NMR spectrum of 3.121 
 
 
Methyl 2-((2S,4aS,6S,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-
dimethyl-5-methyleneoctahydro-2H-chromen-6-yl)-2-methylpropanoate (3.122): The 
acid 3.121 (3.14 g, 7.16 mmol, 1.00 equiv) was dissolved in MeOH:C7H8 (2:1, 75 mL) in a 
250 mL round-bottomed flask with magnetic stirring at rt.  TMSCHN2 (2 M in Et2O, 10.00 
mL, 20 mmol, 2.79 equiv) was added dropwise until the yellow color of excess TMSCHN2 in 
solution persisted.  AcOH (1.50 g, 24.98 mmol, 3.50 mmol) was added dropwise, giving a 
clear solution.  The resulting mixture was concentrated in vacuo and purified via flash 
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chromatography (100:0 to 97.5:2.5 to 95:5 hexanes:EtOAc) to afford ester 3.122 (3.06 g, 94% 
yield) as a clear, viscous oil in an inseparable 6.3:1 diastereomeric ratio (as determined by 
integration of the resonances at δ 3.64 (minor diastereomer) and δ 3.62 (major diastereomer)). 
Analytical data: [α]D28 –89.7 (c =0.60, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 5.01 (s, 1H), 
5.00 (s, 1H), 3.62 (s, 3H), 3.08 (m, 1H), 3.03 (dd, J = 6.0, 2.4 Hz, 1H), 2.08 (m, 1H), 1.95 (dt, 
J = 5.4, 3.6 Hz, 1H), 1.65 (m, 2H), 1.59 (m, 2H), 1.57 (br s, 1H), 1.50 (m, 1H), 1.39 (m, 1H), 
1.29 (s, 3H), 1.28 (s, 3H), 1.22 (s, 3H), 1.21 (s, 3H), 1.16 (s, 3H), 1.08 (s, 3H), 0.84 (s, 9H), 
0.08 (s, 3H), 0.06 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 178.7, 161.4, 110.0, 84.8, 81.0, 
74.9, 51.4, 50.3, 44.3, 39.5, 36.9, 33.1, 28.5, 27.3, 25.6, 25.0, 24.6, 23.9, 23.7, 22.4, 22.1, 18.2, 
-2.1, -2.2; HRMS (ESI+) Calcd. For C26H48O4Si+Na, 475.3220; Found, 475.3221; IR (thin 
film, cm-1) 2954, 2855, 1722, 1601, 1451, 1378, 1169, 1051, 835, 741; TLC (85:15 
hexanes:EtOAc): Rf = 0.66. 
 
3-((2S,4aS,6S,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-5-
methyleneoctahydro-2H-chromen-6-yl)-3-methylbutan-2-one (3.123): A flame-dried, 500-
mL round-bottomed flask was charged with ester 3.122 (3.82 g, 8.44 mmol, 1.00 equiv) and 
Et2O (84 mL) under an atmosphere of N2.  The mixture was cooled to 0 ºC, and MeLi (1.6 M 
in Et2O, 21.09 mL, 33.75 mmol, 4.00 equiv) was added.  The mixture was warmed to rt 
whereupon TLC analysis showed incomplete conversion of the starting material.  A second 
addition of MeLi (4.00 equiv) was carried out, upon which TLC analysis showed remaining 
starting material.  A third addition of MeLi (4.00 equiv) was carried out, upon which TLC 
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analysis showed complete conversion of the starting material.  The reaction mixture was cooled 
to 0 ºC and quenched carefully with saturated NH4Cl(aq.) (25 mL).  The mixture was partitioned 
in a separatory funnel, and the aqueous layer was extracted with Et2O (3 x 20 mL).  The 
combined organic extracts were dried with magnesium sulfate and concentrated in vacuo.  The 
product was purified via flash chromatography (100:0 to 97.5:2.5 to 95:5 hexanes:EtOAc) to 
afford ketone 3.123 (3.52 g, 86% yield) as a clear, viscous oil in an inseparable 7:1 ratio of 
diastereomers (as determined by integration of the resonances at δ 5.05 (major diastereomer) 
and δ 5.03 (minor diastereomer)).  Analytical data: [α]D28 –92.2 (c = 0.60, CHCl3); 1H NMR  
(600 MHz, CDCl3): δ 5.05 (s, 1H), 4.90 (s, 1H), 3.15 (dd, J = 5.4, 4.8 Hz, 1H), 3.04 (m, 1H), 
2.18 (s, 3H), 1.96 (m, 1H), 1.66 (m, 1H), 1.61-1.59 (m, 3H), 1.53 (m, 1H), 1.44 (m, 1H), 1.30 
(s, 3H), 1.23 (s, 3H), 1.22 (s, 3H), 1.16 (br s, 6H), 1.08 (s, 3H), 0.84 (s, 9H), 0.08 (s, 3H), 0.05 
(s, 3H); 13C NMR (150 MHz, CDCl3): δ 215.1, 161.4, 111.1, 84.7, 80.5, 74.8, 54.7, 44.9, 39.4, 
36.8, 33.0, 29.7, 29.4, 27.4, 25.8, 25.0, 24.6, 23.6, 23.5, 22.7, 22.0, 18.1, -2.1, -2.2; HRMS 
(ESI+) Calcd. For C26H48O3Si+Na, 459.3271; Found, 459.3267; IR (thin film, cm
-1) 2955, 
2856, 1694, 1620, 1470, 1377, 1251, 1094, 835; TLC (85:15 hexanes:EtOAc): Rf = 0.54. 
 
3-((2S,4aS,5R,6S,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-5-
(hydroxymethyl)-4a,6-dimethyloctahydro-2H-chromen-6-yl)-3-methylbutan-2-ol 
(3.124): A flame-dried, 250 mL round-bottomed flask was charged with ketone 3.123 (1.63 g, 
3.74 mmol, 1.00 equiv) and THF (70 mL) under an atmosphere of N2.  BH3•THF (1 M in THF, 
16.82 mL, 4.50 equiv) was added, and the mixture was warmed to 50 ºC and stirred until 
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complete conversion of the starting material was observed by TLC analysis, typically 12 h.  
The reaction mixture was then cooled to 0 ºC, and 3 M NaOH(aq.) (7.5 mL) was added slowly 
followed by H2O2 (30% w/w in H2O, 7.5 mL).  The resulting mixture was warmed to rt and 
stirred for 2.5 h, upon which the mixture was partitioned in a separatory funnel, diluted with 
H2O (30 mL), and extracted with Et2O (3 x 20 mL).  The combined organic extracts were dried 
with magnesium sulfate and concentrated in vacuo to afford the crude diol as an inseparable 
mixture of diastereomers at C12c and C6a.  The diastereoselection of this reaction at C4b was 
determined via 1H NMR analysis of the subsequent intermediate (vide infra).  The product was 
purified via flash chromatography (80:20 to 70:30 hexanes:EtOAc) to afford diol 3.124 (1.27 
g, 74% yield) as a white, viscous foam.  This diastereomeric mixture was carried on to the next 
step without further separation. Analytical data: [α]D28 –83.9 (c =0.60, CHCl3); 1H NMR  (600 
MHz, CDCl3): δ 4.18 (m, 2H), 3.88 (t, J = 12.6 Hz, 2H), 3.68 (dd, J = 9.0, 3.0 Hz, 1H), 3.56 
(d, J = 12.0 Hz, 1H), 3.06 (m, 2H), 2.93 (dd, J = 6.0, 4.8 Hz, 1H), 2.86 (dd, J = 7.2, 4.2 Hz, 
1H), 1.98 (m, 3H), 1.76 (s, 1H), 1.59-1.49 (m, 11H), 1.42-1.36 (m, 3H), 1.25 (d, J = 6.0 Hz, 
5H), 1.21 (s, 6H), 1.15 (s, 7H), 1.01 (s, 2H), 0.95 (br s, 9H), 0.90 (br s, 4H), 0.89 (s, 3H), 0.86 
(s, 2H), 0.83 (br s, 22H), 0.07 (s, 7H), 0.05 (s, 7H); 13C NMR (150 MHz, CDCl3): δ 85.1, 84.9, 
84.2, 83.7, 74.9, 68.7, 61.5, 61.0, 54.2, 52.9, 45.8, 45.1, 42.5, 42.4, 39.0, 38.5, 37.9, 37.8, 34.0, 
33.5, 27.4, 27.3, 25.8, 25.2, 25.0, 24.9, 24.6, 21.5, 21.4, 21.2, 19.8, 18.1, 17.8, 17.5, 14.7, 14.2, 
-2.1, -2.2; HRMS (ESI+) Calcd. For C26H52O4Si+Na, 479.3533; Found, 479.3549; IR (thin 
film, cm-1) 3320, 2955, 2855, 1471, 1379, 1251, 1172, 1100, 834, 759; TLC (85:15 
hexanes:EtOAc): Rf = 0.14. 
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Crude 1H NMR spectrum of 3.124. 
 
 
(3S,4aS,6aS,10aR,10bS)-3-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-6a,7,7,10b-
tetramethyl-2,3,5,6,6a,7,10a,10b-octahydro-1H-benzo[f]chromen-8(4aH)-one (3.126): A 
flame-dried, 250 mL round-bottomed flask was charged with CH2Cl2 (70 mL) and (COCl)2 
(1.71 mL, 19.92 mmol, 5.00 equiv) under an atmosphere of N2.  The mixture was cooled to -
78 ºC, and DMSO (2.83 mL, 39.84 mmol, 10.00 equiv) was added slowly.  The mixture was 
allowed to stir 30 min at -78 ºC then the diol 3.124 (1.82 g, 3.98 mmol, 1.00 equiv) was added 
as a solution in CH2Cl2 (10 mL).  The reaction mixture was stirred at this temperature for 2 h 
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then DIPEA (13.88 mL, 79.69 mL, 20.0 equiv) was added.  The reaction was stirred 30 min at 
-78 ºC then warmed to 0 ºC and stirred 15 min. At this time TLC analysis confirmed complete 
conversion of the starting material.  The reaction was quenched with saturated NH4Cl(aq.) (25 
mL), and the mixture was partitioned in a separatory funnel.  The mixture was extracted with 
CH2Cl2 (3 x 20 mL), and the combined organic extracts were washed with brine (20 mL), dried 
with magnesium sulfate and concentrated in vacuo to afford the crude ketoaldehyde 3.125, 
which was carried to the next step without further purification.  (Note: at this stage, a single 
diastereomer was observed in the 1H NMR spectrum of the crude aldehyde, thereby 
establishing complete control of the C4b methine stereocenter in the hydroboration/oxidation 
step.  This crude spectrum is provided below.) 
 
Crude NMR spectrum of 3.125 
 
347 
 
The crude ketoaldehyde 3.125 was dissolved in MeOH:THF (1:1, 80 mL) in a 250 mL round-
bottomed flask and cooled to 0 ºC with magnetic stirring.  2M KOH(aq.) (8 mL) was added, and 
the reaction was warmed to rt and stirred for 12 h.  The resulting mixture was concentrated on 
a rotary evaporator and partitioned with EtOAc (30 mL) and H2O (30 mL) in a separatory 
funnel.  The mixture was extracted with EtOAc (3 x 20 mL), and the combined organic extracts 
were dried with magnesium sulfate and concentrated in vacuo.  The product was purified via 
flash chromatography (100:0 to 97.5:2.5 to 95:5 to 90:10 hexanes:EtOAc) to afford the enone 
3.126 (1.29 g, 75% yield) as a yellow, viscous oil.  Analytical data: [α]D28 –109.0 (c = 0.85, 
CHCl3); 1H NMR  (500 MHz, CDCl3): δ 6.73 (d, J = 12.6 Hz, 1H), 5.99 (dd, J = 7.0, 3.5 Hz, 
1H), 3.14 (dd, J = 9.0, 3.0 Hz, 1H), 2.97 (dd, J = 5.0, 5.0 Hz, 1H), 2.29 (br s, 1H), 1.96 (d, J = 
9.0 Hz, 1H), 1.70-1.58 (m, 6H), 1.43 (m, 1H), 1.23 (s, 3H), 1.17 (s, 3H), 1.07 (s, 3H), 1.00 (s, 
3H), 0.95 (s, 3H), 0.93 (s, 3H), 0.84 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR (150 MHz, 
CDCl3): δ 204.9, 146.2, 129.0, 85.6, 85.0, 74.8, 51.5, 49.7, 43.8, 37.3, 35.5, 30.5, 27.4, 25.8, 
24.9, 23.8, 21.2, 20.3, 18.1, 16.9, 16.6, 14.7, -2.1, -2.2; HRMS (ESI+) Calcd. For 
C26H46O3Si+Na, 457.3114; Found, 457.3129; IR (thin film, cm
-1) 2954, 2855, 1677, 1461, 
1389, 1251, 1174, 1103, 1041, 834, 756; TLC (85:15 hexanes:EtOAc): Rf = 0.43. 
 
((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-
3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)methyl acetate (3.127a): A flame-dried, 20 mL 
scintillation vial was charged with alcohol 3.119 (0.05 g, 0.14 mmol, 1.00 equiv) and CH2Cl2 
under an atmosphere of N2. The mixture was cooled to 0 °C, and NEt3 (0.04 mL, 0.27 mmol, 
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2.00 equiv), DMAP (0.002 g, 0.014 mmol, 0.1 equiv), and lastly Ac2O (0.03 mL, 0.27 mmol, 
2.00 equiv) were added sequentially.  The mixture was allowed to stir at this temperature until 
TLC analysis showed complete consumption of the starting material, typically 3 h.  The 
mixture was diluted with H2O (7 mL) and transferred to a separatory funnel.  The organic layer 
was separated, and the aqueous layer was extracted with CH2Cl2 (3 x 7 mL), dried with 
magnesium sulfate, and concentrated in vacuo.  The product was purified via flash 
chromatography (100:0 to 98:2 to 95:5 to 90:10 hexanes:EtOAc) to afford acetate 3.127a 
(0.046 g, 83% yield) as a clear, viscous oil. Analytical data: [α]D28 -59.0 (c = 1.35, CHCl3); 1H 
NMR  (600 MHz, CDCl3): δ 4.59 (dd, J = 12.0, 5.4 Hz, 2H), 3.19 (dd, J = 6.0, 4.8 Hz, 1H), 
3.08 (dd, J = 6.0, 4.2 Hz, 1H), 2.20 (m, 1H), 2.11 (m, 1H), 2.05 (s, 3H), 1.82 (m, 1H), 1.67 (br 
s, 5H), 1.57 (m, 1H), 1.36 (m, 1H), 1.23 (s, 3H), 1.17 (s, 3H), 0.99 (s, 3H), 0.84 (s, 9H), 0.08 
(s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 171.3, 134.8, 132.2, 85.1, 81.0, 74.9, 
60.4, 36.3, 33.9, 31.6, 27.3, 25.8, 25.0, 24.1, 21.6, 21.2, 19.3, 19.2, 18.1, -2.1, -2.2; HRMS 
(ESI+) Calcd. For C23H42O4Si+Na, 433.2750; Found, 433.2741; IR (thin film, cm
-1) 2955, 
2856, 1771, 1730, 1472, 1377, 1249, 1092, 1039, 835, 759; TLC (90:10 hexanes:EtOAc): Rf 
= 0.54. 
 
((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-
3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)methyl propionate (3.127b): A flame-dried, 20 
mL scintillation vial was charged with CH2Cl2 (3 mL) and propionic acid (0.02 g, 0.27 mmol, 
2.00 equiv) at rt under an atmosphere of N2.  DCC (0.06 g, 0.27 mmol, 2.00 equiv) and DMAP 
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(0.002 g, 0.014 mmol, 0.10 equiv) were added followed lastly by a solution of alcohol 3.119 
(0.05 g, 0.14 mmol, 1.00 equiv) in CH2Cl2 (1 mL), and the reaction was allowed to stir at rt 
until TLC analysis confirmed complete conversion of the starting material, typically 3.5 h.  The 
reaction mixture was filtered through cotton into a separatory funnel, and H2O (10 mL) and 
EtOAc (10 mL) were added.  The mixture was extracted with EtOAc (3 x 10 mL), and the 
combined organic extracts were washed with saturated NaHCO3(aq.) (10 mL), dried with 
magnesium sulfate, and concentrated in vacuo.  The product was purified via flash 
chromatography (100:0 to 98:2 to 95:5 hexanes:EtOAc) to afford ester 3.127b (0.05 g, 86% 
yield) as a clear, viscous oil. Analytical data: [α]D28 -51.4 (c = 1.25, CHCl3); 1H NMR  (600 
MHz, CDCl3): δ 4.60 (dd, J = 12.0, 7.8 Hz, 2H), 3.19 (dd, J = 5.4, 5.4 Hz, 1H), 3.08 (dd, J = 
6.0, 4.2 Hz, 1H), 2.32 (q, J = 7.2 Hz, 2H), 2.19 (m ,1H), 2.09 (dd, J = 12.6, 4.8 Hz, 1H), 1.82 
(dt, J = 6.0, 3.6 Hz, 1H), 1.67 (br s, 5H), 1.56 (m, 1H), 1.37 (m, 1H), 1.23 (s, 3H), 1.17 (s, 3H), 
1.40 (t, J = 7.2 Hz, 3H), 0.99 (s, 3H), 0.84 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H); 13C NMR (150 
MHz, CDCl3): δ 174.6, 134.6, 132.3, 85.1, 81.0, 74.9, 60.3, 36.3, 34.0, 27.7, 27.3, 25.8, 25.0, 
24.2, 21.7, 19.3, 19.2, 18.2, 9.2, -2.1, -2.2; HRMS (ESI+) Calcd. For C24H44O4Si+Na, 
447.2907; Found, 447.2897; IR (thin film, cm-1) 3053, 2955, 2855, 1731, 1540, 1472, 1322, 
1265, 1179, 1071, 835; TLC (90:10 hexanes:EtOAc): Rf = 0.68. 
 
2-(1H-indol-2-yl)propanoic acid (S11): A 20 mL scintillation vial was charged with ethyl 2-
(1H-indol-2-yl)propanoate S10 (0.2 g, 0.92 mmol, 1.00 equiv) and a 3:1 mixture of 
MeOH:THF (5 mL).  LiOH (4 M in H2O, 0.7 mL, 2.76 mmol, 3.00 equiv) was added, and the 
mixture was allowed to stir at rt until complete consumption of the starting material was 
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observed by TLC analysis, typically 6 h.  The reaction mixture was concentrated on a rotary 
evaporator, and the residue was diluted with H2O (10 mL) and transferred to a separatory 
funnel.  The aqueous layer was extracted with EtOAc (2 x 10 mL), and the aqueous layer was 
then acidified to pH=0 with 1 M HCl(aq.) and extracted with CH2Cl2 (3 x 10 mL).  The combined 
CH2Cl2 extracts were dried with magnesium sulfate and concentrated in vacuo to give the crude 
carboxylic acid S11.  This material could not be isolated due to spontaneous decarboxylation, 
but could be carried forward directly to the next step without further purification. 
 
((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-
3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)methyl 2-(1H-indol-2-yl)propanoate (3.127c): 
The crude acid S11 (~4.00 equiv) was dissolved in CH2Cl2 (3 mL) and transferred to a flame-
dried 20 mL scintillation vial under an atmosphere of N2.  DCC (0.095 g, 0.46 mmol, 2.00 
equiv) was added followed by DMAP (0.003 g, 0.023 mmol, 0.10 equiv) and lastly a solution 
of alcohol 3.119 (0.085 g, 0.23 mmol, 1.00 equiv) in CH2Cl2 (1 mL).  The reaction was allowed 
to stir until TLC analysis confirmed complete consumption of the starting material, typically 
20 min.  The reaction mixture was filtered through cotton into a separatory funnel, and H2O 
(10 mL) and EtOAc (10 mL) were added.  The mixture was extracted with EtOAc (3 x 10 mL), 
and the combined organic extracts were washed with saturated NaHCO3(aq.) (10 mL), dried 
with magnesium sulfate, and concentrated in vacuo.  The product was purified via flash 
chromatography (100:0 to 95:5 to 90:10 hexanes:EtOAc) to afford an inseparable mixture of 
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diastereomeric esters 3.127c (0.14 g, 99% yield) as a brown, viscous oil. Analytical data: [α]D28 
-68.4 (c = 0.43, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 8.59 (m, 1H), 7.56 (m, 1H), 7.32 (m, 
1H), 7.15 (m, 1H), 7.09 (m, 1H), 6.37 (br s, 1H), 4.66 (m, 2H), 3.95 (m, 1H), 3.17 (m, 1H), 
3.06-2.98 (m, 1H), 2.21 (m, 1H), 2.10 (m, 1H), 1.68-1.66 (m, 4H), 1.64-1.62 (m, 4H), 1.46 (m, 
2H), 1.32 (m, 2H), 1.23-1.21 (m, 3H), 1.16-1.14 (m, 3H), 0.97-0.96 (m, 3H), 0.86 (s, 9H), 
0.10-0.09 (m, 3H), 0.07 (m, 3H); 13C NMR (150 MHz, CDCl3): δ 173.6, 136.7, 136.6, 136.0, 
135.4, 131.9, 128.0, 121.7, 120.2, 119.7, 110.6, 100.1, 85.1, 85.0, 80.9, 74.8, 61.3, 61.2, 41.5, 
39.3, 39.2, 36.2, 33.9, 31.6, 27.2, 27.1, 26.1, 25.8, 25.2, 25.1, 24.1, 23.3, 21.5, 19.2, 18.1, 17.4, 
17.2, 14.1, -2.2, -2.3; HRMS (ESI+) Calcd. For C32H49NO4Si+Na, 562.3329; Found, 
562.3320; IR (thin film, cm-1) 3392, 2954, 2855, 1716, 1471, 1377, 1250, 1172, 1069, 835; 
TLC (90:10 hexanes:EtOAc): Rf = 0.41.  
 
((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-
3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)methyl 3-((tert-butyldimethylsilyl)oxy)-2-
methylpropanoate (3.127d): A flame-dried, 20 mL scintillation vial was charged with CH2Cl2 
(3 mL) and 3-((tert-butyldimethylsilyl)oxy)-2-methylpropanoic acid S12 (0.05 g, 0.22 mmol, 
2.00 equiv) at rt under an atmosphere of N2.  DCC (0.04 g, 0.22 mmol, 2.00 equiv) and DMAP 
(0.002 g, 0.014 mmol, 0.10 equiv) were added followed lastly by a solution of alcohol 3.119 
(0.04 g, 0.11 mmol, 1.00 equiv) in CH2Cl2 (1 mL), and the reaction was allowed to stir at rt 
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until TLC analysis confirmed complete conversion of the starting material, typically 3.5 h.  The 
reaction mixture was filtered through cotton into a separatory funnel, and H2O (10 mL) and 
EtOAc (10 mL) were added.  The mixture was extracted with EtOAc (3 x 10 mL), and the 
combined organic extracts were washed with saturated NaHCO3(aq.) (10 mL), dried with 
magnesium sulfate, and concentrated in vacuo.  The product was purified via flash 
chromatography (100:0 to 98:2 to 95:5 hexanes:EtOAc) to afford an inseparable mixture of 
diastereomeric esters 3.127d (0.047 g, 76% yield) as a clear, viscous oil. Analytical data: [α]D28 
-42.1 (c = 1.20, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 4.58 (m, 2H), 3.79 (m, 1H), 3.64 (m, 
1H), 3.18 (m, 1H), 3.08 (dd, J = 7.2, 3.6 Hz, 1H), 2.62 (m, 1H), 2.19 (m, 1H), 2.09 (m, 1H), 
1.82 (m, 1H), 1.67-1.66 (m, 5H), 1.57 (m, 2H), 1.37 (m, 1H), 1.23 (s, 3H), 1.17 (s, 3H), 1.14-
1.12 (m, 3H), 0.99 (m, 3H), 0.87 (s, 9H), 0.84 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H), 0.03 (br s, 
6H), 13C NMR (150 MHz, CDCl3): δ 175.1, 134.6, 134.5, 132.3, 85.1, 81.0, 74.9, 65.3, 65.2, 
60.4, 60.3, 42.7, 36.3, 34.1, 34.0, 31.7, 27.4, 27.3, 25.9, 25.8, 25.0, 24.2, 21.7, 21.6, 19.3, 19.2, 
18.2, 13.6, -2.1, -2.2, -5.5; HRMS (ESI+) Calcd. For C31H60O5Si2+Na, 591.3877; Found, 
591.3867; IR (thin film, cm-1) 3053, 2955, 2884, 2857, 1727, 1471, 1377, 1265, 1179, 1049, 
836; TLC (90:10 hexanes:EtOAc): Rf = 0.73. 
 
((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-
3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)methyl (S)-2-bromopropanoate (3.127e): A 
flame-dried, 20 mL scintillation vial was charged with CH2Cl2 (3 mL) and (S)-2-
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bromopropanoic acid S13 (0.04 g, 0.27 mmol, 2.00 equiv) at rt under an atmosphere of N2.  
DCC (0.06 g, 0.27 mmol, 2.00 equiv) and DMAP (0.002 g, 0.014 mmol, 0.10 equiv) were 
added followed lastly by a solution of alcohol 3.119 (0.05 g, 0.14 mmol, 1.00 equiv) in CH2Cl2 
(1 mL), and the reaction was allowed to stir at rt until TLC analysis confirmed complete 
conversion of the starting material, typically 3.5 h.  The reaction mixture was filtered through 
cotton into a separatory funnel, and H2O (10 mL) and EtOAc (10 mL) were added.  The mixture 
was extracted with EtOAc (3 x 10 mL), and the combined organic extracts were washed with 
saturated NaHCO3(aq.) (10 mL), dried with magnesium sulfate, and concentrated in vacuo.  The 
product was purified via flash chromatography (100:0 to 98:2 to 95:5 hexanes:EtOAc) to afford 
ester 3.127e (0.062 g, 90% yield) as a clear, viscous oil. Analytical data: [α]D28 -49.2 (c = 1.50, 
CHCl3); 1H NMR  (600 MHz, CDCl3): δ 4.68 (br s, 1H), 4.36 (q, J = 6.6 Hz, 1H), 3.19 (dd, J 
= 6.0, 4.2  Hz, 1H), 3.08 (dd, J = 6.6, 3.6 Hz, 1H), 2.20 (m, 1H), 2.10 (m, 1H), 1.83-1.81 (m, 
5H), 1.69-1.66 (m, 5H), 1.58 (m, 1H), 1.38 (m, 1H), 1.23 (s, 3H), 1.17 (s, 3H), 1.01 (s, 3H), 
0.84 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 170.4, 135.7, 131.6, 
85.1, 80.9, 74.9, 62.0, 40.3, 36.2, 34.1, 31.7, 27.3, 25.8, 25.0, 24.1, 21.7, 21.6, 19.4, 19.3, 18.1, 
-2.1, -2.2; HRMS (ESI+) Calcd. For C24H43BrO4Si+Na, 525.2012; Found, 525.2004; IR (thin 
film, cm-1) 2929, 2856, 1732, 1472, 1378, 1329, 1217, 1159, 1070, 835; TLC (90:10 
hexanes:EtOAc): Rf = 0.62. 
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((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-
3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)methyl (Z)-2-methylbut-2-enoate (3.127f): A 
flame-dried, 20 mL scintillation vial was charged with CH2Cl2 (3 mL) and angelic acid (0.03 
g, 0.27 mmol, 2.00 equiv) at rt under an atmosphere of N2.  DCC (0.06 g, 0.27 mmol, 2.00 
equiv) and DMAP (0.002 g, 0.014 mmol, 0.10 equiv) were added followed lastly by a solution 
of alcohol 3.119 (0.05 g, 0.14 mmol, 1.00 equiv) in CH2Cl2 (1 mL), and the reaction was 
allowed to stir at rt until TLC analysis confirmed complete conversion of the starting material, 
30 h.  In some cases, an additional 2.00 equiv of angelic acid and DCC were added after 12 h 
to aide starting material conversion.  The reaction mixture was filtered through cotton into a 
separatory funnel, and H2O (10 mL) and EtOAc (10 mL) were added.  The aqueous layer was 
extracted with EtOAc (3 x 10 mL), and the combined organic extracts were washed with 
saturated NaHCO3(aq.) (10 mL), dried with magnesium sulfate, and concentrated in vacuo.  The 
product was purified via flash chromatography (100:0 to 98:2 to 95:5 hexanes:EtOAc) to afford 
ester 3.127f (0.040 g, 59% yield) as a pale yellow, viscous oil. Analytical data: [α]D28 -53.1 (c 
= 1.00, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 6.83 (q, J = 6.6 Hz, 1H), 4.65 (br s, 2H), 3.19 
(dd, J = 5.4, 5.4 Hz, 1H), 3.09 (dd, J = 6.0, 3.6 Hz, 1H), 2.19 (m, 1H), 2.10 (m, 1H), 1.97 (m, 
1H), 1.88-1.83 (m, 4H), 1.79 (d, J = 6.6 Hz, 3H), 1.67 (br s, 4H), 1.56 (m, 2H), 1.37 (m, 1H), 
1.23 (s, 3H), 1.16 (s, 3H), 1.01 (s, 3H), 0.84 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H); 13C NMR (150 
MHz, CDCl3): δ 168.3, 137.4, 136.9, 134.3, 132.4, 128.8, 85.1, 81.0, 74.9, 60.4, 36.2, 34.1, 
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31.7, 31.6, 27.2, 25.8, 25.0, 24.2, 21.7, 19.4, 19.2, 14.4, 12.1, -2.1, -2.2; HRMS (ESI+) Calcd. 
For C26H46O4Si+Na, 473.3063; Found, 473.3055; IR (thin film, cm
-1) 2955, 2855, 1731, 1703, 
1636, 1487, 1361, 1263, 1070, 835, 758; TLC (90:10 hexanes:EtOAc): Rf = 0.65. 
 
((2S,4aS,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-
3,4,4a,7,8,8a-hexahydro-2H-chromen-5-yl)methyl 3-(dimethyl(phenyl)silyl)-2-
methylpropanoate (3.127g): A flame-dried, 20 mL scintillation vial was charged with CH2Cl2 
(5 mL) and 3-(dimethyl(phenyl)silyl)-2-methylpropanoic acid S14 (0.18 g, 0.81 mmol, 2.00 
equiv) at rt under an atmosphere of N2.  DCC (0.17 g, 0.81 mmol, 2.00 equiv) and DMAP 
(0.005 g, 0.04 mmol, 0.10 equiv) were added followed lastly by a solution of alcohol 3.119 
(0.15 g, 0.41 mmol, 1.00 equiv) in CH2Cl2 (2 mL), and the reaction was allowed to stir at rt 
until TLC analysis confirmed complete conversion of the starting material, 5 h.  The reaction 
mixture was filtered through cotton into a separatory funnel, and H2O (10 mL) and EtOAc (10 
mL) were added.  The mixture was extracted with EtOAc (3 x 10 mL), and the combined 
organic extracts were washed with saturated NaHCO3(aq.) (10 mL), dried with magnesium 
sulfate, and concentrated in vacuo.  The product was purified via flash chromatography (100:0 
to 98:2 to 98:2 to 95:5 hexanes:EtOAc) to afford ester 3.127g (0.21 g, 91% yield) as a clear, 
viscous oil. Analytical data: [α]D28 -42.5 (c = 1.30, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 
7.51 (br s, 2H), 7.36 (br s, 3H), 4.56 (dd, J = 7.8, 4.2 Hz, 1H), 4.50 (d, J = 12.0 Hz, 1H), 3.20 
(dd, J = 6.0, 4.2 Hz, 1H), 3.10 (dd, J = 6.0, 3.6 Hz, 1H), 2.54 (m, 1H), 2.20 (m, 1H), 2.10 (m, 
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1H), 1.79 (d, J = 12.6 Hz, 1H), 1.68-1.66 (m, 5H), 1.58 (m, 2H), 1.32 (m, 2H), 1.25 (s, 3H), 
1.19 (s, 3H), 1.15 (d, J = 6.6 Hz, 3H), 1.00 (s, 3H), 0.94-0.89 (m, 2H), 0.87 (s, 9H), 0.31 (br s, 
6H), 0.10 (s, 3H), 0.08 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 177.6, 138.8, 134.5, 133.5, 
132.3, 129.1, 128.9, 127.9, 127.785.1, 81.0, 74.9, 60.3, 36.6, 36.3, 36.2, 34.1, 31.6, 27.3, 27.2, 
25.8, 25.1, 24.1, 21.7, 20.7, 20.6, 20.5, 19.8, 19.3, 19.2, 19.2, 18.1, -2.1, -2.2, -2.3, -2.4, -2.6; 
HRMS (ESI+) Calcd. For C33H56O4Si2+Na, 595.3615; Found, 595.3604; IR (thin film, cm
-1) 
3052, 2956, 2856, 1809, 1718, 1487, 1457, 1361, 1265, 1198, 1047, 835; TLC (90:10 
hexanes:EtOAc): Rf = 0.78. 
 
2-((2S,4aS,6S,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-5-
methyleneoctahydro-2H-chromen-6-yl)-3-(dimethyl(phenyl)silyl)-2-methylpropanoic 
acid (3.128g): A flame-dried, 20 mL scintillation vial was charged with THF (2 mL) under an 
atmosphere of N2.  The mixture was cooled to -78 °C, and a premade solution of LDA (0.5 M 
in THF:hexanes, 0.52 mL, 0.26 mmol, 3.00 equiv) was added followed by a solution of ester 
3.127g (0.05 g, 0.087 mmol, 1.00 equiv) in THF (1 mL).  The reaction was allowed to stir 45 
min at this temperature at which point TMSCl (0.04 mL, 0.26 mmol, 3.00 equiv) was added, 
and the mixture was warmed to rt and stirred 5 min.  The septum was replaced with a screw 
cap, the vial was sealed, and the mixture was warmed to 75 °C and stirred until TLC analysis 
indicated complete consumption of the starting material, typically 12 h.  The mixture was 
cooled to rt and quenched via addition of 1 M HCl(aq.) (4 mL).  The mixture was transferred to 
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a separatory funnel and diluted with Et2O (10 mL).  The organic layer was separated, and the 
aqueous layer was extracted with Et2O (3 x 10 mL).  The combined organic extracts were 
washed with brine (10 mL) and concentrated in vacuo to give the crude rearrangement product 
in a 6.6:1.1:1 diastereomeric ratio.  The diastereomeric ratio was determined by 1H NMR 
spectroscopic analysis of the crude reaction mixture by comparison of the integration of the 
resonances at δ 5.25 (minor diastereomer), δ5.10 (major diastereomer)  and δ 5.04 (minor 
diastereomer, overlapping signals).  The product was purified via flash chromatography (100:0 
to 95:5 to 90:10 hexanes:EtOAc) to afford carboxylic acid 3.128g (0.032 g, 62% yield) as a 
clear viscous oil. Analytical data: [α]D28 -18.3 (c = 1.25, CHCl3); 1H NMR  (600 MHz, CDCl3): 
δ 7.51 (m, 2H), 7.34 (m, 3H), 5.10 (s, 1H), 5.01 (s, 1H), 3.11 (dd, J = 6.0, 4.8 Hz, 1H), 3.01 
(m, 1H), 1.97-1.90 (m, 2H), 1.74 (m, 1H), 1.66-1.54 (m, 6H), 1.38 (s, 3H), 1.27 (m, 2H), 1.22 
(s, 3H), 1.17 (s, 3H), 1.16 (s, 3H), 1.15 (m, 1H), 1.07 (s, 3H), 1.05 (m, 1H), 0.84 (s, 9H), 0.37 
(s, 3H), 0.29 (s, 3H), 0.08 (s, 3H), 0.05 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 184.0, 160.8, 
140.3, 133.5, 128.8, 127.7, 111.7, 84.7, 80.4, 74.8, 52.5, 46.5, 39.3, 36.8, 36.6, 32.7, 30.2, 27.3, 
25.9, 25.0, 24.7, 24.5, 23.3, 23.1, 22.1, 22.1, 18.2, -1.2, -1.4, -2.1, -2.2; HRMS (ESI+) Calcd. 
For C33H56O4Si2+Na, 595.3615; Found, 595.3605; IR (thin film, cm
-1) 3420, 3053, 2956, 2956, 
2855, 1716, 1689, 1487, 1377, 1265, 1093, 896, 835; TLC (90:10 hexanes:EtOAc): Rf = 0.46. 
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Crude 1H NMR spectrum of 3.128g 
 
 
methyl 2-((2S,4aS,6S,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-
dimethyl-5-methyleneoctahydro-2H-chromen-6-yl)-3-(dimethyl(phenyl)silyl)-2-methyl 
propanoate (3.129):  The acid 3.128g (0.060 g, 0.11 mmol, 1.00 equiv) was dissolved in 
MeOH:C7H8 (2:1, 2 mL) in a 20-mL scintillation vial with magnetic stirring at rt.  TMSCHN2 
(2 M in Et2O, 0.4 mL, 0.80 mmol, 7.30 equiv) was added dropwise until the yellow color of 
excess TMSCHN2 in solution persisted.  AcOH (~10 drops) was added dropwise, giving a clear 
solution.  The resulting mixture was concentrated in vacuo and purified via flash 
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chromatography (100:0 to 97.5:2.5 to 95:5 hexanes:EtOAc) to afford ester 3.129 (0.052 g, 85% 
yield) ) as a clear, viscous oil.  Analytical data: 1H NMR  (500 MHz, CDCl3): 7.51-7.49 (m, 
4H), 7.35-7.33 (m, 6H), 5.08 (s, 1H), 4.79 (s, 1H), 3.45 (s, 3H), 3.09 (dd, J = 6.0, 4.5 Hz, 1H), 
3.00 (m, 1H), 1.59-1.55 (m, 5H), 1.31 (s, 3H), 1.21 (s, 3H), 1.18 (s, 3H), 1.15 (s, 3H), 1.05 (s, 
3H), 0.84 (s, 9H), 0.29 (s, 3H), 0.25 (s, 3H), 0.08 (s, 3H), 0.05 (s, 3H). 
 
2-((2S,4aS,6S,8aS)-2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-4a,6-dimethyl-5 
methyleneoctahydro-2H-chromen-6-yl)-3-(dimethyl(phenyl)silyl)-2-methylpropanal 
(3.131): A 20-mL scintillation vial was charged with ester 3.129 (0.03 g, 0.051 mmol, 1.00 
equiv) and CH2Cl2 (1.5 mL) under an atmosphere of N2.  The mixture was cooled to -78 °C, 
and DIBAL-H (1 M solution in hexanes, 0.10 mL, 0.10 mmol, 2.00 equiv) was added slowly.  
TLC analysis showed incomplete conversion of 3.129, and another charge of DIBAL-H (4.00 
equiv) was added.  At this juncture, TLC analysis showed complete conversion of the starting 
material, whereupon the reaction was diluted with acetone (5 mL).  After stirring 10 min at -
78 °C, the mixture was diluted with a saturated aqueous solution of Rochelle’s salt (5 mL).  
The mixture was transferred to a separatory funnel, the organic layer was separated, and the 
aqueous layer was extracted with Et2O (3 x 10 mL).  The combined organic extracts were dried 
with magnesium sulfate and concentrated in vacuo to give the crude alcohol, which was carried 
on directly to the next step. 
The crude residue was dissolved in CH2Cl2 (2 mL) and transferred to a 20-mL scintillation 
vial.  Dess-Martin Periodinane (0.023 g, 0.051 mmol, 1.00 equiv) was added, and the mixture 
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was allowed to stir at rt until complete conversion of the starting material was observed by 
TLC analysis, typically 10 min. The mixture was then quenched via a 1:1 solution of saturated 
NaHCO3(aq.) and saturated Na2S2O3(aq.) (5 mL) and stirred 5 min.  The reaction mixture was 
then diluted with Et2O (10 mL) and partitioned in a separatory funnel.  The aqueous layer was 
extracted with Et2O (3 x 10 mL), and the combined organic extracts were dried with 
magnesium sulfate and concentrated in vacuo.  The product was purified via flash 
chromatography (100:0 to 97.5:2.5 to 95:5 hexanes:EtOAc) to afford aldehyde 3.131 (0.013 g, 
46% yield) as a clear, viscous oil. Analytical data: 1H NMR  (500 MHz, CDCl3): δ 9.74 (s, 
1H), 7.50-7.49 (m, 4H), 7.36-7.33 (m, 6H), 5.08 (s, 1H),  4.78 (s, 1H), 3.01 (m, 2H), 1.92 (d, 
J = 10.0 Hz, 1H), 1.63-1.57 (m, 4H), 1.34 (s, 3H), 1.21 (s, 3H), 1.15 (s, 3H), 1.06 (s, 3H), 1.03 
(s, 3H), 0.84 (s, 9H), 0.32 (s, 3H), 0.29 (s, 3H), 0.07 (s, 3H), 0.05 (s, 3H). 
 
(3S,4aS,6aS,10aR,10bS,E)-3-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-6a,7,7,10b-
tetramethyldecahydro-1H-benzo[f]chromen-8(4aH)-one O-benzyl oxime (3.133): The 
enone 3.126 (1.61 g, 3.70 mmol, 1.00 equiv) was dissolved in EtOAc (60 mL) in a 250 mL 
round-bottomed flask and charged with Pd/C (2.40 g, 1.50 mass equiv).  The reaction mixture 
was placed under 1 atm (balloon) of H2 and stirred until full conversion of the starting material 
was observed by TLC analysis, typically 30 min.  The mixture was then filtered through a pad 
of celite, and the filter cake was washed with two 20 mL portions of EtOAc.  The solution was 
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then concentrated in vacuo to afford the crude ketone, which was carried to the next step 
without further purification. 
The residue was dissolved in MeOH:H2O (5:1, 80 mL) in a 250 mL round-bottomed flask.  
BnONH3Cl (11.84 g, 74.19 mmol, 20.00 equiv) and NaOAc (4.56 g, 55.64 mmol, 15.00 equiv) 
were added, and the resulting suspension was fitted with a reflux condenser and heated to      85 
ºC with stirring until TLC analysis confirmed complete consumption of the starting material, 
typically 16 h.  The reaction mixture was cooled to rt and concentrated on a rotary evaporator.  
The residue was taken up into H2O (30 mL) and CH2Cl2 (30 mL), and the mixture was 
partitioned in a separatory funnel and extracted with CH2Cl2 (3 x 20 mL).  The combined 
organic extracts were washed with H2O (30 mL), dried with magnesium sulfate, and 
concentrated in vacuo.  The product was purified via flash chromatography (100:0 to 98:2 to 
97.5:2.5 to 95:5 hexanes:EtOAc) to afford oxime 3.133 (1.66 g, 83% yield) as a clear, viscous 
oil. Analytical data: [α]D28 –112.8 (c =0.45, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.37-7.28 
(m, 5H), 5.08 (br s, 2H), 3.35 (dd, J = 9.6, 4.2 Hz, 1H), 3.10 (dd, J = 8.4, 3.0 Hz, 1H), 2.88 
(dd, J = 6.0, 4.2 Hz, 1H), 1.82 (m, 2H), 1.66-1.45 (m, 7H), 1.36 (m, 1H), 1.23 (s, 3H), 1.16 (s, 
3H), 1.13 (s, 3H), 1.01 (s, 3H), 0.85 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H); 13C NMR (150 MHz, 
CDCl3): δ 165.2, 138.7, 128.1, 128.0, 127.4, 85.4, 85.3, 75.1, 74.9, 45.9, 45.5, 41.1, 38.2, 36.2, 
31.3, 27.3, 25.8, 25.0, 24.5, 23.3, 21.4, 20.9, 20.0, 19.0, 18.1, 16.8, 13.3, -2.2; HRMS (ESI+) 
Calcd. For C33H55NO3Si+Na, 564.3849; Found, 564.3862; IR (thin film, cm
-1) 2951, 2855, 
1626, 1470, 1378, 1250, 1173, 1040, 898, 835, 757; TLC (85:15 hexanes:EtOAc): Rf = 0.77. 
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((3S,4aS,6aS,7R,10aR,10bS,E)-8-((benzyloxy)imino)-3-(2-((tert-butyldimethylsilyl)oxy) 
propan-2-yl)-6a,7,10b-trimethyldodecahydro-1H-benzo[f] chromen-7-yl)methyl acetate 
(3.135): A 100 mL round-bottomed flask was charged with oxime 3.133 (1.66 g, 3.06 mmol, 
1.00 equiv) and AcOH:Ac2O (1:1, 31 mL) with magnetic stirring at rt.  Pd(OAc)2 (0.10 g, 0.46 
mmol, 0.15 equiv) and PhI(OAc)2 (1.48 g, 4.60 mmol, 1.50 equiv) were added sequentially, 
and the reaction mixture was warmed to 100 ºC.  This temperature was maintained until TLC 
analysis showed complete conversion of the starting material, typically 1 h.  The mixture was 
cooled to rt, diluted with pentane (30 mL) and H2O (20 mL), and transferred to a separatory 
funnel.  Saturated NaHCO3(aq.) (30 mL) was added dropwise into the separatory funnel, and the 
mixture was allowed to stand 10 min upon completion of the addition.  The layers were 
separated, and the aqueous layer was extracted with pentane (3 x 20 mL).  The combined 
organic extracts were dried with magnesium sulfate and concentrated in vacuo to afford the 
crude acetate 3.135 as a single diastereomer (as determined by 1H NMR spectroscopic analysis 
of the crude reaction mixture, which revealed a single compound).  The product was purified 
via flash chromatography (100:0 to 95:5 to 90:10 hexanes:EtOAc) to afford the acetate 3.135 
(1.49 g, 81% yield) as a reddish-brown, viscous oil.  Analytical data: [α]D28 –66.2 (c =0.70, 
CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.34-7.27 (m, 5H), 5.04 (br s, 2H), 4.55 (d, J = 10.8 
Hz, 1H), 4.03 (d, J = 11.4 Hz, 1H), 3.36 (dd, J = 10.8, 13.6 Hz, 1H), 3.09 (dd, J = 8.4, 3.0 Hz, 
1H), 2.88 (dd, J = 5.4, 4.8 Hz, 1H),1.94 (s, 3H), 1.82-1.74 (m, 2H), 1.63-1.52 (m, 8H), 1.35 
(m, 1H), 1.22 (s, 3H), 1.21 (s, 3H), 1.15 (s, 3H), 0.91 (s, 3H), 0.84 (s, 12H), 0.08 (s, 3H), 0.06 
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(s, 3H); 13C NMR (150 MHz, CDCl3): δ 171.1, 161.6, 128.2, 128.0, 127.4, 85.3, 85.1, 75.4, 
74.8, 65.6, 48.4, 46.0, 42.1, 38.2, 36.3, 32.0, 27.3, 25.8, 25.0, 24.4, 21.4, 21.1, 20.8, 20.1, 18.1, 
17.3, 17.0, 13.5, -2.2; HRMS (ESI+) Calcd. For C35H57NO5Si+Na, 622.3904; Found, 
622.3908; IR (thin film, cm-1) 2953, 2884, 1732, 1470, 1380, 1249, 1038, 835, 756; TLC 
(60:40 hexanes:EtOAc): Rf = 0.80. 
 
Crude 1H NMR spectrum of 3.135. 
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(3S,4aS,6aS,7S,10aR,10bS)-7-(hydroxymethyl)-3-(2-hydroxypropan-2-yl)-6a,7,10b-
trimethyldecahydro-1H-benzo[f]chromen-8(4aH)-one (S15): A 50 mL round-bottomed 
flask was charged with acetate 3.135 (0.71 g, 1.18 mmol, 1.00 equiv) and 2M 
HCl(aq.):MeOH:THF:acetone (10:10:10:1, 12 mL).  The mixture was warmed to 85 ºC and 
stirred until full convergence to a single product was observed by TLC analysis, typically 5 h.  
The mixture was cooled to rt and concentrated on a rotary evaporator, and the residue was 
taken up into H2O (15 mL) and CH2Cl2 (15 mL) and partitioned in a separatory funnel.  The 
mixture was extracted with CH2Cl2 (3 x 10 mL), and the combined organic extracts were dried 
with magnesium sulfate and concentrated in vacuo.  The product was purified via flash 
chromatography (60:40 EtOAc:hexanes) to afford hydroxy ketone S15 (0.28 g, 71% yield) as 
a reddish-brown, viscous oil. Analytical data: [α]D28 –159.6 (c = 0.30, CHCl3); 1H NMR  (600 
MHz, CDCl3): δ 4.12 (dd, J = 8.4, 3.0 Hz, 1H), 3.22 (m, 2H), 3.02 (dd, J = 6.0, 3.0 Hz, 1H), 
2.64 (dd, J = 7.2, 3.0 Hz, 1H), 2.59 (br s, 1H), 2.55 (m, 1H), 2.29 (m, 1H), 1.89-1.86 (m, 2H), 
1.80 (m, 1H), 1.70-1.60 (m, 6H), 1.46 (m, 1H), 1.40 (dt, J = 6.0, 3.6 Hz, 1H), 1.31 (s, 3H), 
1.23 (m, 1H), 1.18 (s, 3H), 1.15 (s, 3H), 0.99 (s, 3H), 0.91 (s, 3H); 13C NMR (150 MHz, 
CDCl3): δ 219.3, 85.0, 84.6, 71.8, 63.6, 57.4, 45.3, 42.1, 37.9, 37.6. 36.4, 30.7, 26.1, 23.9, 23.7, 
21.7, 21.2, 18.2, 16.9, 13.5; HRMS (ESI+) Calcd. For C20H34O4+Na, 361.2355; Found, 
361.2360; IR (thin film, cm-1) 3450, 2950, 1692, 1425, 1166, 1102, 735, 685; TLC (60:40 
hexanes:EtOAc): Rf = 0.12. 
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(3S,4aS,6aS,7S,10aR,10bS)-3-(2-hydroxypropan-2-yl)-6a,7,10b-trimethyl-8-
oxododecahydro-1H-benzo[f]chromene-7-carbaldehyde (3.140): A 20 mL scintillation vial 
was charged with alcohol S15 (0.29 g, 0.84 mmol, 1.00 equiv) and CH2Cl2 (8 mL). Dess-
Martin periodinane (0.71 g, 1.68 mmol, 2.00 equiv) was added at rt with stirring.  The reaction 
mixture was allowed to stir at room temperature until TLC analysis confirmed complete 
conversion of the starting material, typically 20 min.  The mixture was then quenched via a 1:1 
solution of saturated NaHCO3(aq.) and saturated Na2S2O3(aq.) (10 mL), and the mixture was 
stirred 5 min.  The reaction mixture was then diluted with Et2O (15 mL) and partitioned in a 
separatory funnel.  The aqueous layer was extracted with Et2O (3 x 10 mL), and the combined 
organic extracts were dried with magnesium sulfate and concentrated in vacuo.  The product 
was purified via flash chromatography (60:40 to 50:50 hexanes:EtOAc) to afford the 
ketoaldehyde 3.140 (0.28 g, 99% yield) as a pale white powder.  Analytical data: mp 121-125 
°C; [α]D28 –223.7 (c = 0.50, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 10.06 (s, 1H), 3.22 (dd, 
J = 9.0, 3.0 Hz, 1H), 3.02 (dd, J = 6.0, 2.4 Hz, 1H), 2.52-2.46 (m, 2H), 1.94-1.82 (m, 3H), 
1.57-1.70 (m, 5H), 1.47 (m, 1H), 1.26 (s, 3H), 1.24 (s, 3H), 1.22 (m, 1H), 1.18 (s, 3H), 1.15 (s, 
3H), 0.94 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 214.0, 204.2, 84.9, 84.6, 71.9, 64.7, 45.1, 
43.4, 37.8, 37.6, 36.5, 31.6, 26.1, 23.7, 23.5, 21.6, 20.9, 19.5, 14.8, 13.6; HRMS (ESI+) Calcd. 
For C20H32O4+Na, 359.2199; Found, 359.2198; IR (thin film, cm
-1) 3019, 2955, 2857, 2400, 
1721, 1388, 1265, 1215, 1098; TLC (60:40 hexanes:EtOAc): Rf = 0.24. 
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(3S,4aS,6aS,7S,10aR,10bS)-7-(1-hydroxyallyl)-3-(2-hydroxypropan-2-yl)-6a,7,10b-
trimethyl-8-vinyldodecahydro-1H-benzo[f]chromen-8-ol (3.142): A flame-dried, 20 mL 
scintillation vial was charged with LiCl (0.30 g, 7.13 mmol, 20.00 equiv equiv), anhydrous 
CeCl3 (0.88 g, 3.57 mmol, 10.00 equiv), and a stir bar in a nitrogen-filled glove box.  The vial 
was removed from the glove box and placed under an N2 atmosphere.  THF (5 mL) was added, 
and this mixture was stirred at rt for 2.5 h.  A separate flame-dried 20 mL scintillation vial was 
charged with aldehyde 3.140 (0.12 g, 0.36 mmol, 1.00 equiv) and THF (2 mL) under an 
atmosphere of N2.  The CeCl3•2LiCl suspension was added to the solution of 3.140 at rt, and 
the resulting mixture was stirred 2.5 h.  The reaction was subsequently cooled to -78 ºC, and 
vinylmagnesium bromide (1 M in THF, 3.57 mL, 3.57 mmol, 10 equiv) was added.  The 
reaction mixture was allowed to stir at this temperature until TLC analysis confirmed complete 
consumption of the starting material, typically 20 min.  The reaction was quenched with MeOH 
(3 mL), and the mixture was immediately warmed to rt upon which 5% AcOH(aq.) (2 mL) and 
Et2O (2 mL) were added with stirring.  Once the vial had reached rt, the solution was 
transferred to a separatory funnel, diluted with H2O (15 mL) and extracted with Et2O (3 x 15 
mL).  The combined organic extracts were washed with saturated NaHCO3(aq.) (10 mL), dried 
with magnesium sulfate and concentrated in vacuo.  The product was purified via flash 
chromatography (80:20 to 70:30 to 60:40 hexanes:EtOAc) to afford an inseparable 2.6:1 
mixture of diol diastereomers 3.142 (0.14 g, 99% yield) as a pale white, viscous foam.  
Analytical data: [α]D28 –182.8 (c = 0.25, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 6.30 (dd, J 
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= 10.8, 6.0 Hz, 1H), 6.14 (m, 1H), 5.24 (d, J = 17.4 Hz, 1H), 5.08 (d, J = 10.8 Hz, 1H), 5.03-
4.99 (m, 2H), 4.40 (d, J = 8.4 Hz, 1H), 3.16 (m, 1H), 2.88 (m, 1H), 1.83 (m, 3H), 1.72 (m, 2H), 
1.59 (m, 3H), 1.53 (s, 3H), 1.45-1.36 (m, 5H), 1.15 (s, 3H), 1.14 (s, 3H), 1.03 (m, 1H), 0.90 (s, 
3H), 0.87 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 145.8, 140.7, 116.4, 112.6, 85.7, 84.5, 80.0, 
79.6, 72.0, 49.4, 47.3, 43.1, 38.0, 36.3, 35.9, 32.4, 26.0, 24.3, 23.6, 21.9, 19.5, 18.6, 17.0, 13.3; 
HRMS (ESI+) Calcd. For C24H40O4+Na, 415.2825; Found, 415.2829; IR (thin film, cm
-1) 
3303, 2949, 2877, 1621, 1461, 1301, 1089, 920, 737; TLC (60:40 hexanes:EtOAc): Rf = 0.32. 
 
(2S,4aS,4bR,9aS,9bS,11aS)-2-(2-hydroxypropan-2-yl)-4a,9a,9b-trimethyl-
3,4,4a,4b,5,6,9,9a,9b,10,11,11a-dodecahydroindeno[5,4-f]chromene-6a,9(2H)-diol 
(3.143): A flame-dried 20 mL scintillation vial was charged with Grubbs’ second generation 
catalyst (0.99 g, 0.12 mmol, 0.20 equiv) and a stir bar in a nitrogen-filled glove box.  The vial 
was removed from the glove box and charged with CH2Cl2 (12 mL) under an atmosphere of 
N2.  Diol 3.142 (0.23 g, 0.59 mmol, 1.00 equiv) was added as a solution in CH2Cl2 (3 mL), and 
the mixture was allowed to stir at rt until complete conversion of the starting material was 
observed by TLC analysis, typically 3 h.  The reaction mixture was concentrated in vacuo, and 
the product was purified via flash chromatography (80:20 to 70:30 to 60:40 hexanes:EtOAc) 
to afford allylic alcohol 3.143 (0.16 g, 73% yield) as a pale-brown viscous foam. Analytical 
data: [α]D28 –62.8 (c = 0.75, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 6.22 (d, J = 5.4 Hz, 1H), 
6.14 (dd, J = 3.0, 2.4 Hz, 1H), 4.42 (br s, 1H), 3.18 (dd, J = 9.0, 3.0 Hz, 1H), 2.95 (dd, J = 7.8, 
3.6 Hz, 1H), 2.69 (br s, 1H), 2.26 (d, J = 5.4 Hz, 1H), 2.22 (br s, 1H), 1.83-1.75 (m, 8H), 1.63 
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(s, 3H), 1.56-1.54 (m, 3H), 1.42 (m, 2H), 1.17 (s, 3H), 1.16 (s, 3H), 0.94 (s, 3H), 0.92 (s, 3H); 
13C NMR (150 MHz, CDCl3): δ 143.2, 137.2, 87.3, 86.0, 84.6, 83.3, 71.9, 52.5, 47.9, 41.8, 
38.3, 36.3, 32.9, 30.4, 26.8, 26.1, 23.9, 23.6, 21.9, 20.2, 17.7, 13.2; HRMS (ESI+) Calcd. For 
C22H36O4+Na, 387.2512; Found, 387.2519; IR (thin film, cm
-1) 3400, 2951, 2675, 1729, 1449, 
1384, 1256, 1097, 1023, 910, 754; TLC (60:40 hexanes:EtOAc): Rf = 0.25. 
 
(2S,4aS,4bR,9aS,9bS,11aS)-2-(2-hydroxypropan-2-yl)-4a,9a,9b-trimethyl-
3,4,4a,4b,5,6,8,9a,9b,10,11,11a-dodecahydroindeno[5,4-f]chromen-9(2H)-one (3.144): A 
flame-dried 20 mL scintillation vial was charged with diol 3.143 (0.15 g, 0.40 mmol, 1.00 
equiv) and CH2Cl2 (9 mL) under and atmosphere of N2.  The mixture was cooled to 0 ºC, and 
TFA (0.15 mL, 2.02 mmol, 5.00 equiv) was added.  The reaction mixture was warmed to rt 
and allowed to stir until complete conversion of the starting material was observed by TLC 
analysis, typically 30 min.  The reaction was quenched with saturated NaHCO3(aq.) (5 mL), and 
the mixture was partitioned in a separatory funnel.  The aqueous layer was extracted with 
CH2Cl2 (3 x 5 mL), and the combined organic extracts were dried with Na2SO4 and 
concentrated in vacuo.  The product was purified via flash chromatography (90:10 to 80:20 to 
70:30 hexanes:EtOAc) to afford the non-conjugated enone 3.144 (0.10 g, 71% yield) as a pale 
brown, viscous oil. Analytical Data: [α]D28 -77.7 (c = 0.50, CHCl3); 1H NMR  (600 MHz, 
CDCl3): δ 5.64 (m, 1H), 3.17 (dd, J = 9.0, 2.4 Hz, 1H), 2.95 (dd, J = 5.4, 4.8 Hz, 1H), 2.83 (m, 
1H), 2.69 (m, 1H), 2.61 (br s,1H), 2.40 (m, 1H), 2.10 (br s, 1H), 1.84 (m, 2H), 1.64 (m, 3H), 
1.55 (m, 2H), 1.43-1.33 (m, 3H), 1.16 (s, 3H), 1.13 (br s, 4H), 1.12 (s, 3H), 0.91 (s, 3H), 0.83 
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(s, 3H); 13C NMR (150 MHz, CDCl3): δ 223.0, 148.2, 116.3, 85.5, 84.4, 71.8, 59.3, 46.6, 43.0, 
41.1, 37.9, 36.5, 30.9, 27.6, 26.1, 24.0, 23.7, 21.8, 21.7, 17.6, 17.4, 13.4; HRMS (ESI+) Calcd. 
For C22H34O3+Na, 369.2406; Found, 369.2398; IR (thin film, cm
-1) 3053, 2979, 2977, 1734, 
1558, 1472, 1373, 1265, 1139, 1086, 971, 921, 704; TLC (80:20 hexanes:EtOAc): Rf = 0.23. 
 
(2S,4aS,4bR,6aR,9aS,9bS,11aS)-2-(2-hydroxypropan-2-yl)-4a,9a,9b-
trimethyltetradecahydroindeno[5,4-f]chromen-9(2H)-one (3.145): A 20 mL scintillation 
vial was charged with ketone 3.144 (0.008 g, 0.02 mmol, 1.00 equiv) and EtOH (2 mL), and 
Pd/C (0.013 g, 1.50 mass equiv) was added.  The reaction mixture was placed under 1 atm H2 
(balloon), and the mixture was allowed to stir overnight.  The reaction was filtered through a 
celite plug, and the filtrate was concentrated on a rotary evaporator to give the crude ketone as 
a single diastereomer (as determined by 1H NMR spectroscopic analysis of the crude reaction 
mixture, which revealed a single compound).  The product was purified via flash 
chromatography (90:10 to 80:20 to 70:30 hexanes:EtOAc) to afford ketone 3.145 as a clear, 
viscous oil. Analytical data: [α]D28 -45.2 (c = 0.35, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 
3.18 (dd, J = 9.0, 3.0 Hz, 1H), 2.92 (d, J = 6.6, 4.2 Hz, 1H), 2.60 (br s, 1H), 2.33 (m, 1H), 2.21 
(m, 1H), 2.03 (m, 1H), 1.92-1.82 (m, 3H), 1.74 (m, 2H), 1.64-1.41 (m, 11H), 1.17 (s, 3H), 1.14 
(s, 3H), 1.10 (s, 3H), 1.04 (s, 3H), 0.85 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 224.9, 85.4, 
84.4, 71.8, 54.5, 47.5, 46.2, 39.3, 38.8, 37.8, 36.3, 32.5, 26.8, 26.2, 26.1, 23.7, 23.5, 21.8, 20.9, 
19.5, 17.3, 13.5; HRMS (ESI+) Calcd. For C22H36O3+Na, 371.2562; Found, 371.2554; IR 
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(thin film, cm-1) 3446, 2955, 2852, 1731, 1636, 1520, 1473, 1396, 1085, 754; TLC (80:20 
hexanes:EtOAc): Rf = 0.20. 
 
Crude 1H NMR Spectrum of 3.145 
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(2S,4aS,4bR,9S,9aS,9bS,11aS)-2-(2-hydroxypropan-2-yl)-4a,9a,9b-trimethyl-
2,3,4,4a,4b,5,6,8,9,9a,9b,10,11,11a-tetradecahydroindeno[5,4-f]chromen-9-ol (3.146): A 
flame-dried 20 mL scintillation vial was charged with diol 3.143 (0.16 g, 0.43 mmol, 1.00 
equiv) and CH2Cl2 (9 mL) under and atmosphere of N2.  The mixture was cooled to 0 ºC, and 
TFA (0.17 mL, 2.14 mmol, 5.00 equiv) was added.  The reaction mixture was warmed to rt 
and allowed to stir until complete conversion of the starting material was observed by TLC 
analysis, typically 30 min.  The reaction was quenched with saturated NaHCO3(aq.) (5 mL), and 
the mixture was partitioned in a separatory funnel.  The aqueous layer was extracted with 
CH2Cl2 (3 x 5 mL), and the combined organic extracts were dried with Na2SO4 and 
concentrated in vacuo to afford the crude non-conjugated enone 3.144, which was carried to 
the next step without further purification. 
A flame-dried 20 mL scintillation vial was charged with the crude ketone 3.144 and THF (5 
mL) under an atmosphere of N2.  The reaction mixture was cooled to 0 ºC, and LiAlH4 (1M in 
THF, 2.00 mL, 2.00 mmol, 4.70 equiv) was added dropwise.  The reaction mixture was allowed 
to stir at this temperature until TLC analysis indicated complete consumption of the starting 
material, typically 30 min.  The reaction was then carefully quenched with saturated NH4Cl(aq.) 
(4 mL) and stirred 5 min at rt.  The resulting mixture was partitioned in a separatory funnel 
and extracted with Et2O (3 x 5 mL).  The combined organic extracts were dried with 
magnesium sulfate and concentrated in vacuo to afford the crude alcohol 3.146 as a single 
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diastereomer (as determined by 1H NMR spectroscopic analysis of the crude reaction mixture, 
which revealed a single compound).  The crude product was purified via flash chromatography 
(80:20 to 70:30 to 60:40 hexanes:EtOAc) to afford alcohol 3.146 (0.90 g, 60% yield) as a pale 
yellow foam. Analytical data: [α]D28 –116.4 (c =0.50, CHCl3); 1H NMR  (600 MHz, CDCl3): 
δ 5.22 (s, 1H), 4.37 (t, J = 8.4 Hz, 1H), 3.18 (dd, J = 9.0, 3.0 Hz, 1H), 2.95 (m, 1H), 2.68 (br 
s, 1H), 2.54 (m, 1H), 2.25 (d, J = 10.8 Hz, 1H), 2.20 (m, 1H), 1.94 (br s, 1H), 1.80 (d, J = 2.4 
Hz, 1H), 1.69-1.59 (m, 6H), 1.50 (m, 1H), 1.42-1.36 (m, 3H), 1.19 (s, 3H), 1.17 (s, 3H), 1.14 
(s, 3H), 0.86 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 148.1, 117.5, 85.8, 85.2, 84.4, 71.9, 55.1, 
48.1, 43.9, 40.9, 38.0, 36.7, 31.8, 27.0, 26.1, 24.6, 23.8, 23.6, 22.8, 21.9, 16.7, 13.5; HRMS 
(ESI+) Calcd. For C22H36O3+Na, 371.2562; Found, 371.2570; IR (thin film, cm
-1) 3433, 2979, 
2678, 2399, 1452, 1373, 1215, 1093, 955, 755, 668; TLC (60:40 hexanes:EtOAc): Rf = 0.36 
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Crude 1H NMR spectrum of 3.146 
 
 
(2S,4aS,4bR,6aS,9aS,9bS,11aS)-2-(2-hydroxypropan-2-yl)-4a,9a,9b-
trimethyltetradecahydroindeno[5,4-f]chromen-9(2H)-one (3.25): A flame-dried, 20 mL 
scintillation vial was charged with Crabtree’s catalyst (0.01 g, 0.01 mmol, 0.15 equiv) in a 
nitrogen-filled glove box.  The vial was sealed with a rubber-septum, removed from the glove 
box, and placed under an atmosphere of N2.  CH2Cl2 (4 mL, freshly degassed via N2 bubbling 
for 30 min) was added followed by a solution of alcohol 3.146 (0.025 g, 0.07 mmol, 1.00 equiv) 
in degassed CH2Cl2 (2 mL), and the resulting mixture was placed under an atmosphere of H2 
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(balloon) and allowed to stir 36 h at rt.  The resulting mixture was concentrated in vacuo to 
afford the crude alcohol 3.148, which was carried forward to the next step without purification.  
Although this material was not isolated, the diastereomeric ratio was determined by 1H NMR 
spectroscopic analysis of the crude reaction mixture, which revealed a single compound.  This 
crude 1H NMR spectrum is included below. 
 
Crude 1H NMR spectrum of 3.148 
 
A 20 mL scintillation vial was charged with the crude alcohol 3.148 and CH2Cl2 (3 mL) with 
magnetic stirring.  Dess-Martin periodinane (0.045 g, 0.11 mmol, 1.50 equiv) was added, and 
the reaction mixture was allowed to stir at rt until complete conversion of the starting materal 
was observed by TLC analysis, typically 20 min.  The reaction was then quenched via a 1:1 
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solution of saturated NaHCO3(aq.) and saturated Na2S2O3(aq.) (3 mL), and the mixture was stirred 
5 min.  The reaction mixture was then diluted with Et2O (5 mL) and partitioned in a separatory 
funnel.  The aqueous layer was extracted with Et2O (3 x 5 mL), and the combined organic 
extracts were dried with magnesium sulfate and concentrated in vacuo.  The product was 
purified via flash chromatography (90:10 to 80:20 to 70:30 hexanes:EtOAc) to afford ketone 
3.25 (0.022 g, 89% yield) as a clear semisolid.  Slow evaporation from HPLC-grade hexanes 
provided crystals suitable for X-ray crystallographic analysis.  Analytical data: mp 125-130 
°C; [α]D27 –89.3 (c = 0.85, CHCl3);     1H NMR  (500 MHz, CDCl3): δ 3.16 (dd, J = 9.0, 3.0 
Hz, 1H), 2.93 (m, 1H), 2.65 (br s, 1H), 2.32 (dd, J = 11.0, 8.5 Hz, 1H), 2.19-2.14 (m, 2H), 2.00 
(m, 1H), 1.78-1.23 (m, 15H), 1.16 (s, 3H), 1.14 (s, 3H), 1.02 (s, 3H), 0.92 (s, 3H), 0.83 (s, 3H); 
13C NMR (150 MHz, CDCl3): δ 221.2, 85.7, 84.4, 71.8, 56.1, 46.9, 40.2, 39.9, 37.8, 37.5, 36.5, 
31.1, 26.1, 25.8, 24.2, 23.8, 23.7, 21.9, 21.2, 18.9, 12.9, 10.3; HRMS (ESI+) Calcd. For 
C22H36O3+Na, 371.2562; Found, 371.2560; IR (thin film, cm
-1) 3566, 3446, 2946, 2876, 1772, 
1731, 1472, 1385, 1259, 1158, 1098, 974, 735; TLC (70:30 hexanes:EtOAc): Rf = 0.60. 
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Note: The following sequence for conversion of 3.25 to paspaline was adapted from the 
previously published protocol by Smith and co-workers.16d 
 
(2S,4aS,4bR,6aS,9aS,9bS,11aS)-2-(2-hydroxypropan-2-yl)-4a,9a,9b-trimethyl-8-(methyl 
thio)tetradecahydroindeno[5,4-f]chromen-9(2H)-one (3.150): A flame-dried, 20 mL 
scintillation vial was cooled to 0 °C and charged with THF (1 mL) and a freshly-prepared 
solution of lithium diisopropylamide (0.5 M in THF, 0.57 mL, 0.29 mmol, 5.00 equiv) under 
an atmosphere of N2. The resulting solution was then charged with a solution of ketone 3.25 
(0.02 g, 0.06 mmol, 1.00 equiv) in THF (0.5 mL), and the reaction mixture was allowed to stir 
15 min at 0 °C.  HMPA (0.6 mL) was added followed by Me2S2 (0.031 mL, 0.34 mmol, 6.00 
equiv), and the reaction was allowed to stir until TLC analysis showed complete conversion of 
the starting material, typically 10 min.  The reaction was quenched via addition of H2O (5 mL).  
The resulting mixture was transferred to a separatory funnel, and the organic layer was 
separated.  The aqueous layer was extracted with Et2O (3 x 5 mL), and the combined organic 
extracts were washed with brine (2 x 10 mL), dried with magnesium sulfate, and concentrated 
in vacuo.  The product was purified via flash chromatography (90:10 to 80:20 to 70:30 
hexanes:EtOAc) to afford an inseparable, diastereomeric mixture of thioethers 3.150 (0.019 g, 
84% yield) as a yellow, viscous oil. Analytical data: [α]D27 – 57.9 (c = 0.70, CHCl3); 1H NMR  
(600 MHz, CDCl3): δ 3.16 (dd, J = 9.0, 3.0 Hz, 1H), 2.94 (m, 2H), 2.61 (br s, 1H), 2.25 (br s, 
3H), 2.22-2.13 (m, 3H), 1.63-1.57 (m, 11H), 1.47 (m, 10H), 1.17 (s, 3H), 1.14 (s, 3H), 1.02 (s, 
3H), 1.01 (s, 3H), 0.83 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 218.4, 85.6, 84.4, 71.8, 56.6, 
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49.8, 46.6, 40.1, 38.1, 37.8, 36.4, 31.8, 31.1, 26.1, 25.2, 24.2, 23.7, 21.8, 21.1, 19.0, 15.4, 12.9, 
11.0; HRMS (ESI+) Calcd. For C23H38O3S+Na, 417.2439; Found, 417.2438; IR (thin film, 
cm-1) 3446, 2946, 2874, 1732, 1652, 1519, 1456, 1386, 1232, 1152, 1086, 946; TLC (70:30 
hexanes:EtOAc): Rf = 0.63. 
 
(2S,4aS,4bR,6aS,9aS,9bS,11aS)-8-(2-aminophenyl)-2-(2-hydroxypropan-2-yl)-4a,9a,9b-
trimethyltetradecahydroindeno[5,4-f]chromen-9(2H)-one (3.151):  A flame-dried, 20 mL 
scintillation vial was charged with a solution of aniline (0.25 M in CH2Cl2, 0.26 mL, 0.07 
mmol, 2.00 equiv) under an atmosphere of N2, and the resulting solution was cooled to -78 °C.  
The lights in the fume hood were turned off, and a solution of tBuOCl (0.25 M in CH2Cl2, 0.26 
mL, 0.07 mmol, 2.00 equiv) was added dropwise.  The reaction mixture was allowed to stir 15 
min, upon which a solution of thioether 3.150 (0.013 g, 0.03 mmol, 1.00 equiv) in CH2Cl2 (1.5 
mL) was added.  The mixture was allowed to stir 50 min, upon which NEt3 (0.02 mL, 0.13 
mmol, 4.00 equiv) was added.  The reaction was then warmed to rt and allowed to stir until a 
bright orange color was observed, typically 5 min.  The resulting solution was diluted with 
H2O (5 mL) and Et2O (10 mL) and partitioned in a separatory funnel.  The organic layer was 
separated, and the aqueous layer was extracted with Et2O (3 x 5 mL).  The combined organic 
extracts were dried with magnesium sulfate and concentrated in vacuo to afford a crude mixture 
of diastereomeric keto-anilines, which was carried directly on to the next step without further 
purification. 
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The residue was taken up into EtOH (1 mL) in a 20 mL scintillation vial, and a slurry of Raney 
Ni in H2O (150 mg) was added.  The reaction mixture was stirred vigorously at rt until complete 
conversion of the intermediate thioether was observed by TLC analysis, typically 1 h.  The 
reaction mixture was filtered through a celite plug, and the resulting solution was concentrated 
in vacuo.   The crude product was purified via flash chromatography (90:10 to 80:20 to 70:30 
to 60:40 hexanes:EtOAc) to afford ketoaniline 3.151 (0.009 g, 62% yield) as yellow, viscous 
oil. Analytical data: [α]D27 +26.6 (c = 0.45, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.06 (m, 
2H), 6.77 (m, 2H), 4.21 (br s, 2H), 3.54 (t, J = 9.0 Hz, 1H), 3.16 (dd, J = 9.6, 2.4 Hz, 1H), 2.94 
(m, 1H), 2.62 (br s, 1H), 2.35 (m, 1H), 2.14-2.04 (m, 3H), 1.84-1.37 (m, 16H), 1.17 (s, 3H), 
1.15 (s, 1H), 1.11 (s, 3H), 0.98 (s, 3H), 0.86 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 221.0, 
146.0, 127.6, 125.8, 125.4, 119.1, 117.5, 85.6, 84.5, 71.8, 57.0, 51.5, 46.8, 40.1, 38.0, 37.8, 
36.5, 31.3, 28.9, 26.1, 25.4, 24.2, 23.7, 21.9, 21.2, 19.2, 12.9, 10.0; HRMS (ESI+) Calcd. For 
C28H41NO3+Na, 462.2984; Found, 462.2983; IR (thin film, cm
-1) 3421, 3053, 2984, 2877, 
2305, 1732, 1652, 1456, 1362, 1265, 738; TLC (70:30 hexanes:EtOAc): Rf = 0.30. 
 
Paspaline (3.1):  A 1 mL dram vial was charged with ketone 3.151 (0.007 g, 0.02 mmol, 1.00 
equiv), CH2Cl2 (1.2 mL), and PTSA (0.002 g, 0.01 mmol, 0.66 equiv).  The vial was sealed, 
and the mixture was warmed to 50 °C and stirred for 16 hours.  The reaction mixture was 
cooled to rt, diluted with H2O (10 mL) and Et2O (10 mL) and transferred to a separatory funnel.  
The organic layer was separated, and the aqueous layer was extracted with Et2O (3 x 5 mL).  
The combined organic extracts were dried with magnesium sulfate and concentrated in vacuo. 
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The product was purified via flash chromatography (90:10 to 80:20 hexanes:EtOAc) to afford 
paspaline (0.006 g, 89% yield) as a yellow foam.  Slow evaporation from HPLC-grade hexanes 
provided crystals suitable for X-ray crystallographic analysis. Analytical data: [α]D25  –16.4 (c 
= 0.30, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.72 (br s, 1H), 7.42 (m, 1H), 7.30 (m, 1H), 
7.07 (m, 2H), 3.21 (dd, J = 9.6, 2.4 Hz, 1H), 3.03 (dd, J = 8.4, 3.6 Hz, 1H), 2.77-2.65 (m, 3H), 
2.32 (dd, J = 10.8, 2.4 Hz, 1H), 1.96 (m, 1H), 1.84-1.77 (m, 3H), 1.70-1.56 (m, 6H), 1.49-1.37 
(m, 3H), 1.19 (s, 3H), 1.17 (s, 3H), 1.13 (s, 3H), 1.03 (s, 3H), 0.88 (s, 3H); 13C NMR (150 
MHz, CDCl3): δ 150.8, 139.3, 125.1, 120.4, 119.5, 118.4, 118.2, 111.4, 85.7, 84.7, 71.9, 53.0, 
48.7, 46.4, 40.0, 37.6, 36.5, 33.9, 27.5, 26.1, 25.2, 24.6, 23.7, 22.0, 21.9, 20.0, 14.6, 12.6; 
HRMS (ESI+) Calcd. For C28H39NO2+H, 422.3059; Found, 422.3056; IR (thin film, cm
-1) 
3565, 3467, 3053, 2982, 2930, 2855, 1455, 1386, 1375, 1331, 1265, 1158, 1087, 1037; TLC 
(70:30 hexanes:EtOAc): Rf = 0.42. 
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Comparison of Reported Analytical Data for Paspaline 
Data 
Type 
Data Reported in 
Isolation Paper4a 
Data Reported by Smith and 
Co-workers16d 
Synthetic Paspaline 
1H NMR 
(CDCl3) 
1H NMR (100 MHz, CDCl3) 
7.82 (s, 1H) 
7.0-7.5 (m, 4H) 
3.68 (q, J = 2.5 Hz, 1H) 
3.3-1.4 (m, 18H) 
1.18 (s, 6H) 
1.13 (s, 3H) 
1.02 (s, 3H) 
0.88 (s, 3H) 
1H NMR (250 MHz, CDCl3) 
7.74 (br s, 1H) 
7.44-7.40 (m, 1H) 
7.31-7.26 (m, 1H) 
7.09-7.06 (m, 2H) 
3.21 (dd, J = 11.8, 3.0 Hz, 1H) 
3.03 (dd, J = 11.3, 4.2 Hz, 1H) 
2.85-2.62 (m, 3H) 
2.32 (dd, J = 12.7, 10.4 Hz, 1H) 
2.04-1.25 (m, 13H) 
1.19 (s, 3H) 
1.17 (s, 3H) 
1.13 (s, 3H) 
1.02 (s, 3H) 
0.88 (s, 3H) 
 
1H NMR (600 MHz, CDCl3) 
7.72 (br s, 1H) 
7.42 (m, 1H) 
7.30 (m, 1H) 
7.07 (m, 2H) 
3.21 (dd, J = 9.6, 2.4 Hz, 1H) 
3.03 (dd, J = 8.4, 3.6 Hz, 1H) 
2.77-2.65 (m, 3H) 
2.32 (dd,J = 10.8, 2.4 Hz, 
1H) 1.96 (m, 1H) 
1.84-1.77 (m, 3H) 
1.70-1.56 (m, 6H) 
1.49-1.37 (m, 3H) 
1.19 (s, 3H) 
1.17 (s, 3H) 
1.13 (s, 3H)  
1.03 (s, 3H)  
0.88 (s, 3H) 
13C NMR 
(CDCl3) 
NA NA 13C NMR (150 MHz, CDCl3) 
150.8, 139.3, 125.1, 120.4, 
119.5, 118.4, 118.2, 111.4, 
85.7, 84.7, 71.9, 53.0, 48.7, 
46.4, 40.0, 37.6, 36.5, 33.9, 
27.5, 26.1, 25.2, 24.6, 23.7, 
22.0, 21.9, 20.0, 14.6, 12.6 
Rotation -23.0 (c = 0.36, CHCl3)  -42.2 (c = 0.64, C6H6) –16.4 (c = 0.30, CHCl3) 
IR 3500, 3450, 2950, 2850, 
1440, 1380, 1360, 1320, 
1280, 1150, 1090, 1030, 
1010, 970, 940, 895, 875 
3550, 3470, 3320, 2980, 2950, 
2850, 1450, 1385, 1375, 1330, 
1300, 1260, 1240, 1160, 1090, 
1035 
3565, 3467, 3053, 2982, 
2930, 2855, 1455, 1386, 
1375, 1331, 1265, 1158, 
1087, 1037 
MS NA m/z 421.2997 (M+, calcd for 
C28H39NO2, 421.3013) 
422.3056 (Calcd. For 
C28H39NO2+H, 422.3059) 
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Computational Details: 
 
Hydroxyketone 3.78: 
 
 
 
 
 
 
 
 
Cartesian Coordinates: 
 
C          0.38546        0.90879       -0.16849 
C          1.73413        1.58994       -0.51067 
C          2.09875        2.70065        0.48898 
C          0.95795        3.68809        0.66408 
C         -0.46509        3.10881        0.89226 
C         -0.37068        1.56788        0.99805 
H         -0.27802        0.90915       -1.03680 
H          2.54204        0.85495       -0.54461 
H          2.32003        2.26173        1.47108 
H          0.15664        1.33392        1.93552 
H          0.54620       -0.14523        0.08789 
H          1.68471        2.02809       -1.51165 
382 
 
H          2.98467        3.25643        0.17773 
O         -1.69458        1.02910        1.07655 
H         -1.62408        0.06885        1.12912 
C         -1.31718        3.53868       -0.32139 
H         -2.32521        3.13649       -0.25078 
H         -1.37610        4.62651       -0.36428 
H         -0.87890        3.19469       -1.26323 
C         -0.96615        3.74892        2.22176 
H         -0.31676        3.37774        3.02538 
H         -0.76610        4.82177        2.15141 
C         -2.43226        3.53603        2.66052 
H         -2.69977        2.48553        2.57142 
H         -2.46197        3.76933        3.73511 
C         -3.43397        4.43288        1.98289 
H         -3.15545        5.48818        1.97574 
C         -4.61612        4.11033        1.44553 
C         -5.16718        2.70863        1.36389 
H         -4.43947        1.94478        1.63475 
H         -6.04066        2.59306        2.01783 
H         -5.51464        2.49005        0.34719 
C         -5.51843        5.17125        0.86394 
H         -5.09080        6.17157        0.95968 
H         -5.71319        4.98733       -0.19991 
H         -6.49723        5.17512        1.35944 
O          1.13979        4.88331        0.61255 
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Hydrazone 3.87: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cartesian Coordinates: 
 
C         -1.58706        2.68188        0.87646 
C         -0.26743        2.85482        0.09964 
C         -0.04916        1.69871       -0.90540 
C         -0.67128        0.41977       -0.41063 
C         -2.20054        0.44181       -0.20137 
C         -2.62780        1.92617        0.04540 
H         -1.41458        2.13073        1.80567 
H         -0.26724        3.80193       -0.44877 
H         -0.55088        1.94371       -1.84972 
N         -0.08880       -0.69814       -0.19218 
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H         -2.72316        2.42606       -0.93155 
H         -1.98677        3.66081        1.16687 
H          0.56884        2.88083        0.79751 
H          1.00408        1.55438       -1.13081 
O         -3.90730        1.92929        0.68252 
H         -4.13426        2.84425        0.88421 
C         -2.58511       -0.44670        0.99533 
H         -3.65727       -0.42029        1.16701 
H         -2.27775       -1.47461        0.80986 
H         -2.08240       -0.11640        1.90739 
C         -2.80907       -0.09244       -1.53598 
H         -2.41954        0.52858       -2.35224 
H         -2.40338       -1.09527       -1.70547 
C         -4.35010       -0.13512       -1.66636 
H         -4.78697        0.77535       -1.25720 
H         -4.57100       -0.12038       -2.74339 
C         -4.99829       -1.36812       -1.09466 
H         -4.55510       -2.30310       -1.44195 
C         -6.05066       -1.46034       -0.27384 
C         -6.78810       -0.28226        0.31161 
H         -6.26749        0.66279        0.16612 
H         -7.79241       -0.19426       -0.12177 
H         -6.92899       -0.41666        1.39031 
C         -6.59302       -2.80687        0.13876 
H         -6.04798       -3.62999       -0.32832 
385 
 
H         -6.53780       -2.93926        1.22616 
H         -7.65164       -2.90790       -0.13090 
N          1.33908       -0.70447       -0.44238 
H          1.54340       -1.66076       -0.72908 
S          2.24863       -0.47532        1.02527 
O          2.16207       -1.63675        1.90726 
O          1.88407        0.85262        1.51069 
C          3.90198       -0.42842        0.33162 
C          4.36514        0.74097       -0.27035 
C          4.70968       -1.55737        0.42501 
C          5.65236        0.76723       -0.78926 
H          3.73039        1.61762       -0.31480 
C          5.99748       -1.51255       -0.10374 
H          4.33972       -2.44706        0.92043 
C          6.48829       -0.35626       -0.71654 
H          6.01827        1.67703       -1.25591 
H          6.63084       -2.39116       -0.03010 
C          7.89322       -0.29966       -1.26135 
H          7.92711        0.20612       -2.22970 
H          8.55218        0.25497       -0.58500 
H          8.31797       -1.29730       -1.38716 
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Non-conjugated enone 3.144: 
 
 
 
 
 
 
 
 
 
 
Cartesian Coordinates 
 
C          3.07284        0.27646       -0.57012 
C          3.67799       -1.09995       -0.33412 
C          2.82409       -2.30537       -0.56760 
C          1.47793       -2.15739        0.16950 
C          0.80618       -0.80269       -0.13254 
C          1.72693        0.41724        0.27484 
C          4.21018        1.21207       -0.08036 
C          5.41555        0.36053        0.33604 
C          4.92366       -1.04576        0.14466 
H          2.62477       -2.41512       -1.64246 
H          0.82104       -2.97698       -0.13199 
H          0.73412       -0.74313       -1.22617 
H          5.70226        0.59584        1.36860 
387 
 
H          5.52141       -1.91755        0.39349 
O          4.17409        2.41729       -0.07150 
C          2.91393        0.56961       -2.08321 
H          2.75595        1.63443       -2.25701 
H          3.82477        0.28111       -2.61522 
H          2.08759        0.01976       -2.53660 
H          6.28146        0.62548       -0.28390 
H          3.34239       -3.21635       -0.25215 
H          1.64100       -2.27515        1.24426 
C          1.00547        1.74995       -0.04230 
H          0.93855        1.88386       -1.12596 
H          1.60610        2.58474        0.32521 
C         -0.42441        1.81937        0.51441 
H         -0.44392        1.79995        1.60776 
H         -0.89268        2.76195        0.21509 
C         -1.23133        0.66890       -0.06110 
H         -1.15200        0.74081       -1.16054 
C         -0.69253       -0.73173        0.33044 
C          2.11980        0.42486        1.77160 
H          2.60874       -0.49707        2.08817 
H          2.80969        1.24781        1.97288 
H          1.26545        0.58321        2.42481 
C         -0.90465       -1.03070        1.82758 
H         -1.95909       -0.95628        2.09040 
H         -0.57522       -2.04465        2.06940 
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H         -0.37254       -0.35049        2.48794 
C         -1.55277       -1.73700       -0.48978 
H         -1.31115       -2.76954       -0.22074 
H         -1.30244       -1.62837       -1.55333 
C         -3.43755       -0.04404       -0.51492 
H         -3.27105        0.19837       -1.57742 
C         -3.06526       -1.51414       -0.30503 
H         -3.62686       -2.12459       -1.01516 
H         -3.36993       -1.84061        0.69223 
O         -2.60900        0.81362        0.27362 
C         -4.90694        0.32004       -0.21075 
C         -5.27818        0.11287        1.26157 
H         -4.64112        0.70998        1.91633 
H         -6.31667        0.41625        1.43321 
H         -5.19000       -0.93663        1.54651 
C         -5.18335        1.76711       -0.63434 
H         -4.96940        1.89756       -1.69806 
H         -6.23639        2.02016       -0.46755 
H         -4.57178        2.46974       -0.06681 
O         -5.65932       -0.57938       -1.04410 
H         -6.59468       -0.37199       -0.93630 
 
 
 
 
389 
 
3.6  REFERENCES 
[1] Sings, H.; Singh, S. The Alkaloids: Chemistry and Biology 2003, 60, 51.  
[2] Miedaner, T.; Geiger, H. H. Toxins  2015, 7, 659 and references therein. 
[3] (a) Steyn, P. S.; Vleggar, R. Progress in the Chemistry of Organic Natural Products; 
Springer-Verlag: New York, 1985. (b) Mantle, P. G.; Mortimer, P. B.; White, E. P. Res. 
Vet. Sci. 1977, 24, 49. (c) DiMenna, M. E.; Mantle, P. B. Ibid, 1977, 24, 347. (d) 
Mantle, P. G.; Day, J. B.; Haigh, C. R.; Penny, H. C. Vet. Rec. 1978, 103, 403. (e) Cole, 
R. J.; Dorner, J. W.; Landsen, J. A.; Cox, R. H.; Pape, C.; Cunfer, B.; Nicholson, S. S.; 
Bedell, D. M. J. Agric. Food. Chem. 1977, 25, 1197. 
[4] (a) Fehr, T.; Acklin, W. Helv. Chem. Acta 1966, 49, 1907. (b) Gysi, R. P. Ph.D. 
Dissertation, Eidgenossiche Technische Hochschule, Zürich, Switzerland, 1973, No. 
4990. (c) Leutwiler, A. Dissertation No. 5163, Eidgenossiche Technische Hochschule, 
Zürich, Switzerland, 1973. 
[5] Munday-Finch, S. C.; Wilkins, A. L.; Miles, C. O. Phytochemistry 1996, 41, 327. 
[6] (a) Cole, R. J.; Dorner, J. W.; Springer, J. P.; Cox, R. H. J. Agric. Food. Chem. 1981, 
29, 293. (b) Gallagher, R. T.; Finer, J.; Clardy, J.; Leutwiler, A.; Weibel, F.; Acklin, 
W.; Arigoni, D. Tetrahedron Lett. 1980, 21, 231 and references therein. 
[7] Ogata, M.; Ueda, J.-y.; Hoshi, M.; Hashimoto, J.; Nakashima, T.; Anzai, K.; Takagi, 
M.; Shin-ya, K. J. Antibiot. 2007, 60, 645. 
[8] (a) Cole, R. J.; Kirksey, J. W.; Wells, J. M. Can. J. Microbiol. 1974, 20, 1159. (b) 
Springer, J. P.; Clardy, J.; Wells, J. M.; Cole, R. J.; Kirksey, J. W. Tetrahedron Lett. 
1975, 16, 2531. 
[9] (a) Bills, G. F.; Giacobbe, R. A.; Lee, S. H.; Peláez, F.; Tkacz, J. S. Mycol. Res. 1992, 
96, 977. (b) Itabashi, T.; Hosoe, T.; Wakana, D.; Fukushima, K.; Takizawa, K.; 
Yaguchi, T.; Okada, K.; Takaki, G. M.; Kawai, K. J. Nat. Med. 2009, 63, 96. 
[10] (a) Brnardic, E.; Doherty, J. B.; Dorsey, J.; Ellwood, C.; Fillmore, M.; Malaska, M.; 
Nelson, K.; Soukri, M. "Preparation of Indole Diterpene Alkaloids as Maxi-K Channel 
Blockers for the Treatment of Glaucoma." WIPO 2009/048559, 2009. (b) Garcia, M. 
L.; Goetz, M. A.; Kaczorowski, G. J.; McManus, O. B.; Monaghan, R. L.; Strohl, W. 
R.; Tkacz, J. S. "Novel Maxi-K Channel Blockers, Methods of Use and Process for 
Making the Same." U. S. Patent 0239863, 2005. (c) Brnardic, E.; Doherty, J. B.; 
Ellwood, C.; Fillmore, M.; Malaska, M. “Maxi-K Channel Blockers and Methods of 
Use.” U. S. Patent 048558, 2009. 
[11] Sheehan, J. J.; Benedetti, B. L.; Barth, A. L. Epilepsia 2009, 50, 711. 
390 
 
[12] (a) Springer, J. P.; Clardy, J. Tetrahedron Lett. 1980, 21, 231. (b) Dorner, J. P.; Cole, 
R. J.; Cox, R. H.; Cunfer, B. M. J. Agric. Food. Chem. 1984, 32, 1069. 
[13] Acklin, W.; Weibel, F.; Arigoni, D. Chimia 1977, 31, 63. 
[14] (a) de Jesus, A. E.; Gorst-Allman, C. P.; Steyn, P. S.; van Heerden, F. R.; Vieggaar, R.; 
Wessels, P. L.; Hull, W.E. J. Chem. Soc., Perkin Trans. 1983, 1863. (b) Fueki, S.; 
Tokiwano, T.; Toshima, H.; Oikawa, H. Org. Lett. 2004, 6, 2697. 
[15] Tagami, K.; Liu, C.; Minami, A.; Noike, M.; Isaka, T.; Fueki, S.; Schichijo, Y.; 
Toshima, H.; Gomi, K.; Dairi, T.; Oikawa, H. J. Am. Chem. Soc. 2013, 135, 1260. 
[16] (a) Smith, A. B. III; Mewshaw, R. J. Am. Chem. Soc. 1985, 107, 1769. (b) Smith, A. 
B. III; Leenay, T. L. Tetrahedron Lett. 1988, 29, 2787. (c) Smith, A. B. III; Leenay, T. 
L. Tetrahedron Lett. 1988, 29, 2791. (d) Mewshaw, R. E.; Taylor, M. D.; Smith, A. B. 
III   J. Org. Chem. 1989, 54, 3449. (e) Smith, A. B. III; Leenay, T. L. J. Am. Chem. 
Soc. 1989, 111, 5761. (f) Smith, A. B. III; Sunazuka, T.; Leenay, T. L.; Kingery-Wood, 
J. J. Am. Chem. Soc.  1990, 112, 8197. (g)  Smith, A. B. III; Kingery-Wood, J.; Leenay, 
T. L.; Nolen, E. G.; Sunazuka, T. J. Am. Chem. Soc. 1992, 114, 1438. (h) Smith, A. B. 
III; Ohta, M.; Clark, W. M.; Leahy, J. W. Tetrahedron Lett. 1993, 34, 3033. (i) Zou, 
Y.; Melvin, J. E.; Gonzales, S. S.; Spafford, M. J.; Smith, A. B. III J. Am. Chem. Soc. 
2015, 137, 7095. 
[17] Partial and total synthetic studies on terpene alkaloids (a) Guile, S. D.; Saxton, J. E.; 
Thornton-Pett, M. J. Chem. Soc. Perkin Trans.  1 1992, 1763. (b) Clark, J. S.; Myatt, 
J.; Roberts, L.; Walshe, N. Synlett  2005, 697-699. (c) Churruca, F.; Fousteris, M.; 
Ishikawa, Y.; Rekowski, M. W.; Hounsou, C.; Surrey, T.; Giannis, A. Org. Lett. 2010, 
12, 2096. (d) Enomoto, M.; Kuwahara, S. J. Org. Chem. 2010, 75, 6286. (e) Bradshaw, 
B.; Etxebarria-Jardi, G.; Bonjoch, J. J. Am. Chem. Soc. 2010, 132, 5966. (f) Oikawa, 
M.; Hashimoto, R.; Sasaki, M. Eur. J. Org. Chem. 2011, 538. (g) Isaka, T.; Hasegawa, 
M.; Toshima, H. Biosci. Biotechnol. Biochem. 2011, 75, 2213. (h) Adachi, M.; Higuchi, 
K.; Thasasa, N.; Yamada, H.; Nishikawa, T. Org. Lett. 2012, 14, 114. (i) Okano, K.; 
Yoshii, Y.; Tokuyama, H. Heterocycles 2012, 84, 1325. (j) Enomoto, S.; Morita, A.; 
Kuwahara, S. Angew. Chem. Int. Ed. 2012, 51, 12833. (k) Bian, M.; Wang, Z.; Xiong, 
X.; Sun, Y.; Matera, C.; Nicolaou, K. C.; Li, A. J. Am. Chem. Soc. 2012, 134, 8078. (l) 
Goetz, A. E.; Silberstein, A. L.; Corsello, M. A.; Garg, N. K.  J. Am. Chem. Soc. 2014, 
136, 3036. 
[18] Gassman, P. G.; van Bergen, T. J.; Gilbert, D. P.; Cue, B. W., Jr. J. Am. Chem. Soc. 
1974, 96, 5495. 
[19] (a) Malinowski, J. T.; Sharpe, R. J.; Johnson, J. S. Science 2013, 340, 180. (b) Sharpe, 
R. J.; Malinowski, J. T.; Johnson, J. S. J. Am. Chem. Soc. 2013, 135, 17990. 
391 
 
[20] (a) Chu, Y.; White, J. B.; Duclos, B. A. Tetrahedron Lett. 2001, 42, 3815. (b) Iguchi, 
M.; Niwa, M.; Yamamura, S. J. Chem. Soc. D.: Chem. Commun. 1971, 974. 
[21] (a) Stewart, I. C.; Ung, T.; Pletnev, A. A.; Berlin, J. M.; Grubbs, R. H.; Schrodi, Y. 
Org. Lett. 2007, 9, 1589. (b) Vorfalt, T.; Leuhausser, S.; Plenio, H. Angew. Chem. Int. 
Ed. 2009, 48, 5191. 
[22] McMurry, J. E.; Fleming, M. P.; Kees, K. L.; Krepski, L. R. J. Org. Chem. 1978, 43, 
3255. 
[23] Parsons, A. T.; Johnson, J. S.; J. Am. Chem. Soc. 2009, 131, 14202. 
[24] Qian, H.; Han, X.; Widenhoefer, R. A. J. Am. Chem. Soc. 2004, 126, 9536. 
[25] Boeckman, R. K. Jr.; Reeder, M. R. J. Org. Chem. 1997, 62, 6456. 
[26] Boxer, M. B.; Yamamoto, H. Org. Lett. 2005, 7, 3127. 
[27] (a) Parsons, A. T.; Smith, A. G.; Neel, A. N.; Johnson, J. S. J. Am. Chem. Soc. 2010, 
132, 9688. (b) Smith, A. G.; Slade, M. C. Org. Lett. 2011, 13, 1996. 
[28] Gharpure, S. J.; Reddy, S. R. B. Org. Lett. 2009, 11, 2519. 
[29] Breit, B.; Zahn, S. K. J. Org. Chem. 2001, 66, 4870. 
[30] Germain, J.; Deslongchamps, P. J. Org. Chem. 2002, 67, 5269. 
[31] (a) Gianturco, M. A.; Friedal, P. Tetrahedron 1963, 19, 2039. (b) House, H. O. In 
Modern Synthetic Reactions; Benjamin: Menlo Park, 1972; pp. 520-532. (c) Stowell, 
J. C.  In Carbanions in Organic Synthesis; Wiley: New York, 1979; pp. 205-210. 
[32] Demir, A. S.; Enders, D. J. J. Prakt. Chem. 1997, 339, 553. 
[33] Piers, E.; Grierson, J. R. J. Org. Chem. 2005, 70, 4652. 
[34] Corey, E. J.; Knapp, S. Tetrahedron Lett. 1976, 17, 3667. 
[35] Hajipour, A. R.; Mahboubghah, N. Org. Prep. Proced. Int. 1999, 31, 112. 
[36] Watanabe, H.; Iwamoto, M.; Nakada, M. J. Org. Chem. 2005, 70, 4652. 
[37] (a) Katoh, T.; Mizumoto, S.; Fudesaka, M.; Nakashima, Y.; Kajimoto, T.; Node, M. 
Synlett 2006, 2076. (b) Katoh, T.; Mizumoto, S.; Fudesaka, M.; Takeo, M.; Kajimoto, 
T.; Node, M. Tetrahedron: Asymmetry 2006, 17, 1655. 
[38] (a) Becke, A. D.; J. Chem. Phys. 1993, 98, 5648. (b) Lee, C. T.; Yang, W. T.; Parr, R. 
G. Phys, Rev. B 1988, 37, 785.  (c) Hariharanan, P. C.; Pople, J. A.; Theor. Chim. Acta. 
1973, 28, 213. (d) Franci, M. M.; Pietro, W. J.; Henre, W. J.; Binley, J. S.; Gordon, M. 
392 
 
S.; Frees, D. J.; Pople, J. A. J. Chem. Phys. 1982, 77, 3654.  See Section 3.5 for more 
details. 
[39] (a) Zhang, W.; Yamamoto, H. J. Am. Chem. Soc. 2007, 129, 286. (b) Wan, K. K.; 
Iwasaki, K.; Umotoy, J. C.; Wolan, D. W.; Shenvi, R. A. Angew. Chem. Int. Ed. 2015, 
54, 2410. 
[40] (a) Shapiro, R. H.; Heath, M. J. J. Am. Chem. Soc. 1967, 89, 5734. (b) Shapiro, R. H.; 
Org. React. (N.Y.), 1975, 23, 405. 
[41] (a) Stork, G.; Darling, S. D. J. Am. Chem. Soc. 1960, 82, 1512. (b) Stork, G.; Rosen, 
P.; Goldman, N.; Coombs, R. V.; Tsuji, J. J. Am. Chem. Soc. 1965, 87, 275. 
[42] Vilkas, M.; Bull. Soc. Chem. Fr. 1959, 1401. 
[43] (a) Stork, G.; Kahn, M. J. Am. Chem. Soc. 1985, 107, 500. (b) Stork, G.; Sher, P. M. J. 
Am. Chem. Soc. 1986, 108, 303. 
[44] (a) Ireland, R. E.; Mueller, R. H. J. Am. Chem. Soc. 1972, 94, 5897. (b) Ireland, R. E.; 
Mueller, R. H.; Willard, A. K. J. Am. Chem. Soc. 1976, 98, 2868. 
[45] Fleming, I.; Henning, R.; Plaut, H. J. Chem. Soc. Chem. Commun. 1984, 29. 
[46] (a) Desai, L. V.; Hull, K. L.; Sanford, M. S. J. Am. Chem. Soc. 2004, 126, 9542. (b) 
Neufeldt, S. R.; Sanford, M. S. Org. Lett. 2010, 12, 532. 
[47] Zhu, C.; Tang, P.; Yu, B. J. Am. Chem. Soc. 2008, 130, 5872. 
[48] Siler, D. A.; Mighion, J. D.; Sorenson, E. J. Angew. Chem. Int. Ed. 2014, 53, 5332. 
[49] Krasovskiy, A.; Kopp, F.; Knochel, P. Angew. Chem., Int. Ed. 2006, 45, 497. 
[50] Abad, A.; Agullo, C.; Arno, M.; Domingo, L. R.; Zaragoza, R. J. J. Org. Chem. 1990, 
55, 2369 and references therein. 
[51] (a) Evans, D. A.; Morrisey, M. J. Am. Chem. Soc. 1984, 106, 3866. (b) Evans, D. A.; 
Morrisey, M. Tetrahedron Lett. 1984, 25, 4637. 
[52] (a) St. André, A. F.; MacPhillamy, H. B.; Nelson, J. A.; Shabica, A. C.; Scholz, C. R. 
J. Am. Chem. Soc. 1952, 74, 5506. (b) Gabbard, R. B.; Segaloff, A. Steroids 1983, 41, 
791. (c) Haddad, M.; Blazejewski, J. C.; Wakselman, C.; Dorai, V.; Duc, I. Eur. J. Med. 
Chem. 1994, 29,  627. (d) Khripach, V. A.; Zhabinskii, V. N.; Fando, G. P.; Kuchto, A. 
I.; Lyakhov, A. S.; Govorova, A. A.; Groen, M. B.; Van Der Louw, J.; De Groot, A. 
Steroids 2004,  69,  495. 
[53] Breit, B.; Zahn, S. K. J. Org. Chem. 2001, 66, 4870. 
393 
 
[54] Xiang, S.-K.; Zhang, B.; Zhang, L.-H.; Cui, Y.; Jiao, N. Chem. Commun. 2011, 47, 
8097. 
[55] Zhang, H.-B.; Liu, L.; Liu, Y.-L.; Chen, Y.-J.; Wang, J.; Wang, D. Synth. Commun. 
2005, 37, 173. 
[56] Westermaier, M.; Mayr, H. Org. Lett. 2006, 8, 4791. 
[57] Zimmerman, H. E.; Wang, P. J. Org. Chem. 2002, 67, 9216. 
[58] Van Goor, F. F.; Burton, W. L.; Compositions for Treatment of Cystic Fibrosis and 
Other Chronic Diseases. U.S. Patent 61254180, 2011. 
[59] Nyfeler, E.; Renaud, P. Org. Lett. 2008, 10, 985. 
[60] Archer, C. H.; Thomas, N. R.; Gani, D. Tetrahedron Asymm. 1993, 4, 1141. 
[61] Hettche, F.; Hoffmann, R. W.; New J. Chem. 2003, 27, 172. 
[62] Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, 
J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; 
Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, 
N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; 
Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; 
Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, 
J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; 
Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, 
J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, 
D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, 
A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; 
Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; 
Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. 
W.; Gonzalez, C.; Pople, J. A. Gaussian 03, revision D.01; Gaussian, Inc.: Wallingford, 
CT, USA, 2004. 
 
 
